U.S. patent number 7,833,527 [Application Number 11/906,078] was granted by the patent office on 2010-11-16 for methods of treating psoriasis using il-17 receptor a antibodies.
This patent grant is currently assigned to Amgen Inc.. Invention is credited to David Fitzpatrick, Jacques J. Peschon, Joel Tocker.
United States Patent |
7,833,527 |
Tocker , et al. |
November 16, 2010 |
Methods of treating psoriasis using IL-17 Receptor A antibodies
Abstract
The present invention relates to IL-17 Receptor A antigen
binding proteins, such as antibodies, and methods for diagnosing
and treating diseases mediated by IL-17 Receptor A activation.
Inventors: |
Tocker; Joel (Issaquah, WA),
Peschon; Jacques J. (Seattle, WA), Fitzpatrick; David
(Fort Collins, CO) |
Assignee: |
Amgen Inc. (Thousand Oaks,
CA)
|
Family
ID: |
39344834 |
Appl.
No.: |
11/906,078 |
Filed: |
September 27, 2007 |
Prior Publication Data
|
|
|
|
Document
Identifier |
Publication Date |
|
US 20080219979 A1 |
Sep 11, 2008 |
|
Related U.S. Patent Documents
|
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
Issue Date |
|
|
60969895 |
Sep 4, 2007 |
|
|
|
|
60873072 |
Dec 5, 2006 |
|
|
|
|
60827882 |
Oct 2, 2006 |
|
|
|
|
Current U.S.
Class: |
424/135.1;
424/145.1; 424/158.1 |
Current CPC
Class: |
A61P
1/16 (20180101); A61P 37/08 (20180101); A61P
17/10 (20180101); A61P 1/12 (20180101); A61P
19/02 (20180101); A61P 19/00 (20180101); A61P
9/10 (20180101); A61P 25/00 (20180101); A61P
31/14 (20180101); A61P 1/04 (20180101); A61P
11/00 (20180101); A61P 11/06 (20180101); C07K
16/2866 (20130101); A61P 17/00 (20180101); A61P
29/00 (20180101); A61K 39/3955 (20130101); A61P
3/00 (20180101); A61P 19/08 (20180101); A61P
25/28 (20180101); A61P 19/04 (20180101); A61P
37/00 (20180101); A61P 5/38 (20180101); A61P
9/00 (20180101); A61P 37/02 (20180101); A61P
37/06 (20180101); A61P 17/06 (20180101); A61P
9/14 (20180101); A61P 21/04 (20180101); A61P
3/10 (20180101); A61K 45/06 (20130101); A61P
1/00 (20180101); A61P 21/00 (20180101); A61P
5/16 (20180101); C07K 2317/21 (20130101); C07K
2317/76 (20130101); C07K 2317/567 (20130101); A61K
2039/505 (20130101); A61K 2039/507 (20130101); C07K
2317/92 (20130101); C07K 2317/565 (20130101); C07K
2317/56 (20130101) |
Current International
Class: |
A61K
39/395 (20060101); A61P 37/02 (20060101) |
Field of
Search: |
;424/135.1,145.1,158.1 |
References Cited
[Referenced By]
U.S. Patent Documents
Foreign Patent Documents
|
|
|
|
|
|
|
WO 95/18826 |
|
Jul 1995 |
|
WO |
|
WO 96/29408 |
|
Sep 1996 |
|
WO |
|
WO 97/04097 |
|
Feb 1997 |
|
WO |
|
WO 98/23284 |
|
Jun 1998 |
|
WO |
|
WO 99/14240 |
|
Mar 1999 |
|
WO |
|
WO 99/60127 |
|
Nov 1999 |
|
WO |
|
WO 00/15759 |
|
Mar 2000 |
|
WO |
|
WO 00/55204 |
|
Sep 2000 |
|
WO |
|
WO 01/68705 |
|
Sep 2001 |
|
WO |
|
WO 01/68859 |
|
Sep 2001 |
|
WO |
|
WO 2004/002519 |
|
Jan 2004 |
|
WO |
|
WO 2005/063290 |
|
Jul 2005 |
|
WO |
|
WO 2006/054059 |
|
May 2006 |
|
WO |
|
WO 2006/088925 |
|
Aug 2006 |
|
WO |
|
Other References
About.com.arthritis (definition for "DMARDS", pp. 1-2; Jul. 2,
2009). cited by examiner .
Webmd.com (definition for "DMARDS"; pp. 1-3; Jul. 2, 2009). cited
by examiner .
Dogra e tal. (Indian J. Dermatol. Venereol. Leprol. 72(4): 256-264
(2006). cited by examiner .
Van de Kerkhof (JEADV 20:639-650 (2006)). cited by examiner .
Nickolof et al. (J. Clin. Invest. 113(12): 1664-1675 (2004)). cited
by examiner .
Peterson (Pharmacol. & Toxicol. 99:104-115 (2006). cited by
examiner .
ClinicalTrials.gov (AMG 827; NCT00975637; pp. 1-4, Dec. 28, 2009).
cited by examiner .
Chabaud, M. and Miossec, P., "The combination of tumor necrosis
factor .alpha. blockade with interleukin-1 and interleukin-17
blockade is more effective for controlling synovial inflammation
and bone resorption in an ex vivo model," Arthritis Rheum,
44(6):1293-1303, 2001. cited by other .
Charles et al., "Regulation of cytokines, cytokine inhibitors, and
acute-phase proteins following anti-TNF-.alpha. therapy in
rheumatoid arthritis," J Immunol, 163:1521-1528, 1999. cited by
other .
Cannetti et al., "IL-18 enhances collagen-induced arthritis by
recruiting neutrophils via TNF-.alpha. and leukotriene B.sub.4," J
Immunol, 171:1009-1015, 2003. cited by other .
Cunnane et al., "Serum amyloid A in the assessment of early
inflammatory arthritis", J. Rheumatol, 27:58-63, 2000. cited by
other .
Fujino et al., "Increased expression of in terleukin 17 in
inflammatory bowel disease," Gut, 52:65-70, 2003. cited by other
.
Green, L. and Jakobovits, A., "Regulation of B cell development by
variable gene complexity in mice reconstituted with human
immunoglobulin yeast artificial chromosomes," J Exp Med,
188(3):483-495, 1998. cited by other .
Green et al., "Antigen-specific human monoclonal antibodies from
mice engineered with huma Ig heavy and light chain YACs," Nat
Genet, 7:13-21, 1994. cited by other .
Harrington et al., "Interleukin 17-producing CD4.sup.+ effector T
cells develop via a lineage distinct from the T helper type 1 and 2
lineages," Nat Immunol, 6(11):1123-1132, 2005. cited by other .
Jia et al., "A novel method of multiplexed competitive antibody
binning for the characterization of monoclonal antibodies," J
Immunol Methods, 288:91-98, 2004. cited by other .
Kauffman et al., "A phase I study evaluating the safety,
pharmacokinetics, and clinical response of a human IL-12 p40
antibody in subjects with plaque psoriasis," J Invest Dermatol,
123:1037-1044, 2004. cited by other .
Kimura, A. et al., "IL-6-dependent and -independent pathways in the
development of interleukin 17-producing T helper cells," Proc Natl
Acad Sci, USA, 104(29):12099-12104, 2007. cited by other .
Kolls, J. and Linden, A., "Interleukin-17 family members and
inflammation," Immunity, 21:467-476, 2004. cited by other .
Konishi et al., "Il-18 contributes to the spontaneous development
of atopic dermatitis-like inflammatory skin lesion independently of
IgE/stat6 under specific pathogen-free conditions," Proc Natl Acad
Sci, USA, 99(17):11340-11345, 2002. cited by other .
Langrish et al., "IL-23 drives a pathogenic T cell population that
induces autoimmune inflammation," J Exp Med, 201(2):233-240, 2005.
cited by other .
Li et al., "The expression of interleukin-17, interferon-gamma, and
macrophage inflammatory protein-3 alpha mRNA in patients with
psoriasis vulgaris", J Huazhong Univ Sci Technolog Med Sci,
24(3):294-296, 2004. cited by other .
Linden et al., "Airway neutrophils and interleukin-17," Eur Respir
J, 15:973-977, 2000. cited by other .
Lubberts et al., "IL-1-independent role of IL-17 in synovial
inflammation and joint destruction during collagen-induced
arthritis," J Immunol, 167:1004-1013, 2001. cited by other .
Lubberts et al., "IL-17 promotes bone erosion in murine
collagen-induced arthritis through loss of the receptor activator
of NF-.kappa.B ligand/osteoprotegerin balance," J Immunol,
170:2655-2662, 2003. cited by other .
Lubberts et al., "The role of T cell interleukin-17 in conducting
destructive arthritis: lessons from animal models," Arthritis Res
Ther, 7:29-37, 2005. cited by other .
Mangan et al., "Transforming growth factor-.beta. induces
development of the T.sub.H17 lineage," Nature, 441:231-234, 2006.
cited by other .
Mannon et al., "Anti-interleukin-12 antibody for active Crohn's
disease," N Engl J Med, 351:2069-2080, 2004. cited by other .
Matusevicius et al., "Interleukin-17 mRNA expression in blood and
CSF mononuclear cells is augmented in multiple sclerosis", Mult
Scler, 5:101-104, 1999. cited by other .
McAllister et al., "Role of IL-17A, IL-17F, and the IL-17 receptor
in regulating growth-related oncogene-.alpha. and granulocyte
colony-stimulating factor in bronchial epithelium: Implications for
airway inflammation in cystic fibrosis," J Immunol, 175:404-412,
2005. cited by other .
Mendez et al., "Functional transplant of megabase human
immunoglobulin loci recapitulates human antibody response in mice,"
Nat Genet, 15:146-156, 1997. cited by other .
Miossec, P., "Interleukin-17 in rheumatoid arthritis," Arthritis
& Rhem, 48(3):594-601, 2003. cited by other .
Molet et al., "IL-17 is increased in asthmatic airways and induces
human bronchial fibroblasts to produce cytokines," J Allergy Clin
Immunol, 108(3):431-438, 2001. cited by other .
Nakae et al., "IL-17 production from activated T cells is required
for the spontaneous development of destructive arthritis in mice
deficient in IL-1 receptor antagonist," Proc Natl Aced Sci, USA,
100(10):5986-5990, 2003. cited by other .
Nakae et al., "Suppression of immune induction of collagen-induced
arthritis in IL-17-deficient mice," J Immunol, 171:6173-6177, 2003.
cited by other .
Nanevicz et al., ";Mechanisms of thrombin receptor agonist
specificity," J Biol Chem, 270(37):21619-21625, 1995. cited by
other .
Numasaki et al., "Regulatory roles of IL-17 and IL-17F in G-CSF
production by lung microvascular endothelial cells stimulated with
IL-1.beta. and/or TNF-.alpha.," Immunol Lett, 95:97-104, 2004.
cited by other .
Oda et al., "Interleukin-17F induces pulmonary neutrophilia and
amplifies antigen-induced allergic response," Am J Respir Crit Care
Med, 171:12-18, 2005. cited by other .
Park et al., "A distinct lineage of CD4 T cells regulates tissue
inflammation by producing interleukin 17," Nat Immunol,
6(11):1133-1141, 2005. cited by other .
Stemmer et al., "Single-step assembly of a gene and entire plasmid
from large numbers of oligodeoxyribonucleotides," Gene, 164:49-53,
1995. cited by other .
Toy et al., "Cutting Edge: Interleukin 17 signals through a
heteromeric receptor complex," J Immunol, 177:36-39, 2006. cited by
other .
Yao et al., "Herpesvirus saimiri encodes a new cytokine, IL-17,
which binds to a novel cytokine receptor," Immunity, 3:811-821,
1995. cited by other .
Ye et al., "Requirement of interleukin 17 receptor signaling for
lung CXC chemokine and granulocyte colony-stimulating factor
expression, neutrophils recruitment, and host defense," J Exp Med,
194(4):519-527, 2001. cited by other .
Yoshimoto et al., "IL-12 up-regulates IL-18 receptor expression on
T cells, Th1 cells, ad B cells: Synergism with IL-18 for
IFN-.gamma. production," J Immunol, 161:3400-3407, 1998. cited by
other .
You et al., "Interleukin-17 receptor-like gene is a novel
antiapoptotic gene highly expressed in androgen-independent
prostate cancer," Cancer Res, 66(1):175-183, 2006. cited by other
.
Ziolkowska et al., "High levels of IL-17 in rheumatoid arthritis
patients: IL-15 triggers in vitro IL-17 production via cyclosporine
A-sensitive mechanism," J Immunol, 164:2832-2838, 2000. cited by
other .
Zupnick, A. and Prives, C., "Mutational analysis of the p53 core
domain L1 loop," J Biol Chem, 281(29):20464-20473, 2006. cited by
other .
Brorson, K. et al., "Mutational analysis of avidity and fine
specificity of anti-levan antibodies," J. Immunol., 163:6694-6701,
1999. cited by other .
Brummell, DA et al., "Probing the combining site of an
anti-carbohydrate antibody by saturation-mutagenesis: role of the
heavy-chain CDR3 residues," Biochem., 32:1180-1187, 1993. cited by
other .
Burks, E. et al., "In vitro scanning saturation mutagenesis of an
antibody binding pocket," Proc. Natl. acad. Sci. USA, 94:412-417,
1997. cited by other .
Colman, P. M., "Effects of amino acid sequence changes on
antibody-antigen interactions," Res. Immunol., 145:33-36, 1994.
cited by other .
Dufner, P. et al., "Harnessing phage and ribosome display for
antibody optimization," Trends Biotechnol., 24(11):523-529, 2006.
cited by other .
Jang, Y. J. et al., "The structural basis for DNA binding by an
anti-DNA autoantibody," Mol. Immunol., 35:1207-1217, 1998. cited by
other .
Kobayashi, H. et al., "Tryptophan H33 plays an important role in
pyrimidine (6-4) pyrimidine photoproduct binding by a high-affinity
antibody," Protein Eng., 12:879-884, 1999. cited by other .
Kumar, S. et al., "Molecular cloning and expressing of the Fabs of
human autoantibodies in Escherichia coli," J. Biol. Chem.,
275(45):35129-35136, 2000. cited by other .
Schnyder, B. et al., "IL-17 reduces TNF-induced Rantes and VCAM-1
expression," Cytokine, 31(3):191-202, 2005. cited by other .
Smith-Gill, S. et al., "Contributions of immunoglobulin heavy and
light chains to antibody specificity for lysozyme and two haptens,"
J. Immunol., 139(12):4135-4144, 1987. cited by other .
Song, M. et al., "Light chain of natural antibody plays a dominant
role in protein antigen binding," Biochem. Biophys. Res. Comm.,
268:390-394, 2000. cited by other .
XP002486817, "Monoclonal anti-human IL-17 R antibody," R&D
Systems, 2004. cited by other .
Gaffen, S. et al., "The IL-17 cytokine family," Vitamins and
Hormones, Academic Press, New York, NY, US, pp. 255-282,
XP009086501, 2006. cited by other .
Hwang, S. and Kim, H., "Expression of IL-17 homologs and their
receptors in the synovial cells of rheumatoid arthritis patients,"
Mol. Cells, 19(2):180-184, 2005. cited by other .
Infante-Duarte, C. et al., "Microbial lipopeptides induce the
production of IL-17 in Th cells," J. Immunol., 165:6107-6115, 2000.
cited by other .
Janeway et al., Immunology, 3.sup.rd edition, Garland Publishing
Inc., p. G3. cited by other .
Joosten et al., "IL-1.alpha..beta. blockade prevents cartilage and
bone destruction in murine type II collagen-induced arthritis,
whereas TNF-.alpha. blockade only ameliorates joint inflammation,"
J. Immunol., 163:5049-5055, 1999. cited by other .
Jovanovic et al., "Stimulation of 92-kd gelatinase (matrix
metalloproteinase 9) production by interleukin-17 in human
monocyte/macrophages," Arthritis Rheum., 43(5):1134-1144, 2000.
cited by other .
Jovanovic, D. et al., "IL-17 stimulates the production and
expression of proinflammatory cytokines, IL-.beta. and TNF-.alpha.,
by human macrophages," J. of Immunol., 160:3513-3521, 1998. cited
by other .
Jovanovic, D. et al., "IL-17 stimulates the secretion of
proinflammatory cytokines by human macrophages," American College
of Rheumatology (ACR) meeting, Poster 1446, Nov. 1997. cited by
other .
Kotake, S., "IL-17 in synovial fluids from patients with rheumatoid
arthritis is a potent stimulator of osteoclastogenesis," J. Clin.
Invest., 103(9):1345-1352, 1999. cited by other .
Kurasawa et al., "Increased interleukin-17 production in patients
with systemic sclerosis," Arthritis. Rheum., 43(11):2455-2463,
2000. cited by other .
Lee et al., "Il-18 E42A mutant is resistant to the inhibitory
effects of HPV-16 E6 and E7 oncogenes on the IL-18-mediated immune
response," Cancer Lett., 229:261-270, 2005. cited by other .
Li et al., "Cloning and characterization of IL-17B and IL-17C, two
new members of the IL-17 cytokine family," PNAS, 97(2):773-778,
2000. cited by other .
Liew, F., "Nitric oxide in infectious and autoimmune diseases,"
CIBA Foundation Symposium, 195:234-244, 1995. cited by other .
Lotz et al., IL-17 promotes cartilage degradation, Arthritis and
Rheumatism, 39 supp.(9):S120, No. 559, 1996. cited by other .
Miller, N. and Vile, R., "Targeted vectors for gene therapy," FASEB
J., 9:190-199, 1995. cited by other .
Mosley et al., "Interleukin-17 family and IL-17 receptors,"
Cytokine & Growth Factor Reviews, 14:155-174, 2003. cited by
other .
Mostarica-Stojkovic, M., "The role of astrocytes in autoimmune and
other inflammatory diseases of the central nervous system,"
Institute of Microbiology and Immunology, School of Medicine,
University of Belgrade, Belgrade, Yugoslavia. cited by other .
Ngo et al., "Computational complexity, protein structure
prediction, and the Levinthal Paradox," in The Protein Folding
Problem and Tertiary Structure Prediction, Mertz and LeGrand, eds.
1994, pp. 491-495. cited by other .
Nicholas et al., "Gene expression in cells infected with
gammaherpesvirus saimiri: Properties of transcripts from two
immediate-early genes," Virol., 179:189-200, 1990. cited by other
.
Niederau et al., "Inflammatory mediators and acute phase proteins
in patients with Crohn's disease and ulcerative colitis,"
Hepato-Gastroenterol., 44:90-107, 1997. cited by other .
Pelidou et al., "enhancement of acute phase and inhibition of
chronic phase of experimental autoimmune neuritis in Lewis rats by
intranasal administration of recombinant mouse interleukin 17:
Potential immunoregulatory role," Exp. Neruol., 163:165-172, 2000.
cited by other .
Rouvier et al., CTLA-8, cloned from an activated T cell, bearing
AU-rich messenger RNA instability sequences, and homologous to a
herpesvirus saimiri gene, J. Immunol., 150(12):5445-5456, 1993.
cited by other .
Spriggs, M. K., "Interleukin-17 and its receptor," J. Clin.
Immunol., 17(5):366-369, 1997. cited by other .
Sykes et al., "Xenograft Tolerance," Immunol. Reviews, 141:245-276,
1994. cited by other .
Teunissen et al., "Interleukin-17 and interferon-.gamma. synergize
in the enhancement of proinflammatory cytokine production by human
keratinocytes," J. Invest. Dermatol., 111:645-649, 1998. cited by
other .
Torrance et al., "Inhibition of cytokine activity in collagen
induced arthritis," University of Washington, Department of
Immunology/Immunex Symposium, poster presentation, Mar. 7, 1997.
cited by other .
Trofatter et al., "An expression-independent catalog of genes from
human chromosome 22," Genome Rsh., 5:214-224, 1995. cited by other
.
Verma, I. And Somia, N., "Gene therapy--promises, problems and
prospects," Nature, 389:239-242, 1997. cited by other .
Wong et al., "Elevation of proinflammatory cytokine (IL-18, IL-17,
IL-12) and Th2 cytokine (IL-4) concentrations in patients with
systemic lupus erythematosus," Lupus, 9:589-593, 2000. cited by
other .
Yao, Z. et al., "Molecular characterization of the human
interleukin (IL)-17 receptor," Cytokine, 9(11):794-800, 1997. cited
by other .
Yao et al., "Complete nucleotide sequence of the mouse CTLA8 gene,"
Gene, 168:223-225 1996. cited by other .
Yao et al., "Human IL-17: A novel cytokine derived from T cells,"
J. Immunol., 155:5483-5486, 1995. cited by other .
Aarvak et al., "Analysis of IL-17 and other cytokines and surface
markers of RA inflammatory T cell clones," American College of
Rheumatology (ACR) meeting, Poster 1448, Nov. 1997. cited by other
.
Aggarwal, S. and Gurney, A., "IL-17: prototype member of an
emerging cytokine family," J Leukocyte Biol, 71:1-8, 2002. cited by
other .
Albanesi et al., "IL-17 is produced by nickel-specific T
lymphocytes and regulates ICAM-1 expression and chemokine
production in human keratinocytes: Synergistic or antagonist
effects with IFN-.gamma. and TNF-.alpha.," J. Immunol.,
162:494-502, 1999. cited by other .
Albrecht et al., "Primary structure of the herpesvirus saimiri
genome," J. Virol., 66(8):5047-5058, 1992. cited by other .
Amin, A. R. et al., "The expression and regulation of nitric oxide
synthase in human osteoarthritis-affected chondrocytes: Evidence
for up-regulated neuronal nitric oxide synthase," J. Exp. Med.,
182:2097-2102, Dec. 1995. cited by other .
Ankarcrona, M. et al., "Interleukin-1.beta.-induced nitric oxide
production activates apoptosis in pancreatic RINm5F cells," Exp
Cell Rsh, 213:172-177, 1994. cited by other .
Antonysamy, M. et al., "Evidence for a role of IL-17 in organ
allograft rejection: IL-17 promotes the functional differentiation
of dendritic cell progenitors," J. Immunol., 162:577-584, 1999.
cited by other .
Arend, W. et al., "Inhibition of the production and effects of
interleukin-1 and tumor necrosis factor .alpha. in rheumatoid
arthritis," Arthritis & Rhem., 38(2):151-160, 1995. cited by
other .
Attur, M. G. et al., "Interleukin-17 up-regulation of nitric oxide
production in human osteoarthritis cartilage," Arthritis &
Rheum., 40(6):1050-1053, 1997. cited by other .
Baragi, V. M. et al., "Transplantation of transduced chondrocytes
protects articular cartilage from interleukin 1-induced
extracellular matrix degradation," J. Clin. Invest.,
96(5):2454-2460, 1995. cited by other .
Bowie et al., "Deciphering the message in protein sequences:
Tolerance to amino acid substitutions," Science, 47:1306-1310,
1990. cited by other .
Caron, J. P. et al., "Chondroprotective effect of intraarticular
injections of interleukin-1 receptor antagonist in experimental
osteoarthritis," Arthritis & Rheum., 39(9):1535-1544, 1996.
cited by other .
Chabaud, M. et al., "Regulation of the effects of IL 17 on IL 6 and
LIF production by RA synoviocytes," American College of
Rheumatology (ACR) meeting, Poster 1449, Nov. 1997. cited by other
.
Chabaud, M. et al., "Human Interluekin-17: A T Cell-Derived
Proinflammatory Cytokine Produced by the Rheumatoid Synovium,"
Arthritis & Rheumatism, 42(5):963-970, 1999. cited by other
.
Chabaud, M. et al., "Contribution of interleukin 17 to synovium
matrix destruction in rheumatoid arthritis," Cytokine,
12(7):1092-1099, 2000. cited by other .
Chabaud, M. et al., "Enhancing effect of IL-17 on IL-1-Induced IL-6
and leukemia inhibitory factor production by rheumatoid arthritis
synoviocytes and its regulation by Th2 cytokines," J. Immunol.,
161:409-414, 1998. cited by other .
Crystal, R., "Transfer of genes to humans: Early lessons and
obstacles to success," Sci., 270:404-410, 1995. cited by other
.
Dudler et al., "In vivo effects of murine recombinant
interleukin-17 on synovial joint in mice," American College of
Rheumatology (ACR) meeting, Poster 1450, Nov. 1997. cited by other
.
Fanslow et al. "Regulation of alloreactivity in vivo by a soluble
form of the interleukin-1 receptor," Science, 248:739-742, 1990.
cited by other .
Fanslow et al., "Regulation of alloreactivity I vivo IL-4 and the
soluble IL-4 receptor," J. Immunol., 47(2):535-540, 1991. cited by
other .
Fossiez et al., "T cell interleukin-17 induces stromal cells to
produce proinflammatory and hematopoietic cytokines," J. Exp. Med.,
183:2593-2603, 1996. cited by other .
Fouilhoux et al., "Production of IL-17 and its regulation in
rheumatoid synovium," American College of Rheumatology (ACR)
meeting, Poster 1447, 1997. cited by other .
Frommel, C. and Holzhutter, H. G., An estimate on the effect of
point mutation and natural selection on the rate of amino acid
replacement in proteins, J. Mol. Evol., 21:233-257, 1985. cited by
other .
GenBank Accession No. H55639. cited by other .
GenBank Accession No. MMU31993. cited by other .
U.S. Appl. No. 12/443,962. cited by other.
|
Primary Examiner: Bristol; Lynn
Attorney, Agent or Firm: Klaniecki; James E.
Parent Case Text
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims the benefit under 35 U.S.C. .sctn.119 of
U.S. Provisional Application Ser. No. 60/969,895, filed Sep. 4,
2007, and U.S. Provisional Application Ser. No. 60/873,072, filed
Dec. 5, 2006 and U.S. Provisional Application Ser. No. 60/827,882,
filed Oct. 2, 2006, which are hereby incorporated by reference.
Claims
What is claimed is:
1. A method of treating psoriasis, comprising administering to a
patient having psoriasis a composition comprising an antibody
selected from the group consisting of: a. an isolated antibody,
comprising a light chain variable domain sequence comprising SEQ ID
NO:40 and a heavy chain variable domain sequence comprising SEQ ID
NO:14; and b. an isolated antibody, comprising a light chain CDR1
comprising SEQ ID NO:224, a light chain CDR2 comprising SEQ ID
NO:225, a light chain CDR3 comprising SEQ ID NO:226, a heavy chain
CDR1 comprising SEQ ID NO:146, a heavy chain CDR2 comprising SEQ ID
NO:147, a heavy chain CDR3 comprising SEQ ID NO:148, wherein said
antibody specifically binds to human IL-17 receptor A and inhibits
the binding of IL-17A to said IL-17 receptor A.
2. The method of claim 1 further comprising administering to said
patient a second treatment comprising a pharmaceutical
composition.
3. The method of claim 1, wherein said antibody is selected from
the group consisting of: a. a human antibody; b. a humanized
antibody; c. a chimeric antibody; d. a monoclonal antibody; e. an
antigen-binding antibody fragment; f. a single chain antibody; g. a
diabody; h. a triabody; i. a tetrabody; j. a Fab fragment; k. a
F(ab')2 fragment; l. an IgD antibody; m. an IgE antibody; n. an IgM
antibody; o. an IgG1 antibody; p. an IgG2 antibody; q. an IgG3
antibody; and r. an IgG4 antibody.
4. The method of claim 1, wherein said composition is a
pharmaceutical composition.
5. A method of treating psoriasis, comprising administering to a
patient having psoriasis a composition comprising an isolated
antibody comprising a light chain CDR1 comprising SEQ ID NO:224, a
light chain CDR2 comprising SEQ ID NO:225, a light chain CDR3
comprising SEQ ID NO:226, a heavy chain CDR1 comprising SEQ ID
NO:146, a heavy chain CDR2 comprising SEQ ID NO:147, a heavy chain
CDR3 comprising SEQ ID NO:148, wherein said antibody specifically
binds to human IL-17 receptor A and inhibits the binding of IL-17A
to said IL-17 receptor A.
6. The method of claim 5, further comprising administering to said
patient a second treatment comprising a pharmaceutical
composition.
7. The method of claim 5, wherein said composition is a
pharmaceutical composition.
8. The method of claim 5, wherein said antibody is selected from
the group consisting of: a. a human antibody; b. a humanized
antibody; c. a chimeric antibody; d. a monoclonal antibody; e. an
antigen-binding antibody fragment; f. a single chain antibody; g. a
diabody; h. a triabody; i. a tetrabody; j. a Fab fragment; k. a
F(ab')2 fragment; l. an IgD antibody; m. an IgE antibody; n. an IgM
antibody; o. an IgG1 antibody; p. an IgG2 antibody; q. an IgG3
antibody; and r. an IgG4 antibody.
9. The method of claim 5, wherein said antibody is selected from
the group consisting of: a. a human antibody; b. a humanized
antibody; c. a chimeric antibody; d. a monoclonal antibody; e. an
antigen-binding antibody fragment; f. a single chain antibody; g. a
Fab fragment; h. a F(ab')2 fragment; i. an IgG1 antibody; and j. an
IgG2 antibody.
10. The method of claim 5, wherein said antibody is a human
antibody.
11. The method of claim 5, wherein said antibody is a monoclonal
antibody.
12. The method of claim 5, wherein said antibody is a human
monoclonal antibody.
13. The method of claim 5, wherein said antibody is a human IgG2
monoclonal antibody.
14. A method of treating psoriasis, comprising administering to a
patient having psoriasis a composition comprising an isolated
antibody comprising a light chain variable domain sequence
comprising SEQ ID NO:40 and a heavy chain variable domain sequence
comprising SEQ ID NO:14, wherein said antibody specifically binds
to human IL-17 receptor A and inhibits the binding of IL-17A to
said IL-17 receptor A.
15. The method of claim 14, further comprising administering to
said patient a second treatment comprising a pharmaceutical
composition.
16. The method of claim 14, wherein said composition is a
pharmaceutical composition.
17. The method of claim 14, wherein said antibody is selected from
the group consisting of: a. a human antibody; b. a humanized
antibody; c. a chimeric antibody; d. a monoclonal antibody; e. an
antigen-binding antibody fragment; f. a single chain antibody; g. a
diabody; h. a triabody; i. a tetrabody; j. a Fab fragment; k. a
F(ab')2 fragment; l. an IgD antibody; m. an IgE antibody; n. an IgM
antibody; o. an IgG1 antibody; p. an IgG2 antibody; q. an IgG3
antibody; and r. an IgG4 antibody.
18. The method of claim 14, wherein said antibody is selected from
the group consisting of: a. a human antibody; b. a humanized
antibody; c. a chimeric antibody; d. a monoclonal antibody; e. an
antigen-binding antibody fragment; f. a single chain antibody; g. a
Fab fragment; h. a F(ab')2 fragment; i. an IgG1 antibody; and j. an
IgG2 antibody.
19. The method of claim 14, wherein said antibody is a human
antibody.
20. The method of claim 14, wherein said antibody is a monoclonal
antibody.
21. The method of claim 14, wherein said antibody is a human
monoclonal antibody.
22. The method of claim 14, wherein said antibody is a human IgG2
monoclonal antibody.
Description
FIELD OF THE INVENTION
The present invention relates to IL-17 Receptor A (IL-17RA or
IL-17R) antibodies and methods for using said antibodies for
diagnosing and treating diseases mediated by IL-17 Receptor A
activation by one or more IL-17 ligands.
BACKGROUND
IL-17A is an inflammatory cytokine initially identified as a
transcript selectively expressed by activated T cells. IL-17RA is a
ubiquitously expressed and shown to bind IL-17A with an affinity of
approximately 0.5 nM (Yao et al., 1995, Immunity 3:811-821). Five
additional IL-17-like ligands (IL-17.beta.-IL-17F) and four
additional IL-17RA-like receptors (IL-17RB-IL-17RE) have been
identified (Kolls and Linden, 2004, Immunity 21:467-476).
IL-17RC has been shown to bind IL-17A and IL-17F. The observations
that IL-17RA deficiency and IL-17RA antibody neutralization ablate
both IL-17A and IL-17F function suggest that IL-17RC cannot deliver
an IL-17A or IL-17F signal in the absence of IL-17RA (Toy et al.,
2006, J. Immunol. 177:36-39; McAllister et al., 2005, J. Immunol.
175:404-412). Additionally, forced expression of IL-17RC in IL-17RA
deficient cells does not restore IL-17A or IL-17F function (Toy et
al., 2006, J. Immunol. 177:36-39).
IL-17A and IL-17F are predominantly expressed by activated
CD4.sup.+ memory T cells (Kolls and Linden, 2004, supra). It has
been proposed that an IL-17A-producing pathogenic CD4+ T cell
subset, ThIL-17, is expanded in the presence of IL-23 (Langrish et
al., 2005, J. Exp. Med. 201:233-240). Additionally, both IL-15 and
the TNF superfamily member OX40L have been shown to induce the
expression of IL-17A (Nakae et al., 2003b, Proc. Natl. Acad. Sci.
U.S.A. 100:5986-5990; Ziolkowska et al., 2000, J. Immunol.
164:2832-2838). IL-6 and TGF-beta also induce the expression of
IL-17A.
IL-17A and IL-17F bind and activate IL-17RA. IL-17RA has been shown
to be important in regulating immune responses. Activation of the
IL-17RA leads to production of cytokines, chemokines, growth
factors, and other proteins that contribute to the symptoms and/or
pathology of numerous diseases. IL-17A is an inflammatory cytokine
that induces the production of cytokines and other mediators
leading to diseases and physiological effects such as inflammation,
cartilage degradation, and bone resorption. IL-17A also plays a
role in a number of inflammatory conditions including arthritis
(rheumatoid arthritis), psoriasis, inflammatory bowel disease,
multiple sclerosis, and asthma. (Li et al., 2004, Huazhong Univ.
Sci. Technolog. Med. Sci. 24:294-296; Fujino et al., 2003, Gut.
52:65-70; Kauffman et al., 2004, J. Invest. Dermatol.
123:1037-1044; Mannon et al., 2004, N. Engl. J. Med. 351:2069-2079;
Matusevicius et al., 1999, Mult Scler 5, 101-104; Linden et al.,
Eur Respir J. 2000 May; 15(5):973-7; Molet et al., 2001, J. Allergy
Clin. Immunol. 108:430-438). Recent studies have suggested that
IL-17F plays a role in the induction of inflammatory responses (Oda
et al., 2006, American J. Resp. Crit. Care Medicine, Jan. 15, 2006;
Numasaki et al., 2004, Immunol Lett. 95:97-104).
Aspects of the invention provide for the treatment of disease using
antibodies that specifically bind IL-17RA and inhibit IL-17RA
activation mediated by IL-17 family members
BRIEF DESCRIPTION OF THE DRAWINGS
FIG. 1 shows that the mean clinical scores of IL-17RA-/- mice
(knockout mice or KO mice) are much lower than that of wild-type
(WT) mice in a CIA model of arthritis.
FIG. 2 shows the delay in experimental autoimmune encephalomyelitis
(EAE) onset for IL-17RA knockout mice compared to wild-type mice in
a myelin oligodendrocyte glycoprotein (MOG)-induced model.
FIG. 3 shows reduced clinical scores in IL-17RA knockout mice as
compared to wild-type mice in a MOG-induced model.
FIG. 4 shows IL-17RA knockout mice have reduced total numbers of
inflammatory cells in BAL fluid compared to wild-type in an
ovalbumin-induced model of asthma.
FIG. 5 shows IL-17RA knockout mice have reduced numbers of
cosinophils (FIG. 5A), neutrophils (FIG. 5B) and lymphocytes (FIG.
5C) in bronchoalveolar lavage (BAL) fluid as compared to wild-type
mice in an ovalbumin-induced model of asthma. FIG. 5D shows no
changes in BAL fluid macrophage observed in either WT or IL-17RA
knockout mice (naive and OVA challenged).
FIG. 6 shows dose-dependent inhibition by an IL-17RA mAb in a
wild-type (WT) collagen-induced arthritis (CIA) model. A P<0.05
was seen when comparing IL-17RA mAb at 100 .mu.g and 300 .mu.g
treatment groups versus control treatment group (days 13, 15 and
16).
FIG. 7 shows the results of therapeutic treatment with IL-17RA mAb.
The data shows stabilized mean clinical scores in wild-type mice in
a standard CIA model of arthritis. These data demonstrate that
IL-17RA inhibition by an IL-17RA antigen binding protein may be
therapeutically useful in treating rheumatoid arthritis (RA),
especially in the preservation of joint bone and cartilage.
FIG. 8 shows that therapeutic treatment with anti-IL-17RA mAb
stabilized mean clinical scores in TNFR p55/p75 knockout mice in a
standard CIA model of arthritis. These data show that IL-17RA
inhibition by an IL-17RA antigen binding protein may be
therapeutically useful in treating RA, especially in the
preservation of joint bone and cartilage. Notably, IL-17RA
inhibition was able to stabilize disease in a model independent of
TNF signaling.
FIG. 9 shows exemplary IL-17RA human mAbs (AM.sub.H14/AM.sub.L14,
AM.sub.H22/AM.sub.L22, AM.sub.H19/AM.sub.L19, and
AM.sub.H18/AM.sub.L18) were able to inhibit cynomolgus
IL-17-induced IL-6 production from JTC-12 cells (cynomolgus kidney
cell line). The (----) line depicts the positive control value of
cynomolgus IL-17 in combination with TNF-alpha. The (-.-.-) line
depicts the positive control value of cynomolgus TNF-alpha. The
(....) line depicts the media control value.
FIG. 10 shows sequence variation in the framework regions of SEQ ID
NO:40 (AM.sub.L14) in relation to germline residues and the effect
on IC50 values.
FIG. 11 shows that the two variants having residues returned to
germline (see FIG. 10) had reduced IL-17A inhibitory activity in
relation to AM.sub.H14/AM.sub.L14, indicating that some variation
in the framework regions was tolerated but that some residues may
influence activity. The (----) line indicates the positive control
value of IL-17 stimulation in the absence of antibody
(approximately 4062 pg/ml).
FIG. 12 shows that the two variants having residues returned to
germline (see FIG. 10) had reduced IL-17F (in combination with
TNF-alpha) inhibitory activity in relation to
AM.sub.H14/AM.sub.L14.
DETAILED DESCRIPTION OF THE INVENTION
The section headings used herein are for organizational purposes
only and are not to be construed as limiting the subject matter
described.
Standard techniques may be used for recombinant DNA,
oligonucleotide synthesis, tissue culture and transformation,
protein purification etc. Enzymatic reactions and purification
techniques may be performed according to the manufacturer's
specifications or as commonly accomplished in the art or as
described herein. The following procedures and techniques may be
generally performed according to conventional methods well known in
the art and as described in various general and more specific
references that are cited and discussed throughout the
specification. See, e.g., Sambrook et al., 2001, Molecular Cloning:
A Laboratory Manual, 3.sup.rd ed., Cold Spring Harbor Laboratory
Press, Cold Spring Harbor, N.Y., which is incorporated herein by
reference for any purpose. Unless specific definitions are
provided, the nomenclature used in connection with, and the
laboratory procedures and techniques of, analytical chemistry,
organic chemistry, and medicinal and pharmaceutical chemistry
described herein are those well known and commonly used in the art.
Standard techniques may be used for chemical synthesis, chemical
analyses, pharmaceutical preparation, formulation, and delivery and
treatment of patients.
IL-17A, IL-17F, and IL-17RA
The biologic activities of IL-17A and IL-17F are dependent upon
IL-17RA, as shown herein using both cells and mice that are
genetically deficient in IL-17RA and with neutralizing mAbs
(monoclonal antibodies) directed against IL-17RA (see Examples
below).
"IL-17 receptor A" or "IL-17RA" (interchangeably used herein, as
well as IL-17 receptor and IL-17R to refer to the same receptor) as
used herein is meant the cell surface receptor and receptor
complexes (such as but not limited to IL-17RA-IL-17RC complex),
that bind IL-17A and IL-17F and as a result initiates a signal
transduction pathway within the cell. IL-17RA proteins may also
include variants. IL-17RA proteins may also include fragments, such
as the extracellular domain that don't have all or part of the
transmembrane and/or the intracellular domain, as well as fragments
of the extracellular domain. The cloning, characterization, and
preparation of IL-17RA are described, for example, in U.S. Pat. No.
6,072,033, which is incorporated herein by reference in its
entirety. The amino acid sequence of the human IL-17RA is shown in
SEQ ID NO:430. Soluble forms of huIL-17RA useful in the methods of
the present invention include the extracellular domain or the
mature form lacking the signal peptide or a fragment of the
extracellular domain that retains the capacity to bind IL-17A
and/or IL-17F, or a heteromeric version of IL-17A and/or IL-17F.
Other forms of IL-17RA include muteins and variants that are at
least between 70% and 99% homologous to the native IL-17RA of SEQ
ID NO:430 and as described in U.S. Pat. No. 6,072,033, so long as
the IL-17RA retains the capacity to bind IL-17A and/or IL-17F, or a
heteromeric version of IL-17A and/or IL-17F. The term "IL-17RA"
also includes post-translational modifications of the IL-17RA amino
acid sequence. Post-translational modifications include, but is not
limited to, N- and O-linked glycosylation.
IL-17RA Antigen Binding Proteins
The present invention provides antigen binding proteins that
specifically bind IL-17RA. Embodiments of antigen binding proteins
comprise peptides and/or polypeptides (that optionally include
post-translational modifications) that specifically bind IL-17RA.
Embodiments of antigen binding proteins comprise antibodies and
fragments thereof, as variously defined herein, that specifically
bind IL-17RA. Aspects of the invention include antibodies that
specifically bind to human IL-17RA and inhibit IL-17A and/or IL-17F
from binding and activating IL-17RA, or a heteromeric complex of
IL-17RA and IL-17RC. Aspects of the invention include antibodies
that specifically bind to human IL-17RA and inhibit an
IL-17A/IL-17F heteromer from binding and activating IL-17RA, or a
heteromeric complex of IL-17RA and IL-17RC. Throughout the
specification, when reference is made to inhibiting IL-17A and/or
IL-17F, it is understood that this also includes inhibiting
heteromers of IL-17A and IL-17F. Aspects of the invention include
antibodies that specifically bind to human IL-17RA and partially or
fully inhibit IL-17RA from forming either a homomeric or
heteromeric functional receptor complex, such as, but not limited
to, an IL-17RA-IL-17RC complex. Aspects of the invention include
antibodies that specifically bind to human IL-17RA and partially or
fully inhibit IL-17RA from forming either a homomeric or
heteromeric functional receptor complex, such as, but not limited
to IL-17RA/IL-17RC complex and do not necessarily inhibit IL-17A
and/or IL-17F or an IL-17A/IL-17F heteromer from binding to IL-17RA
or a IL-17RA heteromeric receptor complex.
The antigen binding proteins of the invention specifically bind to
IL-17RA. "Specifically binds" as used herein means that the antigen
binding protein preferentially binds IL-17RA over other proteins.
In some embodiments "specifically binds" means that the IL-17RA
antigen binding proteins have a higher affinity for IL-17RA than
for other proteins. For example, the equilibrium dissociation
constant is <10.sup.-7 to 10.sup.-11 M, or <10.sup.-8 to
<10.sup.-10 M, or <10.sup.-9 to <10.sup.-10 M.
It is understood that when reference is made to the various
embodiments of the IL-17RA antibodies described herein, that it
also encompasses IL-17RA-binding fragments thereof. An
IL-17RA-binding fragment comprises any of the antibody fragments or
domains described herein that retains the ability to specifically
bind to IL-17RA. Said IL-17RA-binding fragments may be in any of
the scaffolds described herein. Said IL-17RA-binding fragments also
have the capacity to inhibit activation of the IL-17RA, as
described throughout the specification.
In embodiments where the IL-17RA antigen binding protein is used
for therapeutic applications, one characteristic of an IL-17RA
antigen binding protein is that it can inhibit binding of IL-17A
and/or IL-17F to IL-17RA and one or more biological activities of,
or mediated by, IL-17RA. Such antibodies are considered
neutralizing antibodies because of their capacity to inhibit IL-17A
and/or IL-17F from binding and causing IL-17RA signaling and/or
biological activity. In this case, an antigen binding protein
specifically binds IL-17RA and inhibits binding of IL-17A and/or
IL-17F to IL-17RA from anywhere between 10 to 100%, such as by at
least about 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33,
34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50,
51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67,
68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84,
85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% or more
(for example by measuring binding in an in vitro competitive
binding assay as described herein). For example, IL-17RA antibodies
may be tested for neutralizing ability by testing them for the
production of IL-6 in human foreskin fibroblast (HFF) assay (see
for example Examples 8 and 9), or any suitable assay known in the
art. Examples, for illustrative purposes only, of additional
biological activity of IL-17RA (e.g., assay readouts) to test for
inhibition of IL-17RA signaling and/or biological activity include
in vitro and/or in vivo measurement of one or more of IL-8, CXCL1,
CXCL2, GM-CSF, G-CSF, M-CSF, IL-1.beta., TNF.alpha., RANK-L, LIF,
PGE2, IL-12, MMPs (such as but not limited to MMP3 and MMP9),
GRO.alpha., NO, and/or C-telopeptide and the like.
Embodiments of antigen binding proteins comprise a scaffold
structure, as variously define herein, with one or more
complementarity determining regions (CDRs). Embodiments of antigen
binding proteins comprise a scaffold structure with one or more
variable domains, either heavy or light. Embodiments include
antibodies that comprise a light chain variable region selected
from the group consisting of AM.sub.L1 through AM.sub.L26 (SEQ ID
NO:27-53, respectively, with AM.sub.L23 having two versions--SEQ ID
NOs:49 and 50) and/or a heavy chain variable region selected from
the group consisting of AM.sub.H1 through AM.sub.H26 (SEQ ID
NO:1-26, respectively), and fragments, derivatives, muteins, and
variants thereof.
Additional examples of scaffolds that are envisioned include:
fibronectin, neocarzinostatin CBM4-2, lipocalins, T-cell receptor,
protein-A domain (protein Z), Im9, TPR proteins, zinc finger
domains, pVIII, avian pancreatic polypeptide, GCN4, WW domain, Src
homology domain 3, PDZ domains, TEM-1 Beta-lactamase, thioredoxin,
staphylococcal nuclease, PHD-finger domains, CL-2, BPTI, APPI,
HPSTI, ecotin, LACI-D1, LDTI, MTI-II, scorpion toxins, insect
defensin-A peptide, EETI-II, Min-23, CBD, PBP, cytochrome b-562,
Ldl receptor domains, gamma-crystallin, ubiquitin, transferring,
and/or C-type lectin-like domains.
Aspects of the invention include antibodies comprising the
following variable domains: AM.sub.L1/AM.sub.H1 (SEQ ID NO:27/SEQ
ID NO: 1), AM.sub.L2/AM.sub.H2 (SEQ ID NO:28/SEQ ID NO:2),
AM.sub.L3/AM.sub.H3 (SEQ ID NO:29/SEQ ID NO:3), AM.sub.L4/AM.sub.H4
(SEQ ID NO:30/SEQ ID NO:4), AM.sub.L5/AM.sub.H5 (SEQ ID NO:31/SEQ
ID NO:5), AM.sub.L6/AM.sub.H6 (SEQ ID NO:32/SEQ ID NO:6),
AM.sub.L7/AM.sub.H7 (SEQ ID NO:33/SEQ ID NO:7), AM.sub.L8/AM.sub.H8
(SEQ ID NO:34/SEQ ID NO:8), AM.sub.L9/AM.sub.H9 (SEQ ID NO:35/SEQ
ID NO:9), AM.sub.L10/AM.sub.H10 (SEQ ID NO:36/SEQ ID NO: 10),
AM.sub.L11/AM.sub.H11 (SEQ ID NO:37/SEQ ID NO:11),
AM.sub.L12/AM.sub.H12 (SEQ ID NO:38/SEQ ID NO:12),
AM.sub.L13/AM.sub.H13 (SEQ ID NO:39/SEQ ID NO:13),
AM.sub.L14/AM.sub.H14 (SEQ ID NO:40/SEQ ID NO:14),
AM.sub.L15/AM.sub.H15 (SEQ ID NO:41/SEQ ID NO:15),
AM.sub.L16/AM.sub.H16 (SEQ ID NO:42/SEQ ID NO:16),
AM.sub.L17/AM.sub.H17 (SEQ ID NO:43/SEQ ID NO:17),
AM.sub.L18/AM.sub.H18 (SEQ ID NO:44/SEQ ID NO:18),
AM.sub.L19/AM.sub.H19 (SEQ ID NO:45/SEQ ID NO:19),
AM.sub.L20/AM.sub.H20 (SEQ ID NO:46/SEQ ID NO:20),
AM.sub.L21/AM.sub.H21 (SEQ ID NO:47/SEQ ID NO:21),
AM.sub.L22/AM.sub.H22 (SEQ ID NO:48/SEQ ID NO:22),
AM.sub.L23/AM.sub.H23 (SEQ ID NO:49 or SEQ ID NO:50/SEQ ID NO:23),
AM.sub.L24/AM.sub.H24 (SEQ ID NO:51/SEQ ID NO:24),
AM.sub.L25/AM.sub.H25 (SEQ ID NO:52/SEQ ID NO:25),
AM.sub.L26/AM.sub.H26 (SEQ ID NO:53/SEQ ID NO:26), and combinations
thereof.
In a further embodiment, a first amino acid sequence comprises
CDR3, CDR2, and CDR1, and a second amino acid sequence comprises a
CDR3, CDR2, and CDR1 of TABLE 1.
In another embodiment, the antigen binding protein comprises: A) a
heavy chain amino acid sequence that comprises at least one H-CDR1,
H-CDR2, or H-CDR3 of a sequence selected from the group consisting
of SEQ ID NO:1-26; and/or B) a light chain amino acid sequence that
comprises at least one L-CDR1, L-CDR2, or L-CDR3 of a sequence
selected from the group consisting of SEQ ID NO:27-53.
In a further variation, the antigen binding protein comprises A) a
heavy chain amino acid sequence that comprises a H-CDR1, a H-CDR2,
and a H-CDR3 of any of SEQ ID NO:1-26, and B) a light chain amino
acid sequence that comprises a L-CDR1, a L-CDR2, and a L-CDR3 of
any of SEQ ID NO:27-53. In another variation, the antigen binding
protein comprises an amino acid sequence that is of at least 80%,
81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,
94%, 95%, 96%, 97%, 98%, or 99% identical to a heavy chain amino
acid sequence selected from the group consisting of SEQ ID NO:1-26
or a light chain amino acid sequence selected from the group
consisting of SEQ ID NO:27-53.
In certain embodiments, the CDRs include no more than one, two,
three, four, five, or six amino acid additions, deletions, or
substitutions from a H-CDR1 (i.e., CDR1 of the heavy chain, etc.),
H-CDR2, H-CDR3, L-CDR1 (i.e., CDR1 of the light chain, etc.),
L-CDR2, and L-CDR3. See Table 1.
Aspects of the invention include antibodies comprising a heavy
chain variable region selected from the group consisting of SEQ ID
NO:1-26. Aspects of the invention include antibodies comprising a
light chain variable region selected from the group consisting of
SEQ ID NO:27-53. Aspects of the invention include antibodies
comprising a heavy chain variable region selected from the group
consisting of SEQ ID NO:1-26 having no more than one, two, three,
four, five, or six amino acid additions, deletions, or
substitutions. Aspects of the invention include antibodies
comprising a light chain variable region selected from the group
consisting of SEQ ID NO:27-53 having no more than one, two, three,
four, five, or six amino acid additions, deletions, or
substitutions. Aspects of the invention include antibodies
comprising a heavy chain variable region selected from the group
consisting of SEQ ID NO:1-26 having no more than one, two, three,
four, five, or six amino acid additions, deletions, or
substitutions and a light chain variable region selected from the
group consisting of SEQ ID NO:27-53 having no more than one, two,
three, four, five, or six amino acid additions, deletions, or
substitutions.
In other embodiments, the heavy and light chain variable domains of
the antigen binding proteins are defined by having a certain
percent identity to a reference heavy and/or light chain variable
domain. For example, the antigen binding protein comprises A) a
heavy chain variable domain amino acid that is at least 80%, 81%,
82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%,
95%, 96%, 97%, 98%, or 99% identical to a heavy chain amino acid
sequence selected from the group consisting of SEQ ID NO:1-26; and
B) a light chain variable domain amino acid that is at least 80%,
81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,
94%, 95%, 96%, 97%, 98%, or 99% identical to a light chain amino
acid sequence selected from the group consisting of SEQ ID
NOs:27-53.
As a general structure, the antigen binding proteins of the
invention comprise (a) a scaffold, and (b) one or a plurality of
CDRs. A "complementary determining region" or "CDR," as used
herein, refers to a binding protein region that constitutes the
major surface contact points for antigen binding. Embodiments of
the invention include one or more CDRs embedded in a scaffold
structure of the antigen binding protein. The scaffold structure of
the antigen binding proteins may be the framework of an antibody,
or fragment or variant thereof, or may be completely synthetic in
nature. Examples of various scaffold structures of the antigen
binding proteins of the invention are further described
hereinbelow.
The antigen binding proteins of the invention include scaffold
regions and one or more CDRs. An antigen binding protein of the
invention may have between one and six CDRs (as typically do
naturally occurring antibodies), for example, one heavy chain CDR1
("H-CDR1"), and/or one heavy chain CDR2 ("H-CDR2"), and/or one
heavy chain CDR3 ("H-CDR3"), and/or one light chain CDR1
("L-CDR1"), and/or one light chain CDR2 ("L-CDR2"), and/or one
light chain CDR3 ("L-CDR3").
The term "naturally occurring" as used throughout the specification
in connection with biological materials such as peptides,
polypeptides, nucleic acids, host cells, and the like, refers to
materials which are found in nature. In naturally occurring
antibodies, a H-CDR1 typically comprises about five (5) to about
seven (7) amino acids, H-CDR2 typically comprises about sixteen
(16) to about nineteen (19) amino acids, and H-CDR3 typically
comprises about three (3) to about twenty five (25) amino acids.
L-CDR1 typically comprises about ten (10) to about seventeen (17)
amino acids, L-CDR2 typically comprises about seven (7) amino
acids, and L-CDR3 typically comprises about seven (7) to about ten
(10) amino acids. Specific CDRs of the various antibodies of the
invention are provided in TABLE 1 and the Sequence Listing.
TABLE-US-00001 TABLE 1 Corresponding Polynucleotide Sequence Amino
acid SEQ ID NYYWN SEQ ID NO: 266 sequence of NO: 107 CDR 1 of
AM.sub.H1 Vh Amino acid SEQ ID DIYYSGSTNYNPS SEQ ID NO: 267
sequence of NO: 108 LKS CDR 2 of AM.sub.H1 Vh Amino acid SEQ ID
DGELANYYGSGS SEQ ID NO: 268 sequence of NO: 109 YQFYYYYGMDV CDR 3
of AM.sub.H1 Vh Amino acid SEQ ID GYYWS SEQ ID NO: 269 sequence of
NO: 110 CDR 1 of AM.sub.H2 Vh Amino acid SEQ ID EINHSGRTNYNPS SEQ
ID NO: 270 sequence of NO: 111 LKS CDR 2 of AM.sub.H2 Vh Amino acid
SEQ ID GPYYFDSSGYLYY SEQ ID NO: 271 sequence of NO: 112 YYGLDV CDR
3 of AM.sub.H2 Vh Amino acid SEQ ID SYGMH SEQ ID NO: 272 sequence
of NO: 113 CDR 1 of AM.sub.H3 Vh Amino acid SEQ ID VIWYDGSNKHYA SEQ
ID NO: 273 sequence of NO: 114 DSVKG CDR 2 of AM.sub.H3 Vh Amino
acid SEQ ID DTGVY SEQ ID NO: 274 sequence of NO: 115 CDR 3 of
AM.sub.H3 Vh Amino acid SEQ ID SYGMH SEQ ID NO: 275 sequence of NO:
116 CDR 1 of AM.sub.H4 Vh Amino acid SEQ ID VIWYDGSNKHYA SEQ ID NO:
276 sequence of NO: 117 DSVKG CDR 2 of AM.sub.H4 Vh Amino acid SEQ
ID DTGVY SEQ ID NO: 277 sequence of NO: 118 CDR 3 of AM.sub.H4 Vh
Amino acid SEQ ID SYYWS SEQ ID NO: 278 sequence of NO: 119 CDR 1 of
AM.sub.H5 Vh Amino acid SEQ ID RIYRSGNTIYNPSL SEQ ID NO: 279
sequence of NO: 120 KS CDR 2 of AM.sub.H5 Vh Amino acid SEQ ID
ENYSESSGLYYYY SEQ ID NO: 280 sequence of NO: 121 GMDV CDR 3 of
AM.sub.H5 Vh Amino acid SEQ ID RYGIS SEQ ID NO: 281 sequence of NO:
122 CDR 1 of AM.sub.H6 Vh Amino acid SEQ ID WISAYNGNTNYA SEQ ID NO:
282 sequence of NO: 123 QKLQG CDR 2 of AM.sub.H6 Vh Amino acid SEQ
ID RDYDILTGYYNGF SEQ ID NO: 283 sequence of NO: 124 DP CDR 3 of
AM.sub.H6 Vh Amino acid SEQ ID RYGIS SEQ ID NO: 284 sequence of NO:
125 CDR 1 of AM.sub.H7 Vh Amino acid SEQ ID WISAYNGNTNYA SEQ ID NO:
285 sequence of NO: 126 QKLQG CDR 2 of AM.sub.H7 Vh Amino acid SEQ
ID RDYDILTGYYNGF SEQ ID NO: 286 sequence of NO: 127 DP CDR 3 of
AM.sub.H7 Vh Amino acid SEQ ID GYGIS SEQ ID NO: 287 sequence of NO:
128 CDR 1 of AM.sub.H8 Vh Amino acid SEQ ID WISAYNGNTNYA SEQ ID NO:
288 sequence of NO: 129 QNLQG CDR 2 of AM.sub.H8 Vh Amino acid SEQ
ID RDYDILTGYYNGF SEQ ID NO: 289 sequence of NO: 130 DP CDR 3 of
AM.sub.H8 Vh Amino acid SEQ ID RYGIS SEQ ID NO: 290 sequence of NO:
131 CDR 1 of AM.sub.H9 Vh Amino acid SEQ ID WISAYNGNTNYA SEQ ID NO:
291 sequence of NO: 132 QKLQG CDR 2 of AM.sub.H9 Vh Amino acid SEQ
ID RDYDILTGYYNGF SEQ ID NO: 292 sequence of NO: 133 DP CDR 3 of
AM.sub.H9 Vh Amino acid SEQ ID SGGYYWS SEQ ID NO: 293 sequence of
NO: 134 CDR 1 of AM.sub.H10 Vh Amino acid SEQ ID YIYFSGSAYYNPS SEQ
ID NO: 294 sequence of NO: 135 LKS CDR 2 of AM.sub.H10 Vh Amino
acid SEQ ID EYYDSSGYPDAFD SEQ ID NO: 295 sequence of NO: 136 I CDR
3 of AM.sub.H10 Vh Amino acid SEQ ID SYGMH SEQ ID NO: 296 sequence
of NO: 137 CDR 1 of AM.sub.H11 Vh Amino acid SEQ ID VIWYDGSNKYYA
SEQ ID NO: 297 sequence of NO: 138 DSVKG CDR 2 of AM.sub.H11 Vh
Amino acid SEQ ID DTKDY SEQ ID NO: 298 sequence of NO: 139 CDR 3 of
AM.sub.H11 Vh Amino acid SEQ ID SYGIS SEQ ID NO: 299 sequence of
NO: 140 CDR 1 of AM.sub.H12 Vh Amino acid SEQ ID WISTYKGNTNYA SEQ
ID NO: 300 sequence of NO: 141 QKLQG CDR 2 of AM.sub.H12 Vh Amino
acid SEQ ID KQLVFDY SEQ ID NO: 301 sequence of NO: 142 CDR 3 of
AM.sub.H12 Vh Amino acid SEQ ID SYGMQ SEQ ID NO: 302 sequence of
NO: 143 CDR 1 of AM.sub.H13 Vh Amino acid SEQ ID VIWYDGNKKYYA SEQ
ID NO: 303 sequence of NO: 144 DSVKG CDR 2 of AM.sub.H13 Vh Amino
acid SEQ ID GRVRDYYYGMD SEQ ID NO: 304 sequence of NO: 145 V CDR 3
of AM.sub.H13 Vh Amino acid SEQ ID RYGIS SEQ ID NO: 305 sequence of
NO: 146 CDR 1 of AM.sub.H14 Vh Amino acid SEQ ID WISTYSGNTNYA SEQ
ID NO: 306 sequence of NO: 147 QKLQG CDR 2 of AM.sub.H14 Vh Amino
acid SEQ ID RQLYFDY SEQ ID NO: 307 sequence of NO: 148 CDR 3 of
AM.sub.H14 Vh Amino acid SEQ ID SYGMQ SEQ ID NO: 308 sequence of
NO: 149 CDR 1 of AM.sub.H15 Vh Amino acid SEQ ID VIWYDGNKKYYA SEQ
ID NO: 309 sequence of NO: 150 DSVKG CDR 2 of AM.sub.H15 Vh Amino
acid SEQ ID GRVRDYYYGMD SEQ ID NO: 310 sequence of NO: 151 V CDR 3
of AM.sub.H15 Vh Amino acid SEQ ID SYGIS SEQ ID NO: 311 sequence of
NO: 152 CDR 1 of AM.sub.H16 Vh Amino acid SEQ ID WISAYNGNTKYA SEQ
ID NO: 312 sequence of NO: 153 QKLQG CDR 2 of AM.sub.H16 Vh Amino
acid SEQ ID KQLVFDY SEQ ID NO: 313 sequence of NO: 154 CDR 3 of
AM.sub.H16 Vh Amino acid SEQ ID SYGIS SEQ ID NO: 314 sequence of
NO: 155 CDR 1 of
AM.sub.H17 Vh Amino acid SEQ ID WISAYSGNTKYA SEQ ID NO: 315
sequence of NO: 156 QKLQG CDR 2 of AM.sub.H17 Vh Amino acid SEQ ID
KQLVFDY SEQ ID NO: 316 sequence of NO: 157 CDR 3 of AM.sub.H17 Vh
Amino acid SEQ ID DYYMH SEQ ID NO: 317 sequence of NO: 158 CDR 1 of
AM.sub.H18 Vh Amino acid SEQ ID WMHPNSGGTDLA SEQ ID NO: 318
sequence of NO: 159 QRFQG CDR 2 of AM.sub.H18 Vh Amino acid SEQ ID
GGYCSTLSCSFYW SEQ ID NO: 319 sequence of NO: 160 YFDL CDR 3 of
AM.sub.H18 Vh Amino acid SEQ ID SYGIS SEQ ID NO: 320 sequence of
NO: 161 CDR 1 of AM.sub.H19 Vh Amino acid SEQ ID WISAYSGNTKYA SEQ
ID NO: 321 sequence of NO: 162 QKFQG CDR 2 of AM.sub.H19 Vh Amino
acid SEQ ID RQLALDY SEQ ID NO: 322 sequence of NO: 163 CDR 3 of
AM.sub.H19 Vh Amino acid SEQ ID SYSMN SEQ ID NO: 323 sequence of
NO: 164 CDR 1 of AM.sub.H20 Vh Amino acid SEQ ID FISARSSTIYYADS SEQ
ID NO: 324 sequence of NO: 165 VKG CDR 2 of AM.sub.H20 Vh Amino
acid SEQ ID PKVGGGMDV SEQ ID NO: 325 sequence of NO: 166 CDR 3 of
AM.sub.H20 Vh Amino acid SEQ ID SYSMN SEQ ID NO: 326 sequence of
NO: 167 CDR 1 of AM.sub.H21 Vh Amino acid SEQ ID IISSRSSIIHYADSV
SEQ ID NO: 327 sequence of NO: 168 KG CDR 2 of AM.sub.H21 Vh Amino
acid SEQ ID PKVGGGMDV SEQ ID NO: 328 sequence of NO: 169 CDR 3 of
AM.sub.H21 Vh Amino acid SEQ ID RYGIS SEQ ID NO: 329 sequence of
NO: 170 CDR 1 of AM.sub.H22 Vh Amino acid SEQ ID WISAYSGNTNYA SEQ
ID NO: 330 sequence of NO: 171 QKLQG CDR 2 of AM.sub.H22 Vh Amino
acid SEQ ID RQLYFDY SEQ ID NO: 331 sequence of NO: 172 CDR 3 of
AM.sub.H22 Vh Amino acid SEQ ID SYYWS SEQ ID NO: 332 sequence of
NO: 173 CDR 1 of AM.sub.H23 Vh Amino acid SEQ ID RIYPSGRTNYNPS SEQ
ID NO: 333 sequence of NO: 174 LKS CDR 2 of AM.sub.H23 Vh Amino
acid SEQ ID EAYELQLGLYYY SEQ ID NO: 334 sequence of NO: 175 YGMDV
CDR 3 of AM.sub.H23 Vh Amino acid SEQ ID SYYWS SEQ ID NO: 335
sequence of NO: 176 CDR 1 of AM.sub.H24 Vh Amino acid SEQ ID
RIYPSGRTNYNPS SEQ ID NO: 336 sequence of NO: 177 LKS CDR 2 of
AM.sub.H24 Vh Amino acid SEQ ID EAYELQLGLYYY SEQ ID NO: 337
sequence of NO: 178 YGMDV CDR 3 of AM.sub.H24 Vh Amino acid SEQ ID
SGGYYWS SEQ ID NO: 338 sequence of NO: 179 CDR 1 of AM.sub.H25 Vh
Amino acid SEQ ID YSGNTYYNPSLRS SEQ ID NO: 339 sequence of NO: 180
CDR 2 of AM.sub.H25 Vh Amino acid SEQ ID EAGGNSAYYYGM SEQ ID NO:
340 sequence of NO: 181 DV CDR 3 of AM.sub.H25 Vh Amino acid SEQ ID
DYYMS SEQ ID NO: 341 sequence of NO: 182 CDR 1 of AM.sub.H26 Vh
Amino acid SEQ ID YISSSGSTIYYADS SEQ ID NO: 342 sequence of NO: 183
VKG CDR 2 of AM.sub.H26 Vh Amino acid SEQ ID DRTYYFGSGSYEG SEQ ID
NO: 343 sequence of NO: 184 MDV CDR 3 of AM.sub.H26 Vh Amino acid
SEQ ID RASQGIRNDLG SEQ ID NO: 345 sequence of NO: 185 CDR 1 of
AM.sub.L1 Vl Amino acid SEQ ID AASSLQS SEQ ID NO: 346 sequence of
NO: 186 CDR 2 of AM.sub.L1 Vl Amino acid SEQ ID LQHNSNPFT SEQ ID
NO: 347 sequence of NO: 187 CDR 3 of AM.sub.L1 Vl Amino acid SEQ ID
RASQSVSRNLV SEQ ID NO: 348 sequence of NO: 188 CDR 1 of AM.sub.L2
Vl Amino acid SEQ ID GASTRAN SEQ ID NO: 349 sequence of NO: 189 CDR
2 of AM.sub.L2 Vl Amino acid SEQ ID QQYKSWRT SEQ ID NO: 350
sequence of NO: 190 CDR 3 of AM.sub.L2 Vl Amino acid SEQ ID
RASQSISSYLN SEQ ID NO: 351 sequence of NO: 191 CDR 1 of AM.sub.L3
Vl Amino acid SEQ ID AASSLQS SEQ ID NO: 352 sequence of NO: 192 CDR
2 of AM.sub.L3 Vl Amino acid SEQ ID QQSYSTPFT SEQ ID NO: 353
sequence of NO: 193 CDR 3 of AM.sub.L3 Vl Amino acid SEQ ID
RASQSVSRNLA SEQ ID NO: 354 sequence of NO: 194 CDR 1 of AM.sub.L4
Vl Amino acid SEQ ID GASTRAT SEQ ID NO: 355 sequence of NO: 195 CDR
2 of AM.sub.L4 Vl Amino acid SEQ ID QQYNNWPTWT SEQ ID NO: 356
sequence of NO: 196 CDR 3 of AM.sub.L4 Vl Amino acid SEQ ID
RASQGIRNDLG SEQ ID NO: 357 sequence of NO: 197 CDR 1 of AM.sub.L5
Vl Amino acid SEQ ID AASSFQS SEQ ID NO: 358 sequence of NO: 198 CDR
2 of AM.sub.L5 Vl Amino acid SEQ ID LQHNSYPPT SEQ ID NO: 359
sequence of NO: 199 CDR 3 of AM.sub.L5 Vl Amino acid SEQ ID
RASQGIRNDLG SEQ ID NO: 360 sequence of NO: 200 CDR 1 of AM.sub.L6
Vl Amino acid SEQ ID AASSLQS SEQ ID NO: 361 sequence of NO: 201 CDR
2 of AM.sub.L6 Vl Amino acid SEQ ID LQHKSYPLT SEQ ID NO: 362
sequence of NO: 202 CDR 3 of AM.sub.L6 Vl Amino acid SEQ ID
RASQGIRNDLG SEQ ID NO: 363 sequence of NO: 203 CDR 1 of AM.sub.L7
Vl Amino acid SEQ ID AASSLQS SEQ ID NO: 364 sequence of NO: 204 CDR
2 of AM.sub.L7 Vl Amino acid SEQ ID LQHKSYPLT SEQ ID NO: 365
sequence of NO: 205 CDR 3 of AM.sub.L7 Vl
Amino acid SEQ ID RASQGIRNDLG SEQ ID NO: 366 sequence of NO: 206
CDR 1 of AM.sub.L8 Vl Amino acid SEQ ID AASSLQS SEQ ID NO: 367
sequence of NO: 207 CDR 2 of AM.sub.L8 Vl Amino acid SEQ ID
LQHKSYPLT SEQ ID NO: 368 sequence of NO: 208 CDR 3 of AM.sub.L8 Vl
Amino acid SEQ ID RASQGIRNDLG SEQ ID NO: 369 sequence of NO: 209
CDR 1 of AM.sub.L9 Vl Amino acid SEQ ID AASSLQS SEQ ID NO: 370
sequence of NO: 210 CDR 2 of AM.sub.L9 Vl Amino acid SEQ ID
LQHKSYPLT SEQ ID NO: 371 sequence of NO: 211 CDR 3 of AM.sub.L9 Vl
Amino acid SEQ ID RASQGIRSWLA SEQ ID NO: 372 sequence of NO: 212
CDR 1 of AM.sub.L10 Vl Amino acid SEQ ID AASSLQS SEQ ID NO: 373
sequence of NO: 213 CDR 2 of AM.sub.L10 Vl Amino acid SEQ ID
QQANNFPRT SEQ ID NO: 374 sequence of NO: 214 CDR 3 of AM.sub.L10 Vl
Amino acid SEQ ID RASQSVSSNLA SEQ ID NO: 375 sequence of NO: 215
CDR 1 of AM.sub.L11 Vl Amino acid SEQ ID GASTRAA SEQ ID NO: 376
sequence of NO: 216 CDR 2 of AM.sub.L11 Vl Amino acid SEQ ID
QHYINWPKWT SEQ ID NO: 377 sequence of NO: 217 CDR 3 of AM.sub.L11
Vl Amino acid SEQ ID RASQSISSSLA SEQ ID NO: 378 sequence of NO: 218
CDR 1 of AM.sub.L12 Vl Amino acid SEQ ID GASTRAT SEQ ID NO: 379
sequence of NO: 219 CDR 2 of AM.sub.L12 Vl Amino acid SEQ ID
QQYDNWPLT SEQ ID NO: 380 sequence of NO: 220 CDR 3 of AM.sub.L12 Vl
Amino acid SEQ ID KSSQSLLHSDGKT SEQ ID NO: 381 sequence of NO: 221
YLY CDR 1 of AM.sub.L13 Vl Amino acid SEQ ID EVSTRFS SEQ ID NO: 382
sequence of NO: 222 CDR 2 of AM.sub.L13 Vl Amino acid SEQ ID
MQSIQLPLT SEQ ID NO: 383 sequence of NO: 223 CDR 3 of AM.sub.L13 Vl
Amino acid SEQ ID RASQSVSSNLA SEQ ID NO: 384 sequence of NO: 224
CDR 1 of AM.sub.L14 Vl Amino acid SEQ ID DASTRAT SEQ ID NO: 385
sequence of NO: 225 CDR 2 of AM.sub.L14 Vl Amino acid SEQ ID
QQYDNWPLT SEQ ID NO: 386 sequence of NO: 226 CDR 3 of AM.sub.L14 Vl
Amino acid SEQ ID RASQSVSSNLA SEQ ID NO: 387 sequence of NO: 227
CDR 1 of AM.sub.L15 Vl Amino acid SEQ ID DASTRAA SEQ ID NO: 388
sequence of NO: 228 CDR 2 of AM.sub.L15 Vl Amino acid SEQ ID
QQYDNWPLT SEQ ID NO: 389 sequence of NO: 229 CDR 3 of AM.sub.L15 Vl
Amino acid SEQ ID RASQSISTSLA SEQ ID NO: 390 sequence of NO: 230
CDR 1 of AM.sub.L16 Vl Amino acid SEQ ID GTSTRAT SEQ ID NO: 391
sequence of NO: 231 CDR 2 of AM.sub.L16 Vl Amino acid SEQ ID
QQYDIWPLT SEQ ID NO: 392 sequence of NO: 232 CDR 3 of AM.sub.L16 Vl
Amino acid SEQ ID RASQSVSSNLA SEQ ID NO: 393 sequence of NO: 233
CDR 1 of AM.sub.L17 Vl Amino acid SEQ ID GASTRAT SEQ ID NO: 394
sequence of NO: 234 CDR 2 of AM.sub.L17 Vl Amino acid SEQ ID
QQYDNWPLT SEQ ID NO: 395 sequence of NO: 235 CDR 3 of AM.sub.L17 Vl
Amino acid SEQ ID KTSQSVLYSSKNK SEQ ID NO: 396 sequence of NO: 236
NFLA CDR 1 of AM.sub.L18 Vl Amino acid SEQ ID WASTRES SEQ ID NO:
397 sequence of NO: 237 CDR 2 of AM.sub.L18 Vl Amino acid SEQ ID
QQYYSTPFT SEQ ID NO: 398 sequence of NO: 238 CDR 3 of AM.sub.L18 Vl
Amino acid SEQ ID RASQSISSNLA SEQ ID NO: 399 sequence of NO: 239
CDR 1 of AM.sub.L19 Vl Amino acid SEQ ID GASTRAT SEQ ID NO: 400
sequence of NO: 240 CDR 2 of AM.sub.L19 Vl Amino acid SEQ ID
QQYDTWPLT SEQ ID NO: 401 sequence of NO: 241 CDR 3 of AM.sub.L19 Vl
Amino acid SEQ ID RASQGISNYLA SEQ ID NO: 402 sequence of NO: 242
CDR 1 of AM.sub.L20 Vl Amino acid SEQ ID AASTLQS SEQ ID NO: 403
sequence of NO: 243 CDR 2 of AM.sub.L20 Vl Amino acid SEQ ID
QKYNRAPFT SEQ ID NO: 404 sequence of NO: 244 CDR 3 of AM.sub.L20 Vl
Amino acid SEQ ID RASQGISNYLA SEQ ID NO: 405 sequence of NO: 245
CDR 1 of AM.sub.L21 Vl Amino acid SEQ ID AASTLQS SEQ ID NO: 406
sequence of NO: 246 CDR 2 of AM.sub.L21 Vl Amino acid SEQ ID
QKYNRAPFT SEQ ID NO: 407 sequence of NO: 247 CDR 3 of AM.sub.L21 Vl
Amino acid SEQ ID RASQSVSSNLA SEQ ID NO: 408 sequence of NO: 248
CDR 1 of AM.sub.L22 Vl Amino acid SEQ ID DASTRAA SEQ ID NO: 409
sequence of NO: 249 CDR 2 of AM.sub.L22 Vl Amino acid SEQ ID
QQYDNWPLT SEQ ID NO: 410 sequence of NO: 250 CDR 3 of AM.sub.L22 Vl
Amino acid SEQ ID RASQGIINDLG SEQ ID NO: 411 sequence of NO: 251
CDR 1 of AM.sub.L23 Vl version 1 Amino acid SEQ ID AASSLQS SEQ ID
NO: 412 sequence of NO: 252 CDR 2 of AM.sub.L23 Vl version 1 Amino
acid SEQ ID LQHNSYPPT SEQ ID NO: 413 sequence of NO: 253 CDR 3 of
AM.sub.L23 Vl version 1 Amino acid SEQ ID RSSQSLVYSDGHT SEQ ID NO:
414 sequence of NO: 254 CLN CDR 1 of AM.sub.L23 Vl version 2 Aminoa
cid SEQ ID KVSNWDS SEQ ID NO: 415
sequence of NO: 255 CDR 2 of AM.sub.L23 Vl version 2 Amino acid SEQ
ID MQGTHWPLCS SEQ ID NO: 416 sequence of NO: 256 CDR 3 of
AM.sub.L23 Vl version 2 Amino acid SEQ ID RSSQSLVYSDGHT SEQ ID NO:
417 sequence of NO: 257 CLN CDR 1 of AM.sub.L24 Vl Amino acid SEQ
ID KVSNWDS SEQ ID NO: 418 sequence of NO: 258 CDR 2 of AM.sub.L24
Vl Amino acid SEQ ID MQGTHWPLCS SEQ ID NO: 419 sequence of NO: 259
CDR 3 of AM.sub.L24 Vl Amino acid SEQ ID RASQAISIYLA SEQ ID NO: 420
sequence of NO: 260 CDR 1 of AM.sub.L25 Vl Amino acid SEQ ID
AASSLQS SEQ ID NO: 421 sequence of NO: 261 CDR 2 of AM.sub.L25 Vl
Amino acid SEQ ID QQYSSYPRT SEQ ID NO: 422 sequence of NO: 262 CDR
3 of AM.sub.L25 Vl Amino acid SEQ ID RASQSVYSNLA SEQ ID NO: 423
sequence of NO: 263 CDR 1 of AM.sub.L26 Vl Amino acid SEQ ID
GASTRAT SEQ ID NO: 424 sequence of NO: 264 CDR 2 of AM.sub.L26 Vl
Amino acid SEQ ID QQYYNWPWT SEQ ID NO: 425 sequence of NO: 265 CDR
3 of AM.sub.L26 Vl
The general structure and properties of CDRs within naturally
occurring antibodies have been described in the art. Briefly, in a
traditional antibody scaffold, the CDRs are embedded within a
framework in the heavy and light chain variable region where they
constitute the regions largely responsible for antigen binding and
recognition. A variable region comprises at least three heavy or
light chain CDRs, see, supra (Kabat et al., 1991, Sequences of
Proteins of Immunological Interest, Public Health Service N.I.H.,
Bethesda, Md.; see also Chothia and Lesk, 1987, J. Mol. Biol.
196:901-917; Chothia et al., 1989, Nature 342: 877-883), within a
framework region (designated framework regions 1-4, FR1, FR2, FR3,
and FR4, by Kabat et al., 1991, supra; see also Chothia and Lesk,
1987, supra). See, infra. The CDRs provided by the present
invention, however, may not only be used to define the antigen
binding domain of a traditional antibody structure, but may be
embedded in a variety of other scaffold structures, as described
herein.
Antibodies of the invention can comprise any constant region known
in the art. The light chain constant region can be, for example, a
kappa- or lambda-type light chain constant region, e.g., a human
kappa- or lambda-type light chain constant region. The heavy chain
constant region can be, for example, an alpha-, delta-, epsilon-,
gamma-, or mu-type heavy chain constant regions, e.g., a human
alpha-, delta-, epsilon-, gamma-, or mu-type heavy chain constant
region. In one embodiment, the light or heavy chain constant region
is a fragment, derivative, variant, or mutein of a naturally
occurring constant region.
The CDRs of the invention also include consensus sequences derived
from groups of related monoclonal antibodies. The antibodies may be
related by both sequence homology and function, as shown in the
Examples. As described herein, a "consensus sequence" refers to
amino acid sequences having conserved amino acids common among a
number of sequences and variable amino acids that vary within given
amino acid sequences. The CDR consensus sequences of the invention
include CDRs corresponding to each of H-CDR1, H-CDR2, H-CDR3,
L-CDR1, L-CDR2 and L-CDR3.
In another embodiment, the invention provides an antigen binding
protein that specifically binds IL-17RA, wherein said antigen
binding protein comprises at least one H-CDR region of any of SEQ
ID NOs:107-184. Other embodiments include antigen binding proteins
that specifically bind to IL-17RA, wherein said antigen binding
protein comprises at least one L-CDR region of any of SEQ ID
NOs:185-265. Other embodiments include antigen binding proteins
that specifically binds IL-17RA, wherein said antigen binding
protein comprises at least one H-CDR region of any of SEQ ID
NOs:107-184 and at least one L-CDR region of any of SEQ ID
NOs:185-265.
In another embodiment, the invention provides an antigen binding
protein that specifically binds IL-17RA, wherein said antigen
binding protein comprises at least one H-CDR region of any of SEQ
ID NOs:107-184. Other embodiments include antigen binding proteins
that specifically bind to IL-17RA, wherein said antigen binding
protein comprises at least one L-CDR region of any of SEQ ID
NOs:185-265. Other embodiments include antigen binding proteins
that specifically binds IL-17RA, wherein said antigen binding
protein comprises at least one H-CDR region of any of SEQ ID
NOs:107-184 and at least one L-CDR region of any of SEQ ID
NOs:185-265.
In another embodiment, the invention provides an antigen binding
protein that specifically binds IL-17RA, wherein said antigen
binding protein comprises at least three H-CDR regions of any of
SEQ ID NOs:107-184. Other embodiments include antigen binding
proteins that specifically bind to IL-17RA, wherein said antigen
binding protein comprises at least three L-CDR region of any of SEQ
ID NOs:185-265. Other embodiments include antigen binding proteins
that specifically binds IL-17RA, wherein said antigen binding
protein comprises at least three H-CDR region of any of SEQ ID
NOs:107-184 and at least three L-CDR region of any of SEQ ID
NOs:185-265.
In another embodiment, the invention provides an antigen binding
protein that specifically binds IL-17RA, wherein said antigen
binding protein comprises a light chain CDR1 (SEQ ID NO:185), CDR2
(SEQ ID NO:186), CDR3 (SEQ ID NO:187) and heavy chain CDR1 (SEQ ID
NO:107), CDR2 (SEQ ID NO:108), CDR3 (SEQ ID NO:109) of antibody
AM-1; light chain CDR1 (SEQ ID NO:188), CDR2 (SEQ ID NO:189), CDR3
(SEQ ID NO:190) and heavy chain CDR1 (SEQ ID NO:110), CDR2 (SEQ ID
NO:111), CDR3 (SEQ ID NO:112) of antibody AM-2; light chain CDR1
(SEQ ID NO:191), CDR2 (SEQ ID NO:192), CDR3 (SEQ ID NO:193) and
heavy chain CDR1 (SEQ ID NO:113), CDR2 (SEQ ID NO:114), CDR3 (SEQ
ID NO:115) of antibody AM-3; light chain CDR1 (SEQ ID NO:194), CDR2
(SEQ ID NO:195), CDR3 (SEQ ID NO:196) and heavy chain CDR1 (SEQ ID
NO:116), CDR2 (SEQ ID NO:117), CDR3 (SEQ ID NO:118) of antibody
AM-4; light chain CDR1 (SEQ ID NO:197), CDR2 (SEQ ID NO:198), CDR3
(SEQ ID NO:199) and heavy chain CDR1 (SEQ ID NO:119), CDR2 (SEQ ID
NO:120), CDR3 (SEQ ID NO:121) of antibody AM-5; light chain CDR1
(SEQ ID NO:200), CDR2 (SEQ ID NO:201), CDR3 (SEQ ID NO:202) and
heavy chain CDR1 (SEQ ID NO:122), CDR2 (SEQ ID NO:123), CDR3 (SEQ
ID NO:124) of antibody AM-6; light chain CDR1 (SEQ ID NO:203), CDR2
(SEQ ID NO:204), CDR3 (SEQ ID NO:205) and heavy chain CDR1 (SEQ ID
NO:125), CDR2 (SEQ ID NO: 126), CDR3 (SEQ ID NO:127) of antibody
AM-7; light chain CDR1 (SEQ ID NO:206), CDR2 (SEQ ID NO:207), CDR3
(SEQ ID NO:208) and heavy chain CDR1 (SEQ ID NO:128), CDR2 (SEQ ID
NO:129), CDR3 (SEQ ID NO:130) of antibody AM-8; light chain CDR1
(SEQ ID NO:209), CDR2 (SEQ ID NO:210), CDR3 (SEQ ID NO:211) and
heavy chain CDR1 (SEQ ID NO:131), CDR2 (SEQ ID NO:132), CDR3 (SEQ
ID NO:133) of antibody AM-9; light chain CDR1 (SEQ ID NO:212), CDR2
(SEQ ID NO:213), CDR3 (SEQ ID NO:214) and heavy chain CDR1 (SEQ ID
NO:134), CDR2 (SEQ ID NO:135), CDR3 (SEQ ID NO:136) of antibody
AM-10; light chain CDR1 (SEQ ID NO:215), CDR2 (SEQ ID NO:216), CDR3
(SEQ ID NO:217) and heavy chain CDR1 (SEQ ID NO:137), CDR2 (SEQ ID
NO:138), CDR3 (SEQ ID NO:139) of antibody AM-1; light chain CDR1
(SEQ ID NO:218), CDR2 (SEQ ID NO:219), CDR3 (SEQ ID NO:220) and
heavy chain CDR1 (SEQ ID NO:140), CDR2 (SEQ ID NO:141), CDR3 (SEQ
ID NO:142) of antibody AM-12; light chain CDR1 (SEQ ID NO:221),
CDR2 (SEQ ID NO:222), CDR3 (SEQ ID NO:223) and heavy chain CDR1
(SEQ ID NO:143), CDR2 (SEQ ID NO:144), CDR3 (SEQ ID NO:145) of
antibody AM-13; light chain CDR1 (SEQ ID NO:224), CDR2 (SEQ ID
NO:225), CDR3 (SEQ ID NO:226) and heavy chain CDR1 (SEQ ID NO:146),
CDR2 (SEQ ID NO:147), CDR3 (SEQ ID NO:148) of antibody AM-14; light
chain CDR1 (SEQ ID NO:227), CDR2 (SEQ ID NO:228), CDR3 (SEQ ID
NO:229) and heavy chain CDR1 (SEQ ID NO:149), CDR2 (SEQ ID NO:150),
CDR3 (SEQ ID NO:151) of antibody AM-15; light chain CDR1 (SEQ ID
NO:230), CDR2 (SEQ ID NO:231), CDR3 (SEQ ID NO:232) and heavy chain
CDR1 (SEQ ID NO:152), CDR2 (SEQ ID NO:153), CDR3 (SEQ ID NO:154) of
antibody AM-16; light chain CDR1 (SEQ ID NO:233), CDR2 (SEQ ID
NO:234), CDR3 (SEQ ID NO:235) and heavy chain CDR1 (SEQ ID NO:155),
CDR2 (SEQ ID NO:156), CDR3 (SEQ ID NO:157) of antibody AM-17; light
chain CDR1 (SEQ ID NO:236), CDR2 (SEQ ID NO:237), CDR3 (SEQ ID
NO:238) and heavy chain CDR1 (SEQ ID NO:158), CDR2 (SEQ ID NO:159),
CDR3 (SEQ ID NO:160) of antibody AM-18; light chain CDR1 (SEQ ID
NO:239), CDR2 (SEQ ID NO:240), CDR3 (SEQ ID NO:241) and heavy chain
CDR1 (SEQ ID NO:161), CDR2 (SEQ ID NO:162), CDR3 (SEQ ID NO:163) of
antibody AM-19; light chain CDR1 (SEQ ID NO:242), CDR2 (SEQ ID
NO:243), CDR3 (SEQ ID NO:244) and heavy chain CDR1 (SEQ ID NO:164),
CDR2 (SEQ ID NO:165), CDR3 (SEQ ID NO:166) of antibody AM-20; light
chain CDR1 (SEQ ID NO:245), CDR2 (SEQ ID NO:246), CDR3 (SEQ ID
NO:247) and heavy chain CDR1 (SEQ ID NO:167), CDR2 (SEQ ID NO:168),
CDR3 (SEQ ID NO:169) of antibody AM-21; light chain CDR1 (SEQ ID
NO:248), CDR2 (SEQ ID NO:249), CDR3 (SEQ ID NO:250) and heavy chain
CDR1 (SEQ ID NO:170), CDR2 (SEQ ID NO:171), CDR3 (SEQ ID NO:172) of
antibody AM-22; light chain CDR1 (SEQ ID NO:251), CDR2 (SEQ ID
NO:252), CDR3 (SEQ ID NO:253) and heavy chain CDR1 (SEQ ID NO:173),
CDR2 (SEQ ID NO:174), CDR3 (SEQ ID NO:175) of antibody AM-23; light
chain CDR1 (SEQ ID NO:254), CDR2 (SEQ ID NO:255), CDR3 (SEQ ID
NO:256) and heavy chain CDR1 (SEQ ID NO:173), CDR2 (SEQ ID NO:174),
CDR3 (SEQ ID NO:175) of antibody AM-23; light chain CDR1 (SEQ ID
NO:257), CDR2 (SEQ ID NO:258), CDR3 (SEQ ID NO:259) and heavy chain
CDR1 (SEQ ID NO:176), CDR2 (SEQ ID NO:177), CDR3 (SEQ ID NO:178) of
antibody AM-24; light chain CDR1 (SEQ ID NO:260), CDR2 (SEQ ID
NO:261), CDR3 (SEQ ID NO:262) and heavy chain CDR1 (SEQ ID NO:179),
CDR2 (SEQ ID NO:180), CDR3 (SEQ ID NO:181) of antibody AM-25; or
light chain CDR1 (SEQ ID NO:263), CDR2 (SEQ ID NO:264), CDR3 (SEQ
ID NO:265) and heavy chain CDR1 (SEQ ID NO:182), CDR2 (SEQ ID
NO:183), CDR3 (SEQ ID NO:184) of antibody AM-26.
In another embodiment, the invention provides an antigen binding
protein that specifically binds IL-17RA, wherein said antigen
binding protein comprises at least one, two, or three H-CDR regions
of any of SEQ ID NOs:107-184, wherein said H-CDR regions are at
least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%,
92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the
respective H-CDR. Other embodiments include antigen binding
proteins that specifically bind to IL-17RA, wherein said antigen
binding protein comprises at least one, two, or three L-CDR region
of any of SEQ ID NOs:185-265, wherein said L-CDR regions are at
least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%,
92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the
respective L-CDR . Other embodiments include antigen binding
proteins that specifically binds IL-17RA, wherein said antigen
binding protein comprises at least one, two, or three H-CDR regions
of any of SEQ ID NOs:107-184, wherein said H-CDR regions are at
least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%,
92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the
respective H-CDR, and comprises at least one, two, or three L-CDR
region of any of SEQ ID NOs:185-265, wherein said L-CDR regions are
at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%,
91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the
respective L-CDR.
In another embodiment, the invention provides an antigen binding
protein that binds IL-17RA, wherein said antigen binding protein
comprises at least one H-CDR region having no more than one, two,
three, four, five, or six amino acid additions, deletions or
substitutions of any of SEQ ID NOs:107-184 and/or at least one
L-CDR region having no more than one, two, three, four, five, or
six amino acid additions, deletions or substitutions of any of SEQ
ID NOs:185-265.
In another embodiment, the invention provides an antigen binding
protein that binds IL-17RA, wherein said antigen binding protein
comprises one, two, or three H-CDR region having no more than one,
two, three, four, five, or six amino acid additions, deletions or
substitutions of any of SEQ ID NOs:107-184 and/or one, two, or
three L-CDR region having no more than one, two, three, four, five,
or six amino acid additions, deletions or substitutions of any of
SEQ ID NOs:185-265.
Additional embodiments utilize antigen binding proteins comprising
one CDR having no more than one, two, three, four, five, or six
amino acid additions, deletions or substitutions of the sequence
selected from the H-CDR regions of any of SEQ ID NOs:107-184 and a
L-CDR region having no more than one, two, three, four, five, or
six amino acid additions, deletions or substitutions of any of SEQ
ID NOs:185-265 (e.g., the antigen binding protein has two CDR
regions, one H-CDR and one L-CDH. A specific embodiment includes
antigen binding proteins comprising both a H-CDR3 and a L-CDR3
region.
As will be appreciated by those in the art, for any antigen binding
protein comprising more than one CDR from the sequences provided
herein, any combination of CDRs independently selected from the CDR
in TABLE 1 sequences is useful. Thus, antigen binding proteins
comprising one, two, three, four, five, or six independently
selected CDRs can be generated. However, as will be appreciated by
those in the art, specific embodiments generally utilize
combinations of CDRs that are non-repetitive, e.g., antigen binding
proteins are generally not made with two H-CDR2 regions, etc.
In some embodiments, antigen binding proteins are generated that
comprise no more than one, two, three, four, five, or six amino
acid additions, deletions or substitutions of a H-CDR3 region and a
L-CDR3 region, particularly with the H-CDR3 region being selected
from a sequence having no more than one, two, three, four, five, or
six amino acid additions, deletions or substitutions of a H-CDR3
region of any of SEQ ID NOs:107-184 and the L-CDR3 region being
selected from a L-CDR3 consensus sequence having no more than one,
two, three, four, five, or six amino acid additions, deletions or
substitutions of a L-CDR3 region of any of SEQ ID SEQ ID
NOs:185-265.
As noted herein, the antigen binding proteins of the present
invention comprise a scaffold structure into which the CDR(s) of
the invention may be grafted. The genus of IL-17RA antigen binding
proteins comprises the subgenus of antibodies, as variously defined
herein. Aspects include embodiments wherein the scaffold structure
is a traditional, tetrameric antibody structure. Thus, the antigen
binding protein combinations described herein include the
additional components (framework, J and D regions, constant
regions, etc.) that make up a heavy and/or light chain.
Embodiments include the use of human scaffold components. An
exemplary embodiment of a VH variable region grafted into a
traditional antibody scaffold structure is depicted in SEQ ID
NO:427 and an exemplary embodiment of a VL variable region grafted
into a traditional antibody scaffold structure is depicted in SEQ
ID NO:429. Of course it is understood that any antibody scaffold
known in the art may be employed.
In one aspect, the present invention provides antibodies that
comprise a light chain variable region selected from the group
consisting of AM.sub.L1 through AM.sub.L26 and/or a heavy chain
variable region selected from the group consisting of AM.sub.H1
through AM.sub.H26, and fragments, derivatives, muteins, and
variants thereof. Antibodies of the invention include, but are not
limited to: antibodies comprising AM.sub.L1/AM.sub.H1 (SEQ ID
NO:27/SEQ ID NO:1), AM.sub.L2/AM.sub.H2 (SEQ ID NO:28/SEQ ID NO:2),
AM.sub.L3/AM.sub.H3 (SEQ ID NO:29/SEQ ID NO:3), AM.sub.L4/AM.sub.H4
(SEQ ID NO:30/SEQ ID NO:4), AM.sub.L5/AM.sub.H5 (SEQ ID NO:31/SEQ
ID NO:5), AM.sub.L6/AM.sub.H6 (SEQ ID NO:32/SEQ ID NO:6),
AM.sub.L7/AM.sub.H7 (SEQ ID NO:33/SEQ ID NO:7), AM.sub.L8/AM.sub.H8
(SEQ ID NO:34/SEQ ID NO:8), AM.sub.L9/AM.sub.H9 (SEQ ID NO:35/SEQ
ID NO:9), AM.sub.L10/AM.sub.H10 (SEQ ID NO:36/SEQ ID NO: 10),
AM.sub.L11/AM.sub.H11 (SEQ ID NO:37/SEQ ID NO: 11),
AM.sub.L12/AM.sub.H12 (SEQ ID NO:38/SEQ ID NO: 12),
AM.sub.L13/AM.sub.H13 (SEQ ID NO:39/SEQ ID NO: 13),
AM.sub.L14/AM.sub.H14 (SEQ ID NO:40/SEQ ID NO:14),
AM.sub.L15/AM.sub.H15 (SEQ ID NO:41/SEQ ID NO:15),
AM.sub.L16/AM.sub.H16 (SEQ ID NO:42/SEQ ID NO: 16),
AM.sub.L17/AM.sub.H17 (SEQ ID NO:43/SEQ ID NO: 17),
AM.sub.L18/AM.sub.H18 (SEQ ID NO:44/SEQ ID NO:18),
AM.sub.L19/AM.sub.H19 (SEQ ID NO:45/SEQ ID NO:19),
AM.sub.L20/AM.sub.H20 (SEQ ID NO:46/SEQ ID NO:20),
AM.sub.L21/AM.sub.H21 (SEQ ID NO:47/SEQ ID NO:21),
AM.sub.L22/AM.sub.H22 (SEQ ID NO:48/SEQ ID NO:22),
AM.sub.L23/AM.sub.H23 (SEQ ID NO:49 or SEQ ID NO:50/SEQ ID NO:23),
AM.sub.L24/AM.sub.H24 (SEQ ID NO:51/SEQ ID NO:24),
AM.sub.L25/AM.sub.H25 (SEQ ID NO:52/SEQ ID NO:25),
AM.sub.L26/AM.sub.H26 (SEQ ID NO:53/SEQ ID NO:26), as well as
IL-17RA-binding fragments thereof and combinations thereof.
In one embodiment, the present invention provides an antibody
comprising a light chain variable domain comprising a sequence of
amino acids that differs from the sequence of a light chain
variable domain selected from the group consisting of AM.sub.L1
through AM.sub.L26 only at 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5,
4, 3, 2, or 1 residues, wherein each such sequence difference is
independently either a deletion, insertion, or substitution of one
amino acid residue. In another embodiment, the light-chain variable
domain comprises a sequence of amino acids that is at least 70%,
75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%,
92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence
of a light chain variable domain selected from the group consisting
of AM.sub.L1 through AM.sub.L26. In another embodiment, the light
chain variable domain comprises a sequence of amino acids that is
encoded by a nucleotide sequence that is at least 70%, 75%, 80%,
85%, 90%, 95%, 97%, or 99% identical to a nucleotide sequence that
encodes a light chain variable domain selected from the group
consisting of AM.sub.L1 through AM.sub.L26. In another embodiment,
the light chain variable domain comprises a sequence of amino acids
that is encoded by a polynucleotide that hybridizes under
moderately stringent conditions to the complement of a
polynucleotide that encodes a light chain variable domain selected
from the group consisting of AM.sub.L1 through AM.sub.L26. In
another embodiment, the light chain variable domain comprises a
sequence of amino acids that is encoded by a polynucleotide that
hybridizes under moderately stringent conditions to the complement
of a polynucleotide that encodes a light chain variable domain
selected from the group consisting of AM.sub.L1 through AM.sub.L26.
In another embodiment, the light chain variable domain comprises a
sequence of amino acids that is encoded by a polynucleotide that
hybridizes under moderately stringent conditions to a complement of
a light chain polynucleotide provided in any one of AM.sub.L1
through AM.sub.L26 polynucleotide sequences (SEQ ID
NOs:80-106).
In another embodiment, the present invention provides an antibody
comprising a heavy chain variable domain comprising a sequence of
amino acids that differs from the sequence of a heavy chain
variable domain selected from the group consisting of AM.sub.H1
through AM.sub.H26 only at 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5,
4, 3, 2, or 1 residue(s), wherein each such sequence difference is
independently either a deletion, insertion, or substitution of one
amino acid residue. In another embodiment, the heavy chain variable
domain comprises a sequence of amino acids that is at least 70%,
75%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%,
92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to the sequence
of a heavy chain variable domain selected from the group consisting
of AM.sub.H1 through AM.sub.H26. In another embodiment, the heavy
chain variable domain comprises a sequence of amino acids that is
encoded by a nucleotide sequence that is at least 70%, 75%, 80%,
81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,
94%, 95%, 96%, 97%, 98%, or 99% identical to a nucleotide sequence
that encodes a heavy chain variable domain selected from the group
consisting of AM.sub.H1 through AM.sub.H26. In another embodiment,
the heavy chain variable domain comprises a sequence of amino acids
that is encoded by a polynucleotide that hybridizes under
moderately stringent or stringent conditions to the complement of a
polynucleotide that encodes a heavy chain variable domain selected
from the group consisting of AM.sub.H1 through AM.sub.H26. In
another embodiment, the heavy chain variable domain comprises a
sequence of amino acids that is encoded by a polynucleotide that
hybridizes under moderately stringent conditions to the complement
of a polynucleotide that encodes a heavy chain variable domain
selected from the group consisting of AM.sub.H1 through AM.sub.H26.
In another embodiment, the heavy chain variable domain comprises a
sequence of amino acids that is encoded by a polynucleotide that
hybridizes under moderately stringent or stringent conditions to a
complement of a heavy chain polynucleotide provided in any one of
AM.sub.H1 through AM.sub.H26 polynucleotide sequences (SEQ ID
NOs:54-79).
Accordingly, in various embodiments, the antigen binding proteins
of the invention comprise the scaffolds of traditional antibodies,
including human and monoclonal antibodies, bispecific antibodies,
diabodies, minibodies, domain antibodies, synthetic antibodies
(sometimes referred to herein as "antibody mimetics"), chimeric
antibodies, antibody fusions (sometimes referred to as "antibody
conjugates"), and fragments of each, respectively. The above
described CDRs and combinations of CDRs may be grafted into any of
the following scaffolds.
As used herein, the term "antibody" refers to the various forms of
monomeric or multimeric proteins comprising one or more polypeptide
chains that specifically binds to an antigen, as variously
described herein. In certain embodiments, antibodies are produced
by recombinant DNA techniques. In additional embodiments,
antibodies are produced by enzymatic or chemical cleavage of
naturally occurring antibodies. In another aspect, the antibody is
selected from the group consisting of: a) a human antibody; b) a
humanized antibody; c) a chimeric antibody; d) a monoclonal
antibody; e) a polyclonal antibody; f) a recombinant antibody; g)
an antigen-binding antibody fragment; h) a single chain antibody;
i) a diabody; j) a triabody; k) a tetrabody; 1) a Fab fragment; m)
a F(ab').sub.2 fragment; n) an IgD antibody; o) an IgE antibody; p)
an IgM antibody; q) an IgA antibody; r) an IgG1 antibody; s) an
IgG2 antibody; t) an IgG3 antibody; and u) an IgG4 antibody.
Traditional antibody structural units typically comprise a
tetramer. Each tetramer is typically composed of two identical
pairs of polypeptide chains, each pair having one "light"
(typically having a molecular weight of about 25 kDa) and one
"heavy" chain (typically having a molecular weight of about 50-70
kDa). The amino-terminal portion of each chain includes a variable
region of about 100 to 110 or more amino acids primarily
responsible for antigen recognition. The carboxy-terminal portion
of each chain defines a constant region primarily responsible for
effector function. Human light chains are classified as kappa and
lambda light chains. Heavy chains are classified as mu, delta,
gamma, alpha, or epsilon, and define the antibody's isotype as IgM,
IgD, IgG, IgA, and IgE, respectively. IgG has several subclasses,
including, but not limited to IgG1, IgG2, IgG3, and IgG4. IgM has
subclasses, including, but not limited to, IgM1 and IgM2.
Embodiments of the invention include all such classes of antibodies
that incorporate the variable domains or the CDRs of the antigen
binding proteins, as described herein.
Within light and heavy chains, the variable and constant regions
are joined by a "J" region of about twelve (12) or more amino
acids, with the heavy chain also including a "D" region of about
ten (10) more amino acids. See, generally, Paul, W., ed., 1989,
Fundamental Immunology Ch. 7, 2nd ed. Raven Press, N.Y. The
variable regions of each light/heavy chain pair form the antibody
binding site. Scaffolds of the invention include such regions.
Some naturally occurring antibodies, for example found in camels
and llamas, are dimers consisting of two heavy chain and include no
light chains. Muldermans et al., 2001, J. Biotechnol. 74:277-302;
Desmyter et al., 2001, J. Biol. Chem. 276:26285-26290.
Crystallographic studies of a camel antibody have revealed that the
CDR3 regions form a surface that interacts with the antigen and
thus is critical for antigen binding like in the more typical
tetrameric antibodies. The invention encompasses dimeric antibodies
consisting of two heavy chains, or fragments thereof, that can bind
to and/or inhibit the biological activity of IL-17RA.
The variable regions of the heavy and light chains typically
exhibit the same general structure of relatively conserved
framework regions (FR) joined by three hypervariable regions, i.e.,
the complementarity determining regions or CDRs. The CDRs are the
hypervariable regions of an antibody (or antigen binding protein,
as outlined herein), that are responsible for antigen recognition
and binding. The CDRs from the two chains of each pair are aligned
by the framework regions, enabling binding to a specific epitope.
From N-terminal to C-terminal, both light and heavy chains comprise
the domains FR1, CDR1, FR2, CDR2, FR3, CDR3 and FR4. The assignment
of amino acids to each domain is in accordance with the definitions
of Kabat Sequences of Proteins of Immunological Interest. Chothia
et al., 1987, J. Mol. Biol. 196:901-917; Chothia et al., 1989,
Nature 342:878-883. Scaffolds of the invention include such
regions.
CDRs constitute the major surface contact points for antigen
binding. See, e.g., Chothia and Lesk, 1987, J. Mol. Biol.
196:901-917. Further, CDR3 of the light chain and, especially, CDR3
of the heavy chain may constitute the most important determinants
in antigen binding within the light and heavy chain variable
regions. See, e.g., Chothia and Lesk, 1987, supra; Desiderio et
al., 2001, J. Mol. Biol. 310:603-615; Xu and Davis, 2000, Immunity
13:37-45; Desmyter et al., 2001, J. Biol. Chem. 276:26285-26290;
and Muyldernans, 2001, J. Biotechnol. 74:277-302. In some
antibodies, the heavy chain CDR3 appears to constitute the major
area of contact between the antigen and the antibody. Desmyter et
al., 2001, supra. In vitro selection schemes in which CDR3 alone is
varied can be used to vary the binding properties of an antibody.
Muyldermans, 2001, supra; Desiderio et al., 2001, supra.
Naturally occurring antibodies typically include a signal sequence,
which directs the antibody into the cellular pathway for protein
secretion and which is not present in the mature antibody. A
polynucleotide encoding an antibody of the invention may encode a
naturally occurring signal sequence or a heterologous signal
sequence as described below.
In one embodiment, the antigen binding protein is a monoclonal
antibody, comprising from one (1) to six (6) of the depicted CDRs,
as outlined herein (see TABLE 1). The antibodies of the invention
may be of any type including IgM, IgG (including IgG1, IgG2, IgG3,
IgG4), IgD, IgA, or IgE antibody. In specific embodiment, the
antigen binding protein is an IgG type antibody. In an even more
specific embodiment, the antigen binding protein is an IgG2 type
antibody.
In some embodiments, for example when the antigen binding protein
is an antibody with complete heavy and light chains, the CDRs are
all from the same species, e.g., human. Alternatively, for example
in embodiments wherein the antigen binding protein contains less
than six CDRs from the sequences outlined above, additional CDRs
may be either from other species (e.g., murine CDRs), or may be
different human CDRs than those depicted in the sequences. For
example, human H-CDR3 and L-CDR3 regions from the appropriate
sequences identified herein may be used, with H-CDR1, H-CDR2,
L-CDR1 and L-CDR2 being optionally selected from alternate species,
or different human antibody sequences, or combinations thereof. For
example, the CDRs of the invention can replace the CDR regions of
commercially relevant chimeric or humanized antibodies.
Specific embodiments utilize scaffold components of the antigen
binding proteins that are human components.
In some embodiments, however, the scaffold components can be a
mixture from different species. As such, if the antigen binding
protein is an antibody, such antibody may be a chimeric antibody
and/or a humanized antibody. In general, both "chimeric antibodies"
and "humanized antibodies" refer to antibodies that combine regions
from more than one species. For example, "chimeric antibodies"
traditionally comprise variable region(s) from a mouse (or rat, in
some cases) and the constant region(s) from a human.
"Humanized antibodies" generally refer to non-human antibodies that
have had the variable-domain framework regions swapped for
sequences found in human antibodies. Generally, in a humanized
antibody, the entire antibody, except the CDRs, is encoded by a
polynucleotide of human origin or is identical to such an antibody
except within its CDRs. The CDRs, some or all of which are encoded
by nucleic acids originating in a non-human organism, are grafted
into the beta-sheet framework of a human antibody variable region
to create an antibody, the specificity of which is determined by
the engrafted CDRs. The creation of such antibodies is described
in, e.g., WO 92/11018, Jones, 1986, Nature 321:522-525, Verhoeyen
et al., 1988, Science 239:1534-1536. Humanized antibodies can also
be generated using mice with a genetically engineered immune
system. Roque et al., 2004, Biotechnol. Prog. 20:639-654. In the
present invention, the identified CDRs are human, and thus both
humanized and chimeric antibodies in this context include some
non-human CDRs; for example, humanized antibodies may be generated
that comprise the CDRH3 and CDRL3 regions, with one or more of the
other CDR regions being of a different special origin.
In one embodiment, the IL-17RA antigen binding protein is a
multispecific antibody, and notably a bispecific antibody, also
sometimes referred to as "diabodies". These are antibodies that
bind to two (or more) different antigens. Diabodies can be
manufactured in a variety of ways known in the art (Holliger and
Winter, 1993, Current Opinion Biotechnol. 4:446-449), e.g.,
prepared chemically or from hybrid hybridomas.
In one embodiment, the IL-17RA antigen binding protein is a
minibody. Minibodies are minimized antibody-like proteins
comprising a scFv joined to a CH3 domain. Hu et al., 1996, Cancer
Res. 56:3055-3061. In one embodiment, the IL-17RA antigen binding
protein is a domain antibody; see, for example U.S. Pat. No.
6,248,516. Domain antibodies (dAbs) are functional binding domains
of antibodies, corresponding to the variable regions of either the
heavy (VH) or light (VL) chains of human antibodies dABs have a
molecular weight of approximately 13 kDa, or less than one-tenth
the size of a full antibody. dABs are well expressed in a variety
of hosts including bacterial, yeast, and mammalian cell systems. In
addition, dAbs are highly stable and retain activity even after
being subjected to harsh conditions, such as freeze-drying or heat
denaturation. See, for example, U.S. Pat. Nos. 6,291,158;
6,582,915; 6,593,081; 6,172,197; US Serial No. 2004/0110941;
European Patent 0368684; U.S. Pat. No. 6,696,245, WO04/058821,
WO04/003019 and WO03/002609.
In one embodiment, the IL-17RA antigen binding protein is an
antibody fragment, that is a fragment of any of the antibodies
outlined herein that retain binding specificity to IL-17RA. In
various embodiments, the antibody binding proteins comprise, but
are not limited to, a F(ab), F(ab'), F(ab').sub.2, Fv, or a single
chain Fv fragments. At a minimum, an antibody, as meant herein,
comprises a polypeptide that can bind specifically to IL-17RA
comprising all or part of a light or heavy chain variable region,
such as one or more CDRs.
Further examples of IL-17RA-binding antibody fragments include, but
are not limited to, (i) the Fab fragment consisting of VL, VH, CL
and CH1 domains, (ii) the Fd fragment consisting of the VH and CH1
domains, (iii) the Fv fragment consisting of the VL and VH domains
of a single antibody; (iv) the dAb fragment (Ward et al., 1989,
Nature 341:544-546) which consists of a single variable, (v)
isolated CDR regions, (vi) F(ab').sub.2 fragments, a bivalent
fragment comprising two linked Fab fragments (vii) single chain Fv
molecules (scFv), wherein a VH domain and a VL domain are linked by
a peptide linker which allows the two domains to associate to form
an antigen binding site (Bird et al., 1988, Science 242:423-426,
Huston et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:5879-5883),
(viii) bispecific single chain Fv dimers (PCT/US92/09965) and (ix)
"diabodies" or "triabodies", multivalent or multispecific fragments
constructed by gene fusion (Tomlinson et. al., 2000, Methods
Enzymol. 326:461-479; WO94/13804; Holliger et al., 1993, Proc.
Natl. Acad. Sci. U.S.A. 90:6444-6448). The antibody fragments may
be modified. For example, the molecules may be stabilized by the
incorporation of disulphide bridges linking the VH and VL domains
(Reiter et al., 1996, Nature Biotech. 14:1239-1245). Aspects of the
invention include embodiments wherein the non-CDR components of
these fragments are human sequences.
In one embodiment, the IL-17RA antigen binding protein is a fully
human antibody. In this embodiment, as outlined above, specific
structures comprise complete heavy and light chains depicted
comprising the CDR regions. Additional embodiments utilize one or
more of the CDRs of the invention, with the other CDRs, framework
regions, J and D regions, constant regions, etc., coming from other
human antibodies. For example, the CDRs of the invention can
replace the CDRs of any number of human antibodies, particularly
commercially relevant antibodies
Single chain antibodies may be formed by linking heavy and light
chain variable domain (Fv region) fragments via an amino acid
bridge (short peptide linker), resulting in a single polypeptide
chain. Such single-chain Fvs (scFvs) have been prepared by fusing
DNA encoding a peptide linker between DNAs encoding the two
variable domain polypeptides (V.sub.L and V.sub.H). The resulting
polypeptides can fold back on themselves to form antigen-binding
monomers, or they can form multimers (e.g., dimers, trimers, or
tetramers), depending on the length of a flexible linker between
the two variable domains (Kortt et al., 1997, Prot. Eng. 10:423;
Kortt et al., 2001, Biomol. Eng. 18:95-108). By combining different
V.sub.L and V.sub.H-comprising polypeptides, one can form
multimeric scFvs that bind to different epitopes (Kriangkum et al.,
2001, Biomol. Eng. 18:31-40). Techniques developed for the
production of single chain antibodies include those described in
U.S. Pat. No. 4,946,778; Bird, 1988, Science 242:423; Huston et
al., 1988, Proc. Natl. Acad. Sci. USA 85:5879; Ward et al., 1989,
Nature 334:544, de Graaf et al., 2002, Methods Mol. Biol.
178:379-87. Single chain antibodies derived from antibodies
provided herein (including but not limited to scFvs comprising the
variable domain combinations of AM.sub.L1/AM.sub.H1 (SEQ ID
NO:27/SEQ ID NO: 1), AM.sub.L2/AM.sub.H2 (SEQ ID NO:28/SEQ ID
NO:2), AM.sub.L3/AM.sub.H3 (SEQ ID NO:29/SEQ ID NO:3),
AM.sub.L4/AM.sub.H4 (SEQ ID NO:30/SEQ ID NO:4), AM.sub.L5/AM.sub.H5
(SEQ ID NO:31/SEQ ID NO:5), AM.sub.L6/AM.sub.H6 (SEQ ID NO:32/SEQ
ID NO:6), AM.sub.L7/AM.sub.H7 (SEQ ID NO:33/SEQ ID NO:7),
AM.sub.L8/AM.sub.H8 (SEQ ID NO:34/SEQ ID NO:8), AM.sub.L9/AM.sub.H9
(SEQ ID NO:35/SEQ ID NO:9), AM.sub.L10/AM.sub.H10 (SEQ ID NO:36/SEQ
ID NO:10), AM.sub.L11/AM.sub.H11 (SEQ ID NO:37/SEQ ID NO:11),
AM.sub.L12/AM.sub.H12 (SEQ ID NO:38/SEQ ID NO:12),
AM.sub.L13/AM.sub.H13 (SEQ ID NO:39/SEQ ID NO:13),
AM.sub.L14/AM.sub.H14 (SEQ ID NO:40/SEQ ID NO:14),
AM.sub.L15/AM.sub.H15 (SEQ ID NO:41/SEQ ID NO:15),
AM.sub.L16/AM.sub.H46 (SEQ ID NO:42/SEQ ID NO:16),
AM.sub.L17/AM.sub.H17 (SEQ ID NO:43/SEQ ID NO:17),
AM.sub.L18/AM.sub.H18 (SEQ ID NO:44/SEQ ID NO:18),
AM.sub.L19/AM.sub.H19 (SEQ ID NO:45/SEQ ID NO:19),
AM.sub.L20/AM.sub.H20 (SEQ ID NO:46/SEQ ID NO:20),
AM.sub.L21/AM.sub.H21 (SEQ ID NO:47/SEQ ID NO:21),
AM.sub.L22/AM.sub.H22 (SEQ ID NO:48/SEQ ID NO:22),
AM.sub.L23/AM.sub.H23 (SEQ ID NO:49 or SEQ ID NO:50/SEQ ID NO:23),
AM.sub.L24/AM.sub.H24 (SEQ ID NO:51/SEQ ID NO:24),
AM.sub.L25/AM.sub.H25 (SEQ ID NO:52/SEQ ID NO:25),
AM.sub.L26/AM.sub.H26 (SEQ ID NO:53/SEQ ID NO:26), and combinations
thereof are encompassed by the present invention.
In one embodiment, the IL-17RA antigen binding protein is an
antibody fusion protein (sometimes referred to herein as an
"antibody conjugate"). The conjugate partner can be proteinaceous
or non-proteinaceous; the latter generally being generated using
functional groups on the antigen binding protein (see the
discussion on covalent modifications of the antigen binding
proteins) and on the conjugate partner. For example linkers are
known in the art; for example, homo- or hetero-bifunctional linkers
as are well known (see, 1994 Pierce Chemical Company catalog,
technical section on cross-linkers, pages 155-200, incorporated
herein by reference).
In one embodiment, the IL-17RA antigen binding protein is an
antibody analog, sometimes referred to as "synthetic antibodies."
For example, a variety of recent work utilizes either alternative
protein scaffolds or artificial scaffolds with grafted CDRs. Such
scaffolds include, but are not limited to, mutations introduced to
stabilize the three-dimensional structure of the binding protein as
well as wholly synthetic scaffolds consisting for example of
biocompatible polymers. See, for example, Korndorfer et al., 2003,
Proteins: Structure, Function, and Bioinformatics, Volume 53, Issue
1:121-129. Roque et al., 2004, Biotechnol. Prog. 20:639-654. In
addition, peptide antibody mimetics ("PAMs") can be used, as well
as work based on antibody mimetics utilizing fibronection
components as a scaffold.
As it is known in the art, a number of different programs can be
used to identify the degree of sequence identity or similarity a
protein or nucleic acid has to a known sequence.
By "protein," as used herein, is meant at least two covalently
attached amino acids, which includes proteins, polypeptides,
oligopeptides and peptides. In some embodiments, the two or more
covalently attached amino acids are attached by a peptide bond. The
protein may be made up of naturally occurring amino acids and
peptide bonds, for example when the protein is made recombinantly
using expression systems and host cells, as outlined below.
Alternatively, the protein may include synthetic amino acids (e.g.,
homophenylalanine, citrulline, ornithine, and norleucine), or
peptidomimetic structures, i.e., "peptide or protein analogs", such
as peptoids (see, Simon et al., 1992, Proc. Natl. Acad. Sci. U.S.A.
89:9367, incorporated by reference herein), which can be resistant
to proteases or other physiological and/or storage conditions. Such
synthetic amino acids may be incorporated in particular when the
antigen binding protein is synthesized in vitro by conventional
methods well known in the art. In addition, any combination of
peptidomimetic, synthetic and naturally occurring
residues/structures can be used. "Amino acid" also includes imino
acid residues such as proline and hydroxyproline. The amino acid "R
group" or "side chain" may be in either the (L)- or the
(S)-configuration. In a specific embodiment, the amino acids are in
the (L)- or (S)-configuration.
In certain aspects, the invention provides recombinant antigen
binding proteins that bind an IL-17RA, in some embodiments a
recombinant human IL-17RA or portion thereof. In this context, a
"recombinant protein" is a protein made using recombinant
techniques using any techniques and methods known in the art, i.e.,
through the expression of a recombinant nucleic acid as described
herein. Methods and techniques for the production of recombinant
proteins are well known in the art. Embodiments of the invention
include recombinant antigen binding proteins that bind wild-type
IL-17RA and variants thereof.
"Consisting essentially of" means that the amino acid sequence can
vary by about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15%
relative to the recited SEQ ID NO: sequence and still retain
biological activity, as described herein.
In some embodiments, the antigen binding proteins of the invention
are isolated proteins or substantially pure proteins. An "isolated"
protein is unaccompanied by at least some of the material with
which it is normally associated in its natural state, for example
constituting at least about 5%, or at least about 50% by weight of
the total protein in a given sample. It is understood that the
isolated protein may constitute from 5 to 99.9% by weight of the
total protein content depending on the circumstances. For example,
the protein may be made at a significantly higher concentration
through the use of an inducible promoter or high expression
promoter, such that the protein is made at increased concentration
levels. The definition includes the production of an antigen
binding protein in a wide variety of organisms and/or host cells
that are known in the art.
For amino acid sequences, sequence identity and/or similarity is
determined by using standard techniques known in the art,
including, but not limited to, the local sequence identity
algorithm of Smith and Waterman, 1981, Adv. Appl. Math. 2:482, the
sequence identity alignment algorithm of Needleman and Wunsch,
1970, J. Mol. Biol. 48:443, the search for similarity method of
Pearson and Lipman, 1988, Proc. Nat. Acad. Sci. U.S.A. 85:2444,
computerized implementations of these algorithms (GAP, BESTFIT,
FASTA, and TFASTA in the Wisconsin Genetics Software Package,
Genetics Computer Group, 575 Science Drive, Madison, Wis.), the
Best Fit sequence program described by Devereux et al., 1984, Nucl.
Acid Res. 12:387-395, preferably using the default settings, or by
inspection. Preferably, percent identity is calculated by FastDB
based upon the following parameters: mismatch penalty of 1; gap
penalty of 1; gap size penalty of 0.33; and joining penalty of 30,
"Current Methods in Sequence Comparison and Analysis,"
Macromolecule Sequencing and Synthesis, Selected Methods and
Applications, pp 127-149 (1988), Alan R. Liss, Inc. An example of a
useful algorithm is PILEUP. PILEUP creates a multiple sequence
alignment from a group of related sequences using progressive,
pairwise alignments. It can also plot a tree showing the clustering
relationships used to create the alignment. PILEUP uses a
simplification of the progressive alignment method of Feng &
Doolittle, 1987, J. Mol. Evol. 35:351-360; the method is similar to
that described by Higgins and Sharp, 1989, CABIOS 5:151-153. Useful
PILEUP parameters including a default gap weight of 3.00, a default
gap length weight of 0.10, and weighted end gaps.
Another example of a useful algorithm is the BLAST algorithm,
described in: Altschul et al., 1990, J. Mol. Biol. 215:403-410;
Altschul et al., 1997, Nucleic Acids Res. 25:3389-3402; and Karin
et al., 1993, Proc. Natl. Acad. Sci. U.S.A. 90:5873-5787. A
particularly useful BLAST program is the WU-BLAST-2 program which
was obtained from Altschul et al., 1996, Methods in Enzymology
266:460-480. WU-BLAST-2 uses several search parameters, most of
which are set to the default values. The adjustable parameters are
set with the following values: overlap span=1, overlap
fraction=0.125, word threshold (T)=II. The HSP S and HSP S2
parameters are dynamic values and are established by the program
itself depending upon the composition of the particular sequence
and composition of the particular database against which the
sequence of interest is being searched; however, the values may be
adjusted to increase sensitivity.
An additional useful algorithm is gapped BLAST as reported by
Altschul et al., 1993, Nucl. Acids Res. 25:3389-3402. Gapped BLAST
uses BLOSUM-62 substitution scores; threshold T parameter set to 9;
the two-hit method to trigger ungapped extensions, charges gap
lengths of k a cost of 10+k; X.sub.u set to 16, and X.sub.g set to
40 for database search stage and to 67 for the output stage of the
algorithms. Gapped alignments are triggered by a score
corresponding to about 22 bits.
Generally, the amino acid homology, similarity, or identity between
individual variant CDRs are at least 80% to the sequences depicted
herein, and more typically with preferably increasing homologies or
identities of at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,
98%, 99%, and almost 100%. In a similar manner, "percent (%)
nucleic acid sequence identity" with respect to the nucleic acid
sequence of the binding proteins identified herein is defined as
the percentage of nucleotide residues in a candidate sequence that
are identical with the nucleotide residues in the coding sequence
of the antigen binding protein. A specific method utilizes the
BLASTN module of WU-BLAST-2 set to the default parameters, with
overlap span and overlap fraction set to 1 and 0.125,
respectively.
Generally, the nucleic acid sequence homology, similarity, or
identity between the nucleotide sequences encoding individual
variant CDRs and the nucleotide sequences depicted herein are at
least 80%, and more typically with preferably increasing homologies
or identities of at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%,
88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%, and
almost 100%.
Thus, a "variant CDR" is one with the specified homology,
similarity, or identity to the parent CDR of the invention, and
shares biological function, including, but not limited to, at least
80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%,
93%, 94%, 95%, 96%, 97%, 98%, or 99% of the specificity and/or
activity of the parent CDR.
While the site or region for introducing an amino acid sequence
variation is predetermined, the mutation per se need not be
predetermined. For example, in order to optimize the performance of
a mutation at a given site, random mutagenesis may be conducted at
the target codon or region and the expressed antigen binding
protein CDR variants screened for the optimal combination of
desired activity. Techniques for making substitution mutations at
predetermined sites in DNA having a known sequence are well known,
for example, M13 primer mutagenesis and PCR mutagenesis. Screening
of the mutants is done using assays of antigen binding protein
activities, such as IL-17RA binding.
Amino acid substitutions are typically of single residues;
insertions usually will be on the order of from about one (I) to
about twenty (20) amino acid residues, although considerably larger
insertions may be tolerated. Deletions range from about one (1) to
about twenty (20) amino acid residues, although in some cases
deletions may be much larger.
Substitutions, deletions, insertions or any combination thereof may
be used to arrive at a final derivative or variant. Generally these
changes are done on a few amino acids to minimize the alteration of
the molecule, particularly the immunogenicity and specificity of
the antigen binding protein. However, larger changes may be
tolerated in certain circumstances. Conservative substitutions are
generally made in accordance with the following chart depicted as
TABLE 2.
TABLE-US-00002 TABLE 2 Original Residue Exemplary Substitutions Ala
Ser Arg Lys Asn Gln, His Asp Glu Cys Ser Gln Asn Glu Asp Gly Pro
His Asn, Gln Ile Leu, Val Leu Ile, Val Lys Arg, Gln, Glu Met Leu,
Ile Phe Met, Leu, Tyr Ser Thr Thr Ser Trp Tyr Tyr Trp, Phe Val Ile,
Leu
Substantial changes in function or immunological identity are made
by selecting substitutions that are less conservative than those
shown in TABLE 2. For example, substitutions may be made which more
significantly affect: the structure of the polypeptide backbone in
the area of the alteration, for example the alpha-helical or
beta-sheet structure; the charge or hydrophobicity of the molecule
at the target site; or the bulk of the side chain. The
substitutions which in general are expected to produce the greatest
changes in the polypeptide's properties are those in which (a) a
hydrophilic residue, e.g., seryl or threonyl, is substituted for
(or by) a hydrophobic residue, e.g., leucyl, isoleucyl,
phenylalanyl, valyl or alanyl; (b) a cysteine or proline is
substituted for (or by) any other residue; (c) a residue having an
electropositive side chain, e.g., lysyl, arginyl, or histidyl, is
substituted for (or by) an electronegative residue, e.g., glutamyl
or aspartyl; or (d) a residue having a bulky side chain, e.g.,
phenylalanine, is substituted for (or by) one not having a side
chain, e.g., glycine.
The variants typically exhibit the same qualitative biological
activity and will elicit the same immune response as the
naturally-occurring analogue, although variants also are selected
to modify the characteristics of the antigen binding protein
proteins as needed. Alternatively, the variant may be designed such
that the biological activity of the antigen binding protein is
altered. For example, glycosylation sites may be altered or removed
as discussed herein.
Other derivatives of IL-17RA antibodies within the scope of this
invention include covalent or aggregative conjugates of IL-17RA
antibodies, or fragments thereof, with other proteins or
polypeptides, such as by expression of recombinant fusion proteins
comprising heterologous polypeptides fused to the N-terminus or
C-terminus of an IL-17RA antibody polypeptide. For example, the
conjugated peptide may be a heterologous signal (or leader)
polypeptide, e.g., the yeast alpha-factor leader, or a peptide such
as an epitope tag. IL-17RA antibody-containing fusion proteins can
comprise peptides added to facilitate purification or
identification of the IL-17RA antibody (e.g., poly-His). An IL-17RA
antibody polypeptide also can be linked to the FLAG peptide
DYKDDDDK (SEQ ID NO:447) as described in Hopp et al.,
Bio/Technology 6:1204, 1988, and U.S. Pat. No. 5,011,912. The FLAG
peptide is highly antigenic and provides an epitope reversibly
bound by a specific monoclonal antibody (mAb), enabling rapid assay
and facile purification of expressed recombinant protein. Reagents
useful for preparing fusion proteins in which the FLAG peptide is
fused to a given polypeptide are commercially available (Sigma, St.
Louis, Mo.).
Oligomers that contain one or more IL-17RA antibody polypeptides
may be employed as IL-17RA antagonists. Oligomers may be in the
form of covalently-linked or non-covalently-linked dimers, trimers,
or higher oligomers. Oligomers comprising two or more IL-17RA
antibody polypeptides are contemplated for use, with one example
being a homodimer. Other oligomers include heterodimers,
homotrimers, heterotrimers, homotetramers, heterotetramers,
etc.
One embodiment is directed to oligomers comprising multiple IL-17RA
antibody polypeptides joined via covalent or non-covalent
interactions between peptide moieties fused to the IL-17RA antibody
polypeptides. Such peptides may be peptide linkers (spacers), or
peptides that have the property of promoting oligomerization.
Leucine zippers and certain polypeptides derived from antibodies
are among the peptides that can promote oligomerization of IL-17RA
antibody polypeptides attached thereto, as described in more detail
below.
In particular embodiments, the oligomers comprise from two to four
IL-17RA antibody polypeptides. The IL-17RA antibody moieties of the
oligomer may be in any of the forms described above, e.g., variants
or fragments. Preferably, the oligomers comprise IL-17RA antibody
polypeptides that have IL-17RA binding activity.
In one embodiment, an oligomer is prepared using polypeptides
derived from immunoglobulins. Preparation of Fusion Proteins
Comprising Certain Heterologous Polypeptides Fused to Various
Portions of antibody-derived polypeptides (including the Fc domain)
has been described, e.g., by Ashkenazi et al., 1991, PNAS USA
88:10535; Byrn et al., 1990, Nature 344:677; and Hollenbaugh et
al., 1992 "Construction of Immunoglobulin Fusion Proteins", in
Current Protocols in Immunology, Suppl. 4, pages
10.19.1-10.19.11.
One embodiment of the present invention is directed to a dimer
comprising two fusion proteins created by fusing an IL-17RA binding
fragment of an IL-17RA antibody to the Fc region of an antibody.
The dimer can be made by, for example, inserting a gene fusion
encoding the fusion protein into an appropriate expression vector,
expressing the gene fusion in host cells transformed with the
recombinant expression vector, and allowing the expressed fusion
protein to assemble much like antibody molecules, whereupon
interchain disulfide bonds form between the Fc moieties to yield
the dimer.
The term "Fc polypeptide" as used herein includes native and mutein
forms of polypeptides derived from the Fc region of an antibody.
Truncated forms of such polypeptides containing the hinge region
that promotes dimerization also are included. Fusion proteins
comprising Fc moieties (and oligomers formed therefrom) offer the
advantage of facile purification by affinity chromatography over
Protein A or Protein G columns.
One suitable Fc polypeptide, described in PCT application WO
93/10151 (hereby incorporated by reference), is a single chain
polypeptide extending from the N-terminal hinge region to the
native C-terminus of the Fc region of a human IgG antibody. Another
useful Fc polypeptide is the Fc mutein described in U.S. Pat. No.
5,457,035 and in Baum et al., 1994, EMBO J. 13:3992-4001. The amino
acid sequence of this mutein is identical to that of the native Fc
sequence presented in WO 93/10151, except that amino acid 19 has
been changed from Leu to Ala, amino acid 20 has been changed from
Leu to Glu, and amino acid 22 has been changed from Gly to Ala. The
mutein exhibits reduced affinity for Fc receptors.
In other embodiments, the variable portion of the heavy and/or
light chains of an IL-17RA antibody may be substituted for the
variable portion of an antibody heavy and/or light chain.
Alternatively, the oligomer is a fusion protein comprising multiple
IL-17RA antibody polypeptides, with or without peptide linkers
(spacer peptides). Among the suitable peptide linkers are those
described in U.S. Pat. Nos. 4,751,180 and 4,935,233.
Another method for preparing oligomeric IL-17RA antibody
derivatives involves use of a leucine zipper. Leucine zipper
domains are peptides that promote oligomerization of the proteins
in which they are found. Leucine zippers were originally identified
in several DNA-binding proteins (Landschulz et al., 1988, Science
240:1759), and have since been found in a variety of different
proteins. Among the known leucine zippers are naturally occurring
peptides and derivatives thereof that dimerize or trimerize.
Examples of leucine zipper domains suitable for producing soluble
oligomeric proteins are described in PCT application WO 94/10308,
and the leucine zipper derived from lung surfactant protein D (SPD)
described in Hoppe et al., 1994, FEBS Letters 344:191, hereby
incorporated by reference. The use of a modified leucine zipper
that allows for stable trimerization of a heterologous protein
fused thereto is described in Fanslow et al., 1994, Semin. Immunol.
6:267-78. In one approach, recombinant fusion proteins comprising
an IL-17RA antibody fragment or derivative fused to a leucine
zipper peptide are expressed in suitable host cells, and the
soluble oligomeric IL-17RA antibody fragments or derivatives that
form are recovered from the culture supernatant.
Covalent modifications of antigen binding proteins are included
within the scope of this invention, and are generally, but not
always, done post-translationally. For example, several types of
covalent modifications of the antigen binding protein are
introduced into the molecule by reacting specific amino acid
residues of the antigen binding protein with an organic
derivatizing agent that is capable of reacting with selected side
chains or the N- or C-terminal residues.
Cysteinyl residues most commonly are reacted with
.alpha.-haloacetates (and corresponding amines), such as
chloroacetic acid or chloroacetamide, to give carboxymethyl or
carboxyamidomethyl derivatives. Cysteinyl residues also are
derivatized by reaction with bromotrifluoroacetone,
.alpha.-bromo-.beta.-(5-imidozoyl) propionic acid, chloroacetyl
phosphate, N-alkylmaleimides, 3-nitro-2-pyridyl disulfide, methyl
2-pyridyl disulfide, p-chloromercuribenzoate,
2-chloromercuri-4-nitrophenol, or
chloro-7-nitrobenzo-2-oxa-1,3-diazole.
Histidyl residues are derivatized by reaction with
diethylpyrocarbonate at pH 5.5-7.0 because this agent is relatively
specific for the histidyl side chain. Para-bromophenacyl bromide
also is useful; the reaction is preferably performed in 0.1 M
sodium cacodylate at pH 6.0.
Lysinyl and amino terminal residues are reacted with succinic or
other carboxylic acid anhydrides. Derivatization with these agents
has the effect of reversing the charge of the lysinyl residues.
Other suitable reagents for derivatizing alpha-amino-containing
residues include imidoesters such as methyl picolinimidate;
pyridoxal phosphate; pyridoxal; chloroborohydride;
trinitrobenzenesulfonic acid; O-methylisourea; 2,4-pentanedione;
and transaminase-catalyzed reaction with glyoxylate.
Arginyl residues are modified by reaction with one or several
conventional reagents, among them phenylglyoxal, 2,3-butanedione,
1,2-cyclohexanedione, and ninhydrin. Derivatization of arginine
residues requires that the reaction be performed in alkaline
conditions because of the high pK.sub.a of the guanidine functional
group. Furthermore, these reagents may react with the groups of
lysine as well as the arginine epsilon-amino group.
The specific modification of tyrosyl residues may be made, with
particular interest in introducing spectral labels into tyrosyl
residues by reaction with aromatic diazonium compounds or
tetranitromethane. Most commonly, N-acetylimidizole and
tetranitromethane are used to form O-acetyl tyrosyl species and
3-nitro derivatives, respectively. Tyrosyl residues are iodinated
using .sup.125I or .sup.131I to prepare labeled proteins for use in
radioimmunoassay, the chloramine T method described above being
suitable.
Carboxyl side groups (aspartyl or glutamyl) are selectively
modified by reaction with carbodiimides (R'--N.dbd.C.dbd.N--R'),
where R and R' are optionally different alkyl groups, such as
1-cyclohexyl-3-(2-morpholinyl-4-ethyl) carbodiimide or
1-ethyl-3-(4-azonia-4,4-dimethylpentyl) carbodiimide. Furthermore,
aspartyl and glutamyl residues are converted to asparaginyl and
glutaminyl residues by reaction with ammonium ions.
Derivatization with bifunctional agents is useful for crosslinking
antigen binding proteins to a water-insoluble support matrix or
surface for use in a variety of methods. Commonly used crosslinking
agents include, e.g., 1,1-bis(diazoacetyl)-2-phenylethane,
glutaraldehyde, N-hydroxysuccinimide esters, for example, esters
with 4-azidosalicylic acid, homobifunctional imidoesters, including
disuccinimidyl esters such as
3,3'-dithiobis(succinimidylpropionate), and bifunctional maleimides
such as bis-N-maleimido-1,8-octane. Derivatizing agents such as
methyl-3-[(p-azidophenyl)dithio]propioimidate yield
photoactivatable intermediates that are capable of forming
crosslinks in the presence of light. Alternatively, reactive
water-insoluble matrices such as cyanogen bromide-activated
carbohydrates and the reactive substrates described in U.S. Pat.
Nos. 3,969,287; 3,691,016; 4,195,128; 4,247,642; 4,229,537; and
4,330,440 are employed for protein immobilization.
Glutaminyl and asparaginyl residues are frequently deamidated to
the corresponding glutamyl and aspartyl residues, respectively.
Alternatively, these residues are deamidated under mildly acidic
conditions. Either form of these residues falls within the scope of
this invention.
Other modifications include hydroxylation of proline and lysine,
phosphorylation of hydroxyl groups of seryl or threonyl residues,
methylation of the .alpha.-amino groups of lysine, arginine, and
histidine side chains (T. E. Creighton, Proteins: Structure and
Molecular Properties, W. H. Freeman & Co., San Francisco, 1983,
pp. 79-86), acetylation of the N-terminal amine, and amidation of
any C-terminal carboxyl group.
Another type of covalent modification of the antigen binding
protein included within the scope of this invention comprises
altering the glycosylation pattern of the protein. As is known in
the art, glycosylation patterns can depend on both the sequence of
the protein (e.g., the presence or absence of particular
glycosylation amino acid residues, discussed below), or the host
cell or organism in which the protein is produced. Particular
expression systems are discussed below.
Glycosylation of polypeptides is typically either N-linked or
O-linked. N-linked refers to the attachment of the carbohydrate
moiety to the side chain of an asparagine residue. The tri-peptide
sequences asparagine-X-serine and asparagine-X-threonine, where X
is any amino acid except proline, are the recognition sequences for
enzymatic attachment of the carbohydrate moiety to the asparagine
side chain. Thus, the presence of either of these tri-peptide
sequences in a polypeptide creates a potential glycosylation site.
O-linked glycosylation refers to the attachment of one of the
sugars N-acetylgalactosamine, galactose, or xylose, to a
hydroxyamino acid, most commonly serine or threonine, although
5-hydroxyproline or 5-hydroxylysine may also be used.
Addition of glycosylation sites to the antigen binding protein is
conveniently accomplished by altering the amino acid sequence such
that it contains one or more of the above-described tri-peptide
sequences (for N-linked glycosylation sites). The alteration may
also be made by the addition of, or substitution by, one or more
serine or threonine residues to the starting sequence (for O-linked
glycosylation sites). For ease, the antigen binding protein amino
acid sequence is preferably altered through changes at the DNA
level, particularly by mutating the DNA encoding the target
polypeptide at preselected bases such that codons are generated
that will translate into the desired amino acids.
Another means of increasing the number of carbohydrate moieties on
the antigen binding protein is by chemical or enzymatic coupling of
glycosides to the protein. These procedures are advantageous in
that they do not require production of the protein in a host cell
that has glycosylation capabilities for N- and O-linked
glycosylation. Depending on the coupling mode used, the sugar(s)
may be attached to (a) arginine and histidine, (b) free carboxyl
groups, (c) free sulfhydryl groups such as those of cysteine, (d)
free hydroxyl groups such as those of serine, threonine, or
hydroxyproline, (e) aromatic residues such as those of
phenylalanine, tyrosine, or tryptophan, or (f) the amide group of
glutamine. These methods are described in WO 87/05330 published
Sep. 11, 1987, and in Aplin and Wriston, 1981, CRC Crit. Rev.
Biochem., pp. 259-306.
Removal of carbohydrate moieties present on the starting antigen
binding protein may be accomplished chemically or enzymatically.
Chemical deglycosylation requires exposure of the protein to the
compound trifluoromethanesulfonic acid, or an equivalent compound.
This treatment results in the cleavage of most or all sugars except
the linking sugar (N-acetylglucosamine or N-acetylgalactosamine),
while leaving the polypeptide intact. Chemical deglycosylation is
described by Hakimuddin et al., 1987, Arch. Biochem. Biophys.
259:52 and by Edge et al., 1981, Anal. Biochem. 118:131. Enzymatic
cleavage of carbohydrate moieties on polypeptides can be achieved
by the use of a variety of endo- and exo-glycosidases as described
by Thotakura et al., 1987, Meth. Enzymol. 138:350. Glycosylation at
potential glycosylation sites may be prevented by the use of the
compound tunicamycin as described by Duskin et al., 1982, J. Biol.
Chem. 257:3105. Tunicamycin blocks the formation of
protein-N-glycoside linkages.
Another type of covalent modification of the antigen binding
protein comprises linking the antigen binding protein to various
nonproteinaceous polymers, including, but not limited to, various
polyols such as polyethylene glycol, polypropylene glycol or
polyoxyalkylenes, in the manner set forth in U.S. Pat. No.
4,640,835; 4,496,689; 4,301,144; 4,670,417; 4,791,192 or 4,179,337.
In addition, as is known in the art, amino acid substitutions may
be made in various positions within the antigen binding protein to
facilitate the addition of polymers such as PEG.
In some embodiments, the covalent modification of the antigen
binding proteins of the invention comprises the addition of one or
more labels.
The term "labelling group" means any detectable label. Examples of
suitable labelling groups include, but are not limited to, the
following: radioisotopes or radionuclides (e.g., .sup.3H, .sup.14C,
.sup.15N, .sup.35S, .sup.90Y, .sup.99Tc, .sup.111In, .sup.125I,
.sup.131I), fluorescent groups (e.g., FITC, rhodamine, lanthanide
phosphors), enzymatic groups (e.g., horseradish peroxidase,
.beta.-galactosidase, luciferase, alkaline phosphatase),
chemiluminescent groups, biotinyl groups, or predetermined
polypeptide epitopes recognized by a secondary reporter (e.g.,
leucine zipper pair sequences, binding sites for secondary
antibodies, metal binding domains, epitope tags). In some
embodiments, the labelling group is coupled to the antigen binding
protein via spacer arms of various lengths to reduce potential
steric hindrance. Various methods for labelling proteins are known
in the art and may be used in performing the present invention.
In general, labels fall into a variety of classes, depending on the
assay in which they are to be detected: a) isotopic labels, which
may be radioactive or heavy isotopes; b) magnetic labels (e.g.,
magnetic particles); c) redox active moieties; d) optical dyes;
enzymatic groups (e.g. horseradish peroxidase,
.beta.-galactosidase, luciferase, alkaline phosphatase); e)
biotinylated groups; and f) predetermined polypeptide epitopes
recognized by a secondary reporter (e.g., leucine zipper pair
sequences, binding sites for secondary antibodies, metal binding
domains, epitope tags, etc.). In some embodiments, the labeling
group is coupled to the antigen binding protein via spacer arms of
various lengths to reduce potential steric hindrance. Various
methods for labeling proteins are known in the art and may be used
in performing the present invention.
Specific labels include optical dyes, including, but not limited
to, chromophores, phosphors and fluorophores, with the latter being
specific in many instances. Fluorophores can be either "small
molecule" fluores, or proteinaceous fluores.
By "fluorescent label" is meant any molecule that may be detected
via its inherent fluorescent properties. Suitable fluorescent
labels include, but are not limited to, fluorescein, rhodamine,
tetramethylrhodamine, eosin, erythrosin, coumarin,
methyl-coumarins, pyrene, Malacite green, stilbene, Lucifer Yellow,
Cascade BlueJ, Texas Red, IAEDANS, EDANS, BODIPY FL, LC Red 640,
Cy5, Cy5.5, LC Red 705, Oregon green, the Alexa-Fluor dyes (Alexa
Fluor 350, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 546, Alexa
Fluor 568, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 660, Alexa
Fluor 680), Cascade Blue, Cascade Yellow and R-phycoerythrin (PE)
(Molecular Probes, Eugene, Oreg.), FITC, Rhodamine, and Texas Red
(Pierce, Rockford, Ill.), Cy5, Cy5.5, Cy7 (Amersham Life Science,
Pittsburgh, Pa.). Suitable optical dyes, including fluorophores,
are described in Molecular Probes Handbook by Richard P. Haugland,
hereby expressly incorporated by reference.
Suitable proteinaceous fluorescent labels also include, but are not
limited to, green fluorescent protein, including a Renilla,
Ptilosarcus, or Aequorea species of GFP (Chalfie et al., 1994,
Science 263:802-805), EGFP (Clontech Laboratories, Inc., Genbank
Accession Number U55762), blue fluorescent protein (BFP, Quantum
Biotechnologies, Inc. 1801 de Maisonneuve Blvd. West, 8th Floor,
Montreal, Quebec, Canada H3H 1J9; Stauber, 1998, Biotechniques
24:462-471; Heim et al., 1996, Curr. Biol. 6:178-182), enhanced
yellow fluorescent protein (EYFP, Clontech Laboratories, Inc.),
luciferase (Ichiki et al., 1993, J. Immunol. 150:5408-5417), .beta.
galactosidase (Nolan et al., 1988, Proc. Natl. Acad. Sci. U.S.A.
85:2603-2607) and Renilla (WO92/15673, WO95/07463, WO98/14605,
WO98/26277, WO99/49019, U.S. Pat. Nos. 5,292,658, 5,418,155,
5,683,888, 5,741,668, 5,777,079, 5,804,387, 5,874,304, 5,876,995,
5,925,558). All of the above-cited references are expressly
incorporated herein by reference.
Polynucleotides Encoding IL-17RA Antigen Binding Proteins
Encompassed within the invention are nucleic acids encoding IL-17RA
antigen binding proteins, including antibodies, as defined herein.
The polynucleotide sequences for the heavy chain variable regions
AM.sub.H1-26 are found in SEQ ID NOs:54-79, respectively, and the
polynucleotide sequences for the light chain variable regions
AM.sub.L1-26 are found in SEQ ID NOs:80-106, respectively, with
AM.sub.L23 having two version, as shown in SEQ ID NO:102 and 103.
The SEQ ID NOs for the polynucleotide sequences encoding the
H-CDR1, H-CDR2, H-CDR3, L-CDR1, L-CDR2, and L-CDR3 are provided in
TABLE 1.
Aspects of the invention include polynucleotide variants (e.g., due
to degeneracy) that encode the amino acid sequences described
herein.
Nucleotide sequences corresponding to the amino acid sequences
described herein, to be used as probes or primers for the isolation
of nucleic acids or as query sequences for database searches, can
be obtained by "back-translation" from the amino acid sequences, or
by identification of regions of amino acid identity with
polypeptides for which the coding DNA sequence has been identified.
The well-known polymerase chain reaction (PCR) procedure can be
employed to isolate and amplify a DNA sequence encoding a IL-17RA
antigen binding proteins or a desired combination of IL-17RA
antigen binding protein polypeptide fragments. Oligonucleotides
that define the desired termini of the combination of DNA fragments
are employed as 5' and 3' primers. The oligonucleotides can
additionally contain recognition sites for restriction
endonucleases, to facilitate insertion of the amplified combination
of DNA fragments into an expression vector. PCR techniques are
described in Saiki et al., Science 239:487 (1988); Recombinant DNA
Methodology, Wu et al., eds., Academic Press, Inc., San Diego
(1989), pp. 189-196; and PCR Protocols: A Guide to Methods and
Applications, Innis et. al., eds., Academic Press, Inc. (1990).
Nucleic acid molecules of the invention include DNA and RNA in both
single-stranded and double-stranded form, as well as the
corresponding complementary sequences. DNA includes, for example,
cDNA, genomic DNA, chemically synthesized DNA, DNA amplified by
PCR, and combinations thereof. The nucleic acid molecules of the
invention include full-length genes or cDNA molecules as well as a
combination of fragments thereof. The nucleic acids of the
invention are preferentially derived from human sources, but the
invention includes those derived from non-human species, as
well.
An "isolated nucleic acid" is a nucleic acid that has been
separated from adjacent genetic sequences present in the genome of
the organism from which the nucleic acid was isolated, in the case
of nucleic acids isolated from naturally-occurring sources. In the
case of nucleic acids synthesized enzymatically from a template or
chemically, such as PCR products, cDNA molecules, or
oligonucleotides for example, it is understood that the nucleic
acids resulting from such processes are isolated nucleic acids. An
isolated nucleic acid molecule refers to a nucleic acid molecule in
the form of a separate fragment or as a component of a larger
nucleic acid construct. In one preferred embodiment, the nucleic
acids are substantially free from contaminating endogenous
material. The nucleic acid molecule has preferably been derived
from DNA or RNA isolated at least once in substantially pure form
and in a quantity or concentration enabling identification,
manipulation, and recovery of its component nucleotide sequences by
standard biochemical methods (such as those outlined in Sambrook et
al., Molecular Cloning: A Laboratory Manual, 2nd ed., Cold Spring
Harbor Laboratory, Cold Spring Harbor, N.Y. (1989)). Such sequences
are preferably provided and/or constructed in the form of an open
reading frame uninterrupted by internal non-translated sequences,
or introns, that are typically present in eukaryotic genes.
Sequences of non-translated DNA can be present 5' or 3' from an
open reading frame, where the same do not interfere with
manipulation or expression of the coding region.
The present invention also includes nucleic acids that hybridize
under moderately stringent conditions, and more preferably highly
stringent conditions, to nucleic acids encoding IL-17RA antigen
binding proteins as described herein. The basic parameters
affecting the choice of hybridization conditions and guidance for
devising suitable conditions are set forth by Sambrook, Fritsch,
and Maniatis (1989, Molecular Cloning: A Laboratory Manual, Cold
Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., chapters
9 and 11; and Current Protocols in Molecular Biology, 1995, Ausubel
et al., eds., John Wiley & Sons, Inc., sections 2.10 and
6.3-6.4), and can be readily determined by those having ordinary
skill in the art based on, for example, the length and/or base
composition of the DNA. One way of achieving moderately stringent
conditions involves the use of a prewashing solution containing
5.times.SSC, 0.5% SDS, 1.0 mM EDTA (pH 8.0), hybridization buffer
of about 50% formamide, 6.times.SSC, and a hybridization
temperature of about 55 degrees C. (or other similar hybridization
solutions, such as one containing about 50% formamide, with a
hybridization temperature of about 42 degrees C.), and washing
conditions of about 60 degrees C., in 0.5.times.SSC, 0.1% SDS.
Generally, highly stringent conditions are defined as hybridization
conditions as above, but with washing at approximately 68 degrees
C., 0.2.times.SSC, 0.1% SDS. SSPE (1.times.SSPE is 0.15M NaCl, 10
mM NaH.sub.2 PO.sub.4, and 1.25 mM EDTA, pH 7.4) can be substituted
for SSC (1.times.SSC is 0.15M NaCl and 15 mM sodium citrate) in the
hybridization and wash buffers; washes are performed for 15 minutes
after hybridization is complete. It should be understood that the
wash temperature and wash salt concentration can be adjusted as
necessary to achieve a desired degree of stringency by applying the
basic principles that govern hybridization reactions and duplex
stability, as known to those skilled in the art and described
further below (see, e.g., Sambrook et al., 1989). When hybridizing
a nucleic acid to a target nucleic acid of unknown sequence, the
hybrid length is assumed to be that of the hybridizing nucleic
acid. When nucleic acids of known sequence are hybridized, the
hybrid length can be determined by aligning the sequences of the
nucleic acids and identifying the region or regions of optimal
sequence complementarity. The hybridization temperature for hybrids
anticipated to be less than 50 base pairs in length should be 5 to
10.degrees C. less than the melting temperature (Tm) of the hybrid,
where Tm is determined according to the following equations. For
hybrids less than 18 base pairs in length, Tm (degrees C.)=2(# of
A+T bases)+4(# of #G+C bases). For hybrids above 18 base pairs in
length, Tm (degrees C.)=81.5+16.6(log.sub.10 [Na.sup.+])+0.41 (%
G+C)-(600/N), where N is the number of bases in the hybrid, and
[Na.sup.+] is the concentration of sodium ions in the hybridization
buffer ([Na.sup.+] for 1.times.SSC=0.165M). Preferably, each such
hybridizing nucleic acid has a length that is at least 15
nucleotides (or more preferably at least 18 nucleotides, or at
least 20 nucleotides, or at least 25 nucleotides, or at least 30
nucleotides, or at least 40 nucleotides, or most preferably at
least 50 nucleotides), or at least 25% (more preferably at least
50%, or at least 60%, or at least 70%, and most preferably at least
80%) of the length of the nucleic acid of the present invention to
which it hybridizes, and has at least 60% sequence identity (more
preferably at least 70%, at least 75%, at least 80%, at least 81%,
at least 82%, at least 83%, at least 84%, at least 85%, at least
86%, at least 87%, at least 88%, at least 89%, at least 90%, at
least 91%, at least 92%, at least 93%, at least 94%, at least 95%,
at least 96%, at least 97%, at least 98%, or at least 99%, and most
preferably at least 99.5%) with the nucleic acid of the present
invention to which it hybridizes, where sequence identity is
determined by comparing the sequences of the hybridizing nucleic
acids when aligned so as to maximize overlap and identity while
minimizing sequence gaps as described in more detail above.
The variants according to the invention are ordinarily prepared by
site specific mutagenesis of nucleotides in the DNA encoding the
antigen binding protein, using cassette or PCR mutagenesis or other
techniques well known in the art, to produce DNA encoding the
variant, and thereafter expressing the recombinant DNA in cell
culture as outlined herein. However, antigen binding protein
fragments comprising variant CDRs having up to about 100-150
residues may be prepared by in vitro synthesis using established
techniques. The variants typically exhibit the same qualitative
biological activity as the naturally occurring analogue, e.g.,
binding to IL-17RA and inhibiting signaling, although variants can
also be selected which have modified characteristics as will be
more fully outlined below.
As will be appreciated by those in the art, due to the degeneracy
of the genetic code, an extremely large number of nucleic acids may
be made, all of which encode the CDRs (and heavy and light chains
or other components of the antigen binding protein) of the present
invention. Thus, having identified a particular amino acid
sequence, those skilled in the art could make any number of
different nucleic acids, by simply modifying the sequence of one or
more codons in a way which does not change the amino acid sequence
of the encoded protein.
The present invention also provides expression systems and
constructs in the form of plasmids, expression vectors,
transcription or expression cassettes which comprise at least one
polynucleotide as above. In addition, the invention provides host
cells comprising such expression systems or constructs.
Typically, expression vectors used in any of the host cells will
contain sequences for plasmid maintenance and for cloning and
expression of exogenous nucleotide sequences. Such sequences,
collectively referred to as "flanking sequences" in certain
embodiments will typically include one or more of the following
nucleotide sequences: a promoter, one or more enhancer sequences,
an origin of replication, a transcriptional termination sequence, a
complete intron sequence containing a donor and acceptor splice
site, a sequence encoding a leader sequence for polypeptide
secretion, a ribosome binding site, a polyadenylation sequence, a
polylinker region for inserting the nucleic acid encoding the
polypeptide to be expressed, and a selectable marker element. Each
of these sequences is discussed below.
Optionally, the vector may contain a "tag"-encoding sequence, i.e.,
an oligonucleotide molecule located at the 5' or 3' end of the
IL-17A antigen binding protein coding sequence; the oligonucleotide
sequence encodes polyHis (such as hexaHis), or another "tag" such
as FLAG, HA (hemaglutinin influenza virus), or myc, for which
commercially available antibodies exist. This tag is typically
fused to the polypeptide upon expression of the polypeptide, and
can serve as a means for affinity purification or detection of the
IL-17RA antigen binding protein from the host cell. Affinity
purification can be accomplished, for example, by column
chromatography using antibodies against the tag as an affinity
matrix. Optionally, the tag can subsequently be removed from the
purified IL-17RA antigen binding protein by various means such as
using certain peptidases for cleavage.
Flanking sequences may be homologous (i.e., from the same species
and/or strain as the host cell), heterologous (i.e., from a species
other than the host cell species or strain), hybrid (i.e., a
combination of flanking sequences from more than one source),
synthetic or native. As such, the source of a flanking sequence may
be any prokaryotic or eukaryotic organism, any vertebrate or
invertebrate organism, or any plant, provided that the flanking
sequence is functional in, and can be activated by, the host cell
machinery.
Flanking sequences useful in the vectors of this invention may be
obtained by any of several methods well known in the art.
Typically, flanking sequences useful herein will have been
previously identified by mapping and/or by restriction endonuclease
digestion and can thus be isolated from the proper tissue source
using the appropriate restriction endonucleases. In some cases, the
full nucleotide sequence of a flanking sequence may be known. Here,
the flanking sequence may be synthesized using the methods
described herein for nucleic acid synthesis or cloning.
Whether all or only a portion of the flanking sequence is known, it
may be obtained using polymerase chain reaction (PCR) and/or by
screening a genomic library with a suitable probe such as an
oligonucleotide and/or flanking sequence fragment from the same or
another species. Where the flanking sequence is not known, a
fragment of DNA containing a flanking sequence may be isolated from
a larger piece of DNA that may contain, for example, a coding
sequence or even another gene or genes. Isolation may be
accomplished by restriction endonuclease digestion to produce the
proper DNA fragment followed by isolation using agarose gel
purification, Qiagen.RTM. column chromatography (Chatsworth,
Calif.), or other methods known to the skilled artisan. The
selection of suitable enzymes to accomplish this purpose will be
readily apparent to one of ordinary skill in the art.
An origin of replication is typically a part of those prokaryotic
expression vectors purchased commercially, and the origin aids in
the amplification of the vector in a host cell. If the vector of
choice does not contain an origin of replication site, one may be
chemically synthesized based on a known sequence, and ligated into
the vector. For example, the origin of replication from the plasmid
pBR322 (New England Biolabs, Beverly, Mass.) is suitable for most
gram-negative bacteria, and various viral origins (e.g., SV40,
polyoma, adenovirus, vesicular stomatitus virus (VSV), or
papillomaviruses such as HPV or BPV) are useful for cloning vectors
in mammalian cells. Generally, the origin of replication component
is not needed for mammalian expression vectors (for example, the
SV40 origin is often used only because it also contains the virus
early promoter).
A transcription termination sequence is typically located 3' to the
end of a polypeptide coding region and serves to terminate
transcription. Usually, a transcription termination sequence in
prokaryotic cells is a G-C rich fragment followed by a poly-T
sequence. While the sequence is easily cloned from a library or
even purchased commercially as part of a vector, it can also be
readily synthesized using methods for nucleic acid synthesis such
as those described herein.
A selectable marker gene encodes a protein necessary for the
survival and growth of a host cell grown in a selective culture
medium. Typical selection marker genes encode proteins that (a)
confer resistance to antibiotics or other toxins, e.g., ampicillin,
tetracycline, or kanamycin for prokaryotic host cells; (b)
complement auxotrophic deficiencies of the cell; or (c) supply
critical nutrients not available from complex or defined media.
Specific selectable markers are the kanamycin resistance gene, the
ampicillin resistance gene, and the tetracycline resistance gene.
Advantageously, a neomycin resistance gene may also be used for
selection in both prokaryotic and eukaryotic host cells.
Other selectable genes may be used to amplify the gene that will be
expressed. Amplification is the process wherein genes that are
required for production of a protein critical for growth or cell
survival are reiterated in tandem within the chromosomes of
successive generations of recombinant cells. Examples of suitable
selectable markers for mammalian cells include dihydrofolate
reductase (DHFR) and promoterless thymidine kinase genes. Mammalian
cell transformants are placed under selection pressure wherein only
the transformants are uniquely adapted to survive by virtue of the
selectable gene present in the vector. Selection pressure is
imposed by culturing the transformed cells under conditions in
which the concentration of selection agent in the medium is
successively increased, thereby leading to the amplification of
both the selectable gene and the DNA that encodes another gene,
such as an antigen binding protein antibody that binds to IL-17RA
polypeptide. As a result, increased quantities of a polypeptide
such as an IL-17RA antigen binding protein are synthesized from the
amplified DNA.
A ribosome-binding site is usually necessary for translation
initiation of mRNA and is characterized by a Shine-Dalgarno
sequence (prokaryotes) or a Kozak sequence (eukaryotes). The
element is typically located 3' to the promoter and 5' to the
coding sequence of the polypeptide to be expressed.
In some cases, such as where glycosylation is desired in a
eukaryotic host cell expression system, one may manipulate the
various pre- or prosequences to improve glycosylation or yield. For
example, one may alter the peptidase cleavage site of a particular
signal peptide, or add prosequences, which also may affect
glycosylation. The final protein product may have, in the -1
position (relative to the first amino acid of the mature protein)
one or more additional amino acids incident to expression, which
may not have been totally removed. For example, the final protein
product may have one or two amino acid residues found in the
peptidase cleavage site, attached to the amino-terminus.
Alternatively, use of some enzyme cleavage sites may result in a
slightly truncated form of the desired polypeptide, if the enzyme
cuts at such area within the mature polypeptide.
Expression and cloning vectors of the invention will typically
contain a promoter that is recognized by the host organism and
operably linked to the molecule encoding the IL-17RA antigen
binding protein. Promoters are untranscribed sequences located
upstream (i.e., 5') to the start codon of a structural gene
(generally within about 100 to 1000 bp) that control transcription
of the structural gene. Promoters are conventionally grouped into
one of two classes: inducible promoters and constitutive promoters.
Inducible promoters initiate increased levels of transcription from
DNA under their control in response to some change in culture
conditions, such as the presence or absence of a nutrient or a
change in temperature. Constitutive promoters, on the other hand,
uniformly transcribe gene to which they are operably linked, that
is, with little or no control over gene expression. A large number
of promoters, recognized by a variety of potential host cells, are
well known. A suitable promoter is operably linked to the DNA
encoding heavy chain or light chain comprising an IL-17RA antigen
binding protein of the invention by removing the promoter from the
source DNA by restriction enzyme digestion and inserting the
desired promoter sequence into the vector.
Suitable promoters for use with yeast hosts are also well known in
the art. Yeast enhancers are advantageously used with yeast
promoters. Suitable promoters for use with mammalian host cells are
well known and include, but are not limited to, those obtained from
the genomes of viruses such as polyoma virus, fowlpox virus,
adenovirus (such as Adenovirus 2), bovine papilloma virus, avian
sarcoma virus, cytomegalovirus, retroviruses, hepatitis-B virus and
most preferably Simian Virus 40 (SV40). Other suitable mammalian
promoters include heterologous mammalian promoters, for example,
heat-shock promoters and the actin promoter.
Additional promoters which may be of interest include, but are not
limited to: SV40 early promoter (Benoist and Chambon, 1981, Nature
290:304-310); CMV promoter (Thomsen et al., 1984, Proc. Natl. Acad.
U.S.A. 81:659-663); the promoter contained in the 3' long terminal
repeat of Rous sarcoma virus (Yamamoto et al., 1980, Cell
22:787-797); herpes thymidine kinase promoter (Wagner et al., 1981,
Proc. Natl. Acad. Sci. U.S.A. 78:1444-1445); promoter and
regulatory sequences from the metallothionine gene Prinster et al.,
1982, Nature 296:39-42); and prokaryotic promoters such as the
beta-lactamase promoter (VIIIa-Kamaroff et al., 1978, Proc. Natl.
Acad. Sci. U.S.A. 75:3727-3731); or the tac promoter (DeBoer et
al., 1983, Proc. Natl. Acad. Sci. U.S.A. 80:21-25). Also of
interest are the following animal transcriptional control regions,
which exhibit tissue specificity and have been utilized in
transgenic animals: the elastase I gene control region that is
active in pancreatic acinar cells (Swift et al., 1984, Cell
38:639-646; Omitz et al., 1986, Cold Spring Harbor Symp. Quant.
Biol. 50:399-409; MacDonald, 1987, Hepatology 7:425-515); the
insulin gene control region that is active in pancreatic beta cells
(Hanahan, 1985, Nature 315:115-122); the immunoglobulin gene
control region that is active in lymphoid cells (Grosschedl et al.,
1984, Cell 38:647-658; Adames et al., 1985, Nature 318:533-538;
Alexander et al., 1987, Mol. Cell. Biol. 7:1436-1444); the mouse
mammary tumor virus control region that is active in testicular,
breast, lymphoid and mast cells (Leder et al., 1986, Cell
45:485-495); the albumin gene control region that is active in
liver (Pinkert et al., 1987, Genes and Devel. 1:268-276); the
alpha-feto-protein gene control region that is active in liver
(Krumlauf et al., 1985, Mol. Cell. Biol. 5:1639-1648; Hammer et
al., 1987, Science 253:53-58); the alpha 1-antitrypsin gene control
region that is active in liver (Kelsey et al., 1987, Genes and
Devel. 1: 161-171); the beta-globin gene control region that is
active in myeloid cells (Mogram et al., 1985, Nature 315:338-340;
Kollias et al., 1986, Cell 46:89-94); the myelin basic protein gene
control region that is active in oligodendrocyte cells in the brain
(Readhead et al., 1987, Cell 48:703-712); the myosin light chain-2
gene control region that is active in skeletal muscle (Sani, 1985,
Nature 314:283-286); and the gonadotropic releasing hormone gene
control region that is active in the hypothalamus (Mason et al.,
1986, Science 234:1372-1378).
An enhancer sequence may be inserted into the vector to increase
transcription of DNA encoding light chain or heavy chain comprising
an IL-17RA antigen binding protein of the invention by higher
eukaryotes. Enhancers are cis-acting elements of DNA, usually about
10-300 bp in length, that act on the promoter to increase
transcription. Enhancers are relatively orientation and position
independent, having been found at positions both 5' and 3' to the
transcription unit. Several enhancer sequences available from
mammalian genes are known (e.g., globin, elastase, albumin,
alpha-feto-protein and insulin). Typically, however, an enhancer
from a virus is used. The SV40 enhancer, the cytomegalovirus early
promoter enhancer, the polyoma enhancer, and adenovirus enhancers
known in the art are exemplary enhancing elements for the
activation of eukaryotic promoters. While an enhancer may be
positioned in the vector either 5' or 3' to a coding sequence, it
is typically located at a site 5' from the promoter. A sequence
encoding an appropriate native or heterologous signal sequence
(leader sequence or signal peptide) can be incorporated into an
expression vector, to promote extracellular secretion of the
antibody. The choice of signal peptide or leader depends on the
type of host cells in which the antibody is to be produced, and a
heterologous signal sequence can replace the native signal
sequence. Examples of signal peptides that are functional in
mammalian host cells include the following: the signal sequence for
interleukin-7 (IL-7) described in U.S. Pat. No. 4,965,195; the
signal sequence for interleukin-2 receptor described in Cosman et
al., 1984, Nature 312:768; the interleukin-4 receptor signal
peptide described in EP Patent No. 0367 566; the type I
interleukin-1 receptor signal peptide described in U.S. Pat. No.
4,968,607; the type II interleukin-1 receptor signal peptide
described in EP Patent No. 0 460 846.
Expression vectors of the invention may be constructed from a
starting vector such as a commercially available vector. Such
vectors may or may not contain all of the desired flanking
sequences. Where one or more of the flanking sequences described
herein are not already present in the vector, they may be
individually obtained and ligated into the vector. Methods used for
obtaining each of the flanking sequences are well known to one
skilled in the art.
After the vector has been constructed and a nucleic acid molecule
encoding light chain, a heavy chain, or a light chain and a heavy
chain comprising an IL-17RA antigen binding sequence has been
inserted into the proper site of the vector, the completed vector
may be inserted into a suitable host cell for amplification and/or
polypeptide expression. The transformation of an expression vector
for an IL-17RA antigen binding protein into a selected host cell
may be accomplished by well known methods including transfection,
infection, calcium phosphate co-precipitation, electroporation,
microinjection, lipofection, DEAE-dextran mediated transfection, or
other known techniques. The method selected will in part be a
function of the type of host cell to be used. These methods and
other suitable methods are well known to the skilled artisan, and
are set forth, for example, in Sambrook et al., 2001, supra.
A host cell, when cultured under appropriate conditions,
synthesizes an IL-17RA antigen binding protein that can
subsequently be collected from the culture medium (if the host cell
secretes it into the medium) or directly from the host cell
producing it (if it is not secreted). The selection of an
appropriate host cell will depend upon various factors, such as
desired expression levels, polypeptide modifications that are
desirable or necessary for activity (such as glycosylation or
phosphorylation) and ease of folding into a biologically active
molecule. A host cell may be eukaryotic or prokaryotic.
Mammalian cell lines available as hosts for expression are well
known in the art and include, but are not limited to, immortalized
cell lines available from the American Type Culture Collection
(ATCC) and any cell lines used in an expression system known in the
art can be used to make the recombinant polypeptides of the
invention. In general, host cells are transformed with a
recombinant expression vector that comprises DNA encoding a desired
anti-IL-17RA antibody polypeptide. Among the host cells that may be
employed are prokaryotes, yeast or higher eukaryotic cells.
Prokaryotes include gram negative or gram positive organisms, for
example E. coli or bacilli. Higher eukaryotic cells include insect
cells and established cell lines of mammalian origin. Examples of
suitable mammalian host cell lines include the COS-7 line of monkey
kidney cells (ATCC CRL 1651) (Gluzman et al., 1981, Cell 23:175), L
cells, 293 cells, C127 cells, 3T3 cells (ATCC CCL 163), Chinese
hamster ovary (CHO) cells, or their derivatives such as Veggie CHO
and related cell lines which grow in serum-free media (Rasmussen et
al., 1998, Cytotechnology 28: 31), HeLa cells, BHK (ATCC CRL 10)
cell lines, and the CVI/EBNA cell line derived from the African
green monkey kidney cell line CVI (ATCC CCL 70) as described by
McMahan et al., 1991, EMBO J. 10: 2821, human embryonic kidney
cells such as 293, 293 EBNA or MSR 293, human epidermal A431 cells,
human Colo205 cells, other transformed primate cell lines, normal
diploid cells, cell strains derived from in vitro culture of
primary tissue, primary explants, HL-60, U937, HaK or Jurkat cells.
Optionally, mammalian cell lines such as HepG2/3B, KB, NIH 3T3 or
S49, for example, can be used for expression of the polypeptide
when it is desirable to use the polypeptide in various signal
transduction or reporter assays. Alternatively, it is possible to
produce the polypeptide in lower eukaryotes such as yeast or in
prokaryotes such as bacteria. Suitable yeasts include Saccharomyces
cerevisiae, Schizosaccharomyces pombe, Kluyveromyces strains,
Candida, or any yeast strain capable of expressing heterologous
polypeptides. Suitable bacterial strains include Escherichia coli,
Bacillus subtilis, Salmonella typhimurium, or any bacterial strain
capable of expressing heterologous polypeptides. If the polypeptide
is made in yeast or bacteria, it may be desirable to modify the
polypeptide produced therein, for example by phosphorylation or
glycosylation of the appropriate sites, in order to obtain the
functional polypeptide. Such covalent attachments can be
accomplished using known chemical or enzymatic methods. The
polypeptide can also be produced by operably linking the isolated
nucleic acid of the invention to suitable control sequences in one
or more insect expression vectors, and employing an insect
expression system. Materials and Methods for baculovirus/insect
cell expression systems are commercially available in kit form
from, e.g., Invitrogen, San Diego, Calif., U.S.A. (the MaxBac.RTM.
kit), and such methods are well known in the art, as described in
Summers and Smith, Texas Agricultural Experiment Station Bulletin
No. 1555 (1987), and Luckow and Summers, Bio/Technology 6:47
(1988). Cell-free translation systems could also be employed to
produce polypeptides using RNAs derived from nucleic acid
constructs disclosed herein. Appropriate cloning and expression
vectors for use with bacterial, fungal, yeast, and mammalian
cellular hosts are described by Pouwels et al. (Cloning Vectors: A
Laboratory Manual, Elsevier, N.Y., 1985). A host cell that
comprises an isolated nucleic acid of the invention, preferably
operably linked to at least one expression control sequence, is a
"recombinant host cell".
In certain embodiments, cell lines may be selected through
determining which cell lines have high expression levels and
constitutively produce antigen binding proteins with IL-17RA
binding properties. In another embodiment, a cell line from the B
cell lineage that does not make its own antibody but has a capacity
to make and secrete a heterologous antibody can be selected.
Use of IL-17RA Antigen Binding Proteins for Diagnostic And
Therapeutic Purposes
The IL-17RA antigen binding proteins of the invention can be used
in diagnostic assays, e.g., binding assays to detect and/or
quantify IL-17RA expressed in a tissue or cell. The IL-17RA antigen
binding proteins may be used in research to further investigate the
role of IL-17RA in disease. The IL-17RA antigen binding proteins
may be used to further investigate the role of IL-17RA in forming
homomeric and/or heteromeric receptor complexes and the role of
said complexes in disease. The IL-17RA antigen binding proteins may
be used to further investigate the role of IL-17RA activation to
homomeric and/or heteromeric IL-17 ligand complexes. The IL-17RA
antigen binding proteins may be used to further investigate the
role of IL-17RA activation to homomeric and/or heteromeric IL-17
ligand complexes and how said homomeric and/or heteromeric IL-17
ligand complexes relate to disease.
The IL-17RA antigen binding proteins of the present invention can
be used for the prevention or treatment of diseases or conditions
associated with the IL-17A and/or IL-17F activity. A disease or
condition associated with IL-17A and/or IL-17F means any disease,
condition, or pathology whose onset in a patient is caused or
exacerbated by the interaction of IL-17A and/or IL-17F with
IL-17RA. The severity of the disease, condition, or pathology can
also be increased or decreased by the modulating the interaction of
IL-17A and/or IL-17F with IL-17RA or a heterologous complex
comprising IL-17RA and IL-17RC.
Antigen binding proteins of the invention that specifically bind to
IL-17RA may be used in treatment of IL-17RA mediated diseases in a
patient in need thereof. All aspects of the IL-17RA antigen binding
proteins described throughout this specification may be used in the
preparation of a medicament for the treatment of the various
conditions and diseases described herein. In addition, the IL-17RA
antigen binding protein of the invention can be used to inhibit
IL-17RA from forming a complex with its ligand, e.g., IL-17A and/or
IL-17F or any other IL-17 ligand family member that binds IL-17RA
or a heterologous complex comprising IL-17RA and IL-17RC, thereby
modulating the biological activity of IL-17RA in a cell or tissue.
Antigen binding proteins that bind to IL-17RA thus may modulate
and/or inhibit interaction with other binding compounds and as such
may have therapeutic use in ameliorating IL-17RA mediated diseases.
In specific embodiments, IL-17RA antigen binding proteins may
inhibit IL-17A and/or IL-17F from binding IL-17RA, which may result
in disruption of the IL-17RA-induced signal transduction
cascade.
Increased levels of IL-17A and/or involvement of IL-17A mediated
signals in disease pathogenesis have been demonstrated in a variety
of conditions and diseases. Kolls and Linden, 2004, supra; Miossec,
2003, P. Arthritis Rheum. 48:594-601); WO2005/063290; Cannetti et
al., 2003, J. Immunol. 171:1009-1015; Charles et al., 1999, J.
Immunol. 163: 1521-1528; Cunnane et al., 2000, Online J. Rheumatol.
27 :58-63; Yoshimoto, 1998, J. Immunol. 161: 3400-3407),
(WO2005/063290), (Niederau, 1997, Online NLM), (WO2004/002519),
(Tsutsui et al., 2000, supra), (Konishi et al., 2002, Proc. Natl.
Acad. Sci. U.S.A. 99:11340-11345), Ziolkowska et al., 2000, supra).
(Chabaud, 2001, Arth & Rheumatism, 44:1293). Thus, IL-17RA is
said to influence the pathology of these and other diseases or
conditions described herein.
As described herein, a surrogate rat anti-mouse IL-17RA antibody
inhibits the course of disease and reduces bone and cartilage
degradation in both a prophylactic and therapeutic rodent collagen
induced arthritis model (see Examples below). As further evidence
of the efficacy of interrupting the IL-17A/IL-17RA pathway, IL-17RA
knockout mice are resistant to collagen-induced arthritis and
IL-17RA antibody treatment is effective in arthritis induced in
TNFR knockout mice, showing a TNF independent effect (see Example
6).
Inhibiting IL-17RA using the antigen binding proteins disclosed
herein represents a novel and effective mechanism to inhibit the
symptoms and pathology of inflammatory and autoimmune diseases, and
in particular inflammation and joint degradation found in
rheumatoid arthritis (RA), Preclinical data and data from RA
patient tissues suggest the potential to provide efficacy in those
who failed TNF inhibitor therapy and to confer added benefit in
combination with TNF inhibitors, IL-6 inhibitors, and IL-1
inhibitors.
The antigen binding proteins described herein may be used in
combination (pre-treatment, post-treatment, or concurrent
treatment) with any of one or more TNF inhibitors for the treatment
or prevention of the diseases and disorders recited herein, such as
but not limited to, all forms of soluble TNF receptors including
Etanercept (such as ENBREL.RTM.), as well as all forms of monomeric
or multimeric p75 and/or p55 TNF receptor molecules and fragments
thereof; anti-human TNF antibodies, such as but not limited to,
Infliximab (such as REMICADE.RTM.), and D2E7 (such as HUMIRA.RTM.),
and the like. Such TNF inhibitors include compounds and proteins
which block in vivo synthesis or extracellular release of TNF. In a
specific embodiment, the present invention is directed to the use
of an IL-17RA antigen binding protein in combination
(pre-treatment, post-treatment, or concurrent treatment) with any
of one or more of the following TNF inhibitors: TNF binding
proteins (soluble TNF receptor type-I and soluble TNF receptor
type-II ("sTNFRs"), as defined herein), anti-TNF antibodies,
granulocyte colony stimulating factor; thalidomide; BN 50730;
tenidap; E 5531; tiapafant PCA 4248; nimesulide; panavir; rolipram;
RP 73401; peptide T; MDL 201,449A;
(1R,3S)-Cis-1-[9-(2,6-diaminopurinyl)]-3-hydroxy-4-cyclopentene
hydrochloride;
(1R,3R)-trans-1-(9-(2,6-diamino)purine]-3-acetoxycyclopentane;
(1R,3R)-trans-1-[9-adenyl)-3-azidocyclopentane hydrochloride and
(1R,3R)-trans-1-(6-hydroxy-purin-9-yl)-3-azidocyclo-pentane. TNF
binding proteins are disclosed in the art (EP 308 378, EP 422 339,
GB 2 218 101, EP 393 438, WO 90/13575, EP 398 327, EP 412 486, WO
91/03553, EP 418 014, JP 127,800/1991, EP 433 900, U.S. Pat. No.
5,136,021, GB 2 246 569, EP 464 533, WO 92/01002, WO 92/13095, WO
92/16221, EP 512 528, EP 526 905, WO 93/07863, EP 568 928, WO
93/21946, WO 93/19777, EP 417 563, WO 94/06476, and PCT
International Application No. PCT/US97/12244).
For example, EP 393 438 and EP 422 339 teach the amino acid and
nucleic acid sequences of a soluble TNF receptor type I (also known
as "sTNFR-I" or "30 kDa TNF inhibitor") and a soluble TNF receptor
type II (also known as "sTNFR-II" or "40 kDa TNF inhibitor"),
collectively termed "sTNFRs", as well as modified forms thereof
(e.g., fragments, functional derivatives and variants). EP 393 438
and EP 422 339 also disclose methods for isolating the genes
responsible for coding the inhibitors, cloning the gene in suitable
vectors and cell types and expressing the gene to produce the
inhibitors. Additionally, polyvalent forms (i.e., molecules
comprising more than one active moiety) of sTNFR-1 and sTNFR-II
have also been disclosed. In one embodiment, the polyvalent form
may be constructed by chemically coupling at least one TNF
inhibitor and another moiety with any clinically acceptable linker,
for example polyethylene glycol (WO 92/16221 and WO 95/34326), by a
peptide linker (Neve et al. (1996), Cytokine, 8(5):365-370, by
chemically coupling to biotin and then binding to avidin (WO
91/03553) and, finally, by combining chimeric antibody molecules
(U.S. Pat. No. 5,116,964, WO 89/09622, WO 91/16437 and EP
315062.
Anti-TNF antibodies include the MAK 195F Fab antibody (Holler et
al. (1993), 1st International Symposium on Cytokines in Bone Marrow
Transplantation, 147); CDP 571 anti-TNF monoclonal antibody (Rankin
et al. (1995), British Journal of Rheumatology, 34:334-342); BAY X
1351 murine anti-tumor necrosis factor monoclonal antibody (Kieft
et al. (1995), 7th European Congress of Clinical Microbiology and
Infectious Diseases, page 9); CenTNF cA2 anti-TNF monoclonal
antibody (Elliott et al. (1994), Lancet, 344:1125-1127 and Elliott
et al. (1994), Lancet, 344:1105-1110).
The antigen binding proteins described herein may be used in
combination with all forms of IL-1 inhibitors, such as but not
limited to, kineret (for example ANAKINRA.RTM.). Interleukin-1
receptor antagonist (IL-1ra) is a human protein that acts as a
natural inhibitor of interleukin-1. Interleukin-1 receptor
antagonists, as well as the methods of making and methods of using
thereof, are described in U.S. Pat. No. 5,075,222; WO 91/08285; WO
91/17184; AU 9173636; WO 92/16221; WO 93/21946; WO 94/06457; WO
94/21275; FR 2706772; WO 94/21235; DE 4219626; WO 94/20517; WO
96/22793 and WO 97/28828. The proteins include glycosylated as well
as non-glycosylated IL-1 receptor antagonists. Specifically, three
preferred forms of IL-1ra (IL-1raa, IL-1rap and IL-1rax), each
being encoded by the same DNA coding sequence and variants thereof,
are disclosed and described in U.S. Pat. No. 5,075,222. Methods for
producing IL-1 inhibitors, particularly IL-1ras, are also disclosed
in the U.S. Pat. No. 5,075,222. An additional class of
interleukin-1 inhibitors includes compounds capable of specifically
preventing activation of cellular receptors to IL-1. Such compounds
include IL-1 binding proteins, such as soluble receptors and
monoclonal antibodies. Such compounds also include monoclonal
antibodies to the receptors. A further class of interleukin-1
inhibitors includes compounds and proteins that block in vivo
synthesis and/or extracellular release of IL-1. Such compounds
include agents that affect transcription of IL-1 genes or
processing of IL-1 preproteins.
The antigen binding proteins described herein may be used in
combination with all forms of CD28 inhibitors, such as but not
limited to, abatacept (for example ORENCIA.RTM.).
The antigen binding proteins described herein may be used in
combination with all forms of IL-6 and/or IL-6 receptor inhibitors,
such as but not limited to, abatacept (for example
ACTEMRA.RTM.).
The antigen binding proteins may be used in combination with one or
more cytokines, lymphokines, hematopoietic factor(s), and/or an
anti-inflammatory agent.
Treatment of the diseases and disorders recited herein can include
the use of first line drugs for control of pain and inflammation in
combination (pretreatment, post-treatment, or concurrent treatment)
with treatment with one or more of the antigen binding proteins
provided herein. These drugs are classified as non-steroidal,
anti-inflammatory drugs (NSAIDs). Secondary treatments include
corticosteroids, slow acting antirheumatic drugs (SAARDs), or
disease modifying (DM) drugs. Information regarding the following
compounds can be found in The Merck Manual of Diagnosis and
Therapy, Sixteenth Edition, Merck, Sharp & Dohme Research
Laboratories, Merck & Co., Rahway, N.J. (1992) and in
Pharmaprojects, PJB Publications Ltd.
In a specific embodiment, the present invention is directed to the
use of an antigen binding protein and any of one or more NSAIDs for
the treatment of the diseases and disorders recited herein. NSAIDs
owe their anti-inflammatory action, at least in part, to the
inhibition of prostaglandin synthesis (Goodman and Gilman in "The
Pharmacological Basis of Therapeutics," MacMillan 7th Edition
(1985)). NSAIDs can be characterized into at least nine groups: (1)
salicylic acid derivatives; (2) propionic acid derivatives; (3)
acetic acid derivatives; (4) fenamic acid derivatives; (5)
carboxylic acid derivatives; (6) butyric acid derivatives; (7)
oxicams; (8) pyrazoles and (9) pyrazolones.
In another specific embodiment, the present invention is directed
to the use of an antigen binding protein in combination
(pretreatment, post-treatment, or concurrent treatment) with any of
one or more salicylic acid derivatives, prodrug esters or
pharmaceutically acceptable salts thereof. Such salicylic acid
derivatives, prodrug esters and pharmaceutically acceptable salts
thereof comprise: acetaminosalol, aloxiprin, aspirin, benorylate,
bromosaligenin, calcium acetylsalicylate, choline magnesium
trisalicylate, magnesium salicylate, choline salicylate,
diflusinal, etersalate, fendosal, gentisic acid, glycol salicylate,
imidazole salicylate, lysine acetylsalicylate, mesalamine,
morpholine salicylate, 1-naphthyl salicylate, olsalazine,
parsalmide, phenyl acetylsalicylate, phenyl salicylate,
salacetamide, salicylamide O-acetic acid, salsalate, sodium
salicylate and sulfasalazine. Structurally related salicylic acid
derivatives having similar analgesic and anti-inflammatory
properties are also intended to be encompassed by this group.
In an additional specific embodiment, the present invention is
directed to the use of an antigen binding protein in combination
(pretreatment, post-treatment, or concurrent treatment) with any of
one or more propionic acid derivatives, prodrug esters or
pharmaceutically acceptable salts thereof. The propionic acid
derivatives, prodrug esters, and pharmaceutically acceptable salts
thereof comprise: alminoprofen, benoxaprofen, bucloxic acid,
carprofen, dexindoprofen, fenoprofen, flunoxaprofen, fluprofen,
flurbiprofen, furcloprofen, ibuprofen, ibuprofen aluminum,
ibuproxam, indoprofen, isoprofen, ketoprofen, loxoprofen,
miroprofen, naproxen, naproxen sodium, oxaprozin, piketoprofen,
pimeprofen, pirprofen, pranoprofen, protizinic acid,
pyridoxiprofen, suprofen, tiaprofenic acid and tioxaprofen.
Structurally related propionic acid derivatives having similar
analgesic and anti-inflammatory properties are also intended to be
encompassed by this group.
In yet another specific embodiment, the present invention is
directed to the use of an antigen binding protein in combination
(pretreatment, post-treatment, or concurrent treatment) with any of
one or more acetic acid derivatives, prodrug esters or
pharmaceutically acceptable salts thereof. The acetic acid
derivatives, prodrug esters, and pharmaceutically acceptable salts
thereof comprise: acemetacin, alclofenac, amfenac, bufexamac,
cinmetacin, clopirac, delmetacin, diclofenac potassium, diclofenac
sodium, etodolac, felbinac, fenclofenac, fenclorac, fenclozic acid,
fentiazac, furofenac, glucametacin, ibufenac, indomethacin,
isofezolac, isoxepac, lonazolac, metiazinic acid, oxametacin,
oxpinac, pimetacin, proglumetacin, sulindac, talmetacin, tiaramide,
tiopinac, tolmetin, tolmetin sodium, zidometacin and zomepirac.
Structurally related acetic acid derivatives having similar
analgesic and anti-inflammatory properties are also intended to be
encompassed by this group.
In another specific embodiment, the present invention is directed
to the use of an antigen binding protein in combination
(pretreatment, post-treatment, or concurrent treatment) with any of
one or more fenamic acid derivatives, prodrug esters or
pharmaceutically acceptable salts thereof. The fenamic acid
derivatives, prodrug esters and pharmaceutically acceptable salts
thereof comprise: enfenamic acid, etofenamate, flufenamic acid,
isonixin, meclofenamic acid, meclofenamate sodium, medofenamic
acid, mefenamic acid, niflumic acid, talniflumate, terofenamate,
tolfenamic acid and ufenamate. Structurally related fenamic acid
derivatives having similar analgesic and anti-inflammatory
properties are also intended to be encompassed by this group.
In an additional specific embodiment, the present invention is
directed to the use of an antigen binding protein in combination
(pretreatment, post-treatment, or concurrent treatment) with any of
one or more carboxylic acid derivatives, prodrug esters or
pharmaceutically acceptable salts thereof. The carboxylic acid
derivatives, prodrug esters, and pharmaceutically acceptable salts
thereof which can be used comprise: clidanac, diflunisal,
flufenisal, inoridine, ketorolac and tinoridine. Structurally
related carboxylic acid derivatives having similar analgesic and
anti-inflammatory properties are also intended to be encompassed by
this group.
In yet another specific embodiment, the present invention is
directed to the use of an antigen binding protein in combination
(pretreatment, post-treatment, or concurrent treatment) with any of
one or more butyric acid derivatives, prodrug esters or
pharmaceutically acceptable salts thereof. The butyric acid
derivatives, prodrug esters, and pharmaceutically acceptable salts
thereof comprise: bumadizon, butibufen, fenbufen and xenbucin.
Structurally related butyric acid derivatives having similar
analgesic and anti-inflammatory properties are also intended to be
encompassed by this group.
In another specific embodiment, the present invention is directed
to the use of an antigen binding protein in combination
(pretreatment, post-treatment, or concurrent treatment) with any of
one or more oxicams, prodrug esters, or pharmaceutically acceptable
salts thereof. The oxicams, prodrug esters, and pharmaceutically
acceptable salts thereof comprise: droxicam, enolicam, isoxicam,
piroxicam, sudoxicam, tenoxicam and 4-hydroxyl-1,2-benzothiazine
1,1-dioxide 4-(N-phenyl)-carboxamide. Structurally related oxicams
having similar analgesic and anti-inflammatory properties are also
intended to be encompassed by this group.
In still another specific embodiment, the present invention is
directed to the use of an antigen binding protein in combination
(pretreatment, post-treatment, or concurrent treatment) with any of
one or more pyrazoles, prodrug esters, or pharmaceutically
acceptable salts thereof. The pyrazoles, prodrug esters, and
pharmaceutically acceptable salts thereof which may be used
comprise: difenamizole and epirizole. Structurally related
pyrazoles having similar analgesic and anti-inflammatory properties
are also intended to be encompassed by this group.
In an additional specific embodiment, the present invention is
directed to the use of an antigen binding protein in combination
(pretreatment, post-treatment or, concurrent treatment) with any of
one or more pyrazolones, prodrug esters, or pharmaceutically
acceptable salts thereof. The pyrazolones, prodrug esters and
pharmaceutically acceptable salts thereof which may be used
comprise: apazone, azapropazone, benzpiperylon, feprazone,
mofebutazone, morazone, oxyphenbutazone, phenylbutazone,
pipebuzone, propylphenazone, ramifenazone, suxibuzone and
thiazolinobutazone. Structurally related pyrazalones having similar
analgesic and anti-inflammatory properties are also intended to be
encompassed by this group.
In another specific embodiment, the present invention is directed
to the use of an antigen binding protein in combination
(pretreatment, post-treatment, or concurrent treatment) with any of
one or more of the following NSAIDs: .epsilon.-acetamidocaproic
acid, S-adenosyl-methionine, 3-amino-4-hydroxybutyric acid,
amixetrine, anitrazafen, antrafenine, bendazac, bendazac lysinate,
benzydamine, beprozin, broperamole, bucolome, bufezolac,
ciproquazone, cloximate, dazidamine, deboxamet, detomidine,
difenpiramide, difenpyramide, difisalamine, ditazol, emorfazone,
fanetizole mesylate, fenflumizole, floctafenine, flumizole,
flunixin, fluproquazone, fopirtoline, fosfosal, guaimesal,
guaiazolene, isonixirn, lefetamine HCl, leflunomide, lofemizole,
lotifazole, lysin clonixinate, meseclazone, nabumetone, nictindole,
nimesulide, orgotein, orpanoxin, oxaceprol, oxapadol, paranyline,
perisoxal, perisoxal citrate, pifoxime, piproxen, pirazolac,
pirfenidone, proquazone, proxazole, thielavin B, tiflamizole,
timegadine, tolectin, tolpadol, tryptamid and those designated by
company code number such as 480156S, AA861, AD1590, AFP802, AFP860,
AI77B, AP504, AU8001, BPPC, BW540C, CHINOIN 121, CN100, EB382,
EL508, F1044, FK-506, GV3658, ITF182, KCNTEI6090, KME4, LA2851,
MR714, MR897, MY309, ONO3144, PR823, PV102, PV108, R830, RS2131,
SCR152, SH440, SIR133, SPAS510, SQ27239, ST281, SY6001, TA60,
TAI-901 (4-benzoyl-1-indancarboxylic acid), TVX2706, U60257, UR2301
and WY41770. Structurally related NSAIDs having similar analgesic
and anti-inflammatory properties to the NSAIDs are also intended to
be encompassed by this group.
In still another specific embodiment, the present invention is
directed to the use of an antigen binding protein in combination
(pretreatment, post-treatment or concurrent treatment) with any of
one or more corticosteroids, prodrug esters or pharmaceutically
acceptable salts thereof for the treatment of the diseases and
disorders recited herein, including acute and chronic inflammation
such as rheumatic diseases, graft versus host disease and multiple
sclerosis. Corticosteroids, prodrug esters and pharmaceutically
acceptable salts thereof include hydrocortisone and compounds which
are derived from hydrocortisone, such as 21-acetoxypregnenolone,
alclomerasone, algestone, amcinonide, beclomethasone,
betamethasone, betamethasone valerate, budesonide,
chloroprednisone, clobetasol, clobetasol propionate, clobetasone,
clobetasone butyrate, clocortolone, cloprednol, corticosterone,
cortisone, cortivazol, deflazacon, desonide, desoximerasone,
dexamethasone, diflorasone, diflucortolone, difluprednate,
enoxolone, fluazacort, flucloronide, flumethasone, flumethasone
pivalate, flucinolone acetonide, flunisolide, fluocinonide,
fluorocinolone acetonide, fluocortin butyl, fluocortolone,
fluocortolone hexanoate, diflucortolone valerate, fluorometholone,
fluperolone acetate, fluprednidene acetate, fluprednisolone,
flurandenolide, formocortal, halcinonide, halometasone, halopredone
acetate, hydro-cortamate, hydrocortisone, hydrocortisone acetate,
hydro-cortisone butyrate, hydrocortisone phosphate, hydrocortisone
21-sodium succinate, hydrocortisone tebutate, mazipredone,
medrysone, meprednisone, methylprednisolone, mometasone furoate,
paramethasone, prednicarbate, prednisolone, prednisolone
21-diedryaminoacetate, prednisolone sodium phosphate, prednisolone
sodium succinate, prednisolone sodium 21-m-sulfobenzoate,
prednisolone sodium 21-stearoglycolate, prednisolone tebutate,
prednisolone 21-trimethylacetate, prednisone, prednival,
prednylidene, prednylidene 21-diethylaminoacetate, tixocortol,
triamcinolone, triamcinolone acetonide, triamcinolone benetonide
and triamcinolone hexacetonide. Structurally related
corticosteroids having similar analgesic and anti-inflammatory
properties are also intended to be encompassed by this group.
In another specific embodiment, the present invention is directed
to the use of an antigen binding protein in combination
(pretreatment, post-treatment, or concurrent treatment) with any of
one or more slow-acting antirheumatic drugs (SAARDs) or disease
modifying antirheumatic drugs (DMARDS), prodrug esters, or
pharmaceutically acceptable salts thereof for the treatment of the
diseases and disorders recited herein, including acute and chronic
inflammation such as rheumatic diseases, graft versus host disease
and multiple sclerosis. SAARDs or DMARDS, prodrug esters and
pharmaceutically acceptable salts thereof comprise: allocupreide
sodium, auranofin, aurothioglucose, aurothioglycanide,
azathioprine, brequinar sodium, bucillamine, calcium
3-aurothio-2-propanol-1-sulfonate, chlorambucil, chloroquine,
clobuzarit, cuproxoline, cyclo-phosphamide, cyclosporin, dapsone,
15-deoxyspergualin, diacerein, glucosamine, gold salts (e.g.,
cycloquine gold salt, gold sodium thiomalate, gold sodium
thiosulfate), hydroxychloroquine, hydroxychloroquine sulfate,
hydroxyurea, kebuzone, levamisole, lobenzarit, melittin,
6-mercaptopurine, methotrexate, mizoribine, mycophenolate mofetil,
myoral, nitrogen mustard, D-penicillamine, pyridinol imidazoles
such as SKNF86002 and SB203580, rapamycin, thiols, thymopoietin and
vincristine. Structurally related SAARDs or DMARDs having similar
analgesic and anti-inflammatory properties are also intended to be
encompassed by this group.
In another specific embodiment, the present invention is directed
to the use of an antigen binding protein in combination
(pretreatment, post-treatment, or concurrent treatment) with any of
one or more COX2 inhibitors, prodrug esters or pharmaceutically
acceptable salts thereof for the treatment of the diseases and
disorders recited herein, including acute and chronic inflammation.
Examples of COX2 inhibitors, prodrug esters or pharmaceutically
acceptable salts thereof include, for example, celecoxib.
Structurally related COX2 inhibitors having similar analgesic and
anti-inflammatory properties are also intended to be encompassed by
this group. Examples of COX-2 selective inhibitors include but not
limited to etoricoxib, valdecoxib, celecoxib, licofelone,
lumiracoxib, rofecoxib, and the like.
In still another specific embodiment, the present invention is
directed to the use of an antigen binding protein in combination
(pretreatment, post-treatment, or concurrent treatment) with any of
one or more antimicrobials, prodrug esters or pharmaceutically
acceptable salts thereof for the treatment of the diseases and
disorders recited herein, including acute and chronic inflammation.
Antimicrobials include, for example, the broad classes of
penicillins, cephalosporins and other beta-lactams,
aminoglycosides, azoles, quinolones, macrolides, rifamycins,
tetracyclines, sulfonamides, lincosamides and polymyxins. The
penicillins include, but are not limited to penicillin G,
penicillin V, methicillin, nafcillin, oxacillin, cloxacillin,
dicloxacillin, floxacillin, ampicillin, ampicillin/sulbactam,
amoxicillin, amoxicillin/clavulanate, hetacillin, cyclacillin,
bacampicillin, carbenicillin, carbenicillin indanyl, ticarcillin,
ticarcillin/clavulanate, azlocillin, meziocillin, peperacillin, and
mecillinam. The cephalosporins and other beta-lactams include, but
are not limited to cephalothin, cephapirin, cephalexin, cephradine,
cefazolin, cefadroxil, cefaclor, cefamandole, cefotetan, cefoxitin,
ceruroxime, cefonicid, ceforadine, cefixime, cefotaxime,
moxalactam, ceftizoxime, cetriaxone, cephoperazone, ceftazidime,
imipenem and aztreonam. The aminoglycosides include, but are not
limited to streptomycin, gentamicin, tobramycin, amikacin,
netilmicin, kanamycin and neomycin. The azoles include, but are not
limited to fluconazole. The quinolones include, but are not limited
to nalidixic acid, norfloxacin, enoxacin, ciprofloxacin, ofloxacin,
sparfloxacin and temafloxacin. The macrolides include, but are not
limited to erythomycin, spiramycin and azithromycin. The rifamycins
include, but are not limited to rifampin. The tetracyclines
include, but are not limited to spicycline, chlortetracycline,
clomocycline, demeclocycline, deoxycycline, guamecycline,
lymecycline, meclocycline, methacycline, minocycline,
oxytetracycline, penimepicycline, pipacycline, rolitetracycline,
sancycline, senociclin and tetracycline. The sulfonamides include,
but are not limited to sulfanilamide, sulfamethoxazole,
sulfacetamide, sulfadiazine, sulfisoxazole and co-trimoxazole
(trimethoprim/sulfamethoxazole). The lincosamides include, but are
not limited to clindamycin and lincomycin. The polymyxins
(polypeptides) include, but are not limited to polymyxin B and
colistin.
The most cited activity of IL-17A in vitro is the induction of
neutrophil mobilizing cytokines and chemokines by stromal cells
(e.g. GM-CSF, IL6, IL8). These activities are potently enhanced in
the presence of TNF (Ruddy et al., 2004). Similarly the biologic
activities of IL-17F are also enhanced by TNF co-stimulus. Of
particular note with respect to a pathogenic role for IL-17A in
cartilage destruction and bone erosion associated with rheumatoid
arthritis, IL-17A induces the expression of NO, MMPs, PGE2 and
RANKL and plays a role in antigen specific T and B cell activation
(Kolls and Linden, 2004, supra; Lubberts et al., 2005, Arthritis.
Res. Ther. 7:29-37). Therefore, the antigen binding proteins may be
used to inhibit the IL-17A and/or IL-17F/IL-17RA pathway and
subsequent production of NO, MMPs, PGE2 and/or RANKL and treat
diseases associated with the IL-17A and/or IL-17F upregulation of
NO, MMPs, PGE2 and/or RANKL, as well as other proinflammatory
mediators described herein.
In addition to the presence of elevated levels of IL-17A in the
synovial fluid of rheumatoid arthritis patients, several lines of
evidence suggest that IL-17A is a key pathogenic cytokine in
arthritis. First, administration of IL-17A to the joints of mice
exacerbates the symptoms of collagen-induced arthritis (Lubberts et
al., 2003, J. Immunol. 170:2655-2662). Second, soluble IL-17RA.Fc
inhibits collagen breakdown in human RA synovial and bone explant
cultures and attenuates the symptoms in collagen induced arthritis
in the mouse (Chabaud and Miossec, 2001, Arthritis Rheum.
44:1293-1303) (Lubberts et al., 2001, J. Immunol. 167:1004-1013)).
As predicted from the low affinity interaction between IL-17F and
IL-17R, IL-17R-Fc does not neutralize the activity of IL-17F and so
these effects are specific to IL-17A antagonism. Third, mice
lacking IL-17A are resistant to IL-1-induced arthritis and have
suppressed collagen-induced arthritis (Nakae et al., 2003a, J.
Immunol. 171:6173-6177; Nakae et al., 2003b, supra). These data
indicate that IL-17A signaling through IL-17RA is an important
mediator of inflammation and joint damage in arthritis. The antigen
binding proteins may be used to inhibit IL-17A and/or
IL-17F/IL-17RA activity and thereby reduce the inflammation and
joint damage in arthritis.
In rheumatoid arthritis, elevated levels of mature IL-17A have been
demonstrated in patient sera and synovial fluid. In some studies,
IL-17A levels were shown to correlate with disease activity and
response to disease modifying treatment. Extremely elevated serum
levels of IL-17A have consistently been measured in systemic
Juvenile Idiopathic Arthritis and the closely related Adult-Onset
Still's Disease. WO2005/063290; Cannetti et al., 2003, J. Immunol.
171:1009-1015; Charles et al., 1999, J. Immunol. 163: 1521-1528;
Cunnane et al., 2000, Online J. Rheumatol. 27 :58-63; Yoshimoto,
1998, J Immunol. 161: 3400-3407. The antigen binding proteins may
be used to inhibit IL-17A and/or IL-17F/IL-17RA activity and
thereby treat systemic Juvenile Idiopathic Arthritis and
Adult-Onset Still's Disease.
Various other autoimmune diseases have been associated with
increased levels of IL-17A either in diseased tissue or in the
serum. These include Systemic Lupus Erythematosus, atopic
dermatitis, myasthenia gravis, type I diabetes, and sarcoidosis.
IL-17A may also be involved in asthma and GvHD. The antigen binding
proteins taught herein may be used to reduce the effects of the
IL-17A and/or IL-17F/IL-17RA pathway in these diseases.
The antigen binding proteins may be used to reduce IL-17RA
activity, comprising administering an antigen binding protein. The
present invention is also directed to methods of inhibiting binding
and/or signaling of IL-17A and/or IL-17F to IL-17RA comprising
providing the antigen binding protein of the invention to IL-17RA.
In certain embodiments, the antigen binding protein inhibits
binding and/or signaling of IL-17A and IL-17F to IL-17RA. In
additional embodiments, the antigen binding protein inhibits
binding and/or signaling of IL-17A but not IL-17F to IL-17RA. In
other embodiments, the antigen binding protein inhibits binding
and/or signaling of IL-17F and not IL-17A to IL-17RA.
The IL-17RA antigen binding proteins may be used in treating
disease states associated with IL-17RA activity, comprising
administering an antigen binding protein. Disease states associated
with IL-17RA activity includes, but is not limited to, the
consequences, symptoms, and/or the pathology associated with
IL-17RA activity. The antigen binding proteins may be used to
inhibit the production of one or more of an inflammatory cytokine,
chemokine, matrix metalloproteinase, or other molecule associated
with IL-17RA activation, comprising administering an antigen
binding protein. The antigen binding proteins may be used in
methods of inhibiting production of molecules such as but is not
limited to: IL-6, IL-8, CXCL1, CXCL2, GM-CSF, G-CSF, M-CSF,
IL-1.beta., TNF.alpha., RANK-L, LIF, PGE2, IL-12, MMPs (such as but
not limited to MMP3 and MMP9), GRO.alpha., NO, and/or C-telopeptide
and the like, comprising administering an antigen binding protein.
The antigen binding proteins inhibit proinflammatory and
proautoimmune immune responses and may be used to treat diseases
associated with activity of the IL-17A and/or IL-17F/IL-17RA
pathway.
Aspects of the invention include antibodies that specifically bind
to human IL-17RA and partially or fully inhibit IL-17RA from
forming either a homomeric or heteromeric functional receptor
complex, such as, but not limited to IL-17RA/IL-17RC complex and do
not necessarily inhibit IL-17A and/or IL-17F or an IL-17A/IL-17F
heteromer from binding to IL-17RA or a IL-17RA heteromeric receptor
complex. Thus, disease states associated with IL-17RC are also
associated with IL-17RA due to the fact that IL-17RC cannot signal
without IL-17RA. For example, see You, Z., et al., Cancer Res.,
2006 Jan. 1; 66(1):175-83 and You, Z., et al., Neoplasia, 2007
June; 9(6):464-70.
The IL-17RA antigen binding proteins may be used in methods of
treating IL-17RA associated disease (i.e., disease states),
comprising administering an IL-17RA antigen binding protein. The
IL-17RA antigen binding protein may be used to treat diseases
including, but are not limited to, inflammation, autoimmune
disease, cartilage inflammation, and/or bone degradation,
arthritis, rheumatoid arthritis, juvenile arthritis, juvenile
rheumatoid arthritis, pauciarticular juvenile rheumatoid arthritis,
polyarticular juvenile rheumatoid arthritis, systemic onset
juvenile rheumatoid arthritis, juvenile ankylosing spondylitis,
juvenile enteropathic arthritis, juvenile reactive arthritis,
juvenile Reiter's Syndrome, SEA Syndrome (Seronegativity,
Enthesopathy, Arthropathy Syndrome), juvenile dermatomyositis,
juvenile psoriatic arthritis, juvenile scleroderma, juvenile
systemic lupus erythematosus, juvenile vasculitis, pauciarticular
rheumatoid arthritis, polyarticular rheumatoid arthritis, systemic
onset rheumatoid arthritis, ankylosing spondylitis, enteropathic
arthritis, reactive arthritis, Reiter's Syndrome, SEA Syndrome
(Seronegativity, Enthesopathy, Arthropathy Syndrome),
dermatomyositis, psoriatic arthritis, scleroderma, vasculitis,
myolitis, polymyolitis, dermatomyolitis, osteoarthritis,
polyarteritis nodossa, Wegener's granulomatosis, arteritis,
ploymyalgia rheumatica, sarcoidosis, scleroderma, sclerosis,
primary biliary sclerosis, sclerosing cholangitis, Sjogren's
syndrome, psoriasis, plaque psoriasis, guttate psoriasis, inverse
psoriasis, pustular psoriasis, erythrodermic psoriasis, dermatitis,
atopic dermatitis, atherosclerosis, lupus, Still's disease,
Systemic Lupus Erythematosus (SLE), myasthenia gravis, inflammatory
bowel disease (IBD), Crohn's disease, ulcerative colitis, celiac
disease, multiple sclerosis (MS), asthma, COPD, Guillain-Barre
disease, Type I diabetes mellitus, Graves' disease, Addison's
disease, Raynaud's phenomenon, autoimmune hepatitis, GVHD, and the
like.
Chronic viral hepatitis affects over 500 million people worldwide,
including approximately 10 million in the U.S. and Europe with
chronic hepatitis C infections. A significant proportion of chronic
hepatitis patients develop progressive liver fibrosis and/or
hepatocellular carcinoma. While viral hepatitis vaccines are
available or in development, current therapy for infected
individuals relies on long courses of the combination of antiviral
drugs and interferon-alpha (INF-.alpha.). INF-.alpha. is thought to
be beneficial in treating viral hepatitis through its proven
antiviral immunological activities and antiproliferative effects on
fibroblasts, but the duration and level of its use is limited by
severe side effects.
Recent data describes how INF-.alpha. may be directly apoptotic for
Th17 cells (American Association for Immunologists, abstract no.
42.8, May 12-16, 2006, Boston). Th17 cells are a distinct subset of
CD4+ T-cells responsible for producing IL-17A and IL-17F in
response to IL-23 (Harrington, et al., Nature Imm, 2005 vol. 6, no.
11, 1123-1132 and Park, et al., Nature Imm, 2005 vol. 6, no. 11,
1133-1141). We believe this suggests a new mechanism of action for
INF-.alpha. in chronic viral hepatitis that does not involve direct
action of INF-.alpha. on virus or fibroblasts, but indirect actions
on Th17 cells. Furthermore, it has recently been discovered that
Tumor Growth Factor-Beta (TGF-.beta.) and/or IL-6, (see for
example, Kimera, A., et al., PNAS U.S.A., 2007 Jul. 17;
104(29):12099-104), both pro-fibrotic cytokine, also induces the
development of TH17 cells by upregulating IL-23 receptor expression
and thereby conferring responsiveness to IL-23 ((Mangan, et al.,
Nature, 2006 vol. 441 no. 11, 231-234). Responsiveness to IL-23
induces the differentiation of naive CD4+ T-cells into TH17 cells.
As mentioned above, the TH17 cells are responsible for releasing
IL-17A and IL-17F, and IL-17A is known to have various stimulatory
effects on fibroblasts in a number of tissues and organs. Taken
together, we believe that inhibition of the IL-17RA-IL-17A/IL-17F
pathway may offer a therapeutic benefit in the progressive fibrosis
of chronic viral hepatitis.
An added benefit of inhibiting the IL-17RA-IL-17A/IL-17F pathway in
the treatment of viral hepatitis is that one may reduce the dosage
of INF-.alpha. given to the patient and consequently limit the
deleterious side effects associated with INF-.alpha. therapy. A
further benefit of inhibiting the IL-17RA-IL-17A/IL-17F pathway in
the treatment of viral hepatitis is the possibility of achieving a
synergistic therapeutic effect with INF-A therapy in combination
with IL-17RA-IL-17A/IL-17F antagonist therapy, or other antagonists
as described in more detail below.
Therefore, aspects of the invention are drawn to methods of
treating the pathology associated with viral hepatitis by
inhibiting the interaction between IL-17RA and IL-17A and/or
IL-17F. Further aspects of the invention are drawn to methods of
inhibiting fibrosis by inhibiting the interaction between IL-17RA
and IL-17A and/or IL-17F. Further aspects of the invention are
drawn to methods of treating fibrosis associated with viral
hepatitis by inhibiting the interaction between IL-17RA and IL-17A
and/or IL-17F. Antagonists of the IL-17RA-IL-17A/IL-17F pathway may
be used to inhibit the interaction between IL-17RA and IL-17A
and/or IL-17F. Antagonists of the IL-17RA-IL-17A pathway include
the IL-17RA antigen binding proteins described herein, as well as
IL-17RA proteins (as well as biologically active fragments and
fusion proteins thereof, such as IL-17RA-Fc fusion proteins), as
well as antigen binding-proteins, such as antibodies and
biologically active fragments thereof, that bind to IL-17A and
inhibit IL-17A from activating IL-17RA, as well as antigen binding
proteins, such as antibodies and biologically active fragments
thereof, that bind to IL-17F and inhibit IL-17F from activating
IL-17RA.
Additional aspects are drawn to methods of treating the pathology
associated with viral hepatitis by antagonizing the IL-23-IL-23
receptor (IL-23R) pathway. Further aspects of the invention are
drawn to methods of inhibiting fibrosis by antagonizing the
IL-23-IL-23R pathway. Further aspects of the invention are drawn to
methods of treating fibrosis associated with viral hepatitis by
antagonizing the IL-23-IL-23R pathway. By antagonizing the
IL-23-IL-23R pathway, one prevents the IL-23-induced
differentiation of the TH17 cells and thereby ultimately limit the
amount of circulating IL-17A and IL-17F, which may reduce the
pathology associated with viral hepatitis. Antagonists to the
IL-23-IL-23R pathway include antigen binding proteins, such as
antibodies and biologically active fragments thereof, that bind to
IL-23 and block IL-23 from activating IL-23R. Additional
antagonists to IL-23-IL-23R pathway include antigen binding
proteins, such as antibodies and biologically active fragments
thereof, that bind to IL-23R and block IL-23 from activating
IL-23R. Additional antagonists to IL-23-IL-23R pathway include
IL-23R proteins, as well as biologically active fragments and
fusion proteins thereof, such as IL-23R-Fc fusion proteins, that
bind IL-23 and block IL-23 from activating IL-23R.
Additional aspects are drawn to methods of treating the pathology
associated with viral hepatitis by antagonizing the
TGF-.beta.-TGF-.beta.RI/TGF-.beta.RII pathway. Further aspects of
the invention are drawn to methods of inhibiting fibrosis by
antagonizing the TGF-.beta.-TGF-.beta.RI/TGF-.beta.RII pathway.
Further aspects of the invention are drawn to methods of treating
fibrosis associated with viral hepatitis by antagonizing the
TGF-.beta.-TGF-.beta.RI/TGF-.beta.RII pathway. By antagonizing the
TGF-.beta.-TGF-.beta.RI/TGF-.beta.RII pathway, one prevents the
TGF-.beta.-induced development of the TH17 cells and thereby
ultimately limit the amount of circulating IL-17A and IL-17F, which
may reduce the pathology associated with viral hepatitis.
Antagonists to the TGF-.beta.-TGF-.beta.RI/TGF-.beta.RII pathway
include antigen binding proteins, such as antibodies and
biologically active fragments thereof, that bind to TGF-.beta. and
block TGF-.beta.from activating TGF-.beta.RI and/or TGF-.beta.RII.
Additional antagonists to the TGF-.beta.-TGF-.beta.RI/TGF-.beta.RII
pathway include antigen binding proteins, such as antibodies and
biologically active fragments thereof, that bind to TGF-.beta.RI or
TGF-.beta.RII and block TGF-.beta. from activating TGF-.beta.RI or
TGF-.beta.RII.
Additional aspects are drawn to methods of treating the pathology
associated with viral hepatitis by antagonizing the IL-6-IL-6R
pathway. Further aspects of the invention are drawn to methods of
inhibiting fibrosis by antagonizing the IL-6-IL-6R pathway. Further
aspects of the invention are drawn to methods of treating fibrosis
associated with viral hepatitis by antagonizing the IL-6-IL-6R
pathway. By antagonizing the IL-6-IL-6R pathway, one may reduce the
pathology associated with viral hepatitis. Antagonists to the
IL-6-IL-6R pathway include antigen binding proteins, such as
antibodies and biologically active fragments thereof, that bind to
IL-6 and block IL-6 from activating IL-6R. Additional antagonists
to the IL-6-IL-6R pathway include antigen binding proteins, such as
antibodies and biologically active fragments thereof, that bind to
IL-6R and block IL-6 from activating IL-6R.
Further aspects include combination therapy using the antagonists
of the IL-17RA-IL-17A/IL-17F pathway, IL-23-IL-23R pathway,
TGF-.beta.-TGF-.beta.RI/TGF-.beta.RII pathway, and/or the
IL-6-IL-6R pathway mentioned above in combination with each other,
as well as in combination with art-recognized hepatitis therapies,
such as but not limited to, interferon, and in particular
INF-.alpha.. All permutations of these combinations are
envisioned.
Further aspects include combination therapy using the antagonists
of the IL-17RA-IL-17A/IL-17F pathway, IL-23-IL-23R pathway,
TGF-.beta.-TGF-.beta.RI/TGF-.beta.RII pathway, and/or the
IL-6-IL-6R pathway mentioned above in combination with each other,
as well as in combination with art-recognized hepatitis therapies,
such as but not limited to, interferon, and in particular
INF-.alpha., as well as with antiviral agents, such as but not
limited to Adefovir dipivoxil, acyclic analogues of deoxyadenosine
monophosphate (Adefovir, Tenofovir disoproxil fumarate), (-)
enantiomer of the deoxycytidine analogue 2'-deoxy-3'-thiacytidine
(Lamivudine), carbocyclic deoxyguanosine analogues (Entecavir),
L-nucleosides (.beta.-L-2'-Deoxythymidine,
.beta.-L-2'-deoxycytidine, and .beta.-L-2'-deoxyadenosine),
[(-)-.beta.-2',3'-dideoxy-5-fluoro-3'-thiacytidine]
(Emtricitabine), 1-.beta.-2,6-Diaminopurine dioxalane (DAPD,
amdoxovir), 2'-Fluoro-5-methyl-.beta.-L-arabinofuranosyluridine
(L-FMAU, clevudine), Famciclovir, and/or Penciclovir. All
permutations of these combinations are envisioned.
Diagnostic Methods
The antigen binding proteins of the invention can be used for
diagnostic purposes to detect, diagnose, or monitor diseases and/or
conditions associated with IL-17A or IL-17RA. The invention
provides for the detection of the presence of IL-17RA in a sample
using classical immunohistological methods known to those of skill
in the art (e.g., Tijssen, 1993, Practice and Theory of Enzyme
Immunoassays, vol 15 (Eds R. H. Burdon and P. H. van Knippenberg,
Elsevier, Amsterdam); Zola, 1987, Monoclonal Antibodies: A Manual
of Techniques, pp. 147-158 (CRC Press, Inc.); Jalkanen et al.,
1985, J. Cell. Biol. 101:976-985; Jalkanen et al., 1987, J. Cell
Biol. 105:3087-3096). The detection of IL-17RA can be performed in
vivo or in vitro.
Diagnostic applications provided herein include use of the antigen
binding proteins to detect expression of IL-17RA and binding of the
ligands to IL-17RA. Examples of methods useful in the detection of
the presence of IL-17RA include immunoassays, such as the enzyme
linked immunosorbent assay (ELISA) and the radioimmunoassay
(RIA).
For diagnostic applications, the antigen binding protein typically
will be labeled with a detectable labeling group. Suitable labeling
groups include, but are not limited to, the following:
radioisotopes or radionuclides (e.g., .sup.3H, .sup.14C, .sup.15N,
.sup.35S, .sup.90Y, .sup.99Tc, .sup.111In, .sup.125I, .sup.131I),
fluorescent groups (e.g., FITC, rhodamine, lanthanide phosphors),
enzymatic groups (e.g., horseradish peroxidase,
.beta.-galactosidase, luciferase, alkaline phosphatase),
chemiluminescent groups, biotinyl groups, or predetermined
polypeptide epitopes recognized by a secondary reporter (e.g.,
leucine zipper pair sequences, binding sites for secondary
antibodies, metal binding domains, epitope tags). In some
embodiments, the labelling group is coupled to the antigen binding
protein via spacer arms of various lengths to reduce potential
steric hindrance. Various methods for labelling proteins are known
in the art and may be used in performing the present invention.
One aspect of the invention provides for identifying a cell or
cells that express IL-17RA. In a specific embodiment, the antigen
binding protein is labeled with a labeling group and the binding of
the labeled antigen binding protein to IL-17RA is detected. In a
further specific embodiment, the binding of the antigen binding
protein to IL-17RA detected in vivo. In a further specific
embodiment, the antigen binding protein-IL-17RA is isolated and
measured using techniques known in the art. See, for example,
Harlow and Lane, 1988, Antibodies: A Laboratory Manual, N.Y.: Cold
Spring Harbor (ed. 1991 and periodic supplements); John E. Coligan,
ed., 1993, Current Protocols In Immunology New York: John Wiley
& Sons.
Another aspect of the invention provides for detecting the presence
of a test molecule that competes for binding to IL-17RA with the
antigen binding proteins of the invention. An example of one such
assay would involve detecting the amount of free antigen binding
protein in a solution containing an amount of IL-17RA in the
presence or absence of the test molecule. An increase in the amount
of free antigen binding protein (i.e., the antigen binding protein
not bound to IL-17RA) would indicate that the test molecule is
capable of competing for IL-17RA binding with the antigen binding
protein. In one embodiment, the antigen binding protein is labeled
with a labeling group. Alternatively, the test molecule is labeled
and the amount of free test molecule is monitored in the presence
and absence of an antigen binding protein.
Aspects of the invention include the use of the IL-17RA antigen
binding proteins in in vitro assays for research purposes, such as
to inhibit production of molecules such as but is not limited to:
IL-6, IL-8, CXCL1, CXCL2, GM-CSF, G-CSF, M-CSF, IL-1.beta.,
TNF.alpha., RANK-L, LIF, PGE2, IL-12, MMPs (such as but not limited
to MMP3 and MMP9), GRO.alpha., NO, and/or C-telopeptide and the
like. Antibodies directed against an IL-17RA can be used, for
example, in purifying IL-17RA proteins by immunoaffinity
chromatography.
Pharmaceutical Formulations, Routes of Administration
In some embodiments, the invention provides pharmaceutical
compositions comprising a therapeutically effective amount of one
or a plurality of the antigen binding proteins of the invention
together with a pharmaceutically acceptable diluent, carrier,
solubilizer, emulsifier, preservative, and/or adjuvant. In
addition, the invention provides methods of treating a patient by
administering such pharmaceutical composition. The term "patient"
includes human and animal subjects.
Pharmaceutical compositions comprising one or more antigen binding
proteins may be used to reduce IL-17RA activity. Pharmaceutical
compositions comprising one or more antigen binding proteins may be
used in treating the consequences, symptoms, and/or the pathology
associated with IL-17RA activity. Pharmaceutical compositions
comprising one or more antigen binding proteins may be used in
methods of inhibiting binding and/or signaling of IL-17A and/or
IL-17F to IL-17RA comprising providing the antigen binding protein
of the invention to IL-17RA. In certain embodiments, the antigen
binding protein inhibits binding and/or signaling of IL-17A and
IL-17F to IL-17RA. In additional embodiments, pharmaceutical
compositions comprising one or more antigen binding proteins may be
used in methods of inhibiting binding and/or signaling of IL-17A
but not IL-17F to IL-17RA. In other embodiments, pharmaceutical
compositions comprising one or more antigen binding proteins may be
used in methods of inhibiting binding and/or signaling of IL-17F
and not IL-17A to IL-17RA. Aspects of the invention include
antibodies that specifically bind to human IL-17RA and inhibit
IL-17A and/or IL-17F from binding and activating IL-17RA, or a
heteromeric complex of IL-17RA and IL-17RC. Aspects of the
invention include antibodies that specifically bind to human
IL-17RA and inhibit an IL-17A/IL-17F heteromer from binding and
activating IL-17RA, or a heteromeric complex of IL-17RA and
IL-17RC. Throughout the specification, when reference is made to
inhibiting IL-17A and/or IL-17F, it is understood that this also
includes inhibiting heteromers of IL-17A and IL-17F. Aspects of the
invention include antibodies that specifically bind to human
IL-17RA and partially or fully inhibit IL-17RA from forming either
a homomeric or heteromeric functional receptor complex, such as,
but not limited to IL-17RA-IL-17RC complex. Aspects of the
invention include antibodies that specifically bind to human
IL-17RA and partially or fully inhibit IL-17RA from forming either
a homomeric or heteromeric functional receptor complex, such as,
but not limited to IL-17RA/IL-17RC complex and do not necessarily
inhibit IL-17A and/or IL-17F or an IL-17A/IL-17F heteromer from
binding to IL-17RA or a IL-17RA heteromeric receptor complex.
Pharmaceutical compositions comprising one or more IL-17RA antigen
binding proteins described herein may be used in methods of
treating the consequences, symptoms, and/or the pathology
associated with IL-17RA activity. Pharmaceutical compositions
comprising one or more IL-17RA antigen binding proteins may be used
in methods of inhibiting the production of one or more of an
inflammatory cytokine, chemokine, matrix metalloproteinase, or
other molecule associated with IL-17RA activation, comprising
administering an IL-17RA antigen binding protein. Pharmaceutical
compositions comprising one or more antigen binding proteins may be
used in methods of inhibiting production of IL-6, IL-8, GM-CSF, NO,
MMPs, PGE2 RANKL, and/or C-telopeptide, and the like.
Pharmaceutical compositions comprising one or more IL-17RA antigen
binding proteins may be used to treat diseases and conditions
including, but are not limited to, inflammation, autoimmune
disease, cartilage inflammation, and/or bone degradation,
arthritis, rheumatoid arthritis, juvenile arthritis, juvenile
rheumatoid arthritis, pauciarticular juvenile rheumatoid arthritis,
polyarticular juvenile rheumatoid arthritis, systemic onset
juvenile rheumatoid arthritis, juvenile ankylosing spondylitis,
juvenile enteropathic arthritis, juvenile reactive arthritis,
juvenile Reiter's Syndrome, SEA Syndrome (Seronegativity,
Enthesopathy, Arthropathy Syndrome), juvenile dermatomyositis,
juvenile psoriatic arthritis, juvenile scleroderma, juvenile
systemic lupus erythematosus, juvenile vasculitis, pauciarticular
rheumatoid arthritis, polyarticular rheumatoid arthritis, systemic
onset rheumatoid arthritis, ankylosing spondylitis, enteropathic
arthritis, reactive arthritis, Reiter's Syndrome, SEA Syndrome
(Seronegativity, Enthesopathy, Arthropathy Syndrome),
dermatomyositis, psoriatic arthritis, scleroderma, systemic lupus
erythematosus, vasculitis, myolitis, polymyolitis, dermatomyolitis,
osteoarthritis, polyarteritis nodossa, Wegener's granulomatosis,
arteritis, ploymyalgia rheumatica, sarcoidosis, scleroderma,
sclerosis, primary biliary sclerosis, sclerosing cholangitis,
Sjogren's syndrome, psoriasis, plaque psoriasis, guttate psoriasis,
inverse psoriasis, pustular psoriasis, erythrodermic psoriasis,
dermatitis, atopic dermatitis, atherosclerosis, lupus, Still's
disease, Systemic Lupus Erythematosus (SLE), myasthenia gravis,
inflammatory bowel disease (IBD), Crohn's disease, ulcerative
colitis, celiac disease, multiple sclerosis (MS), asthma, COPD,
Guillain-Barre disease, Type I diabetes mellitus, Graves' disease,
Addison's disease, Raynaud's phenomenon, autoimmune hepatitis,
GVHD, and the like
Preferably, acceptable formulation materials are nontoxic to
recipients at the dosages and concentrations employed. In specific
embodiments, pharmaceutical compositions comprising a
therapeutically effective amount of IL-17RA antigen binding
proteins are provided.
In certain embodiments, acceptable formulation materials preferably
are nontoxic to recipients at the dosages and concentrations
employed. In certain embodiments, the pharmaceutical composition
may contain formulation materials for modifying, maintaining or
preserving, for example, the pH, osmolarity, viscosity, clarity,
color, isotonicity, odor, sterility, stability, rate of dissolution
or release, adsorption or penetration of the composition. In such
embodiments, suitable formulation materials include, but are not
limited to, amino acids (such as glycine, glutamine, asparagine,
arginine or lysine); antimicrobials; antioxidants (such as ascorbic
acid, sodium sulfite or sodium hydrogen-sulfite); buffers (such as
borate, bicarbonate, Tris-HCl, citrates, phosphates or other
organic acids); bulking agents (such as mannitol or glycine);
chelating agents (such as ethylenediamine tetraacetic acid (EDTA));
complexing agents (such as caffeine, polyvinylpyrrolidone,
beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin); fillers;
monosaccharides; disaccharides; and other carbohydrates (such as
glucose, mannose or dextrins); proteins (such as serum albumin,
gelatin or immunoglobulins); coloring, flavoring and diluting
agents; emulsifying agents; hydrophilic polymers (such as
polyvinylpyrrolidone); low molecular weight polypeptides;
salt-forming counterions (such as sodium); preservatives (such as
benzalkonium chloride, benzoic acid, salicylic acid, thimerosal,
phenethyl alcohol, methylparaben, propylparaben, chlorhexidine,
sorbic acid or hydrogen peroxide); solvents (such as glycerin,
propylene glycol or polyethylene glycol); sugar alcohols (such as
mannitol or sorbitol); suspending agents; surfactants or wetting
agents (such as pluronics, PEG, sorbitan esters, polysorbates such
as polysorbate 20, polysorbate, triton, tromethamine, lecithin,
cholesterol, tyloxapol); stability enhancing agents (such as
sucrose or sorbitol); tonicity enhancing agents (such as alkali
metal halides, preferably sodium or potassium chloride, mannitol
sorbitol); delivery vehicles; diluents; excipients and/or
pharmaceutical adjuvants. See, REMINGTON'S PHARMACEUTICAL SCIENCES,
18" Edition, (A. R. Genrmo, ed.), 1990, Mack Publishing
Company.
In certain embodiments, the optimal pharmaceutical composition will
be determined by one skilled in the art depending upon, for
example, the intended route of administration, delivery format and
desired dosage. See, for example, REMINGTON'S PHARMACEUTICAL
SCIENCES, supra. In certain embodiments, such compositions may
influence the physical state, stability, rate of in vivo release
and rate of in vivo clearance of the antigen binding proteins of
the invention. In certain embodiments, the primary vehicle or
carrier in a pharmaceutical composition may be either aqueous or
non-aqueous in nature. For example, a suitable vehicle or carrier
may be water for injection, physiological saline solution or
artificial cerebrospinal fluid, possibly supplemented with other
materials common in compositions for parenteral administration.
Neutral buffered saline or saline mixed with serum albumin are
further exemplary vehicles. In specific embodiments, pharmaceutical
compositions comprise Tris buffer of about pH 7.0-8.5, or acetate
buffer of about pH 4.0-5.5, and may further include sorbitol or a
suitable substitute therefor. In certain embodiments of the
invention, IL-17RA antigen binding protein compositions may be
prepared for storage by mixing the selected composition having the
desired degree of purity with optional formulation agents
(REMINGTON'S PHARMACEUTICAL SCIENCES, supra) in the form of a
lyophilized cake or an aqueous solution. Further, in certain
embodiments, the IL-17RA antigen binding protein product may be
formulated as a lyophilizate using appropriate excipients such as
sucrose.
The pharmaceutical compositions of the invention can be selected
for parenteral delivery. Alternatively, the compositions may be
selected for inhalation or for delivery through the digestive
tract, such as orally. Preparation of such pharmaceutically
acceptable compositions is within the skill of the art. The
formulation components are present preferably in concentrations
that are acceptable to the site of administration. In certain
embodiments, buffers are used to maintain the composition at
physiological pH or at a slightly lower pH, typically within a pH
range of from about 5 to about 8.
When parenteral administration is contemplated, the therapeutic
compositions for use in this invention may be provided in the form
of a pyrogen-free, parenterally acceptable aqueous solution
comprising the desired IL-17RA antigen binding protein in a
pharmaceutically acceptable vehicle. A particularly suitable
vehicle for parenteral injection is sterile distilled water in
which the IL-17RA antigen binding protein is formulated as a
sterile, isotonic solution, properly preserved. In certain
embodiments, the preparation can involve the formulation of the
desired molecule with an agent, such as injectable microspheres,
bio-erodible particles, polymeric compounds (such as polylactic
acid or polyglycolic acid), beads or liposomes, that may provide
controlled or sustained release of the product which can be
delivered via depot injection. In certain embodiments, hyaluronic
acid may also be used, having the effect of promoting sustained
duration in the circulation. In certain embodiments, implantable
drug delivery devices may be used to introduce the desired antigen
binding protein.
Pharmaceutical compositions of the invention can be formulated for
inhalation. In these embodiments, IL-17RA antigen binding proteins
are advantageously formulated as a dry, inhalable powder. In
specific embodiments, IL-17RA antigen binding protein inhalation
solutions may also be formulated with a propellant for aerosol
delivery. In certain embodiments, solutions may be nebulized.
Pulmonary administration and formulation methods therefore are
further described in International Patent Application No.
PCT/US94/001875, which is incorporated by reference and describes
pulmonary delivery of chemically modified proteins. It is also
contemplated that formulations can be administered orally. IL-17RA
antigen binding proteins that are administered in this fashion can
be formulated with or without carriers customarily used in the
compounding of solid dosage forms such as tablets and capsules. In
certain embodiments, a capsule may be designed to release the
active portion of the formulation at the point in the
gastrointestinal tract when bioavailability is maximized and
pre-systemic degradation is minimized. Additional agents can be
included to facilitate absorption of the IL-17RA antigen binding
protein. Diluents, flavorings, low melting point waxes, vegetable
oils, lubricants, suspending agents, tablet disintegrating agents,
and binders may also be employed.
A pharmaceutical composition of the invention is preferably
provided to comprise an effective quantity of one or a plurality of
IL-17RA antigen binding proteins in a mixture with non-toxic
excipients that are suitable for the manufacture of tablets. By
dissolving the tablets in sterile water, or another appropriate
vehicle, solutions may be prepared in unit-dose form. Suitable
excipients include, but are not limited to, inert diluents, such as
calcium carbonate, sodium carbonate or bicarbonate, lactose, or
calcium phosphate; or binding agents, such as starch, gelatin, or
acacia; or lubricating agents such as magnesium stearate, stearic
acid, or talc.
Additional pharmaceutical compositions will be evident to those
skilled in the art, including formulations involving IL-17RA
antigen binding proteins in sustained- or controlled-delivery
formulations. Techniques for formulating a variety of other
sustained- or controlled-delivery means, such as liposome carriers,
bio-erodible microparticles or porous beads and depot injections,
are also known to those skilled in the art. See, for example,
International Patent Application No. PCT/US93/00829, which is
incorporated by reference and describes controlled release of
porous polymeric microparticles for delivery of pharmaceutical
compositions. Sustained-release preparations may include
semipermeable polymer matrices in the form of shaped articles,
e.g., films, or microcapsules. Sustained release matrices may
include polyesters, hydrogels, polylactides (as disclosed in U.S.
Pat. No. 3,773,919 and European Patent Application Publication No.
EP 058481, each of which is incorporated by reference), copolymers
of L-glutamic acid and gamma ethyl-L-glutamate (Sidman et al.,
1983, Biopolymers 2:547-556), poly (2-hydroxyethyl-methacrylate)
(Langer et al., 1981, J. Biomed. Mater. Res. 15:167-277 and Langer,
1982, Chem. Tech. 12:98-105), ethylene vinyl acetate (Langer et
al., 1981, supra) or poly-D(-)-3-hydroxybutyric acid (European
Patent Application Publication No. EP 133,988). Sustained release
compositions may also include liposomes that can be prepared by any
of several methods known in the art. See, e.g., Eppstein et al.,
1985, Proc. Natl. Acad. Sci. U.S.A. 82:3688-3692; European Patent
Application Publication Nos. EP 036,676; EP 088,046 and EP 143,949,
incorporated by reference.
Pharmaceutical compositions used for in vivo administration are
typically provided as sterile preparations. Sterilization can be
accomplished by filtration through sterile filtration membranes.
When the composition is lyophilized, sterilization using this
method may be conducted either prior to or following lyophilization
and reconstitution. Compositions for parenteral administration can
be stored in lyophilized form or in a solution. Parenteral
compositions generally are placed into a container having a sterile
access port, for example, an intravenous solution bag or vial
having a stopper pierceable by a hypodermic injection needle.
Aspects of the invention includes self-buffering IL-17RA antigen
binding protein formulations, which can be used as pharmaceutical
compositions, as described in international patent application WO
06138181A2 (PCT/US2006/022599), which is incorporated by reference
in its entirety herein. One embodiment provides self-buffering
IL-17RA antigen binding protein formulations comprising an IL-17RA
antigen binding protein in which the total salt concentration is
less than 150 mM.
One embodiment provides self-buffering IL-17RA antigen binding
protein formulations that further comprise an IL-17RA antigen
binding protein and one or more polyols and/or one or more
surfactants. One embodiment provides self-buffering IL-117RA
antigen binding protein formulations comprising an IL-17RA antigen
binding protein, in which the total salt concentration is less than
150 mM, that further comprise one or more excipients, including but
not limited to, pharmaceutically acceptable salts; osmotic
balancing agents (tonicity agents); surfactants, polyols,
anti-oxidants; antibiotics; antimycotics; bulking agents;
lyoprotectants; anti-foaming agents; chelating agents;
preservatives; colorants; and analgesics. One embodiment provides
self-buffering IL-17RA antigen binding protein formulations
comprising an IL-17RA antigen binding protein and one or more other
pharmaceutically active agents.
One embodiment provides self-buffering IL-17RA antigen binding
protein formulations comprising an IL-17RA antigen binding protein,
wherein the IL-17RA antigen binding protein has a buffer capacity
per unit volume per pH unit of at least that of approximately: 2.0
or 3.0 or 4.0 or 5.0 or 6.50 or 8.00 or 10.0 or 15.0 or 20.0 or
30.0 or 40.0 or 50.0 or 75.0 or 100 or 125 or 150 or 200 or 250 or
300 or 350 or 400 or 500 or 700 or 1,000 or 1,500 or 2,000 or 2,500
or 3,000 or 4,000 or 5,000 mM sodium acetate buffer in pure water
over the range of pH 5.0 to 4.0 or pH 5.0 to 5.5, or at least 2.0
mM, or at least 3.0 mM, or at least 4.0 mM or at least 5.0 mM, or
at least 7.5 mM, or at least 10 mM, or at least 20 mM.
One embodiment provides self-buffering IL-17RA antigen binding
protein formulations wherein, exclusive of the buffer capacity of
the protein, the buffer capacity per unit volume per pH unit of the
formulation is equal to or less than that of 1.0 or 1.5 or 2.0 or
3.0 or 4.0 or 5.0 mM sodium acetate buffer in pure water over the
range of pH 4.0 to 5.0 or pH 5.0 to 5.5, or optionally less than
that of 1.0 mM, optionally less than that of 2.0 mM, optionally
less than that of 2.5 mM, optionally less than that of 3.0 mM, and
optionally less than that of 5.0 mM.
One embodiment provides self-buffering IL-17RA antigen binding
protein formulations comprising an IL-17RA antigen binding protein
wherein over the range of plus or minus 1 pH unit from the pH of
the formulation, the buffer capacity of the IL-17RA antigen binding
protein is at least approximately: 1.00 or 1.50 or 1.63 or 2.00 or
3.00 or 4.00 or 5.00 or 6.50 or 8.00 or 10.0 or 15.0 or 20.0 or
30.0 or 40.0 or 50.0 or 75.0 or 100 or 125 or 150 or 200 or 250 or
300 or 350 or 400 or 500 or 700 or 1,000 or 1,500 or 2,000 or 2,500
or 3,000 or 4,000 or 5,000 mEq per liter per pH unit, optionally at
least approximately 1.00, optionally at least approximately 1.50,
optionally at least approximately 1.63, optionally at least
approximately 2.00, optionally at least approximately 3.00,
optionally at least approximately 5.0, optionally at least
approximately 10.0, and optionally at least approximately 20.0. One
embodiment provides self-buffering IL-17RA antigen binding protein
formulations comprising an IL-17RA antigen binding protein wherein
over the range of plus or minus 1 pH unit from the pH of the
formulation, exclusive of the IL-17RA antigen binding protein, the
buffer capacity per unit volume per pH unit of the formulation is
equal to or less than that of 0.50 or 1.00 or 1.50 or 2.00 or 3.00
or 4.00 or 5.00 or 6.50 or 8.00 or 10.0 or 20.0 or 25.0 mM sodium
acetate buffer in pure water over the range pH 5.0 to 4.0 or pH 5.0
to 5.5.
One embodiment provides self-buffering IL-17RA antigen binding
protein formulations comprising an IL-17RA antigen binding protein
wherein over a range of plus or minus 1 pH unit from a desired pH,
the protein provides at least approximately 55%, 60%, 65%, 70%,
75%, 80%, 85%, 90%, 95%, 97%, 98%, 99%, or 99.5% of the buffer
capacity of the formulation, optionally at least approximately 75%,
optionally at least approximately 85%, optionally at least
approximately 90%, optionally at least approximately 95%,
optionally at least approximately 99% of the buffer capacity of the
formulation.
One embodiment provides self-buffering IL-17RA antigen binding
protein formulations comprising an IL-17RA antigen binding protein
wherein the concentration of the IL-17RA antigen binding protein is
between approximately: 20 and 400, or 20 and 300, or 20 and 250, or
20 and 200, or 20 and 150 mg/ml, optionally between approximately
20 and 400 mg/ml, optionally between approximately 20 and 250, and
optionally between approximately 20 and 150 mg/ml.
One embodiment provides self-buffering IL-17RA antigen binding
protein formulations comprising an IL-17RA antigen binding protein
wherein the pH maintained by the buffering action of the IL-17RA
antigen binding protein is between approximately: 3.5 and 8.0, or
4.0 and 6.0, or 4.0 and 5.5, or 4.0 and 5.0, optionally between
approximately 3.5 and 8.0, and optionally between approximately 4.0
and 5.5.
One embodiment provides self-buffering IL-17RA antigen binding
protein formulations comprising an IL-17RA antigen binding protein
wherein the salt concentration is less than: 150 mM or 125 mM or
100 mM or 75 mM or 50 mM or 25 mM, optionally 150 mM, optionally
125 mM, optionally 100 mM, optionally 75 mM, optionally 50 mM, and
optionally 25 mM.
One embodiment provides self-buffering IL-17RA antigen binding
protein formulations comprising an IL-17RA antigen binding protein
and one or more pharmaceutically acceptable salts; polyols;
surfactants; osmotic balancing agents; tonicity agents;
anti-oxidants; antibiotics; antimycotics; bulking agents;
lyoprotectants; anti-foaming agents; chelating agents;
preservatives; colorants; analgesics; or additional pharmaceutical
agents.
One embodiment provides self-buffering IL-17RA antigen binding
protein formulations comprising an IL-17RA antigen binding protein
and one or more pharmaceutically acceptable polyols in an amount
that is hypotonic, isotonic, or hypertonic, preferably
approximately isotonic, particularly preferably isotonic, such as
but not limited to any one or more of sorbitol, mannitol, sucrose,
trehalose, or glycerol, optionally approximately 5% sorbitol, 5%
mannitol, 9% sucrose, 9% trehalose, or 2.5% glycerol.
One embodiment provides self-buffering IL-17RA antigen binding
protein formulations comprising an IL-17RA antigen binding protein
further comprising a surfactant, preferably one or more of
polysorbate 20, polysorbate 80, other fatty acid esters of
sorbitan, polyethoxylates, and poloxamer 188, preferably
polysorbate 20 or polysorbate 80, optionally approximately 0.001 to
0.1% polysorbate 20 or polysorbate 80, optionally approximately
0.002 to 0.02% polysorbate 20 or polysorbate 80, or optionally
0.002 to 0.02% polysorbate 20 or polysorbate 80.
One embodiment provides self-buffering IL-17RA antigen binding
protein formulations comprising an IL-17RA antigen binding protein
wherein the formulation is sterile and suitable for treatment of a
human or non-human subject.
One embodiment provides self-buffering IL-17RA antigen binding
protein formulations comprising an IL-17RA antigen binding protein
and a solvent, the IL-17RA antigen binding protein having a buffer
capacity per unit volume per pH unit of at least that of 4.0 mM
sodium acetate in water over the range of pH 4.0 to 5.0 or pH 5.0
to 5.5, wherein the buffer capacity per unit volume of the
formulation exclusive of the IL-17RA antigen binding protein is
equal to or less than that of 2.0 mM sodium acetate in water over
the same ranges preferably determined in the same way.
One embodiment provides self-buffering IL-17RA antigen binding
protein formulations comprising an IL-17RA antigen binding protein
and a solvent, wherein at the pH of the formulation the buffer
capacity of the protein is at least 1.63 mEq per liter for a pH
change of the formulation of plus or minus 1 pH unit wherein the
buffer capacity of the formulation exclusive of the protein is
equal to or less than 0.81 mEq per liter at the pH of the
formulation for a pH change of plus or minus 1 pH unit.
One embodiment provides self-buffering IL-17RA antigen binding
protein formulations comprising an IL-17RA antigen binding protein,
wherein the formulation is in the form of a lyophilate which upon
reconstitution provides a formulation in accordance with any of the
foregoing or following.
One embodiment provides self-buffering IL-17RA antigen binding
protein formulations in a kit comprising one or more vials
containing a self-buffering IL-17RA antigen binding protein
formulation or a lyophilate of a self-buffering IL-17RA antigen
binding protein formulation in accordance with any of the foregoing
or the following, and instructions regarding use thereof.
One embodiment provides a process for preparing a self-buffering
IL-17RA antigen binding protein formulation or a lyophilate thereof
according to any of the foregoing or the following, comprising
removing residual buffer using a counter ion.
One embodiment provides a process for preparing a self-buffering
IL-17RA antigen binding protein formulation or a lyophilate thereof
according to any of the foregoing or the following, comprising
removing residual buffer using any one or more of the following in
the presence of a counter ion: chromatography, dialysis, and/or
tangential flow filtration.
One embodiment provides a process for preparing a self-buffering
IL-17RA antigen binding protein formulation or a lyophilate thereof
according to any of the foregoing or the following, comprising
removing residual buffer using tangential flow filtration.
One embodiment provides a process for preparing a self-buffering
IL-17RA antigen binding protein formulation or a lyophilate thereof
according to any of the foregoing or the following comprising a
step of dialysis against a solution at a pH below that of the
preparation, and, if necessary, adjusting the pH thereafter by
addition of dilute acid or dilute base.
As discussed above, certain embodiments provide self-buffering
IL-17RA antigen binding proteins protein compositions, particularly
pharmaceutical IL-17RA antigen binding protein compositions, that
comprise, in addition to the IL-17RA antigen binding protein, one
or more excipients such as those illustratively described in this
section and elsewhere herein. Excipients can be used in the
invention in this regard for a wide variety of purposes, such as
adjusting physical, chemical, or biological properties of
formulations, such as adjustment of viscosity, and or processes of
the invention to improve effectiveness and or to stabilize such
formulations and processes against degradation and spoilage due to,
for instance, stresses that occur during manufacturing, shipping,
storage, pre-use preparation, administration, and thereafter.
A variety of expositions are available on protein stabilization and
formulation materials and methods useful in this regard, such as
Arakawa et al., "Solvent interactions in pharmaceutical
formulations," Pharm Res. 8(3): 285-91 (1991); Kendrick et al.,
"Physical stabilization of proteins in aqueous solution," in:
RATIONAL DESIGN OF STABLE PROTEIN FORMULATIONS: THEORY AND
PRACTICE, Carpenter and Manning, eds. Pharmaceutical Biotechnology.
13: 61-84 (2002), and Randolph et al., "Surfactant-protein
interactions," Pharm Biotechnol. 13: 159-75 (2002), each of which
is herein incorporated by reference in its entirety, particularly
in parts pertinent to excipients and processes of the same for
self-buffering protein formulations in accordance with the current
invention, especially as to protein pharmaceutical products and
processes for veterinary and/or human medical uses.
Various excipients useful in the invention are listed in TABLE 3
and further described below.
TABLE-US-00003 TABLE 3 Types of Excipients and Their Functions
Function Type Liquids Lyophilates Tonicity Provides isotonicity to
the formulation such that Stabilizers include cryo and
lyoprotectants Agents/ it is suitable for injection Examples
include polyols, sugars and polymers Stabilizers Examples include
polyols, salts, and amino acids Cryoprotectants protect proteins
from freezing Help maintain the protein in a more compact stresses
state (polyols) Lyoprotectants stabilize proteins in the
freezedried Minimize electrostatic, solution protein-protein state
interactions (salts) Bulking Not applicable Used to enhance product
elegance and to prevent Agents blowout Provides structural strength
to the lyo cake Examples include mannitol and glycine Surfactants
Prevent/control aggregation, particle formation Employed if
aggregation during the and surface adsorption of drug
lyophilization process is an issue Examples include polysorbate 20
and 80 May serve to reduce reconstitution times Examples include
polysorbate 20 and 80 Anti-oxidants Control protein oxidation
Usually not employed, molecular reactions in the lyophilized cake
are greatly retarded Metal A specific metal ion is included in a
liquid May be included if a specific metal ion is Ions/ formulation
only as a co-factor included only as a co-factor Chelating Divalent
cations such as zinc and magnesium are Chelating agents are
generally not needed in Agents utilized in suspension formulations
lyophilized formulations Chelating agents are used to inhibit heavy
metal ion catalyzed reactions Preservatives Important particularly
for multi-dose For multi-dose formulations only formulations
Provides protection against microbial growth in Protects against
microbial growth, formulation Example: benzyl alcohol Is usually
included in the reconstitution diluent (e.g. bWFI)
Salts may be used in accordance with certain embodiments of the
invention to, for example, adjust the ionic strength and/or the
isotonicity of a self-buffering formulation and/or to improve the
solubility and/or physical stability of a self-buffering protein or
other ingredient of a self-buffering protein composition in
accordance with the invention.
As is well known, ions can stabilize the native state of proteins
by binding to charged residues on the protein's surface and by
shielding charged and polar groups in the protein and reducing the
strength of their electrostatic interactions, attractive, and
repulsive interactions. Ions also can stabilize the denatured state
of a protein by binding to, in particular, the denatured peptide
linkages (--CONH) of the protein. Furthermore, ionic interaction
with charged and polar groups in a protein also can reduce
intermolecular electrostatic interactions and, thereby, prevent or
reduce protein aggregation and insolubility.
Ionic species differ significantly in their effects on proteins. A
number of categorical rankings of ions and their effects on
proteins have been developed that can be used in formulating
self-buffering protein compositions in accordance with the
invention. One example is the Hofmeister series, which ranks ionic
and polar non-ionic solutes by their effect on the conformational
stability of proteins in solution. Stabilizing solutes are referred
to as "kosmotropic." Destabilizing solutes are referred to as
chaotropic. Kosmotropes commonly are used at high concentrations
(e.g., >1 molar ammonium sulfate) to precipitate proteins from
solution ("salting-out"). Chaotropes commonly are used to denture
and/or to solubilize proteins ("salting-in"). The relative
effectiveness of ions to "salt-in" and "salt-out" defines their
position in the Hofmeister series.
In addition to their utilities and their drawbacks (as discussed
above) salts also are effective for reducing the viscosity of
protein formulations and can be used in the invention for that
purpose.
In order to maintain isotonicity in a parenteral formulation in
accordance with preferred embodiments of the invention, improve
protein solubility and/or stability, improve viscosity
characteristics, avoid deleterious salt effects on protein
stability and aggregation, and prevent salt-mediated protein
degradation, the salt concentration in self-buffering formulations
in accordance with various preferred embodiments of the invention
are less than 150 mM (as to monovalent ions) and 150 mEq/liter for
multivalent ions. In this regard, in certain particularly preferred
embodiments of the invention, the total salt concentration is from
about 75 mEq/L to about 140 mEq/L.
Free amino acids can be used in self-buffering IL-17RA antigen
binding protein formulations in accordance with various embodiments
of the invention as bulking agents, stabilizers, and antioxidants,
as well as other standard uses. However, amino acids included in
self-buffering IL-17RA antigen binding protein formulations do not
provide buffering action. For this reason, those with significant
buffer capacity either are not employed, are not employed at any pH
around which they have significant buffering activity, or are used
at low concentration so that, as a result, their buffer capacity in
the formulation is not significant. This is particularly the case
for histidine and other amino acids that commonly are used as
buffers in pharmaceutical formulations.
Subject to the foregoing consideration, lysine, proline, serine,
and alanine can be used for stabilizing proteins in a formulation.
Glycine is useful in lyophilization to ensure correct cake
structure and properties. Arginine may be useful to inhibit protein
aggregation, in both liquid and lyophilized formulations.
Methionine is useful as an antioxidant.
Polyols include sugars, e.g., mannitol, sucrose, and sorbitol and
polyhydric alcohols such as, for instance, glycerol and propylene
glycol, and, for purposes of discussion herein, polyethylene glycol
(PEG) and related substances. Polyols are kosmotropic. They are
useful stabilizing agents in both liquid and lyophilized
formulations to protect proteins from physical and chemical
degradation processes. Polyols also are useful for adjusting the
tonicity of formulations.
Among polyols useful in select embodiments of the invention is
mannitol, commonly used to ensure structural stability of the cake
in lyophilized formulations. It ensures structural stability to the
cake. It is generally used with a lyoprotectant, e.g., sucrose.
Sorbitol and sucrose are among preferred agents for adjusting
tonicity and as stabilizers to protect against freeze-thaw stresses
during transport or the preparation of bulks during the
manufacturing process. Reducing sugars (which contain free aldehyde
or ketone groups), such as glucose and lactose, can glycate surface
lysine and arginine residues. Therefore, they generally are not
among preferred polyols for use in accordance with the invention.
In addition, sugars that form such reactive species, such as
sucrose, which is hydrolyzed to fructose and glucose under acidic
conditions, and consequently engenders glycation, also is not among
preferred amino acids of the invention in this regard. PEG is
useful to stabilize proteins and as a cryoprotectant and can be
used in the invention in this regard, such as it is in
Recombinate.RTM..
Embodiments of the self-buffering IL-17RA antigen binding protein
formulations further comprise surfactants. Protein molecules may be
susceptible to adsorption on surfaces and to denaturation and
consequent aggregation at air-liquid, solid-liquid, and
liquid-liquid interfaces. These effects generally scale inversely
with protein concentration. These deleterious interactions
generally scale inversely with protein concentration and typically
are exacerbated by physical agitation, such as that generated
during the shipping and handling of a product.
Surfactants routinely are used to prevent, minimize, or reduce
surface adsorption. Useful surfactants in the invention in this
regard include polysorbate 20, polysorbate 80, other fatty acid
esters of sorbitan polyethoxylates, and poloxamer 188.
Surfactants also are commonly used to control protein
conformational stability. The use of surfactants in this regard is
protein-specific since, any given surfactant typically will
stabilize some proteins and destabilize others.
Polysorbates are susceptible to oxidative degradation and often, as
supplied, contain sufficient quantities of peroxides to cause
oxidation of protein residue side-chains, especially methionine.
Consequently, polysorbates should be used carefully, and when used,
should be employed at their lowest effective concentration. In this
regard, polysorbates exemplify the general rule that excipients
should be used in their lowest effective concentrations.
Embodiments of the self-buffering IL-17RA antigen binding protein
formulations further comprise one or more antioxidants. To some
extent deleterious oxidation of proteins can be prevented in
pharmaceutical formulations by maintaining proper levels of ambient
oxygen and temperature and by avoiding exposure to light.
Antioxidant excipients can be used as well to prevent oxidative
degradation of proteins. Among useful antioxidants in this regard
are reducing agents, oxygen/free-radical scavengers, and chelating
agents. Antioxidants for use in therapeutic protein formulations in
accordance with the invention preferably are water-soluble and
maintain their activity throughout the shelf life of a product.
EDTA is a preferred antioxidant in accordance with the invention in
this regard and can be used in the invention in much the same way
it has been used in formulations of acidic fibroblast growth factor
and in products such as Kineret.RTM. and Ontak.RTM.).
Antioxidants can damage proteins. For instance, reducing agents,
such as glutathione in particular, can disrupt intramolecular
disulfide linkages. Thus, antioxidants for use in the invention are
selected to, among other things, eliminate or sufficiently reduce
the possibility of themselves damaging proteins in the
formulation.
Formulations in accordance with the invention may include metal
ions that are protein co-factors and that are necessary to form
protein coordination complexes, such as zinc necessary to form
certain insulin suspensions. Metal ions also can inhibit some
processes that degrade proteins. However, metal ions also catalyze
physical and chemical processes that degrade proteins.
Magnesium ions (10-120 mM) can be used to inhibit isomerization of
aspartic acid to isoaspartic acid. Ca.sup.+2 ions (up to 100 mM)
can increase the stability of human deoxyribonuclease (rhDNase,
Pulmozyme.RTM.). Mg.sup.+2, Mn.sup.+2, and Zn.sup.+2, however, can
destabilize rhDNase. Similarly, Ca.sup.+2 and Sr.sup.+2 can
stabilize Factor VIII, it can be destabilized by Mg.sup.+2,
Mn.sup.+2 and Zn.sup.+2, Cu.sup.+2 and Fe.sup.+2 and its
aggregation can be increased by Al.sup.+3 ions.
Embodiments of the self-buffering IL-17RA antigen binding protein
formulations further comprise one or more preservatives.
Preservatives are necessary when developing multi-dose parenteral
formulations that involve more than one extraction from the same
container. Their primary function is to inhibit microbial growth
and ensure product sterility throughout the shelf-life or term of
use of the drug product. Commonly used preservatives include benzyl
alcohol, phenol and m-cresol. Although preservatives have a long
history of use with small-molecule parenterals, the development of
protein formulations that includes preservatives can be
challenging. Preservatives almost always have a destabilizing
effect (aggregation) on proteins, and this has become a major
factor in limiting their use in multi-dose protein formulations. To
date, most protein drugs have been formulated for single-use only.
However, when multi-dose formulations are possible, they have the
added advantage of enabling patient convenience, and increased
marketability. A good example is that of human growth hormone (hGH)
where the development of preserved formulations has led to
commercialization of more convenient, multi-use injection pen
presentations. At least four such pen devices containing preserved
formulations of hGH are currently available on the market.
Norditropin.RTM. (liquid, Novo Nordisk), Nutropin AQ.RTM. (liquid,
Genentech) & Genotropin (lyophilized-dual chamber cartridge,
Pharmacia & Upjohn) contain phenol while Somatrope.RTM. (Eli
Lilly) is formulated with m-cresol.
Several aspects need to be considered during the formulation and
development of preserved dosage forms. The effective preservative
concentration in the drug product must be optimized. This requires
testing a given preservative in the dosage form with concentration
ranges that confer anti-microbial effectiveness without
compromising protein stability. For example, three preservatives
were successfully screened in the development of a liquid
formulation for interleukin-1 receptor (Type I) using differential
scanning calorimetry (DSC). The preservatives were rank ordered
based on their impact on stability at concentrations commonly used
in marketed products.
As might be expected, development of liquid formulations containing
preservatives are more challenging than lyophilized formulations.
Freeze-dried products can be lyophilized without the preservative
and reconstituted with a preservative containing diluent at the
time of use. This shortens the time for which a preservative is in
contact with the protein, significantly minimizing the associated
stability risks. With liquid formulations, preservative
effectiveness and stability have to be maintained over the entire
product shelf-life (.about.18 to 24 months). An important point to
note is that preservative effectiveness has to be demonstrated in
the final formulation containing the active drug and all excipient
components.
Self-buffering IL-17RA antigen binding protein formulations
generally will be designed for specific routes and methods of
administration, for specific administration dosages and frequencies
of administration, for specific treatments of specific diseases,
with ranges of bio-availability and persistence, among other
things. Formulations thus may be designed in accordance with the
invention for delivery by any suitable route, including but not
limited to orally, aurally, opthalmically, rectally, and vaginally,
and by parenteral routes, including intravenous and intraarterial
injection, intramuscular injection, and subcutaneous injection.
Compositions in accordance with the invention may be produced using
well-known, routine methods for making, formulating, and using
proteins, particularly pharmaceutical proteins. In certain of the
preferred embodiments of a number of aspects of the invention in
this regard, methods for preparing the compositions comprise the
use of counter ions to remove residual buffering agents. In this
regard the term counter ion is any polar or charged constituent
that acts to displace buffer from the composition during its
preparation. Counter ions useful in this regard include, for
instance, glycine, chloride, sulfate, and phosphate. The term
counter ion in this regard is used to mean much the same thing as
displacement ion.
Residual buffering agents can be removed using the counter ions in
this regard, using a variety of well-known methods, including but
not limited to, standard methods of dialysis and high performance
membrane diffusion-based methods such as tangential flow
diafiltration. Methods for residual buffer removal employing a
counter ion in this regard can also, in some cases, be carried out
using size exclusion chromatography.
In certain related preferred embodiments in this regard,
compositions in accordance with the invention are prepared by a
process that involves dialysis against a bufferless solution at a
pH below that of the preparation containing the self-buffering
protein. In particularly preferred embodiments of the invention in
this regard, the bufferless solution comprises counter ions,
particularly those that facilitate removal of residual buffer and
do not adversely affect the self-buffering protein or the
formulation thereof. In further particularly preferred embodiments
of the invention in this regard, following dialysis the pH of the
preparation is adjusted to the desired pH using dilute acid or
dilute base.
In certain related particularly preferred embodiments in this
regard, compositions in accordance with the invention are prepared
by a process that involves tangential flow diafiltration against a
bufferless solution at a pH below that of the preparation
containing the self-buffering protein. In particularly preferred
embodiments of the invention in this regard, the bufferless
solution comprises counter ions, particularly those that facilitate
removal of residual buffer and do not adversely affect the
self-buffering protein or the formulation thereof. In further
particularly preferred embodiments of the invention in this regard,
following diafiltration the pH of the preparation is adjusted to
the desired pH using dilute acid or dilute base.
Once the pharmaceutical composition has been formulated, it may be
stored in sterile vials as a solution, suspension, gel, emulsion,
solid, crystal, or as a dehydrated or lyophilized powder. Such
formulations may be stored either in a ready-to-use form or in a
form (e.g., lyophilized) that is reconstituted prior to
administration. The invention also provides kits for producing a
single-dose administration unit. The kits of the invention may each
contain both a first container having a dried protein and a second
container having an aqueous formulation. In certain embodiments of
this invention, kits containing single and multi-chambered
pre-filled syringes (e.g., liquid syringes and lyosyringes) are
provided.
The therapeutically effective amount of an IL-17RA antigen binding
protein-containing pharmaceutical composition to be employed will
depend, for example, upon the therapeutic context and objectives.
One skilled in the art will appreciate that the appropriate dosage
levels for treatment will vary depending, in part, upon the
molecule delivered, the indication for which the IL-17RA antigen
binding protein is being used, the route of administration, and the
size (body weight, body surface or organ size) and/or condition
(the age and general health) of the patient. In certain
embodiments, the clinician may titer the dosage and modify the
route of administration to obtain the optimal therapeutic effect. A
typical dosage may range from about 0.1 .mu.g/kg to up to about 30
mg/kg or more, depending on the factors mentioned above. In
specific embodiments, the dosage may range from 0.1 .mu.g/kg up to
about 30 mg/kg, optionally from 1 .mu.g/kg up to about 30 mg/kg or
from 10 .mu.g/kg up to about 5 mg/kg.
Dosing frequency will depend upon the pharmacokinetic parameters of
the particular IL-17RA antigen binding protein in the formulation
used. Typically, a clinician administers the composition until a
dosage is reached that achieves the desired effect. The composition
may therefore be administered as a single dose, or as two or more
doses (which may or may not contain the same amount of the desired
molecule) over time, or as a continuous infusion via an
implantation device or catheter. Further refinement of the
appropriate dosage is routinely made by those of ordinary skill in
the art and is within the ambit of tasks routinely performed by
them. Appropriate dosages may be ascertained through use of
appropriate dose-response data. In certain embodiments, the antigen
binding proteins of the invention can be administered to patients
throughout an extended time period. Chronic administration of an
antigen binding protein of the invention minimizes the adverse
immune or allergic response commonly associated with antigen
binding proteins that are not fully human, for example an antibody
raised against a human antigen in a non-human animal, for example,
a non-fully human antibody or non-human antibody produced in a
non-human species.
The route of administration of the pharmaceutical composition is in
accord with known methods, e.g., orally, through injection by
intravenous, intraperitoneal, intracerebral (intra-parenchymal),
intracerebroventricular, intramuscular, intra-ocular,
intraarterial, intraportal, or intralesional routes; by sustained
release systems or by implantation devices. In certain embodiments,
the compositions may be administered by bolus injection or
continuously by infusion, or by implantation device.
The composition also may be administered locally via implantation
of a membrane, sponge or another appropriate material onto which
the desired molecule has been absorbed or encapsulated. In certain
embodiments, where an implantation device is used, the device may
be implanted into any suitable tissue or organ, and delivery of the
desired molecule may be via diffusion, timed-release bolus, or
continuous administration.
It also may be desirable to use IL-17RA antigen binding protein
pharmaceutical compositions according to the invention ex vivo. In
such instances, cells, tissues or organs that have been removed
from the patient are exposed to IL-17RA antigen binding protein
pharmaceutical compositions after which the cells, tissues and/or
organs are subsequently implanted back into the patient.
In particular, IL-17RA antigen binding proteins can be delivered by
implanting certain cells that have been genetically engineered,
using methods such as those described herein, to express and
secrete the polypeptide. In certain embodiments, such cells may be
animal or human cells, and may be autologous, heterologous, or
xenogeneic. In certain embodiments, the cells may be immortalized.
In other embodiments, in order to decrease the chance of an
immunological response, the cells may be encapsulated to avoid
infiltration of surrounding tissues. In further embodiments, the
encapsulation materials are typically biocompatible, semi-permeable
polymeric enclosures or membranes that allow the release of the
protein product(s) but prevent the destruction of the cells by the
patient's immune system or by other detrimental factors from the
surrounding tissues.
All references cited within the body of the instant specification
are hereby expressly incorporated by reference in their
entirety.
EXAMPLES
The following examples, including the experiments conducted and the
results achieved, are provided for illustrative purposes only and
are not to be construed as limiting the invention.
Example 1
IL-17RA knockout mice were generated as described in Ye et al.,
2001, J. Exp. Med. 194:519-527 and tested in a standard collagen
induced arthritis (CIA) model. Briefly, Genomic clones encoding
murine IL-17R were isolated from a 129 derived lambda library using
a murine IL-17R cDNA probe and mapped by a combination of PCR,
restriction digest, and sequence analyses using deposited genomic
sequences corresponding to IL-17R locus on mouse chromosome 6
(GenBank/EMBL/DDBJ accession no. AC018559). A gene targeting vector
was constructed by replacing 5.7 kb of genomic sequence containing
exons 4-11 (corresponding to nucleotides 445-1,172 of the murine
IL-17R cDNA) with a PGKneo cassette. A thymidine kinase cassette
(MC-TK) was inserted into the 5' end of the vector. 129 derived
embryonic stem (ES) cells were electroporated with the targeting
vector and selected in the presence of G418 and ganciclovir as
described. ES clones carrying a targeted mutation in IL-17R were
identified by a combination of PCR and genomic Southern blot
analyses and were injected into C57BL/6 blastocysts. The resulting
male chimeras were crossed to C57BL/6 females to generate mice
heterozygous for the IL-17R mutation (IL-17R.sup.+/-), which were
subsequently intercrossed to generate IL-17R-deficient mice
(IL-17RKO). These mice were moved to a C57BL/6 background by five
successive backcrosses to C57BL/6 mice.
IL-17RA knockout mice showed reduced mean clinical score in the CIA
model, as shown in FIG. 1 (see also Kolls et al., 2001, J. Ex. Med.
194:519-527; Lubberts at al., 2005, supra). In addition, the
IL-17RA knockout mice showed only a 5% incidence of disease,
whereas the wild-type mice showed a 71% incidence of disease.
Example 2
The histopathology of CIA-induced IL-17RA-/- mice and IL-17RA
expressing mice was compared to determine the correlation between
induced arthritis and the absence of IL-17RA signaling.
Mice were prepared as described in Example 1. The animals were
sacrificed at fifteen to twenty weeks of age, and the
histopathology of joints from the sacrificed animals were then
examined. Histopathology of bone and cartilage in IL-17RA-/-
knock-out mice and IL-17A/IL-17R expression mice (WT C57/BL6 (No.
2-18)) showed subchondral bone erosion of the talus and marked
joint architecture disruption of tarsal-metatarsal joints
(subchondral bone and articular cartilage erosion), as well as
reactive periosteal bone formation (osteophytosis). Histopathology
of ankle joints from mice deficient in IL-17RA-/- in an
experimentally induced CIA model showed little joint inflammation
and joint cartilage and bone erosion. However, the histopathologic
analysis of an ankle joint of the rear paw of IL-17RA expressing
mice showed marked chronic active inflammation. The significantly
reduced incidence of joint inflammation and joint and bone erosion
as compared to WT mice further implicates IL-17RA and IL-17RA
signaling in inflammation and erosion.
Example 3
A model of MOG (Myelin Oligodendrocyte
Glycoprotein)-peptide-induced EAE model mice deficient in IL-17RA
showed a delay in the onset of arthritis as well as an overall
reduction in clinical scores as compared to WT mice.
IL-17RA knockout mice were prepared as described in Example 1. FIG.
2 shows the incidence and median onset of arthritis as a function
of time for both IL-17RA -/- and IL-17RA wild-type mice. 15 out of
15 of the IL-17RA expressing wild-type mice exhibited arthritic
symptoms, with a mean onset of 13 days. By contrast, 14 of 15
IL-17RA -/- mice exhibited arthritic symptoms, with a mean onset of
22 days (p<0.0001 versus wild-type).
Clinical scores of IL-17RA-/- knockout mice show a lower mean
clinical score, with a later onset, than wild-type mice. FIG. 3
shows reduced clinical scores in IL-17RA-/- knockout mice as
compared to wild-type mice in a MOG-induced model. The IL-17RA-/-
knockout population showed a significantly later onset of arthritis
than the IL-17RA expressing wild-type population. Further, the
IL-17RA-/- knockout population had a lower mean clinical score at
all time points for onset of arthritis. The longer mean onset of
arthritis and lower mean clinical score for arthritis observed in
IL-17RA-/- mutants as compared to IL-17RA-expressing wild-type
animals further implicates IL-17RA signaling in inflammation and
erosion.
Example 4
Ovalbumin sensitized and challenged IL-17RA KO mice show a
significant reduction of inflammatory cells in BAL (bronchoalveolar
lavage) fluid compared to wild-type mice. IL-17RA KO mice were
prepared as described in Example 1, and then challenged
intra-nasally with ovalbumin. The number of inflammatory cells in
the IL-17RA KO population were compared to the IL-17RA expressing
wild-type population. FIG. 4 shows IL-17RA KO mice have reduced
total numbers of inflammatory cells in BAL fluid than IL-17RA
expressing wild-type mice in an ovalbumin-induced of asthma
post-third challenge.
The IL-17RA KO mouse population was compared to IL-17RA expressing
wild-type mice for the incidence of eosinophils (A), neutrophils
(B), lymphocytes (C) and macrophages (D) in BAL fluid in an
ovalbumin-induced model of asthma. FIGS. 5A-5D show that IL-17RA KO
mice have reduced numbers of eosinophils (5A), neutrophils (5B) and
lymphocytes (5C) in BAL fluid in the IL-17RA KO population as
compared to the IL-17RA expressing wild-type population. No changes
in BAL fluid macrophage (5D) were noted in either wile-type or
IL-17RA KO mice (naive and OVA-challenged). These data suggest that
IL-17RA signaling is important in regulating immune-mediated
inflammatory responses.
Example 5
IL-17RA antibodies were shown to reduce incidence of arthritis in a
CIA (Collagen-Induced Arthritis) mouse model when administered
prophylactically and therapeutically. The IL-17RA inhibition
reduced clinical arthritis in both a prophylactic and therapeutic
manner for several models if CIA.
The surrogate neutralizing mouse IL-17RA mAb administered
prophylactically reduced mean clinical scores in wild-type CIA
model in a dose-dependent manner. FIG. 6 shows the dose-dependent
inhibition by IL-17RA mAb in wild-type CIA model. Mice were treated
with either IL-17RA mAb or control Ig on a Monday, Wednesday and
Friday schedule for 2.5 weeks post boost. Administration of 100
.mu.g and 300 .mu.g of IL-17RA antibodies resulted in a lower
clinical score for 18 days post-boost than compared to isotype
control Ig.
A reduction in bone loss and cartilage erosion in the joint was
associated with the reduction of mean clinical scores at the 300
.mu.g dose of the IL-17RA mAb. Histopathologic analysis and
radiographic images analysis were compared to the IgG control. By
both means of analysis, the ankle joint of the near paw of CBA/1
male mouse treated with an IL-18R mAb (isotype control) showed
marked inflammation: subchondrial bone erosion of the talus, marked
joint architecture disruption of tarsal-metatarsal joints
(subchondrial bone and articular cartilage erosion), and reactive
periosteal bone formation (osteophytosis). In stark contrast, the
ankle joint of the rear paw of a DBA/1 mouse treated with 300 .mu.g
anti-IL-17RA mAb showed well-defined joint spaces, lack of edema
and lack of periosteal reactive bone or lytic lesions indicated
reduced bone loss and cartilage erosion.
Example 6
IL-17RA inhibition was also shown to be effective in a CIA model
when dosing was initiated after the onset of clinical signs (i.e,
therapeutic dosing protocol) in a wild-type and TNFR p55/p75 KO
model. Treatment was initiated approximately 6-7 days post collagen
introduction in both models. FIG. 7 shows that therapeutic
treatment with anti-IL-17RA mAb stabilized mean clinical scores in
both wild-type mice. FIG. 8 shows that therapeutic treatment with
anti-IL-17RA mAb stabilized mean clinical scores in TNFR p55/p75 KO
models. Mice were treated with either an anti-IL-17RA mAb,
anti-IL-1R mAb, or control Ig on a Monday, Wednesday and Friday
schedule for 2 weeks post randomization into therapeutic treatment
groups. These data are representative of 2 independent experiments
performed in both WT and TNFR p55/p75 KO CIA models. Administering
anti-IL-17RA mAbs showed a reduced clinical score as compared to
control IgG in CIA induced wild-type mice. Surprisingly, the
similar efficacy of anti-IL-17RA mAbs in the TNF p55/p75 KO model
stabilized CIA independently of TNF signaling. This data suggests
anti-IL-17RA antigen binding protein therapy may pick up
non-responders to anti-TNF therapies. Combination therapy of an
anti-IL-17RA antigen binding protein with anti-TNF therapies may be
more beneficial than either alone.
Example 7
The development of fully human monoclonal antibodies directed
against human IL-17RA was carried out using Abgenix (now Amgen
Fremont Inc.) XenoMouse.RTM. technology (U.S. Pat. Nos. 6,114,598;
6,162,963; 6,833,268; 7,049,426; 7,064,244, which are incorporated
herein by reference in their entirety; Green et al, 1994, Nature
Genetics 7:13-21; Mendez et al., 1997, Nature Genetics 15:146-156;
Green and Jakobovitis, 1998, J. Ex. Med. 188:483-495)). TABLE 4
shows the portions of the IL-17RA protein used as an immunogen and
cell lines used to generate and screen anti-IL-17RA antibodies.
TABLE-US-00004 TABLE 4 Reagent Description IL-17RA.Fc Human IL-17RA
extracellular domain with a C-terminal human Fc domain. Expressed
in a stable CHO cell line. IL-17RA-FLAG-polyHis Human IL-17RA
extracellular domain (SEQ ID NO: 431) with a C-terminal
FLAG-polyHis tag. Expressed by transient transfection in COS PKB
cells. IL-17RA CHO cells Human IL-17RA full-length expressed on the
surface of CHO cells.
IgG2 XenoMouse.RTM. mice were immunized/boosted with IL-17RA-Fc
(group 1) and IL-17RA-FLAG-polyHis (group 2). Serum titers were
monitored by ELISA and mice with the best titers were fused to
generate hybridomas. The resulting polyclonal supernatants were
screened for binding to IL-17RA by ELISA, and the positive
supernatants were screened for binding to IL-17RA CHO cells by
FMAT. Positive supernatants were subjected to additional screening.
IgG2 XenoMouse.RTM. mice were immunized with the following
immunogens: IL-17RA-Fc (group 3) and IL-17RA-FLAG-pHis (group 4)
and were tested following additional immunizations.
Example 8
The anti-IL-17RA antibodies were characterized. Non-clonal
hybridoma supernatants were prepared in volumes of 1-2 mls (the Ig
concentrations were not determined for these supernatants). The
anti-IL-17RA non-clonal hybridoma supernatants were initially
screened by FACS for their ability to inhibit biotinylated human
IL-17A binding to CHO cells over-expressing human IL-17RA and
another CHO cell line over-expressing cynomolgus IL-17RA. Nonclonal
supernatants that were able to completely or nearly completely
inhibit binding of human IL-17A to CHO-huIL-17RA and
CHO-cynoIL-17RA were subsequently screened at several dilutions in
an IL-17A-induced cytokine/chemokine secretion assay using a human
foreskin fibroblast (HFF) cell line. Anti-IL-17RA non-clonal
supernatants were incubated with HFF cells (5000 cells/well in 96
well plate) for 30 minutes at 36.degree. C. and then stimulated
overnight with either IL-17A (5 ng/ml) alone or IL-17F (20 ng/ml)
and TNF-alpha (5 ng/ml). Fibroblast culture supernatants were then
analyzed by ELISA for the presence of either IL-6 or GRO-alpha.
Anti-IL-17RA non-clonal hybridomas were selected for sub-cloning
based on their performance in the CHO-IL-17RA FACS assay and HFF
bioassay. An example of the selection is shown in TABLES 5, 6, and
7.
TABLE-US-00005 TABLE 5 HFF Bioassay Repeat assays 1:4 dil. 1:32 1:4
1:32 1:128 % inhibition of IL-6 % positive % positive MFI
production Neg. Cntl. 1.09 1.57 10 IL-17 biot. (500 ng/ml) 8.85
10.22 77 Supernatant I.D. 1 1.34 1.78 9 56 14 2 (incl.
AM.sub.H15/AM.sub.L15) 0.60 3.77 6 80 72 98 91 81 3 1.04 1.60 8 46
-5 4 (incl. AM.sub.H14/AM.sub.L14) 1.72 0.79 10 90 82 99 92 84 5
1.59 1.43 11 76 52 6 1.45 1.93 14 82 79 7 1.00 1.28 8 71 58 8 1.43
1.60 14 69 31 9 1.34 2.28 18 59 20 10 0.79 1.96 11 58 -2 11 1.93
1.69 11 72 21 12 2.23 1.69 8 69 7 13 (incl. 1.49 0.49 6 82 53
AM.sub.H21/AM.sub.L21) 14 1.01 1.25 8 63 23 15 1.31 1.45 9 74 45 16
1.39 0.72 8 58 4 17 0.91 0.94 7 73 38 18 1.37 2.85 13 49 6 19 1.47
1.15 8 74 61 20 1.60 1.20 7 72 46 21 1.30 1.65 8 47 4 22 0.93 1.02
8 54 16 23 1.08 1.12 7 72 59
In TABLE 5, anti-IL-17RA non-clonal hybridoma supernatants were
screened for binding to IL-17RA. The first half of TABLE 5 shows
the % positive and mean fluorescent intensity (MFI) in results from
flow cytometry (i.e, FACS). The % positive shows inhibition of
biotin-huIL-17A binding to huIL-17RA.sup.+ CHO cells by the
non-clonal hybridoma supernatants. The MFI column shows inhibition
of biotinylated huIL-17A binding to cyno IL-17RA.sup.+ CHO cells by
the non-clonal hybridoma supernatants. The second half of TABLE 5
shows the HFF binding intensity for the non-clonal and mAbs as
measured by the % intensity of IL-6 production. The first 2 columns
show an IL-17A/HFF bioassay with non-clonal hybridoma supernatants
and the last 4 columns are repeat IL-17A/HFF bioassay results with
non-clonal hybridoma supernatants.
TABLE-US-00006 TABLE 6 FACS results on 293-Cyno IL-17RA- expressing
Cells HFF bioassay repeat 1:4 dilution 1:32 1:4 1:32 1:128 1:512 %
positive % positive MFI % inhibition of IL-6 production Neg. Cntl
1.09 1.57 1.0 IL-17 biot. (500 ng/ml) 8.85 10.22 77 Supernatant
I.D. 1 (incl. 1.32 1.4 9 AM.sub.H11/AM.sub.L11) 2 0.87 2.92 9 3 1.0
4.47 16 4 1.03 5.01 17 5 0.6 6.53 18 6 (incl. 0.73 4.55 9
AM.sub.H5/AM.sub.L5) 7 0.59 5.18 8 8 0.45 7.25 7 9 2.34 2.36 6 61
36 10 6.76 8.35 64 37 12 11 0.78 1.16 6 61 24 12 0.61 1.64 6 74 56
71 67 45 35 13 2.98 5.48 22 -2 -13 14 5.34 10.64 49 22 2 3 39 31 34
15 0.5 3.24 11 51 -7 16 (incl. 0.54 2.93 18 92 72 91 73 73 29
AM.sub.H22/AM.sub.L22) 17 1.25 2.2 17 -8 -76 18 0.61 0.99 7 73 28
19 (incl. AM.sub.H23) 0.69 1.72 10 79 72 86 76 67 50 20 1.53 1.94
31 5 -31 21 6.66 9.63 66 -15 4 22 6.33 10.32 71 1 14 23 0.3 2.55 7
50 35 24 0.24 4.11 6 34 15 25 0.81 0.99 8 -49 11 26 0.43 1.31 7 67
48 27 0.7 1.23 11 50 26 28 0.58 1.32 9 56 47 29 (incl. 0.8 1.85 11
77 76 90 87 79 66 AM.sub.H1/AM.sub.L1) 30 0.69 1.55 11 40 16 31
0.56 1.96 12 12 -11 32 0.21 1.11 8 46 7 33 1.24 1.15 13 68 43 34
0.74 0.81 11 36 8 35 0.71 1.37 9 65 21 36 0.57 1.21 7 78 32 37 0.59
1.0 8 71 3 38 0.65 1.43 8 63 -38 39 0.28 1.23 7 43 -21 40 0.35 2.48
9 50 -39 41 0.64 1.61 8 49 -19 42 0.12 1.04 8 87 68 96 92 80 66 43
0.21 1.12 11 79 34 44 0.32 1.33 8 68 -3 45 0.74 1.68 10 40 -16 46
0.58 1.74 10 64 7
TABLE 6 shows IL-17RA non-clonal hybridoma supernatant screening
data. The % positive and MFI columns show results from flow
cytometry (FACS). The % positive columns show inhibition of
biotin-huIL-17A binding to huIL-17RA.sup.+ CHO cells by the
non-clonal hybridoma supernatants. The MFI column shows inhibition
of biotinylated huIL-17A binding to cyno IL-17RA.sup.+ CHO cells by
the non-clonal hybridoma supernatants. The first 2 HFF bioassay
columns are IL-17A/HFF bioassay with non-clonal hybridoma
supernatants and the last 4 bioassay columns are repeat IL-17A/HFF
bioassay results with selected non-clonal hybridoma supernatants. A
number of supernatants were selected for sub-cloning.
TABLE-US-00007 TABLE 7 HFF bioassay 1:4 1:32 1:128 % % inhibition
of positive MFI IL-6 Production Neg. Cntl 1.09 1.57 10 IL-17 biot.
(500 ng/ml) 8.85 10.22 77 Supernatant I.D. 1 1.85 1.33 10 29 9 21 2
1.08 1.46 16 90 61 50 3 1.29 1.39 22 33 10 4 4 1.55 1.33 18 53 66
58 5 1.69 0.7 8 76 46 30 6 (incl. AM.sub.H13/AM.sub.L13) 1.52 0.89
6 73 78 75 7 1.54 0.98 7 79 71 45 8 1.78 3.44 34 73 63 30 9 6.34
8.45 53 57 48 34 10 1.23 1.58 10 82 71 31 11 1.62 2.1 28 -10 -6 -10
12 1.15 1.04 16 71 63 37 13 2.43 1.67 12 58 23 -4 14 1.43 1.03 13
42 17 18 15 1.62 1.59 18 67 59 31 16 1.79 2.2 25 61 57 45 17 0.91
1.85 10 49 54 23 18 (incl. AM.sub.H12/AM.sub.L12) 1 1.36 6 75 82 61
19 (incl. AM.sub.H17/AM.sub.L17) 1.75 1.23 8 90 81 73 20 2.31 0.49
9 35 20 38 21 (incl. AM.sub.H16/AM.sub.L16) 1.84 0.76 6 86 90
71
TABLE 7 shows anti-IL-17RA non-clonal hybridoma supernatant
screening data. The first two columns are flow cytometry data
(FACS). The % positive columns show inhibition of biotin-hulL-17A
binding to hulL-17RA.sup.+ CHO cells by the non-clonal hybridoma
supernatants. The MFI column shows inhibition of biotinylated
hulL-17A binding to cynomolgus IL-17RA.sup.+ CHO cells by the
non-clonal hybridoma supernatants. The final three columns show
IL-17A/HFF bioassay results with non-clonal hybridoma supernatants.
Supernatants 6, 18, 19 and 21 were selected for subcloning.
TABLE-US-00008 TABLE 8 IL-17A/HFF Low bioassay resolution BIAcore
Sub-clone ID IC.sub.50 (nM) K.sub.D(nM) 1. Subclone of
(AM.sub.H14/AM.sub.L14) 0.12 0.69 2. Subclone of
(AM.sub.H14/AM.sub.L14)2 0.20 ND 3. Subclone of
(AM.sub.H14/AM.sub.L14)3 0.075 ND 4. Subclone of
(AM.sub.H21/AM.sub.L21) 2.3 ND 5. Subclone of
(AM.sub.H21/AM.sub.L21) 3.1 ND 6. Subclone of
(AM.sub.H21/AM.sub.L21) 3.3 16.7 7. Subclone of
(AM.sub.H20/AM.sub.L20) 8.1 ND 8. Subclone of
(AM.sub.H20/AM.sub.L20) 6.6 ND 9. Subclone of
(AM.sub.H20/AM.sub.L20) 6.7 11.6 10. Subclone of
(AM.sub.H19/AM.sub.L19) 0.22 3.1 11. Subclone of
(AM.sub.H19/AM.sub.L19) 1.1 ND 12. Subclone of
(AM.sub.H19/AM.sub.L19) 0.50 ND 13. Subclone of
(AM.sub.H13/AM.sub.L13) >10 7.6 14. Subclone of
(AM.sub.H18/AM.sub.L18) 0.44 ND 15. Subclone of
(AM.sub.H18/AM.sub.L18) 0.40 ND 16. Subclone of
(AM.sub.H18/AM.sub.L18) 0.17 14.9 17. Subclone of
(AM.sub.H12/AM.sub.L12) 3.5 ND 18. Subclone of
(AM.sub.H12/AM.sub.L12) 3.7 8.2 20. Subclone of
(AM.sub.H12/AM.sub.L12) 5.5 ND 21. Subclone of
(AM.sub.H17/AM.sub.L17) 2.5 8.2 22. Subclone of
(AM.sub.H17/AM.sub.L17) 5.3 ND 23. Subclone of
(AM.sub.H17/AM.sub.L17) 0.57 ND 24. Subclone of
(AM.sub.H16/AM.sub.L16) 1.6 ND 25. Subclone of
(AM.sub.H16/AM.sub.L16) 2.3 6.2 26. Subclone of
(AM.sub.H16/AM.sub.L16) 1.4 ND 27. Subclone of
(AM.sub.H22/AM.sub.L22) 0.046 1.5 28. Subclone of
(AM.sub.H22/AM.sub.L22) 0.09 ND 29. Subclone of
(AM.sub.H22/AM.sub.L22) 0.07 ND ND = not determined
TABLE 8 shows IL-17A/HFF bioassay IC50 values and low resolution
BIAcore.RTM. K.sub.D values for subcloned hybridomas. Lower IC50
and K.sub.D values in the IL-17A/HFF IL-17RA binding assays showed
that the IL-17RA mAbs inhibited binding of IL-17A to IL-17 receptor
A. Antibodies were selected for further characterization based on
low K.sub.D values for inhibiting IL-17A binding to human
IL-17RA.
Example 9
IL-17RA human mAb clones having the heavy and light chain sequences
(AM.sub.H22/AM.sub.L22), (AM.sub.H19/AM.sub.L19),
(AM.sub.H18/AM.sub.L18) and (AM.sub.H14/AM.sub.L14) were selected
for recombinant mAb production and further bioassay
characterization. TABLE 9 below shows IC50 values for the selected
Abs in the HFF bioassay and a primary lung fibroblast bioassay
against both IL-17A and IL-17F.
TABLE-US-00009 TABLE 9 IL-17A/HFF IL-17F/HFF IL-17A/lung IL-17RA
mAb IC50 (nM) IC50 (nM) fibroblast IC50 (nM)
(AM.sub.H14/AM.sub.L14) 0.13 0.067 0.04 (AM.sub.H22/AM.sub.L22)
0.10 0.033 0.14 (AM.sub.H19/AM.sub.L19) 0.20 0.087 0.22
(AM.sub.H18/AM.sub.L18) 0.33 0.073 0.081
The selected human mAbs inhibited IL-17A binding to IL-17RA. In
addition to the lower IC50 values observed for IL-17A binding to
IL-17RA, the selected human mAbs exhibited reduced IC50 values
inhibiting the binding of IL-17F to IL-17RA (second column).
Therefore, the selected human mAbs inhibit both IL-17A-IL-17RA
binding and IL-17F-IL-17RA binding.
Example 10
Exemplary IL-17RA human mAbs were tested in a cynomolgus bioassay
utilizing the cynomolgus-derived kidney epithelial cell line JTC-12
stimulated with cynomolgus IL-17A. FIG. 9 shows IL-17RA mAbs having
the heavy and light chain sequences (AM.sub.H22/AM.sub.L22),
(AM.sub.H19/AM.sub.L19), (AM.sub.H18/AM.sub.L18) and
(AM.sub.H14/AM.sub.L14) in the inhibition of cynomolgus
IL-17A-induced IL-6 production from JTC-12 cells. The (----) line
depicts the positive control value of cynomolgus IL-17 in
combination with TNF-alpha. The (-.-.-) line depicts the positive
control value of cynomolgus TNF-alpha. The (....) line depicts the
media control value. JTC-12 cells were preincubated for 30 mins
with anti-IL-17RA mAbs and then stimulated overnight with
cynomolgus IL-17A (5 ng/ml) and human TNF-alpha (5 ng/ml). FIG. 9
shows that each antibody was able to inhibit cynomolgus IL-17A from
binding IL-17RA and inhibit IL-17RA activation, as determined by
IL-6 production from JTC-12 cells. The IL-17RA antibody
(AM.sub.H14/AM.sub.L14) was able to antagonize cynomolgus
IL-17A-induced IL-6 production from JTC-12 cells with an IC50 of
approximately 1.2 nM.
Example 11
In vitro binding of IL-17RA mAbs was assayed. The binding
affinities of IL-17RA antibodies were measured by surface plasmon
resonance using a Biacore 30000 instrument by standard methods
known in the art. Antibody candidates were captured on CM4 chips
derivatized with goat anti-human IgG (H+L) antibody (Jackson Immuno
Research, Bar Harbor, Me.). A CM4 chip coated with goat anti-human
IgG (H+L) antibody but without captured antibody was used as a
reference. Soluble huIL-17RA-FLAG-polyHis (SEQ ID NO:431) at a
concentration range of 0.46-1000 nM was flowed over the chips for 2
minutes (association phase) followed by a 15-30 minute
disassociation phase. FLAG peptide, Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys
(DYKDDDDK) (SEQ ID NO:447) as described in Hopp et al.,
Bio/Technology 6:1204, 1988, and U.S. Pat. No. 5,011,912 enables
rapid assay and facile purification of expressed recombinant
protein. Reagents useful for preparing fusion proteins in which the
FLAG peptide is fused to a given polypeptide are commercially
available (Sigma, St. Louis, Mo.).
Experiments were conducted at 25.degree. C. using a 50 uL/min flow
rate. Data was fit to a 1:1 Model+Local Rmax using BIAeval
Software.RTM. (v4.1).
TABLE-US-00010 TABLE 10 Human Antibody k.sub.a (1/Ms) K.sub.D (1/s)
K.sub.A (1/M) K.sub.D (M) (AM.sub.H14/AM.sub.L14) 2.60 .times.
10.sup.5 6.22 .times. 10.sup.-5 4.18 .times. 10.sup.9 2.39 .times.
10.sup.-10 (AM.sub.H22/AM.sub.L22) 2.35 .times. 10.sup.5 1.17
.times. 10.sup.-4 2.01 .times. 10.sup.9 4.98 .times. 10.sup.-10
(AM.sub.H19/AM.sub.L19) 1.42 .times. 10.sup.5 1.14 .times.
10.sup.-4 1.25 .times. 10.sup.9 8.02 .times. 10.sup.-10
(AM.sub.H18/AM.sub.L18) 1.02 .times. 10.sup.5 1.01 .times.
10.sup.-3 1.01 .times. 10.sup.8 9.88 .times. 10.sup.-9
TABLE 10 shows the K.sub.D of the human mAb clones was on the order
of 10.sup.-10 to 10.sup.-9, with the clone having the heavy and
light chain sequences (AM.sub.H14/AM.sub.L14) having the highest
affinity. Each of the human monoclonal antibodies' kinetic data was
consistent with the equilibrium data. The antibody with the heavy
and light chain variable sequences (AM.sub.H14/AM.sub.L14; SEQ ID
NO:14 and SEQ ID NO:40, respectively) had the highest affinity for
IL-17RA, as well as the slowest off-rate.
Example 12
The agonistic potential of IL-17RA human mAb having the heavy and
light chain variable sequences (AM.sub.H14/AM.sub.L14) was assessed
in vitro. The IL-17RA mAb (AM.sub.H14/AM.sub.L14) was tested for
its agonist effects on HFF cells. IL-17RA mAb having the heavy and
light chain sequences (AM.sub.H14/AM.sub.L14) was also tested under
conditions of cross-linking with goat anti-human F(ab').sup.2, goat
anti-human IgG and mouse anti-human IgG prior to incubation on HFF
cells. Recombinant IL-17RA mAb AM.sub.H14/AM.sub.L14 at 0, 0.1,
0.5, 1, 1.5 and 10 .mu.g/ml, alone and pre-cross linked with murine
anti-human IgG (Zymed/Invitrogen, San Diego, Calif.), goat
anti-human F(ab').sup.2 (Goat a-h-Fab) and goat anti-human IgG
(Goat a-h IgG) were incubated overnight with HFF cells. GRO-alpha
was assessed by ELISA. IL-17A alone served as a positive control
for GRO-alpha production in this experiment. These data are
representative of 2 independent experiments. IL-17RA mAb
(AM.sub.H14/AM.sub.L14) alone had no effect on HFF cells.
Pre-crosslinking anti-IL-17RA mAb (AM.sub.H14/AM.sub.L14) had no
effect on GRO-alpha production from HFF cells. These data
demonstrate that anti-IL-17RA mAb (AM.sub.H14/AM.sub.L14) either
alone or pre-cross-linked and incubated with HFF cells was unable
to induce a GRO-alpha response and therefore is not an agonistic
mAb to IL-17RA.
Example 13
The effects of the germline (GL) changes to IL-17RA mAb
AM.sub.H14/AM.sub.L14 were tested in the HFF bioassay. FIG. 10
shows sequence variation in the framework regions of SEQ ID NO:40
(AM.sub.L14) in relation to germline residues and the effect on
IC50 values. SEQ ID NO:40 (AM.sub.L14) contains four non-germline
residues in the framework, two in FR2 and two in FR3. Standard
site-directed mutagenesis methods were used to generate germline
versions A and B of AM.sub.H14/AM.sub.L14. These variants were
tested in the IL-17A and IL-17F HFF bioassay: HFF cells were
preincubated for 30 mins with various anti-IL-17RA mAbs and then
stimulated overnight with IL-17 (5 ng/ml).
FIG. 11 shows that the two variants that had the residues returned
to germline (see FIG. 10) had reduced IL-17A inhibitory activity in
relation to AM.sub.H14/AM.sub.L14, indicating that some variation
in the framework regions was tolerated but that some residues may
influence activity. The (----) line indicates the positive control
value of IL-17 stimulation in the absence of antibody
(approximately 4062 pg/ml). The media-only control gave a value of
approximately 71 pg/ml.
FIG. 12 shows that the two variants that had the residues returned
to germline (see FIG. 10) had reduced IL-17F inhibitory activity in
relation to AM.sub.H14/AM.sub.L14, indicating that some variation
in the framework regions was tolerated but that some residues may
influence activity. The positive control value of IL-17F in
combination with TNF-alpha stimulation in the absence of antibody
was approximately 10994 pg/ml, the value for TNF-alpha only was
approximately 1534 pg/ml, and the media-only control gave a value
of approximately 55 pg/ml.
SEQUENCE LISTINGS
1
4701131PRTHomo sapiens 1Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu
Val Lys Pro Ser Glu1 5 10 15Thr Leu Ser Leu Thr Cys Thr Val Ser Gly
Gly Ser Ile Ser Asn Tyr 20 25 30Tyr Trp Asn Trp Ile Arg Gln Ser Pro
Gly Lys Gly Leu Glu Trp Ile 35 40 45Gly Asp Ile Tyr Tyr Ser Gly Ser
Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60Ser Arg Val Thr Ile Ser Val
Asp Thr Ser Lys Asn Gln Phe Ser Leu65 70 75 80Lys Leu Ser Ser Val
Thr Thr Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Arg Asp Gly Glu
Leu Ala Asn Tyr Tyr Gly Ser Gly Ser Tyr Gln Phe 100 105 110Tyr Tyr
Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr 115 120
125Val Ser Ser 1302127PRTHomo sapiens 2Gln Val Gln Leu Gln Gln Trp
Gly Ala Gly Leu Leu Lys Pro Ser Glu1 5 10 15Thr Leu Ser Leu Thr Cys
Ala Val Ser Gly Gly Ser Phe Ser Gly Tyr 20 25 30Tyr Trp Ser Trp Ile
Arg Gln Pro Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45Gly Glu Ile Asn
His Ser Gly Arg Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60Ser Arg Val
Thr Ile Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu65 70 75 80Lys
Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90
95Arg Gly Pro Tyr Tyr Phe Asp Ser Ser Gly Tyr Leu Tyr Tyr Tyr Tyr
100 105 110Gly Leu Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser
Ser 115 120 1253114PRTHomo sapiens 3Gln Val Gln Leu Val Glu Ser Gly
Gly Gly Val Val Gln Pro Gly Arg1 5 10 15Ser Leu Arg Leu Ser Cys Ala
Ala Ser Gly Ile Asn Phe Ser Ser Tyr 20 25 30Gly Met His Trp Val Arg
Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala Val Ile Trp Tyr
Asp Gly Ser Asn Lys His Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe
Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Gln
Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala
Arg Asp Thr Gly Val Tyr Trp Gly Gln Gly Thr Leu Val Thr Val 100 105
110Ser Ser4114PRTHomo sapiens 4Gln Val Gln Leu Val Glu Ser Gly Gly
Gly Val Val Gln Pro Gly Arg1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala
Ser Gly Ile Asn Phe Ser Ser Tyr 20 25 30Gly Met His Trp Val Arg Gln
Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala Val Ile Trp Tyr Asp
Gly Ser Asn Lys His Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr
Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75 80Leu Gln Met
Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg
Asp Thr Gly Val Tyr Trp Gly Gln Gly Thr Leu Val Thr Val 100 105
110Ser Ser5125PRTHomo sapiens 5Gln Val Gln Leu Gln Glu Ser Gly Pro
Gly Leu Val Lys Pro Ser Glu1 5 10 15Thr Leu Pro Leu Thr Cys Thr Val
Ser Gly Gly Ser Ile Arg Ser Tyr 20 25 30Tyr Trp Ser Trp Ile Arg Gln
Pro Ala Gly Lys Gly Leu Glu Trp Ile 35 40 45Gly Arg Ile Tyr Arg Ser
Gly Asn Thr Ile Tyr Asn Pro Ser Leu Lys 50 55 60Ser Arg Val Thr Met
Ser Ile Asp Thr Ser Lys Asn Gln Phe Ser Leu65 70 75 80Thr Leu Ser
Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Arg Glu
Asn Tyr Ser Glu Ser Ser Gly Leu Tyr Tyr Tyr Tyr Gly Met 100 105
110Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 120
1256124PRTHomo sapiens 6Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val
Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly
Tyr Thr Leu Thr Arg Tyr 20 25 30Gly Ile Ser Trp Val Arg Gln Ala Pro
Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Trp Ile Ser Ala Tyr Asn Gly
Asn Thr Asn Tyr Ala Gln Lys Leu 50 55 60Gln Gly Arg Val Thr Met Thr
Thr Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75 80Met Glu Leu Arg Ser
Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Arg Asp
Tyr Asp Ile Leu Thr Gly Tyr Tyr Asn Gly Phe Asp 100 105 110Pro Trp
Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 1207124PRTHomo sapiens
7Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5
10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Leu Thr Arg
Tyr 20 25 30Gly Ile Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu
Trp Met 35 40 45Gly Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala
Gln Lys Leu 50 55 60Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr
Ser Thr Ala Tyr65 70 75 80Met Glu Leu Arg Ser Leu Arg Ser Asp Asp
Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Arg Asp Tyr Asp Ile Leu Thr
Gly Tyr Tyr Asn Gly Phe Asp 100 105 110Pro Trp Gly Gln Gly Thr Leu
Val Thr Val Ser Ser 115 1208124PRTHomo sapiens 8Gln Val Gln Leu Val
Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val
Ser Cys Lys Ala Ser Gly Asn Thr Phe Thr Gly Tyr 20 25 30Gly Ile Ser
Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Trp
Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Asn Leu 50 55 60Gln
Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75
80Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys
85 90 95Ala Arg Arg Asp Tyr Asp Ile Leu Thr Gly Tyr Tyr Asn Gly Phe
Asp 100 105 110Pro Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115
1209124PRTHomo sapiens 9Gln Val Gln Leu Val Gln Ser Gly Val Glu Val
Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser Gly
Tyr Thr Leu Thr Arg Tyr 20 25 30Gly Ile Ser Trp Val Arg Gln Ala Pro
Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Trp Ile Ser Ala Tyr Asn Gly
Asn Thr Asn Tyr Ala Gln Lys Leu 50 55 60Gln Gly Arg Val Thr Met Thr
Thr Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75 80Met Glu Leu Arg Ser
Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Arg Asp
Tyr Asp Ile Leu Thr Gly Tyr Tyr Asn Gly Phe Asp 100 105 110Pro Trp
Gly Gln Gly Thr Leu Val Thr Val Ser Ser 115 12010124PRTHomo sapiens
10Gln Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln1
5 10 15Thr Leu Ser Leu Thr Cys Thr Val Ser Gly Gly Ser Ile Ser Ser
Gly 20 25 30Gly Tyr Tyr Trp Ser Trp Ile Arg Gln His Pro Gly Lys Gly
Leu Glu 35 40 45Trp Ile Gly Tyr Ile Tyr Phe Ser Gly Ser Ala Tyr Tyr
Asn Pro Ser 50 55 60Leu Lys Ser Arg Val Ala Ile Ser Val Asp Thr Ser
Lys Asn Gln Phe65 70 75 80Ser Leu Lys Leu Ser Ser Val Thr Ala Ala
Asp Thr Ala Val Tyr Tyr 85 90 95Cys Ala Arg Glu Tyr Tyr Asp Ser Ser
Gly Tyr Pro Asp Ala Phe Asp 100 105 110Ile Trp Gly Gln Gly Thr Met
Val Thr Val Ser Ser 115 12011114PRTHomo sapiens 11Gln Val Gln Leu
Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1 5 10 15Ser Leu Arg
Leu Ser Cys Ala Thr Ser Gly Ile Thr Phe Ser Ser Tyr 20 25 30Gly Met
His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala
Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 50 55
60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65
70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
Cys 85 90 95Ala Arg Asp Thr Lys Asp Tyr Trp Gly Gln Gly Thr Leu Val
Thr Val 100 105 110Ser Ser12116PRTHomo sapiens 12Gln Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys
Val Ser Cys Lys Ala Ser Gly Tyr Thr Leu Thr Ser Tyr 20 25 30Gly Ile
Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly
Trp Ile Ser Thr Tyr Lys Gly Asn Thr Asn Tyr Ala Gln Lys Leu 50 55
60Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr65
70 75 80Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr
Cys 85 90 95Ala Arg Lys Gln Leu Val Phe Asp Tyr Trp Gly Gln Gly Thr
Leu Val 100 105 110Thr Val Ser Ser 11513121PRTHomo sapiens 13Gln
Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1 5 10
15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30Gly Met Gln Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
Val 35 40 45Ala Val Ile Trp Tyr Asp Gly Asn Lys Lys Tyr Tyr Ala Asp
Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn
Thr Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95Ala Arg Gly Arg Val Arg Asp Tyr Tyr Tyr
Gly Met Asp Val Trp Gly 100 105 110Gln Gly Thr Thr Val Thr Val Ser
Ser 115 12014116PRTHomo sapiens 14Gln Val Gln Leu Val Gln Ser Gly
Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val Ser Cys Lys
Ala Ser Gly Tyr Thr Phe Thr Arg Tyr 20 25 30Gly Ile Ser Trp Val Arg
Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Trp Ile Ser Thr
Tyr Ser Gly Asn Thr Asn Tyr Ala Gln Lys Leu 50 55 60Gln Gly Arg Val
Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75 80Met Glu
Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala
Arg Arg Gln Leu Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 100 105
110Thr Val Ser Ser 11515121PRTHomo sapiens 15Gln Val Gln Leu Val
Glu Ser Gly Gly Gly Val Val Gln Pro Gly Arg1 5 10 15Ser Leu Arg Leu
Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr 20 25 30Gly Met Gln
Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45Ala Val
Ile Trp Tyr Asp Gly Asn Lys Lys Tyr Tyr Ala Asp Ser Val 50 55 60Lys
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr65 70 75
80Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95Ala Arg Gly Arg Val Arg Asp Tyr Tyr Tyr Gly Met Asp Val Trp
Gly 100 105 110Gln Gly Thr Thr Val Thr Val Ser Ser 115
12016116PRTHomo sapiens 16Gln Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser
Gly Tyr Thr Phe Thr Ser Tyr 20 25 30Gly Ile Ser Trp Val Arg Gln Ala
Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Trp Ile Ser Ala Tyr Asn
Gly Asn Thr Lys Tyr Ala Gln Lys Leu 50 55 60Gln Gly Arg Val Thr Met
Thr Thr Asp Thr Ser Thr Ser Thr Val Tyr65 70 75 80Met Glu Leu Arg
Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Lys
Gln Leu Val Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110Thr
Val Ser Ser 11517116PRTHomo sapiens 17Gln Val Gln Leu Val Gln Ser
Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ala Val Lys Val Ser Cys
Lys Ala Thr Gly Tyr Thr Leu Thr Ser Tyr 20 25 30Gly Ile Ser Trp Val
Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Trp Ile Ser
Ala Tyr Ser Gly Asn Thr Lys Tyr Ala Gln Lys Leu 50 55 60Gln Gly Arg
Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75 80Met
Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90
95Ala Arg Lys Gln Leu Val Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val
100 105 110Thr Val Ser Ser 11518126PRTHomo sapiens 18Gln Val Gln
Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val
Lys Val Ser Cys Lys Ala Ser Gly Tyr Ser Phe Thr Asp Tyr 20 25 30Tyr
Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40
45Gly Trp Met His Pro Asn Ser Gly Gly Thr Asp Leu Ala Gln Arg Phe
50 55 60Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala
Tyr65 70 75 80Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val
Tyr Tyr Cys 85 90 95Ala Arg Gly Gly Tyr Cys Ser Thr Leu Ser Cys Ser
Phe Tyr Trp Tyr 100 105 110Phe Asp Leu Trp Gly Arg Gly Thr Leu Val
Thr Val Ser Ser 115 120 12519116PRTHomo sapiens 19Gln Val Gln Leu
Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys
Val Ser Cys Lys Ala Ser Gly Tyr Thr Leu Thr Ser Tyr 20 25 30Gly Ile
Ser Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly
Trp Ile Ser Ala Tyr Ser Gly Asn Thr Lys Tyr Ala Gln Lys Phe 50 55
60Gln Gly Arg Val Thr Met Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr65
70 75 80Met Glu Leu Arg Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr
Cys 85 90 95Ala Arg Arg Gln Leu Ala Leu Asp Tyr Trp Gly Gln Gly Thr
Leu Val 100 105 110Thr Val Ser Ser 11520118PRTHomo sapiens 20Glu
Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly1 5 10
15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
Val 35 40 45Ser Phe Ile Ser Ala Arg Ser Ser Thr Ile Tyr Tyr Ala Asp
Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn
Ser Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95Ala Arg Pro Lys Val Gly Gly Gly Met Asp
Val Trp Gly Gln Gly Thr 100 105 110Thr Val Thr Val Ser Ser
11521118PRTHomo sapiens 21Glu Val Gln Leu Val Glu Ser Gly Gly Gly
Ser Val Gln Pro Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser
Gly Phe Thr Phe Ser Ser Tyr
20 25 30Ser Met Asn Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
Val 35 40 45Ser Ile Ile Ser Ser Arg Ser Ser Ile Ile His Tyr Ala Asp
Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn
Ser Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Asp Glu Asp Thr
Ala Val Tyr Tyr Cys 85 90 95Ala Arg Pro Lys Val Gly Gly Gly Met Asp
Val Trp Gly Gln Gly Thr 100 105 110Thr Val Thr Val Ser Ser
11522116PRTHomo sapiens 22Gln Val Gln Leu Val Gln Ser Gly Ala Glu
Val Lys Lys Pro Gly Ala1 5 10 15Ser Val Lys Val Ser Cys Lys Ala Ser
Gly Tyr Thr Phe Thr Arg Tyr 20 25 30Gly Ile Ser Trp Val Arg Gln Ala
Pro Gly Gln Gly Leu Glu Trp Met 35 40 45Gly Trp Ile Ser Ala Tyr Ser
Gly Asn Thr Asn Tyr Ala Gln Lys Leu 50 55 60Gln Gly Arg Val Thr Met
Thr Thr Asp Thr Ser Thr Ser Thr Ala Tyr65 70 75 80Met Glu Leu Arg
Ser Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Arg
Gln Leu Tyr Phe Asp Tyr Trp Gly Gln Gly Thr Leu Val 100 105 110Thr
Val Ser Ser 11523125PRTHomo sapiens 23Gln Val Gln Leu Gln Glu Ser
Gly Pro Gly Leu Val Lys Pro Ser Glu1 5 10 15Thr Leu Ser Leu Thr Cys
Thr Val Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30Tyr Trp Ser Trp Ile
Arg Gln Pro Ala Gly Lys Arg Leu Glu Trp Ile 35 40 45Gly Arg Ile Tyr
Pro Ser Gly Arg Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60Ser Arg Val
Thr Met Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu65 70 75 80Lys
Leu Ser Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90
95Arg Glu Ala Tyr Glu Leu Gln Leu Gly Leu Tyr Tyr Tyr Tyr Gly Met
100 105 110Asp Val Trp Gly Gln Gly Thr Pro Val Thr Val Ser Ser 115
120 12524125PRTHomo sapiens 24Gln Val Gln Leu Gln Glu Ser Gly Pro
Gly Leu Val Lys Pro Ser Glu1 5 10 15Thr Leu Ser Leu Thr Cys Thr Val
Ser Gly Gly Ser Ile Ser Ser Tyr 20 25 30Tyr Trp Ser Trp Ile Arg Gln
Ala Ala Gly Lys Arg Leu Glu Trp Ile 35 40 45Gly Arg Ile Tyr Pro Ser
Gly Arg Thr Asn Tyr Asn Pro Ser Leu Lys 50 55 60Ser Arg Val Thr Met
Ser Val Asp Thr Ser Lys Asn Gln Phe Ser Leu65 70 75 80Lys Leu Ser
Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr Cys Ala 85 90 95Arg Glu
Ala Tyr Glu Leu Gln Leu Gly Leu Tyr Tyr Tyr Tyr Gly Met 100 105
110Asp Val Trp Gly Gln Gly Thr Pro Val Thr Val Ser Ser 115 120
12525124PRTHomo sapiens 25Gln Val Gln Leu Gln Glu Ser Gly Pro Gly
Leu Val Lys Pro Ser Gln1 5 10 15Thr Leu Ser Leu Thr Cys Thr Val Ser
Gly Gly Ser Ile Ser Ser Gly 20 25 30Gly Tyr Tyr Trp Ser Trp Ile Arg
Gln His Pro Gly Lys Gly Leu Glu 35 40 45Trp Ile Gly Tyr Ile Tyr Tyr
Ser Gly Asn Thr Tyr Tyr Asn Pro Ser 50 55 60Leu Arg Ser Arg Val Thr
Ile Ser Val Asp Thr Ser Lys Asn Gln Phe65 70 75 80Ser Leu Lys Leu
Asn Ser Val Thr Ala Ala Asp Thr Ala Val Tyr Tyr 85 90 95Cys Ala Arg
Glu Ala Gly Gly Asn Ser Ala Tyr Tyr Tyr Gly Met Asp 100 105 110Val
Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser 115 12026125PRTHomo
sapiens 26Gln Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro
Gly Gly1 5 10 15Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe
Ser Asp Tyr 20 25 30Tyr Met Ser Trp Ile Arg Gln Ala Pro Gly Lys Gly
Leu Glu Trp Val 35 40 45Ser Tyr Ile Ser Ser Ser Gly Ser Thr Ile Tyr
Tyr Ala Asp Ser Val 50 55 60Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn
Ala Lys Asn Ser Leu Tyr65 70 75 80Leu Gln Met Asn Ser Leu Arg Ala
Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95Ala Arg Asp Arg Thr Tyr Tyr
Phe Gly Ser Gly Ser Tyr Glu Gly Met 100 105 110Asp Val Trp Gly Gln
Gly Thr Thr Val Thr Val Ser Ser 115 120 12527107PRTHomo sapiens
27Asp Ile Leu Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn
Asp 20 25 30Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg
Leu Ile 35 40 45Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln
His Asn Ser Asn Pro Phe 85 90 95Thr Phe Gly Pro Gly Thr Lys Val Asp
Ile Lys 100 10528106PRTHomo sapiens 28Glu Ile Val Met Thr Gln Ser
Pro Ala Thr Leu Ser Val Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser
Cys Arg Ala Ser Gln Ser Val Ser Arg Asn 20 25 30Leu Val Trp Tyr Gln
Gln Arg Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45Tyr Gly Ala Ser
Thr Arg Ala Asn Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60Ser Gly Ser
Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser65 70 75 80Glu
Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Lys Ser Trp Arg Thr 85 90
95Phe Gly Gln Gly Ser Lys Val Glu Ile Lys 100 10529107PRTHomo
sapiens 29Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile
Arg Asn Asp 20 25 30Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
Lys Arg Leu Ile 35 40 45Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro
Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr
Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys
Leu Gln His Lys Ser Tyr Pro Leu 85 90 95Thr Phe Gly Gly Gly Thr Lys
Val Glu Ile Lys 100 10530108PRTHomo sapiens 30Glu Ile Val Met Thr
Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly1 5 10 15Glu Arg Ala Thr
Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Arg Asn 20 25 30Leu Ala Trp
Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45Tyr Gly
Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60Ser
Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser65 70 75
80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asn Asn Trp Pro Thr
85 90 95Trp Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100
10531107PRTHomo sapiens 31Asp Ile Gln Met Thr Gln Ser Pro Ser Ser
Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala
Ser Gln Gly Ile Arg Asn Asp 20 25 30Leu Gly Trp Tyr Gln Gln Lys Pro
Gly Lys Ala Pro Lys Arg Leu Ile 35 40 45Tyr Ala Ala Ser Ser Phe Gln
Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Gly
Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala
Thr Tyr Tyr Cys Leu Gln His Asn Ser Tyr Pro Pro 85 90 95Thr Phe Gly
Gln Gly Thr Lys Val Glu Ile Lys 100 10532107PRTHomo sapiens 32Asp
Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10
15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp
20 25 30Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu
Ile 35 40 45Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg Phe
Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser
Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His
Lys Ser Tyr Pro Leu 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu Ile
Lys 100 10533107PRTHomo sapiens 33Asp Ile Gln Met Thr Gln Ser Pro
Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys
Arg Ala Ser Gln Gly Ile Arg Asn Asp 20 25 30Leu Gly Trp Tyr Gln Gln
Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile 35 40 45Tyr Ala Ala Ser Ser
Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly
Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp
Phe Ala Thr Tyr Tyr Cys Leu Gln His Lys Ser Tyr Pro Leu 85 90 95Thr
Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 10534107PRTHomo sapiens
34Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Arg Asn
Asp 20 25 30Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Arg
Leu Ile 35 40 45Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys Leu Gln
His Lys Ser Tyr Pro Leu 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu
Ile Lys 100 10535107PRTHomo sapiens 35Asp Ile Gln Met Thr Gln Ser
Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr
Cys Arg Ala Ser Gln Gly Ile Arg Asn Asp 20 25 30Leu Gly Trp Tyr Gln
Gln Lys Pro Gly Lys Ala Pro Lys Arg Leu Ile 35 40 45Tyr Ala Ala Ser
Ser Leu Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser
Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu
Asp Phe Ala Thr Tyr Tyr Cys Leu Gln His Lys Ser Tyr Pro Leu 85 90
95Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 10536107PRTHomo
sapiens 36Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Val Ser Ala Ser
Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile
Arg Ser Trp 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
Lys Leu Leu Ile 35 40 45Phe Ala Ala Ser Ser Leu Gln Ser Gly Val Pro
Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr
Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys
Gln Gln Ala Asn Asn Phe Pro Arg 85 90 95Thr Phe Gly Gln Gly Thr Lys
Val Glu Ile Lys 100 10537108PRTHomo sapiens 37Glu Ile Val Met Thr
Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly1 5 10 15Glu Arg Ala Thr
Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 20 25 30Leu Ala Trp
Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45Tyr Gly
Ala Ser Thr Arg Ala Ala Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60Gly
Gly Ser Gly Thr Ala Phe Thr Leu Thr Ile Ser Asn Leu Gln Ser65 70 75
80Glu Asp Phe Ala Val Tyr Tyr Cys Gln His Tyr Ile Asn Trp Pro Lys
85 90 95Trp Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys 100
10538107PRTHomo sapiens 38Glu Ile Val Met Thr Gln Ser Pro Ala Thr
Leu Ser Val Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala
Ser Gln Ser Ile Ser Ser Ser 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro
Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45Tyr Gly Ala Ser Thr Arg Ala
Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu
Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser65 70 75 80Glu Asn Phe Ala
Val Tyr Tyr Cys Gln Gln Tyr Asp Asn Trp Pro Leu 85 90 95Thr Phe Gly
Gly Gly Thr Lys Val Glu Ile Lys 100 10539112PRTHomo sapiens 39Asp
Ile Val Met Thr Gln Thr Pro Leu Ser Leu Ser Val Thr Pro Gly1 5 10
15Gln Pro Ala Ser Ile Ala Cys Lys Ser Ser Gln Ser Leu Leu His Ser
20 25 30Asp Gly Lys Thr Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln
Pro 35 40 45Pro Gln Leu Leu Ile Tyr Glu Val Ser Thr Arg Phe Ser Gly
Val Pro 50 55 60Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
Leu Lys Ile65 70 75 80Ser Arg Val Glu Ala Glu Asp Val Gly Val Phe
Tyr Cys Met Gln Ser 85 90 95Ile Gln Leu Pro Leu Thr Phe Gly Gly Gly
Thr Lys Val Glu Ile Lys 100 105 11040107PRTHomo sapiens 40Glu Ile
Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly1 5 10 15Glu
Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 20 25
30Leu Ala Trp Phe Gln Gln Lys Pro Gly Gln Ala Pro Arg Pro Leu Ile
35 40 45Tyr Asp Ala Ser Thr Arg Ala Thr Gly Val Pro Ala Arg Phe Ser
Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu
Gln Ser65 70 75 80Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp
Asn Trp Pro Leu 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 10541107PRTHomo sapiens 41Glu Ile Val Met Thr Gln Ser Pro Ala
Thr Leu Ser Val Ser Pro Gly1 5 10 15Glu Arg Val Thr Leu Ser Cys Arg
Ala Ser Gln Ser Val Ser Ser Asn 20 25 30Leu Ala Trp Phe Gln Gln Lys
Pro Gly Gln Ala Pro Arg Pro Leu Ile 35 40 45Tyr Asp Ala Ser Thr Arg
Ala Ala Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr
Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser65 70 75 80Glu Asp Phe
Ala Val Tyr Tyr Cys Gln Gln Tyr Asp Asn Trp Pro Leu 85 90 95Thr Phe
Gly Gly Gly Thr Lys Val Glu Ile Lys 100 10542107PRTHomo sapiens
42Glu Ile Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly1
5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Thr
Ser 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu
Leu Ile 35 40 45Tyr Gly Thr Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser
Ser Leu Gln Ser65 70 75 80Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln
Tyr Asp Ile Trp Pro Leu 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu
Ile Lys 100 10543107PRTHomo sapiens 43Glu Ile Val Met Thr Gln Ser
Pro Ala Thr Leu
Ser Val Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser
Gln Ser Val Ser Ser Asn 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly
Gln Ala Pro Arg Leu Leu Ile 35 40 45Tyr Gly Ala Ser Thr Arg Ala Thr
Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe
Thr Leu Thr Ile Ser Ser Leu Gln Ser65 70 75 80Glu Asp Phe Ala Val
Tyr Ser Cys Gln Gln Tyr Asp Asn Trp Pro Leu 85 90 95Thr Phe Gly Gly
Gly Thr Lys Val Glu Ile Lys 100 10544113PRTHomo sapiens 44Asp Ile
Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly1 5 10 15Glu
Arg Ala Thr Ile Asn Cys Lys Thr Ser Gln Ser Val Leu Tyr Ser 20 25
30Ser Lys Asn Lys Asn Phe Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln
35 40 45Pro Leu Asn Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly
Val 50 55 60Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr
Leu Thr65 70 75 80Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr
Tyr Cys Gln Gln 85 90 95Tyr Tyr Ser Thr Pro Phe Thr Phe Gly Pro Gly
Thr Lys Val Asp Ile 100 105 110Lys45107PRTHomo sapiens 45Glu Ile
Val Met Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly1 5 10 15Glu
Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Ile Ser Ser Asn 20 25
30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile
35 40 45Tyr Gly Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser
Asp 50 55 60Asn Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Ser Leu
Gln Ser65 70 75 80Glu Asp Phe Ala Val Tyr Phe Cys Gln Gln Tyr Asp
Thr Trp Pro Leu 85 90 95Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys
100 10546107PRTHomo sapiens 46Asp Ile Gln Met Thr Gln Ser Pro Ser
Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile Thr Cys Arg
Ala Ser Gln Gly Ile Ser Asn Tyr 20 25 30Leu Ala Trp Tyr Gln Gln Lys
Pro Gly Lys Phe Pro Glu Leu Leu Ile 35 40 45Tyr Ala Ala Ser Thr Leu
Gln Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr
Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Val
Ala Thr Tyr Tyr Cys Gln Lys Tyr Asn Arg Ala Pro Phe 85 90 95Thr Phe
Gly Pro Gly Thr Lys Val Asp Ile Lys 100 10547107PRTHomo sapiens
47Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1
5 10 15Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn
Tyr 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Phe Pro Glu Leu
Leu Ile 35 40 45Tyr Ala Ala Ser Thr Leu Gln Ser Gly Val Pro Ser Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Gln Pro65 70 75 80Glu Asp Val Ala Thr Tyr Tyr Cys Gln Lys
Tyr Asn Arg Ala Pro Phe 85 90 95Thr Phe Gly Pro Gly Thr Lys Val Asp
Ile Lys 100 10548107PRTHomo sapiens 48Glu Ile Val Met Thr Gln Ser
Pro Ala Thr Leu Ser Val Ser Pro Gly1 5 10 15Glu Arg Val Thr Leu Ser
Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 20 25 30Leu Ala Trp Phe Gln
Gln Lys Pro Gly Gln Ala Pro Arg Pro Leu Ile 35 40 45Tyr Asp Ala Ser
Thr Arg Ala Ala Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60Ser Gly Ser
Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser65 70 75 80Glu
Asp Phe Ala Val Tyr Tyr Cys Gln Gln Tyr Asp Asn Trp Pro Leu 85 90
95Thr Phe Gly Gly Gly Thr Lys Val Glu Ile Lys 100 10549107PRTHomo
sapiens 49Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser
Val Gly1 5 10 15Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Gly Ile
Ile Asn Asp 20 25 30Leu Gly Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro
Lys Arg Leu Ile 35 40 45Tyr Ala Ala Ser Ser Leu Gln Ser Gly Val Pro
Ser Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu Phe Thr Phe Thr
Ile Ser Ser Leu Gln Pro65 70 75 80Glu Asp Phe Ala Thr Tyr Tyr Cys
Leu Gln His Asn Ser Tyr Pro Pro 85 90 95Thr Phe Gly Gln Gly Thr Lys
Val Glu Ile Lys 100 10550113PRTHomo sapiens 50Asp Ile Val Met Thr
Gln Ser Pro Leu Ser Leu Pro Val Thr Leu Gly1 5 10 15Gln Pro Ala Ser
Ile Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser 20 25 30Asp Gly His
Thr Cys Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45Pro Arg
Arg Leu Ile Tyr Lys Val Ser Asn Trp Asp Ser Gly Val Pro 50 55 60Asp
Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65 70 75
80Ser Arg Val Glu Ala Asp Asp Val Gly Val Tyr Tyr Cys Met Gln Gly
85 90 95Thr His Trp Pro Leu Cys Ser Phe Gly Gln Gly Thr Lys Leu Glu
Ile 100 105 110Lys51113PRTHomo sapiens 51Asp Ile Val Met Thr Gln
Ser Pro Leu Ser Leu Pro Val Thr Leu Gly1 5 10 15Gln Pro Ala Ser Ile
Ser Cys Arg Ser Ser Gln Ser Leu Val Tyr Ser 20 25 30Asp Gly His Thr
Cys Leu Asn Trp Phe Gln Gln Arg Pro Gly Gln Ser 35 40 45Pro Arg Arg
Leu Ile Tyr Lys Val Ser Asn Trp Asp Ser Gly Val Pro 50 55 60Asp Arg
Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile65 70 75
80Ser Arg Val Glu Ala Asp Asp Val Gly Val Tyr Tyr Cys Met Gln Gly
85 90 95Thr His Trp Pro Leu Cys Ser Phe Gly Gln Gly Thr Lys Leu Glu
Ile 100 105 110Lys52107PRTHomo sapiens 52Asp Ile Gln Met Thr Gln
Ser Pro Ser Ser Leu Ser Ala Ser Val Gly1 5 10 15Asp Arg Val Thr Ile
Thr Cys Arg Ala Ser Gln Ala Ile Ser Ile Tyr 20 25 30Leu Ala Trp Phe
Gln Gln Lys Pro Gly Lys Ala Pro Lys Ser Leu Ile 35 40 45Tyr Ala Ala
Ser Ser Leu Gln Ser Gly Val Pro Ser Lys Phe Ser Gly 50 55 60Ser Val
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80Glu Asp Phe Ala Thr Tyr Tyr Cys Gln Gln Tyr Ser Ser Tyr Pro Arg
85 90 95Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100
10553107PRTHomo sapiens 53Glu Ile Leu Met Thr Gln Ser Pro Ala Thr
Leu Ser Val Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala
Ser Gln Ser Val Tyr Ser Asn 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro
Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45Ser Gly Ala Ser Thr Arg Ala
Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Glu
Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser65 70 75 80Glu Asp Phe Ala
Val Tyr Tyr Cys Gln Gln Tyr Tyr Asn Trp Pro Trp 85 90 95Thr Phe Gly
Gln Gly Thr Lys Val Glu Ile Lys 100 10554393DNAHomo sapiens
54caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc
60acctgcactg tctcaggtgg ctccatcagt aattactact ggaactggat ccggcagtcc
120ccagggaagg gactggagtg gattggggat atctattaca gtgggagcac
caactacaac 180ccctccctca agagtcgagt caccatatca gtagacacgt
ccaagaacca gttctccctg 240aagctgagct ctgtgaccac tgcggacacg
gccgtgtatt actgtgcgag agatggggaa 300ctcgccaatt actatggttc
ggggagttat cagttctact actactacgg tatggacgtc 360tggggccaag
ggaccacggt caccgtctcc tca 39355381DNAHomo sapiens 55caggtgcagc
tacagcagtg gggcgcagga ctgttgaagc cttcggagac cctgtccctc 60acctgcgctg
tctctggtgg gtccttcagt ggttactact ggagctggat ccgccagccc
120ccagggaagg ggctggaatg gattggggaa atcaatcata gtggacgcac
caattacaac 180ccgtccctca agagtcgagt caccatatca gtagacacgt
ccaagaacca gttctccctg 240aagctgagct ctgtgaccgc cgcggacacg
gctgtttatt actgtgcgag aggcccttat 300tactttgata gtagtggtta
cctttactac tactacggtt tggacgtctg gggccaaggg 360accacggtca
ccgtctcctc a 38156342DNAHomo sapiens 56caggtgcagc tggtggagtc
tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60tcctgtgcag cgtctggaat
caacttcagt agctatggca tgcactgggt ccgccaggct 120ccaggcaagg
ggctggagtg ggtggcagtt atatggtatg atggaagtaa taaacactat
180gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa
cacgctgtat 240ctgcaaatga acagcctgag agccgaggac acggctgtgt
attactgtgc gagagatact 300ggggtctact ggggccaggg aaccctggtc
accgtctcct ca 34257342DNAHomo sapiens 57caggtgcagc tggtggagtc
tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60tcctgtgcag cgtctggaat
caacttcagt agctatggca tgcactgggt ccgccaggct 120ccaggcaagg
ggctggagtg ggtggcagtt atatggtatg atggaagtaa taaacactat
180gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa
cacgctgtat 240ctgcaaatga acagcctgag agccgaggac acggctgtgt
attactgtgc gagagatact 300ggggtctact ggggccaggg aaccctggtc
accgtctcct ca 34258375DNAHomo sapiens 58caggtgcagc tgcaggagtc
gggcccagga ctggtgaagc cttcggagac cctgcccctc 60acctgcactg tctctggtgg
ctccatcaga agttactact ggagctggat ccggcagccc 120gccgggaagg
gactggagtg gattgggcgt atctatcgca gtgggaacac catctacaac
180ccctccctca agagtcgagt caccatgtca atagacacgt ccaagaacca
gttctccctg 240acgctgagtt ctgtgaccgc cgcggacacg gccgtgtatt
actgtgcgag agagaattac 300tctgagagta gtggtctcta ctactactac
ggtatggacg tctggggcca agggaccacg 360gtcaccgtct cctca
37559372DNAHomo sapiens 59caggttcagc tggtgcagtc tggagctgag
gtgaagaagc ctggggcctc agtgaaggtc 60tcctgcaagg cttctggtta caccttaacc
agatatggta tcagctgggt gcgacaggcc 120cctggacaag ggcttgagtg
gatgggttgg atcagcgctt acaatggtaa cacaaactat 180gcacagaagc
tccagggcag agtcaccatg accacagaca cgtccacgag cacagcctac
240atggagctga ggagcctgag atctgacgac acggccgtgt attactgtgc
gagaagggat 300tacgatattt tgactggtta ttataacggg ttcgacccct
ggggccaggg aaccctggtc 360accgtctcct ca 37260372DNAHomo sapiens
60caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc
60tcctgcaagg cttctggtta caccttaacc agatatggta tcagctgggt gcgacaggcc
120cctggacaag ggcttgagtg gatgggttgg atcagcgctt acaatggtaa
cacaaactat 180gcacagaagc tccagggcag agtcaccatg accacagaca
cgtccacgag cacagcctac 240atggagctga ggagcctgag atctgacgac
acggccgtgt attactgtgc gagaagggat 300tacgatattt tgactggtta
ttataacggg ttcgacccct ggggccaggg aaccctggtc 360accgtctcct ca
37261372DNAHomo sapiens 61caggttcagc tggtgcagtc tggagctgag
gtgaagaagc ctggggcctc agtgaaggtc 60tcctgcaagg cttctggtaa cacctttacc
ggctatggta tcagctgggt gcgacaggcc 120cctggacaag ggcttgagtg
gatgggatgg atcagcgctt acaatggtaa cacaaactat 180gcacagaacc
tccagggcag agtcaccatg accacagaca catccacgag cacagcctac
240atggagctga ggagcctgag atctgacgac acggccgtgt attactgtgc
gagaagggat 300tacgatattt tgactggtta ttataacggg ttcgacccct
ggggccaggg aaccctggtc 360accgtctcct ca 37262372DNAHomo sapiens
62caggttcagc tggtgcagtc tggagttgag gtgaagaagc ctggggcctc agtgaaggtc
60tcctgcaagg cttctggtta caccttaacc agatatggta tcagctgggt gcgacaggcc
120cctggacaag ggcttgagtg gatgggttgg atcagcgctt acaatggtaa
cacaaactat 180gcacagaagc tccagggcag agtcaccatg accacagaca
catccacgag cacagcctac 240atggagctga ggagcctgag atctgacgac
acggccgtgt attactgtgc gagaagggat 300tacgatattt tgactggtta
ttataacggg ttcgacccct ggggccaggg aaccctggtc 360accgtctcct ca
37263372DNAHomo sapiens 63caggtgcagc tgcaggagtc gggcccagga
ctggtgaagc cttcacagac cctgtccctc 60acctgcactg tctctggtgg ctccatcagc
agtggtggtt actactggag ctggatccgc 120cagcaccccg ggaagggcct
ggagtggatt gggtacatct atttcagtgg gagcgcctac 180tacaacccgt
ccctcaagag tcgagtcgcc atatcagtgg acacgtctaa gaaccagttc
240tccctgaagc tgagctctgt gactgccgcg gacacggccg tatattactg
tgcgagagaa 300tactatgata gtagtggtta ccccgatgct tttgatatct
ggggccaagg gacaatggtc 360accgtctcct ca 37264342DNAHomo sapiens
64caggtgcaac tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc
60tcctgtgcaa cgtccggaat caccttcagt agctatggca tgcactgggt ccgccaggct
120ccaggcaagg ggctggagtg ggtggcagtt atatggtatg atggaagtaa
taaatattat 180gcagactccg tgaagggccg attcaccatc tccagagaca
attccaagaa cacgctgtat 240ctgcaaatga acagcctgag agccgaggac
acggctgtgt attactgtgc gagagatacg 300aaggactact ggggccaggg
aaccctggtc accgtctcct ca 34265348DNAHomo sapiens 65caggttcagc
tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60tcctgcaagg
cttctggtta caccctcacc agctatggta tcagctgggt gcgacaggcc
120cctggacaag gacttgagtg gatgggatgg atcagcactt acaaaggtaa
cacaaactat 180gcacagaagc tccagggcag agtcaccatg accacagaca
catccacgag cacagcctac 240atggaactga ggagcctgag atctgacgac
acggccgtgt attactgtgc gagaaagcag 300ctcgtctttg actactgggg
tcagggaacc ctggtcaccg tctcctca 34866363DNAHomo sapiens 66caggtgcagc
tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc 60tcctgtgcag
cgtctggatt caccttcagt agctatggca tgcagtgggt ccgccaggct
120ccaggcaagg ggctggagtg ggtggcagtt atatggtatg atggaaataa
gaaatactat 180gcagactccg tgaagggccg attcaccatc tccagagaca
attccaagaa cacgctgtat 240ctgcaaatga acagcctgag agccgaggac
acggctgtgt attactgtgc gagaggacgt 300gttagggact actactacgg
tatggacgtc tggggccaag ggaccacggt caccgtctcc 360tca 36367350DNAHomo
sapiens 67caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc
agtgaaggtc 60tcctgcaagg cttctggtta cacctttacc agatatggta tcagctgggt
gcgacaggcc 120cctggacaag ggcttgagtg gatgggatgg atcagcactt
acagtggtaa cacaaactat 180gcacagaagc tccagggcag agtcaccatg
accacagaca catccacgag cacagcctac 240atggagctga ggagcctgag
atctgacgac acggccgtgt attactgtgc gagacggcag 300ctttactttg
actactgggg ccagggaacc ctggtcaccg tctcctcagc 35068363DNAHomo sapiens
68caggtgcagc tggtggagtc tgggggaggc gtggtccagc ctgggaggtc cctgagactc
60tcctgtgcag cgtctggatt caccttcagt agctatggca tgcagtgggt ccgccaggct
120ccaggcaagg ggctggagtg ggtggcagtt atatggtatg atggaaataa
gaaatactat 180gcagactccg tgaagggccg attcaccatc tccagagaca
attccaagaa cacgctgtat 240ctgcaaatga acagcctgag agccgaggac
acggctgtgt attactgtgc gagaggacgt 300gttagggact actactacgg
tatggacgtc tggggccaag ggaccacggt caccgtctcc 360tca 36369348DNAHomo
sapiens 69caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggcctc
agtgaaggtc 60tcctgcaagg cttctggtta cacctttacc agctatggta tcagctgggt
gcgacaggcc 120cctggacaag ggcttgagtg gatgggatgg atcagcgctt
acaatggtaa cacaaagtat 180gcacagaagc tccagggcag agtcaccatg
accacagaca catccacgag cacagtctac 240atggagctga ggagcctgag
atctgacgac acggccgtgt attactgtgc gagaaagcag 300ctcgtctttg
actactgggg ccagggaacc ctggtcaccg tctcctca 34870348DNAHomo sapiens
70caggttcagc tggtgcagtc tggagctgag gtgaagaagc ctggggccgc agtgaaggtc
60tcctgcaagg ctactggtta caccttgacc agctatggta tcagctgggt gcgacaggcc
120cctggacaag ggcttgagtg gatgggatgg atcagcgctt acagtggtaa
tacaaagtat 180gcacagaagc tccagggcag agtcaccatg accacagaca
catccacgag cacagcctac 240atggagctga ggagcctgag atctgacgac
acggccgtgt attactgtgc gagaaagcag 300ctcgtctttg actactgggg
ccagggaacc ctggtcaccg tctcctca 34871378DNAHomo sapiens 71caggtgcagc
tggtgcagtc tggggctgag gtgaagaagc ctggggcctc agtgaaggtc 60tcctgcaagg
cttctggata ctccttcacc gactactaca tgcactgggt gcgacaggcc
120cctggacaag gacttgagtg gatgggatgg atgcacccta acagtggtgg
cacagactta 180gcacagaggt ttcagggcag ggtcaccatg accagggaca
cgtccatcag cacagcctac 240atggagctga gcaggctgag atctgacgac
acggccgtgt attactgtgc gagaggggga 300tattgtagta ctttgagctg
ctccttctac tggtacttcg atctctgggg ccgtggcacc 360ctggtcactg tctcctca
37872348DNAHomo sapiens 72caggttcagc tggtgcagtc tggagctgag
gtgaagaagc ctggggcctc agtgaaggtc 60tcctgcaagg cttctggtta caccttgacc
agctatggaa tcagttgggt gcgacaggcc 120cctggacaag ggcttgagtg
gatgggatgg atcagcgctt acagtggtaa cacaaagtat 180gcacagaagt
tccagggcag agtcaccatg accacagaca catccacgag cacagcctac
240atggagctga ggagcctgag atctgacgac acggccgtgt attactgtgc
gagaaggcag 300ctcgcgttgg actactgggg ccagggaacc ctggtcaccg tctcctca
34873354DNAHomo sapiens 73gaggtgcagc tggtggagtc tgggggaggc
ttggtacagc ctggggggtc cctgagactc 60tcctgtgcag cctctggatt caccttcagc
agctatagca tgaactgggt ccgccaggct 120ccagggaagg ggctggagtg
ggtttcattc attagtgcta gaagtagtac catatactac 180gcagactctg
tgaagggccg attcaccatc tccagagaca atgccaagaa ctcactgtat
240ctgcaaatga acagcctgag agacgaggac acggctgtgt attactgtgc
gagacctaaa 300gtggggggcg gtatggacgt ctggggccaa ggaaccacgg
tcaccgtctc ctca 35474354DNAHomo sapiens 74gaggtgcagt tggtggagtc
tgggggaggc tcggtacagc ctggggggtc cctgagactc 60tcctgtgcag cctctggatt
caccttcagt agctatagca tgaactgggt ccgccaggct 120ccagggaagg
ggctggagtg ggtttcaatc attagtagta gaagtagtat catacactac
180gcagactctg tgaagggccg attcaccatc tccagagaca atgccaagaa
ctcactgtat 240ctgcaaatga acagcctgag agacgaggac acggctgtgt
attactgtgc gagacctaaa 300gtggggggcg gtatggacgt ctggggccaa
gggaccacgg tcaccgtctc ctca 35475348DNAHomo sapiens 75caggttcagc
tggtgcagtc tggagctgag gtgaagaagc ctggggcctc agtgaaggtc 60tcctgcaagg
cttctggtta cacctttacc agatatggta tcagctgggt gcgacaggcc
120cctggacaag ggcttgagtg gatgggatgg atcagcgctt acagtggtaa
cacaaactat 180gcacagaagc tccagggcag agtcaccatg accacagaca
catccacgag cacagcctac 240atggagctga ggagcctgag atctgacgac
acggccgtgt attactgtgc gagacggcag 300ctttactttg actactgggg
ccagggaacc ctggtcaccg tctcctca 34876375DNAHomo sapiens 76caggtgcagc
tgcaggagtc gggcccagga ctggtgaagc cttcggagac cctgtccctc 60acctgcactg
tcactggtgg ctccatcagg agttactact ggagctggat ccggcagccc
120gccgggaaga gactggagtg gattgggcgt atctatccca gtgggagaac
caactacaac 180ccctccctca agagtcgagt caccatgtca gtagacacgt
ccaagaacca gttctccctg 240aagctgagct ctgtgaccgc cgcggacacg
gccgtgtatt actgtgcgag agaggcatat 300gagctgcaac tgggcctcta
ctactactac ggtatggacg tctggggcca agggaccccg 360gtcaccgtct cctca
37577375DNAHomo sapiens 77caggtgcagc tgcaggagtc gggcccagga
ctggtgaagc cttcggagac cctgtccctc 60acctgcactg tcactggtgg ctccatcagg
agttactact ggagctggat ccggcaggcc 120gccgggaaga gactggagtg
gattgggcgt atctatccca gtgggagaac caactacaac 180ccctccctca
agagtcgagt caccatgtca gtagacacgt ccaagaacca gttctccctg
240aagctgagct ctgtgaccgc cgcggacacg gccgtgtatt actgtgcgag
agaggcatat 300gagctgcaac tgggcctcta ctactactac ggtatggacg
tctggggcca agggaccccg 360gtcaccgtct cctca 37578372DNAHomo sapiens
78caggtgcagc tgcaggagtc gggcccagga ctggtgaagc cttcacagac cctgtccctc
60acctgcactg tctctggtgg ctccatcagc agtggtggtt actactggag ctggatccgc
120cagcacccag ggaagggcct ggagtggatt gggtacatct attacagtgg
gaacacctac 180tacaacccgt ccctcaggag tcgagttacc atatcagttg
acacgtctaa gaaccagttc 240tccctgaagc tgaactctgt gactgccgcg
gacacggccg tgtattactg tgcgagagag 300gccggtggta actccgccta
ctactacggt atggacgtct ggggccaagg gaccacggtc 360accgtctcct ca
37279375DNAHomo sapiens 79caggtgcagc tggtggagtc tgggggaggc
ttggtcaagc ctggagggtc cctgagactc 60tcctgtgcag cctctggatt caccttcagt
gactactaca tgagctggat ccgccaggct 120ccagggaagg ggctggagtg
ggtttcatac attagtagta gtggtagtac catatactac 180gcagactctg
tgaagggccg attcaccatc tccagggaca acgccaagaa ctcactgtat
240ctgcaaatga acagcctgag agccgaggac acggccgtgt attactgtgc
gagagatcgc 300acgtattact ttggttcggg gagttatgaa gggatggacg
tctggggcca agggaccacg 360gtcaccgtct cctca 37580321DNAHomo sapiens
80gacatcctga tgacccagtc tccatcctcc ctgtctgcat ctgtcggaga cagagtcacc
60atcacttgcc gggcaagtca gggcattaga aatgatttag gctggtatca gcagaaacca
120gggaaagccc ctaagcgcct gatctatgct gcatccagtt tgcaaagtgg
ggtcccatcc 180aggttcagcg gcagtggctc tgggacagaa ttcactctca
caatcagcag cctgcagcct 240gaagattttg caacttatta ctgtctacag
cataatagta acccattcac tttcggccct 300gggaccaaag tggatatcaa a
32181318DNAHomo sapiens 81gaaatagtga tgacgcagtc tccagccacc
ctgtctgtgt ctccagggga aagagccacc 60ctctcctgca gggccagtca gagtgttagc
agaaacttag tctggtacca gcagagacct 120ggccaggctc ccaggctcct
catctatggg gcatccacta gggccaatgg tatcccagcc 180aggttcagtg
gcagtgggtc agggacagaa ttcactctca ccatcagcag cctgcagtct
240gaagattttg cagtttatta ctgtcagcag tataaaagct ggcggacgtt
cggccaaggg 300tccaaggtgg aaatcaaa 31882321DNAHomo sapiens
82gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc
60atcacttgcc gggcaagtca gagcattagc agctatttaa attggtatca gcagaaacca
120gggaaagccc ctaagctcct gatctatgct gcatccagtt tgcaaagtgg
ggtcccatca 180aggttcagtg gcagtggatc tgggacagat ttcactctca
ccatcagcag tctgcaacct 240gaagattttg caacttacta ctgtcaacag
agttacagta ccccattcac tttcggccct 300gggaccaaag tggatatcaa a
32183324DNAHomo sapiens 83gaaatagtga tgacgcagtc tccagccacc
ctgtctgtgt ctccagggga aagagccacc 60ctctcctgca gggccagtca gagtgttagt
aggaatttag cctggtacca gcagaaacct 120ggccaggctc ccaggctcct
catctatggt gcatccacca gggccactgg tatcccagcc 180aggttcagtg
gcagtgggtc tgggacagag ttcactctca ccatcagcag cctgcagtct
240gaagattttg cagtttatta ctgtcagcag tataataact ggcccacgtg
gacgttcggc 300caagggacca aggtggaaat caaa 32484321DNAHomo sapiens
84gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc
60atcacttgcc gggcaagtca gggcattaga aatgatttag gctggtatca gcagaagcca
120gggaaagccc ctaaacgcct gatctatgct gcatccagtt tccaaagtgg
ggtcccatca 180aggttcagcg gcagtggatc tgggacagga ttcactctca
caatcagcag cctgcagcct 240gaagattttg caacttatta ctgtctacag
cataatagtt accctccgac gttcggccaa 300gggaccaagg tggaaatcaa a
32185321DNAHomo sapiens 85gacatccaga tgacccagtc tccatcctcc
ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc gggcaagtca gggcattaga
aatgatttag gctggtatca gcagaaacca 120gggaaagccc ctaagcgcct
gatctatgct gcatccagtt tgcaaagtgg ggtcccatca 180aggttcagcg
gcagtggatc tgggacagaa ttcactctca caatcagcag cctgcagcct
240gaagattttg caacttatta ctgtctacag cataaaagtt acccgctcac
tttcggcgga 300gggaccaagg tggagatcaa a 32186321DNAHomo sapiens
86gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc
60atcacttgcc gggcaagtca gggcattaga aatgatttag gctggtatca gcagaaacca
120gggaaagccc ctaagcgcct gatctatgct gcatccagtt tgcaaagtgg
ggtcccatca 180aggttcagcg gcagtggatc tgggacagaa ttcactctca
caatcagcag cctgcagcct 240gaagattttg caacttatta ctgtctacag
cataaaagtt acccgctcac tttcggcgga 300gggaccaagg tggagatcaa a
32187321DNAHomo sapiens 87gacatccaga tgacccagtc tccatcctcc
ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc gggcaagtca gggcattaga
aatgatttag gctggtatca gcagaaacca 120gggaaagccc ctaagcgcct
gatctatgct gcatccagtt tgcaaagtgg ggtcccatca 180aggttcagcg
gcagtggatc tgggacagaa ttcactctca caatcagcag cctgcagcct
240gaagattttg caacttatta ctgtctacag cataagagtt acccgctcac
tttcggcgga 300gggaccaagg tggagatcaa a 32188321DNAHomo sapiens
88gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc
60atcacttgcc gggcaagtca gggcattaga aatgatttag gctggtatca gcagaaacca
120gggaaagccc ctaagcgcct gatctacgct gcatccagtt tgcaaagtgg
ggtcccatca 180aggttcagcg gcagtggatc tgggacagaa ttcactctca
caatcagcag cctgcagcct 240gaagattttg caacttatta ctgtctacag
cataaaagtt acccgctcac tttcggcgga 300gggaccaagg tggagatcaa a
32189321DNAHomo sapiens 89gacatccaga tgacccagtc tccatcttcc
gtgtctgcat ctgtaggaga cagagtcacc 60atcacttgtc gggcgagtca gggtattagg
agctggttag cctggtatca gcagaaacca 120gggaaagccc ctaagctcct
gatctttgct gcatccagtt tgcaaagtgg ggtcccatca 180aggttcagcg
gcagtggatc tgggacagaa ttcactctca ccatcagcag cctgcagcct
240gaagattttg caacttacta ttgtcaacag gctaacaatt tccctcggac
gttcggccaa 300gggaccaagg tggaaatcaa a 32190324DNAHomo sapiens
90gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga aagagccacc
60ctctcctgca gggccagtca gagtgttagc agcaacttag cctggtacca gcagaaacct
120ggccaggctc ccaggctcct catctatggt gcatccacca gggccgctgg
tatcccagcc 180aggttcagtg gcggtgggtc tgggacagcg ttcactctca
ccatcagcaa cctacagtct 240gaagattttg cagtttatta ctgtcagcac
tatataaact ggcctaagtg gacgttcggc 300caagggacca aggtggacat caaa
32491321DNAHomo sapiens 91gaaatagtaa tgacgcagtc tccagccacc
ctgtctgtgt ctccagggga aagagccacc 60ctctcctgca gggccagtca gagtattagc
agcagcttag cctggtacca gcagaaacct 120ggccaggctc ccaggctcct
catctatggt gcatccacca gggccactgg tatcccagcc 180aggttcagtg
gcagtgggtc tgggacagag ttcactctca ccatcagcag cctgcagtct
240gaaaattttg cagtttatta ctgtcagcaa tatgataact ggccgctcac
tttcggcgga 300gggaccaagg tggagatcaa a 32192336DNAHomo sapiens
92gatattgtga tgacccagac tccactctct ctgtccgtca cccctggaca gccggcctcc
60atcgcctgca agtctagtca gagcctcctg catagtgatg gaaagaccta tttgtattgg
120tacctgcaga agccaggcca gcctccacag ctcctgatct atgaagtttc
cacccggttc 180tctggagtgc cagataggtt cagtggcagc gggtcaggga
cagatttcac actgaaaatc 240agccgggtgg aggctgagga tgttggggtt
ttttactgca tgcaaagtat acagcttccg 300ctcactttcg gcggagggac
caaggtggag atcaaa 33693321DNAHomo sapiens 93gaaatagtga tgacgcagtc
tccagccacc ctgtctgtgt ctcctgggga aagagccacc 60ctctcctgca gggccagtca
gagtgttagc agcaacttag cctggttcca gcagaaacct 120ggccaggctc
ccaggcccct catctatgat gcatccacca gggccactgg tgtcccagcc
180aggttcagtg gcagtgggtc tgggacagac ttcactctca ccatcagcag
cctgcagtct 240gaagattttg cagtttatta ctgtcagcag tatgataact
ggccgctcac tttcggcgga 300gggaccaagg tggagatcaa a 32194321DNAHomo
sapiens 94gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga
aagagtcacc 60ctctcctgca gggccagtca gagtgttagc agcaacttag cctggttcca
gcagaaacct 120ggccaggctc ccaggcccct catctatgat gcatccacca
gggccgctgg tatcccagcc 180aggttcagtg gcagtgggtc tgggacagac
ttcactctca ccatcagcag cctgcagtct 240gaagattttg cagtttatta
ctgtcagcag tatgataact ggccgctcac tttcggcgga 300gggaccaagg
tggagatcaa a 32195324DNAHomo sapiens 95gaaatagtga tgacgcagtc
tccagccacc ctgtctgtgt ctccagggga aagagccacc 60ctctcctgca gggccagtca
gagtattagc accagcttag cctggtacca gcagaaacct 120ggccaggctc
ccaggctcct catctatggt acatccacca gggccactgg tatcccagcc
180aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagcag
cctgcagtct 240gaagattttg cagtttattt ctgtcaacag tatgatatct
ggccgctcac tttcggcgga 300gggaccaagg tggagatcaa acga 32496321DNAHomo
sapiens 96gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga
aagagccacc 60ctctcctgca gggccagtca gagtgttagc agcaacttag cctggtacca
gcagaaacct 120ggccaggctc ccaggctcct catctatggt gcatccacca
gggccactgg tatcccagcc 180aggttcagtg gcagtgggtc tgggacagag
ttcactctca ccatcagcag cctgcagtct 240gaagattttg cagtttattc
ctgtcagcag tatgataact ggccgctcac tttcggcgga 300gggaccaagg
tggagatcaa a 32197339DNAHomo sapiens 97gacatcgtga tgacccagtc
tccagactcc ctggctgtgt ctctgggcga gagggccacc 60atcaactgca agaccagcca
gagtgtttta tacagctcca aaaacaagaa cttcttagct 120tggtatcagc
agaaaccagg acagcctctt aacctgctca tttactgggc atctacccgg
180gaatccgggg tccctgaccg attcagtggc agcgggtctg ggacagattt
cactctcacc 240atcagcagcc tgcaggctga agatgtggca gtttattact
gtcagcaata ttatagtact 300ccattcactt tcggccctgg gaccaaagtg gatatcaaa
33998321DNAHomo sapiens 98gaaatagtga tgacgcagtc tccagccacc
ctgtctgtgt ctccagggga aagagccacc 60ctctcctgca gggccagtca gagtattagc
agcaacttag cctggtacca gcagaaacct 120ggccaggctc ccaggctcct
catctatggt gcatccacca gggccactgg tatcccagcc 180aggttcagtg
acaatgggtc tgggacagag ttcactctca ccatcagcag cctgcagtct
240gaagattttg cagtttattt ctgtcagcag tatgatacct ggcctctcac
tttcggcggc 300gggaccaagg tggagatcaa a 32199321DNAHomo sapiens
99gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc
60atcacttgcc gggcgagtca gggcattagc aattatttag cctggtatca gcagaaacca
120gggaaatttc ctgagctcct gatctatgct gcatccactt tacaatcagg
ggtcccatct 180cggttcagtg gcagtggatc tgggacagat ttcactctca
ccatcagcag cctgcagcct 240gaagatgttg caacttatta ctgtcaaaag
tataaccgtg ccccattcac tttcggccct 300gggaccaaag tggatatcaa a
321100321DNAHomo sapiens 100gacatccaga tgacccagtc tccatcctcc
ctgtctgcat ctgtaggaga cagagtcacc 60atcacttgcc gggcgagtca gggcattagc
aattatttag cctggtatca gcagaaacca 120gggaaatttc ctgagctcct
gatctatgct gcatccactt tgcaatcagg ggtcccatct 180cggttcagtg
gcagtggatc tgggacagat ttcactctca ccatcagcag cctgcagcct
240gaagatgttg caacttatta ctgtcaaaag tataaccgtg ccccattcac
tttcggccct 300gggaccaaag tggatatcaa a 321101321DNAHomo sapiens
101gaaatagtga tgacgcagtc tccagccacc ctgtctgtgt ctccagggga
aagagtcacc 60ctctcctgca gggccagtca gagtgttagc agcaacttag cctggttcca
gcagaaacct 120ggccaggctc ccaggcccct catctatgat gcatccacca
gggccgctgg tatcccagcc 180aggttcagtg gcagtgggtc tgggacagac
ttcactctca ccatcagcag cctgcagtct 240gaagattttg cagtttatta
ctgtcagcag tatgataact ggccgctcac tttcggcgga 300gggaccaagg
tggagatcaa a 321102321DNAHomo sapiens 102gacatccaga tgacccagtc
tccatcctcc ctgtctgcat ctgttggaga cagagtcacc 60atctcttgcc gggcaagtca
gggcattata aatgatttag gctggtatca gcagaaacca 120gggaaagccc
ctaagcgcct gatctatgct gcatccagtt tgcaaagtgg ggtcccatca
180aggttcagcg gcagtggatc tgggacagaa ttcactttca caatcagcag
cctgcagcct 240gaagattttg caacttatta ctgtctacag cataatagtt
accctccgac gttcggccaa 300gggaccaagg tggaaatcaa a 321103339DNAHomo
sapiens 103gatattgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca
gccggcctcc 60atctcctgca ggtctagtca aagcctcgta tatagtgatg gacacacctg
cttgaattgg 120tttcagcaga ggccaggcca atctccaagg cgcctaattt
ataaggtttc taactgggac 180tctggggtcc cagacagatt cagcggcagt
gggtcaggca ctgatttcac actgaaaatc 240agcagggtgg aggctgacga
tgttggggtt tattactgca tgcaaggtac acactggcct 300ctgtgcagtt
ttggccaggg gaccaagctg gagatcaaa 339104339DNAHomo sapiens
104gatattgtga tgactcagtc tccactctcc ctgcccgtca cccttggaca
gccggcctcc 60atctcctgca ggtctagtca aagcctcgta tatagtgatg gacacacctg
cttgaattgg 120tttcagcaga ggccaggcca atctccaagg cgcctaattt
ataaggtttc taactgggac 180tctggggtcc cagacagatt cagcggcagt
gggtcaggca ctgatttcac actgaaaatc 240agcagggtgg aggctgacga
tgttggggtt tattactgca tgcaaggtac acactggcct 300ctgtgcagtt
ttggccaggg gaccaagctg gagatcaaa 339105321DNAHomo sapiens
105gacatccaga tgacccagtc tccatcctca ctgtctgcat ctgtaggaga
cagagtcacc 60atcacttgtc gggcgagtca ggccattagc atttatttag cctggtttca
gcagaaacca 120gggaaagccc ctaagtccct gatctatgct gcatccagtt
tgcaaagtgg ggtcccatca 180aagttcagcg gcagtgtatc tgggacagat
ttcactctca ccatcagcag cctgcagcct 240gaagattttg caacttatta
ctgccaacag tatagtagtt accctcggac gttcggccaa 300gggaccaagg
tggaaatcaa a 321106321DNAHomo sapiens 106gaaatattga tgacgcagtc
tccagccacc ctgtctgtgt ctccagggga aagagccacc 60ctctcctgca gggccagtca
gagtgtttac agcaacttag cctggtacca gcagaaacct 120ggccaggctc
ccagactcct catctctggt gcttccacca gggccactgg tatcccagcc
180aggttcagtg gcagtgggtc tgggacagag ttcactctca ccatcagcag
cctgcagtct 240gaagattttg cagtttatta ctgtcagcag tattataact
ggccgtggac gttcggccaa 300gggaccaagg tggaaatcaa a 3211075PRTHomo
sapiens 107Asn Tyr Tyr Trp Asn1 510816PRTHomo sapiens 108Asp Ile
Tyr Tyr Ser Gly Ser Thr Asn Tyr Asn Pro Ser Leu Lys Ser1 5 10
1510923PRTHomo sapiens 109Asp Gly Glu Leu Ala Asn Tyr Tyr Gly Ser
Gly Ser Tyr Gln Phe Tyr1 5 10 15Tyr Tyr Tyr Gly Met Asp Val
201105PRTHomo sapiens 110Gly Tyr Tyr Trp Ser1 511116PRTHomo sapiens
111Glu Ile Asn His Ser Gly Arg Thr Asn Tyr Asn Pro Ser Leu Lys Ser1
5 10 1511219PRTHomo sapiens 112Gly Pro Tyr Tyr Phe Asp Ser Ser Gly
Tyr Leu Tyr Tyr Tyr Tyr Gly1 5 10 15Leu Asp Val1135PRTHomo sapiens
113Ser Tyr Gly Met His1 511417PRTHomo sapiens 114Val Ile Trp Tyr
Asp Gly Ser Asn Lys His Tyr Ala Asp Ser Val Lys1 5 10
15Gly1155PRTHomo sapiens 115Asp Thr Gly Val Tyr1 51165PRTHomo
sapiens 116Ser Tyr Gly Met His1 511717PRTHomo sapiens 117Val Ile
Trp Tyr Asp Gly Ser Asn Lys His Tyr Ala Asp Ser Val Lys1 5 10
15Gly1185PRTHomo sapiens 118Asp Thr Gly Val Tyr1 51195PRTHomo
sapiens 119Ser Tyr Tyr Trp Ser1 512016PRTHomo sapiens 120Arg Ile
Tyr Arg Ser Gly Asn Thr Ile Tyr Asn Pro Ser Leu Lys Ser1 5 10
1512117PRTHomo sapiens 121Glu Asn Tyr Ser Glu Ser Ser Gly Leu Tyr
Tyr Tyr Tyr Gly Met Asp1 5 10 15Val1225PRTHomo sapiens 122Arg Tyr
Gly Ile Ser1 512317PRTHomo sapiens 123Trp Ile Ser Ala Tyr Asn Gly
Asn Thr Asn Tyr Ala Gln Lys Leu Gln1 5 10 15Gly12415PRTHomo sapiens
124Arg Asp Tyr Asp Ile Leu Thr Gly Tyr Tyr Asn Gly Phe Asp Pro1 5
10 151255PRTHomo sapiens 125Arg Tyr Gly Ile Ser1 512617PRTHomo
sapiens 126Trp Ile Ser Ala Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Lys
Leu Gln1 5 10 15Gly12715PRTHomo sapiens 127Arg Asp Tyr Asp Ile Leu
Thr Gly Tyr Tyr Asn Gly Phe Asp Pro1 5 10 151285PRTHomo sapiens
128Gly Tyr Gly Ile Ser1 512917PRTHomo sapiens 129Trp Ile Ser Ala
Tyr Asn Gly Asn Thr Asn Tyr Ala Gln Asn Leu Gln1 5 10
15Gly13015PRTHomo sapiens 130Arg Asp Tyr Asp Ile Leu Thr Gly Tyr
Tyr Asn Gly Phe Asp Pro1 5 10 151315PRTHomo sapiens 131Arg Tyr Gly
Ile Ser1 513217PRTHomo sapiens 132Trp Ile Ser Ala Tyr Asn Gly Asn
Thr Asn Tyr Ala Gln Lys Leu Gln1 5 10 15Gly13315PRTHomo sapiens
133Arg Asp Tyr Asp Ile Leu Thr Gly Tyr Tyr Asn Gly Phe Asp Pro1 5
10 151347PRTHomo sapiens 134Ser Gly Gly Tyr Tyr Trp Ser1
513516PRTHomo sapiens 135Tyr Ile Tyr Phe Ser Gly Ser Ala Tyr Tyr
Asn Pro Ser Leu Lys Ser1 5 10 1513614PRTHomo sapiens 136Glu Tyr Tyr
Asp Ser Ser Gly Tyr Pro Asp Ala Phe Asp Ile1 5 101375PRTHomo
sapiens 137Ser Tyr Gly Met His1 513817PRTHomo sapiens 138Val Ile
Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val Lys1 5 10
15Gly1395PRTHomo sapiens 139Asp Thr Lys Asp Tyr1 51405PRTHomo
sapiens 140Ser Tyr Gly Ile Ser1 514117PRTHomo sapiens 141Trp Ile
Ser Thr Tyr Lys Gly Asn Thr Asn Tyr Ala Gln Lys Leu Gln1 5 10
15Gly1427PRTHomo sapiens 142Lys Gln Leu Val Phe Asp Tyr1
51435PRTHomo sapiens 143Ser Tyr Gly Met Gln1 514417PRTHomo sapiens
144Val Ile Trp Tyr Asp Gly Asn Lys Lys Tyr Tyr Ala Asp Ser Val Lys1
5 10 15Gly14512PRTHomo sapiens 145Gly Arg Val Arg Asp Tyr Tyr Tyr
Gly Met Asp Val1 5 101465PRTHomo sapiens 146Arg Tyr Gly Ile Ser1
514717PRTHomo sapiens 147Trp Ile Ser Thr Tyr Ser Gly Asn Thr Asn
Tyr Ala Gln Lys Leu Gln1 5 10 15Gly1487PRTHomo sapiens 148Arg Gln
Leu Tyr Phe Asp Tyr1 51495PRTHomo sapiens 149Ser Tyr Gly Met Gln1
515017PRTHomo sapiens 150Val Ile Trp Tyr Asp Gly Asn Lys Lys Tyr
Tyr Ala Asp Ser Val Lys1 5 10 15Gly15112PRTHomo sapiens 151Gly Arg
Val Arg Asp Tyr Tyr Tyr Gly Met Asp Val1 5 101525PRTHomo sapiens
152Ser Tyr Gly Ile Ser1 515317PRTHomo sapiens 153Trp Ile Ser Ala
Tyr Asn Gly Asn Thr Lys Tyr Ala Gln Lys Leu Gln1 5 10
15Gly1547PRTHomo sapiens 154Lys Gln Leu Val Phe Asp Tyr1
51555PRTHomo sapiens 155Ser Tyr Gly Ile Ser1 515617PRTHomo sapiens
156Trp Ile Ser Ala Tyr Ser Gly Asn Thr Lys Tyr Ala Gln Lys Leu Gln1
5 10 15Gly1577PRTHomo sapiens 157Lys Gln Leu Val Phe Asp Tyr1
51585PRTHomo sapiens 158Asp Tyr Tyr Met His1 515917PRTHomo sapiens
159Trp Met His Pro Asn Ser Gly Gly Thr Asp Leu Ala Gln Arg Phe Gln1
5 10 15Gly16017PRTHomo sapiens 160Gly Gly Tyr Cys Ser Thr Leu Ser
Cys Ser Phe Tyr Trp Tyr Phe Asp1 5 10 15Leu1615PRTHomo sapiens
161Ser Tyr Gly Ile Ser1 516217PRTHomo sapiens 162Trp Ile Ser Ala
Tyr Ser Gly Asn Thr Lys Tyr Ala Gln Lys Phe Gln1 5 10
15Gly1637PRTHomo sapiens 163Arg Gln Leu Ala Leu Asp Tyr1
51645PRTHomo sapiens 164Ser Tyr Ser Met Asn1 516517PRTHomo sapiens
165Phe Ile Ser Ala Arg Ser Ser Thr Ile Tyr Tyr Ala Asp Ser Val Lys1
5 10 15Gly1669PRTHomo sapiens 166Pro Lys Val Gly Gly Gly Met Asp
Val1 51675PRTHomo sapiens 167Ser Tyr Ser Met Asn1 516817PRTHomo
sapiens 168Ile Ile Ser Ser Arg Ser Ser Ile Ile His Tyr Ala Asp Ser
Val Lys1 5 10 15Gly1699PRTHomo sapiens 169Pro Lys Val Gly Gly Gly
Met Asp Val1 51705PRTHomo sapiens 170Arg Tyr Gly Ile Ser1
517117PRTHomo sapiens 171Trp Ile Ser Ala Tyr Ser Gly Asn Thr Asn
Tyr Ala Gln Lys Leu Gln1 5 10 15Gly1727PRTHomo sapiens 172Arg Gln
Leu Tyr Phe Asp Tyr1 51735PRTHomo sapiens 173Ser Tyr Tyr Trp Ser1
517416PRTHomo sapiens 174Arg Ile Tyr Pro Ser Gly Arg Thr Asn Tyr
Asn Pro Ser Leu Lys Ser1 5 10 1517517PRTHomo sapiens 175Glu Ala Tyr
Glu Leu Gln Leu Gly Leu Tyr Tyr Tyr Tyr Gly Met Asp1 5 10
15Val1765PRTHomo sapiens 176Ser Tyr Tyr Trp Ser1 517716PRTHomo
sapiens 177Arg Ile Tyr Pro Ser Gly Arg Thr Asn Tyr Asn Pro Ser Leu
Lys Ser1 5 10 1517817PRTHomo sapiens 178Glu Ala Tyr Glu Leu Gln Leu
Gly Leu Tyr Tyr Tyr Tyr Gly Met Asp1 5 10 15Val1797PRTHomo sapiens
179Ser Gly Gly Tyr Tyr Trp Ser1 518013PRTHomo sapiens 180Tyr Ser
Gly Asn Thr Tyr Tyr Asn Pro Ser Leu Arg Ser1 5 1018114PRTHomo
sapiens 181Glu Ala Gly Gly Asn Ser Ala Tyr Tyr Tyr Gly Met Asp Val1
5 101825PRTHomo sapiens 182Asp Tyr Tyr Met Ser1 518317PRTHomo
sapiens 183Tyr Ile Ser Ser Ser Gly Ser Thr Ile Tyr Tyr Ala Asp Ser
Val Lys1 5 10 15Gly18416PRTHomo sapiens 184Asp Arg Thr Tyr Tyr Phe
Gly Ser Gly Ser Tyr Glu Gly Met Asp Val1 5 10 1518511PRTHomo
sapiens 185Arg Ala Ser Gln Gly Ile Arg Asn Asp Leu Gly1 5
101867PRTHomo sapiens 186Ala Ala Ser Ser Leu Gln Ser1 51879PRTHomo
sapiens 187Leu Gln His Asn Ser Asn Pro Phe Thr1 518811PRTHomo
sapiens 188Arg Ala Ser Gln Ser Val Ser Arg Asn Leu Val1 5
101897PRTHomo sapiens 189Gly Ala Ser Thr Arg Ala Asn1 51908PRTHomo
sapiens 190Gln Gln Tyr Lys Ser Trp Arg Thr1 519111PRTHomo sapiens
191Arg Ala Ser Gln Ser Ile Ser Ser Tyr Leu Asn1 5 101927PRTHomo
sapiens 192Ala Ala Ser Ser Leu Gln Ser1 51939PRTHomo sapiens 193Gln
Gln Ser Tyr Ser Thr Pro Phe Thr1 519411PRTHomo sapiens 194Arg Ala
Ser Gln Ser Val Ser Arg Asn Leu Ala1 5 101957PRTHomo sapiens 195Gly
Ala Ser Thr Arg Ala Thr1 519610PRTHomo sapiens 196Gln Gln Tyr Asn
Asn Trp Pro Thr Trp Thr1 5 1019711PRTHomo sapiens 197Arg Ala Ser
Gln Gly Ile Arg Asn Asp Leu Gly1 5 101987PRTHomo sapiens 198Ala Ala
Ser Ser Phe Gln Ser1 51999PRTHomo sapiens 199Leu Gln His Asn Ser
Tyr Pro Pro Thr1 520011PRTHomo sapiens 200Arg Ala Ser Gln Gly Ile
Arg Asn Asp Leu Gly1 5 102017PRTHomo sapiens 201Ala Ala Ser Ser Leu
Gln Ser1 52029PRTHomo sapiens 202Leu Gln His Lys Ser Tyr Pro Leu
Thr1 520311PRTHomo sapiens 203Arg Ala Ser Gln Gly Ile Arg Asn Asp
Leu Gly1 5 102047PRTHomo sapiens 204Ala Ala Ser Ser Leu Gln Ser1
52059PRTHomo sapiens 205Leu Gln His Lys Ser Tyr Pro Leu Thr1
520611PRTHomo sapiens 206Arg Ala Ser Gln Gly Ile Arg Asn Asp Leu
Gly1 5 102077PRTHomo sapiens 207Ala Ala Ser Ser Leu Gln Ser1
52089PRTHomo sapiens 208Leu Gln His Lys Ser Tyr Pro Leu Thr1
520911PRTHomo sapiens 209Arg Ala Ser Gln Gly Ile Arg Asn Asp Leu
Gly1 5 102107PRTHomo sapiens 210Ala Ala Ser Ser Leu Gln Ser1
52119PRTHomo sapiens 211Leu Gln His Lys Ser Tyr Pro Leu Thr1
521211PRTHomo sapiens 212Arg Ala Ser Gln Gly Ile Arg Ser Trp Leu
Ala1 5 102137PRTHomo sapiens 213Ala Ala Ser Ser Leu Gln Ser1
52149PRTHomo sapiens 214Gln Gln Ala Asn Asn Phe Pro Arg Thr1
521511PRTHomo sapiens 215Arg Ala Ser Gln Ser Val Ser Ser Asn Leu
Ala1 5 102167PRTHomo sapiens 216Gly Ala Ser Thr Arg Ala Ala1
521710PRTHomo sapiens 217Gln His Tyr Ile Asn Trp Pro Lys Trp Thr1 5
1021811PRTHomo sapiens 218Arg Ala Ser Gln Ser Ile Ser Ser Ser Leu
Ala1 5 102197PRTHomo sapiens 219Gly Ala Ser Thr Arg Ala Thr1
52209PRTHomo sapiens 220Gln Gln Tyr Asp Asn Trp Pro Leu Thr1
522116PRTHomo sapiens 221Lys Ser Ser Gln Ser Leu Leu His Ser Asp
Gly Lys Thr Tyr Leu Tyr1 5 10 152227PRTHomo sapiens 222Glu Val Ser
Thr Arg Phe Ser1 52239PRTHomo sapiens 223Met Gln Ser Ile Gln Leu
Pro Leu Thr1 522411PRTHomo sapiens 224Arg Ala Ser Gln Ser Val Ser
Ser Asn Leu Ala1 5 102257PRTHomo sapiens 225Asp Ala Ser Thr Arg Ala
Thr1 52269PRTHomo sapiens 226Gln Gln Tyr Asp Asn Trp Pro Leu Thr1
522711PRTHomo sapiens 227Arg Ala Ser Gln Ser Val Ser Ser Asn Leu
Ala1 5 102287PRTHomo sapiens 228Asp Ala Ser Thr Arg Ala Ala1
52299PRTHomo sapiens 229Gln Gln Tyr Asp Asn Trp Pro Leu Thr1
523011PRTHomo sapiens 230Arg Ala Ser Gln Ser Ile Ser Thr Ser Leu
Ala1 5 102317PRTHomo sapiens 231Gly Thr Ser Thr Arg Ala Thr1
52329PRTHomo sapiens 232Gln Gln Tyr Asp Ile Trp Pro Leu Thr1
523311PRTHomo sapiens 233Arg Ala Ser Gln Ser Val Ser Ser Asn Leu
Ala1 5 102347PRTHomo sapiens 234Gly Ala Ser Thr Arg Ala Thr1
52359PRTHomo sapiens 235Gln Gln Tyr Asp Asn Trp Pro Leu Thr1
523617PRTHomo sapiens 236Lys Thr Ser Gln Ser Val Leu Tyr Ser Ser
Lys Asn Lys Asn Phe Leu1 5 10 15Ala2377PRTHomo sapiens 237Trp Ala
Ser Thr Arg Glu Ser1 52389PRTHomo sapiens 238Gln Gln Tyr Tyr Ser
Thr Pro Phe Thr1 523911PRTHomo sapiens 239Arg Ala Ser Gln Ser Ile
Ser Ser Asn Leu Ala1 5 102407PRTHomo sapiens 240Gly Ala Ser Thr Arg
Ala Thr1 52419PRTHomo sapiens 241Gln Gln Tyr Asp Thr Trp Pro Leu
Thr1 524211PRTHomo sapiens 242Arg Ala Ser Gln Gly Ile Ser Asn Tyr
Leu Ala1 5 102437PRTHomo sapiens 243Ala Ala Ser Thr Leu Gln Ser1
52449PRTHomo sapiens 244Gln Lys Tyr Asn Arg Ala Pro Phe Thr1
524511PRTHomo sapiens 245Arg Ala Ser Gln Gly Ile Ser Asn Tyr Leu
Ala1 5 102467PRTHomo sapiens 246Ala Ala Ser Thr Leu Gln Ser1
52479PRTHomo sapiens 247Gln Lys Tyr Asn Arg Ala Pro Phe Thr1
524811PRTHomo sapiens 248Arg Ala Ser Gln Ser Val Ser Ser Asn Leu
Ala1 5 102497PRTHomo sapiens 249Asp Ala Ser Thr Arg Ala Ala1
52509PRTHomo sapiens 250Gln Gln Tyr Asp Asn Trp Pro Leu Thr1
525111PRTHomo sapiens 251Arg Ala Ser Gln Gly Ile Ile Asn Asp Leu
Gly1 5 102527PRTHomo sapiens 252Ala Ala Ser Ser Leu Gln Ser1
52539PRTHomo sapiens 253Leu Gln His Asn Ser Tyr Pro Pro Thr1
525416PRTHomo sapiens 254Arg Ser Ser Gln Ser Leu Val Tyr Ser Asp
Gly His Thr Cys Leu Asn1 5 10 152557PRTHomo sapiens 255Lys Val Ser
Asn Trp Asp Ser1 525610PRTHomo sapiens 256Met Gln Gly Thr His Trp
Pro Leu Cys Ser1 5 1025716PRTHomo sapiens 257Arg Ser Ser Gln Ser
Leu Val Tyr Ser Asp Gly His Thr Cys Leu Asn1 5 10 152587PRTHomo
sapiens 258Lys Val Ser Asn Trp Asp Ser1 525910PRTHomo sapiens
259Met Gln Gly Thr His Trp Pro Leu Cys Ser1 5 1026011PRTHomo
sapiens 260Arg Ala Ser Gln Ala Ile Ser Ile Tyr Leu Ala1 5
102617PRTHomo sapiens 261Ala Ala Ser Ser Leu Gln Ser1 52629PRTHomo
sapiens 262Gln Gln Tyr Ser Ser Tyr Pro Arg Thr1 526311PRTHomo
sapiens 263Arg Ala Ser Gln Ser Val Tyr Ser Asn Leu Ala1 5
102647PRTHomo sapiens 264Gly Ala Ser Thr Arg Ala Thr1 52659PRTHomo
sapiens 265Gln Gln Tyr Tyr Asn Trp Pro Trp Thr1 526615DNAHomo
sapiens 266aattactact ggaac 1526775DNAHomo sapiens 267ccagggaagg
gactggagtg gattggggat atctattaca gtgggagcac caactacaac 60ccctccctca
agagt 7526869DNAHomo sapiens 268gatggggaac tcgccaatta ctatggttcg
gggagttatc agttctacta ctactacggt 60atggacgtc 6926915DNAHomo sapiens
269ggttactact ggagc 1527048DNAHomo sapiens 270gaaatcaatc atagtggacg
caccaattac aacccgtccc tcaagagt 4827157DNAHomo sapiens 271ggcccttatt
actttgatag tagtggttac ctttactact actacggttt ggacgtc 5727215DNAHomo
sapiens 272agctatggca tgcac 1527351DNAHomo sapiens 273gttatatggt
atgatggaag taataaacac tatgcagact ccgtgaaggg c 5127415DNAHomo
sapiens 274gatactgggg tctac 1527515DNAHomo sapiens 275agctatggca
tgcac 1527651DNAHomo sapiens 276gttatatggt atgatggaag taataaacac
tatgcagact ccgtgaaggg c 5127715DNAHomo sapiens 277gatactgggg tctac
1527815DNAHomo sapiens 278agttactact ggagc 1527948DNAHomo sapiens
279cgtatctatc gcagtgggaa caccatctac aacccctccc tcaagagt
4828051DNAHomo sapiens 280gagaattact ctgagagtag tggtctctac
tactactacg gtatggacgt c 5128115DNAHomo sapiens 281agatatggta tcagc
1528251DNAHomo sapiens 282tggatcagcg cttacaatgg taacacaaac
tatgcacaga agctccaggg c 5128345DNAHomo sapiens 283agggattacg
atattttgac tggttattat aacgggttcg acccc 4528415DNAHomo sapiens
284agatatggta tcagc 1528551DNAHomo sapiens 285tggatcagcg cttacaatgg
taacacaaac tatgcacaga agctccaggg c 5128645DNAHomo sapiens
286agggattacg atattttgac tggttattat aacgggttcg acccc 4528715DNAHomo
sapiens 287ggctatggta tcagc 1528851DNAHomo sapiens 288tggatcagcg
cttacaatgg taacacaaac tatgcacaga acctccaggg c 5128945DNAHomo
sapiens 289agggattacg atattttgac tggttattat aacgggttcg acccc
4529015DNAHomo sapiens 290agatatggta tcagc 1529150DNAHomo sapiens
291tggatcagcg cttacaatgg taacacaaac tatgcacaga agctccaggg
5029245DNAHomo sapiens 292agggattacg atattttgac tggttattat
aacgggttcg acccc 4529321DNAHomo sapiens 293agtggtggtt actactggag c
2129448DNAHomo sapiens 294tacatctatt tcagtgggag cgcctactac
aacccgtccc tcaagagt 4829542DNAHomo sapiens 295gaatactatg atagtagtgg
ttaccccgat gcttttgata tc 4229615DNAHomo sapiens 296agctatggca tgcac
1529751DNAHomo sapiens 297gttatatggt atgatggaag taataaatat
tatgcagact ccgtgaaggg c 5129815DNAHomo sapiens 298gatacgaagg actac
1529915DNAHomo sapiens 299agctatggta tcagc 1530051DNAHomo sapiens
300tggatcagca cttacaaagg taacacaaac tatgcacaga agctccaggg c
5130121DNAHomo sapiens 301aagcagctcg tctttgacta c 2130215DNAHomo
sapiens 302agctatggca tgcag 1530351DNAHomo sapiens 303gttatatggt
atgatggaaa taagaaatac tatgcagact ccgtgaaggg c 5130436DNAHomo
sapiens 304ggacgtgtta gggactacta ctacggtatg gacgtc 3630515DNAHomo
sapiens 305agatatggta tcagc 1530651DNAHomo sapiens 306tggatcagca
cttacagtgg taacacaaac tatgcacaga agctccaggg c 5130721DNAHomo
sapiens 307cggcagcttt actttgacta c 2130815DNAHomo sapiens
308agctatggca tgcag 1530951DNAHomo sapiens 309gttatatggt atgatggaaa
taagaaatac tatgcagact ccgtgaaggg c 5131036DNAHomo sapiens
310ggacgtgtta gggactacta ctacggtatg gacgtc 3631115DNAHomo sapiens
311agctatggta tcagc 1531251DNAHomo sapiens 312tggatcagcg cttacaatgg
taacacaaag tatgcacaga agctccaggg c 5131321DNAHomo sapiens
313aagcagctcg tctttgacta c 2131415DNAHomo sapiens 314agctatggta
tcagc
1531551DNAHomo sapiens 315tggatcagcg cttacagtgg taatacaaag
tatgcacaga agctccaggg c 5131621DNAHomo sapiens 316aagcagctcg
tctttgacta c 2131715DNAHomo sapiens 317gactactaca tgcac
1531851DNAHomo sapiens 318tggatgcacc ctaacagtgg tggcacagac
ttagcacaga ggtttcaggg c 5131951DNAHomo sapiens 319gggggatatt
gtagtacttt gagctgctcc ttctactggt acttcgatct c 5132015DNAHomo
sapiens 320agctatggaa tcagt 1532151DNAHomo sapiens 321tggatcagcg
cttacagtgg taacacaaag tatgcacaga agttccaggg c 5132221DNAHomo
sapiens 322aggcagctcg cgttggacta c 2132315DNAHomo sapiens
323agctatagca tgaac 1532451DNAHomo sapiens 324ttcattagtg ctagaagtag
taccatatac tacgcagact ctgtgaaggg c 5132527DNAHomo sapiens
325cctaaagtgg ggggcggtat ggacgtc 2732615DNAHomo sapiens
326agctatagca tgaac 1532751DNAHomo sapiens 327atcattagta gtagaagtag
tatcatacac tacgcagact ctgtgaaggg c 5132827DNAHomo sapiens
328cctaaagtgg ggggcggtat ggacgtc 2732915DNAHomo sapiens
329agatatggta tcagc 1533051DNAHomo sapiens 330tggatcagcg cttacagtgg
taacacaaac tatgcacaga agctccaggg c 5133121DNAHomo sapiens
331cggcagcttt actttgacta c 2133215DNAHomo sapiens 332agttactact
ggagc 1533348DNAHomo sapiens 333cgtatctatc ccagtgggag aaccaactac
aacccctccc tcaagagt 4833451DNAHomo sapiens 334gaggcatatg agctgcaact
gggcctctac tactactacg gtatggacgt c 5133515DNAHomo sapiens
335agttactact ggagc 1533648DNAHomo sapiens 336cgtatctatc ccagtgggag
aaccaactac aacccctccc tcaagagt 4833751DNAHomo sapiens 337gaggcatatg
agctgcaact gggcctctac tactactacg gtatggacgt c 5133821DNAHomo
sapiens 338agtggtggtt actactggag c 2133939DNAHomo sapiens
339tacagtggga acacctacta caacccgtcc ctcaggagt 3934042DNAHomo
sapiens 340gaggccggtg gtaactccgc ctactactac ggtatggacg tc
4234115DNAHomo sapiens 341gactactaca tgagc 1534251DNAHomo sapiens
342tacattagta gtagtcgtag taccatatac tacgcagact ctgtgaaggg c
5134348DNAHomo sapiens 343gatcgcacgt attactttgg ttcggggagt
tatgaaggga tggacgtc 4834488PRTHomo sapiens 344Glu Ile Val Met Thr
Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly1 5 10 15Glu Arg Ala Thr
Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 20 25 30Leu Ala Trp
Phe Gln Gln Lys Pro Gly Gln Ala Pro Arg Pro Leu Ile 35 40 45Tyr Asp
Ala Ser Thr Arg Ala Thr Gly Val Pro Ala Arg Phe Ser Gly 50 55 60Ser
Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser65 70 75
80Glu Asp Phe Ala Val Tyr Tyr Cys 8534533DNAHomo sapiens
345cgggcaagtc agggcattag aaatgattta ggc 3334621DNAHomo sapiens
346gctgcatcca gtttgcaaag t 2134727DNAHomo sapiens 347ctacagcata
atagtaaccc attcact 2734833DNAHomo sapiens 348agggccagtc agagtgttag
cagaaactta gtc 3334921DNAHomo sapiens 349ggggcatcca ctagggccaa t
2135024DNAHomo sapiens 350cagcagtata aaagctggcg gacg 2435133DNAHomo
sapiens 351cgggcaagtc agagcattag cagctattta aat 3335221DNAHomo
sapiens 352gctgcatcca gtttgcaaag t 2135327DNAHomo sapiens
353caacagagtt acagtacccc attcact 2735433DNAHomo sapiens
354agggccagtc agagtgttag taggaattta gcc 3335521DNAHomo sapiens
355ggtgcatcca ccagggccac t 2135630DNAHomo sapiens 356cagcagtata
ataactggcc cacgtggacg 3035733DNAHomo sapiens 357cgggcaagtc
agggcattag aaatgattta ggc 3335821DNAHomo sapiens 358gctgcatcca
gtttccaaag t 2135927DNAHomo sapiens 359ctacagcata atagttaccc
tccgacg 2736033DNAHomo sapiens 360cgggcaagtc agggcattag aaatgattta
ggc 3336121DNAHomo sapiens 361gctgcatcca gtttgcaaag t
2136227DNAHomo sapiens 362ctacagcata aaagttaccc gctcact
2736333DNAHomo sapiens 363cgggcaagtc agggcattag aaatgattta ggc
3336421DNAHomo sapiens 364gctgcatcca gtttgcaaag t 2136527DNAHomo
sapiens 365ctacagcata aaagttaccc gctcact 2736633DNAHomo sapiens
366cgggcaagtc agggcattag aaatgattta ggc 3336721DNAHomo sapiens
367gctgcatcca gtttgcaaag t 2136827DNAHomo sapiens 368ctacagcata
agagttaccc gctcact 2736930DNAHomo sapiens 369cgggcaagtc agggcattag
aaatgattta 3037021DNAHomo sapiens 370gctgcatcca gtttgcaaag t
2137127DNAHomo sapiens 371ctacagcata aaagttaccc gctcact
2737233DNAHomo sapiens 372cgggcgagtc agggtattag gagctggtta gcc
3337321DNAHomo sapiens 373gctgcatcca gtttgcaaag t 2137427DNAHomo
sapiens 374caacaggcta acaatttccc tcggacg 2737533DNAHomo sapiens
375agggccagtc agagtgttag cagcaactta gcc 3337621DNAHomo sapiens
376ggtgcatcca ccagggccgc t 2137730DNAHomo sapiens 377cagcactata
taaactggcc taagtggacg 3037833DNAHomo sapiens 378agggccagtc
agagtattag cagcagctta gcc 3337921DNAHomo sapiens 379ggtgcatcca
ccagggccac t 2138027DNAHomo sapiens 380cagcaatatg ataactggcc
gctcact 2738148DNAHomo sapiens 381aagtctagtc agagcctcct gcatagtgat
ggaaagacct atttgtat 4838221DNAHomo sapiens 382gaagtttcca cccggttctc
t 2138327DNAHomo sapiens 383atgcaaagta tacagcttcc gctcact
2738433DNAHomo sapiens 384agggccagtc agagtgttag cagcaactta gcc
3338521DNAHomo sapiens 385gatgcatcca ccagggccac t 2138627DNAHomo
sapiens 386cagcagtatg ataactggcc gctcact 2738733DNAHomo sapiens
387agggccagtc agagtgttag cagcaactta gcc 3338821DNAHomo sapiens
388gatgcatcca ccagggccgc t 2138927DNAHomo sapiens 389cagcagtatg
ataactggcc gctcact 2739033DNAHomo sapiens 390agggccagtc agagtattag
caccagctta gcc 3339121DNAHomo sapiens 391ggtacatcca ccagggccac t
2139227DNAHomo sapiens 392caacagtatg atatctggcc gctcact
2739333DNAHomo sapiens 393agggccagtc agagtgttag cagcaactta gcc
3339421DNAHomo sapiens 394ggtgcatcca ccagggccac t 2139527DNAHomo
sapiens 395cagcagtatg ataactggcc gctcact 2739651DNAHomo sapiens
396aagaccagcc agagtgtttt atacagctcc aaaaacaaga acttcttagc t
5139721DNAHomo sapiens 397tgggcatcta cccgggaatc c 2139827DNAHomo
sapiens 398cagcaatatt atagtactcc attcact 2739933DNAHomo sapiens
399agggccagtc agagtattag cagcaactta gcc 3340021DNAHomo sapiens
400ggtgcatcca ccagggccac t 2140127DNAHomo sapiens 401cagcagtatg
atacctggcc tctcact 2740233DNAHomo sapiens 402cgggcgagtc agggcattag
caattattta gcc 3340321DNAHomo sapiens 403gctgcatcca ctttacaatc a
2140427DNAHomo sapiens 404caaaagtata accgtgcccc attcact
2740533DNAHomo sapiens 405cgggcgagtc agggcattag caattattta gcc
3340621DNAHomo sapiens 406gctgcatcca ctttgcaatc a 2140727DNAHomo
sapiens 407caaaagtata accgtgcccc attcact 2740833DNAHomo sapiens
408agggccagtc agagtgttag cagcaactta gcc 3340921DNAHomo sapiens
409gatgcatcca ccagggccgc t 2141027DNAHomo sapiens 410cagcagtatg
ataactggcc gctcact 2741133DNAHomo sapiens 411cgggcaagtc agggcattat
aaatgattta ggc 3341221DNAHomo sapiens 412gctgcatcca gtttgcaaag t
2141327DNAHomo sapiens 413ctacagcata atagttaccc tccgacg
2741448DNAHomo sapiens 414aggtctagtc aaagcctcgt atatagtgat
ggacacacct gcttgaat 4841521DNAHomo sapiens 415aaggtttcta actgggactc
t 2141630DNAHomo sapiens 416atgcaaggta cacactggcc tctgtgcagt
3041748DNAHomo sapiens 417aggtctagtc aaagcctcgt atatagtgat
ggacacacct gcttgaat 4841821DNAHomo sapiens 418aaggtttcta actgggactc
t 2141930DNAHomo sapiens 419atgcaaggta cacactggcc tctgtgcagt
3042033DNAHomo sapiens 420cgggcgagtc aggccattag catttattta gcc
3342121DNAHomo sapiens 421gctgcatcca gtttgcaaag t 2142227DNAHomo
sapiens 422caacagtata gtagttaccc tcggacg 2742333DNAHomo sapiens
423agggccagtc agagtgttta cagcaactta gcc 3342421DNAHomo sapiens
424ggtgcttcca ccagggccac t 2142527DNAHomo sapiens 425cagcagtatt
ataactggcc gtggacg 274261409DNAHomo sapiensCDS(16)..(1398)
426gtcgacgccg ccacc atg gag tgg acc tgg agg gtc ctt ttc ttg gtg gca
51 Met Glu Trp Thr Trp Arg Val Leu Phe Leu Val Ala 1 5 10gca gca
aca ggt gcc cac tcc cag gtt cag ctg gtg cag tct gga gct 99Ala Ala
Thr Gly Ala His Ser Gln Val Gln Leu Val Gln Ser Gly Ala 15 20 25gag
gtg aag aag cct ggg gcc tca gtg aag gtc tcc tgc aag gct tct 147Glu
Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser 30 35
40ggt tac acc ttt acc aga tat ggt atc agc tgg gtg cga cag gcc cct
195Gly Tyr Thr Phe Thr Arg Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro
45 50 55 60gga caa ggg ctt gag tgg atg gga tgg atc agc act tac agt
ggt aac 243Gly Gln Gly Leu Glu Trp Met Gly Trp Ile Ser Thr Tyr Ser
Gly Asn 65 70 75aca aac tat gca cag aag ctc cag ggc aga gtc acc atg
acc aca gac 291Thr Asn Tyr Ala Gln Lys Leu Gln Gly Arg Val Thr Met
Thr Thr Asp 80 85 90aca tcc acg agc aca gcc tac atg gag ctg agg agc
ctg aga tct gac 339Thr Ser Thr Ser Thr Ala Tyr Met Glu Leu Arg Ser
Leu Arg Ser Asp 95 100 105gac acg gcc gtg tat tac tgt gcg aga cgg
cag ctt tac ttt gac tac 387Asp Thr Ala Val Tyr Tyr Cys Ala Arg Arg
Gln Leu Tyr Phe Asp Tyr 110 115 120tgg ggc cag gga acc ctg gtc acc
gtc tcc tca gct agc acc aag ggc 435Trp Gly Gln Gly Thr Leu Val Thr
Val Ser Ser Ala Ser Thr Lys Gly125 130 135 140cca tcg gtc ttc ccc
ctg gcg ccc tgc tcc agg agc acc tcc gag agc 483Pro Ser Val Phe Pro
Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser 145 150 155aca gcg gcc
ctg ggc tgc ctg gtc aag gac tac ttc ccc gaa ccg gtg 531Thr Ala Ala
Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val 160 165 170acg
gtg tcg tgg aac tca ggc gct ctg acc agc ggc gtg cac acc ttc 579Thr
Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe 175 180
185cca gct gtc cta cag tcc tca gga ctc tac tcc ctc agc agc gtg gtg
627Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
190 195 200acc gtg ccc tcc agc aac ttc ggc acc cag acc tac acc tgc
aac gta 675Thr Val Pro Ser Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys
Asn Val205 210 215 220gat cac aag ccc agc aac acc aag gtg gac aag
aca gtt gag cgc aaa 723Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys
Thr Val Glu Arg Lys 225 230 235tgt tgt gtc gag tgc cca ccg tgc cca
gca cca cct gtg gca gga ccg 771Cys Cys Val Glu Cys Pro Pro Cys Pro
Ala Pro Pro Val Ala Gly Pro 240 245 250tca gtc ttc ctc ttc ccc cca
aaa ccc aag gac acc ctc atg atc tcc 819Ser Val Phe Leu Phe Pro Pro
Lys Pro Lys Asp Thr Leu Met Ile Ser 255 260 265cgg acc cct gag gtc
acg tgc gtg gtg gtg gac gtg agc cac gaa gac 867Arg Thr Pro Glu Val
Thr Cys Val Val Val Asp Val Ser His Glu Asp 270 275 280ccc gag gtc
cag ttc aac tgg tac gtg gac ggc gtg gag gtg cat aat 915Pro Glu Val
Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn285 290 295
300gcc aag aca aag cca cgg gag gag cag ttc aac agc acg ttc cgt gtg
963Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Val
305 310 315gtc agc gtc ctc acc gtt gtg cac cag gac tgg ctg aac ggc
aag gag 1011Val Ser Val Leu Thr Val Val His Gln Asp Trp Leu Asn Gly
Lys Glu 320 325 330tac aag tgc aag gtc tcc aac aaa ggc ctc cca gcc
ccc atc gag aaa 1059Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ala
Pro Ile Glu Lys 335 340 345acc atc tcc aaa acc aaa ggg cag ccc cga
gaa cca cag gtg tac acc 1107Thr Ile Ser Lys Thr Lys Gly Gln Pro Arg
Glu Pro Gln Val Tyr Thr 350 355 360ctg ccc cca tcc cgg gag gag atg
acc aag aac cag gtc agc ctg acc 1155Leu Pro Pro Ser Arg Glu Glu Met
Thr Lys Asn Gln Val Ser Leu Thr365 370 375 380tgc ctg gtc aaa ggc
ttc tac ccc agc gac atc gcc gtg gag tgg gag 1203Cys Leu Val Lys Gly
Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu 385 390 395agc aat ggg
cag ccg gag aac aac tac aag acc aca cct ccc atg ctg 1251Ser Asn Gly
Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu 400 405 410gac
tcc gac ggc tcc ttc ttc ctc tac agc aag ctc acc gtg gac aag 1299Asp
Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys 415 420
425agc agg tgg cag cag ggg aac gtc ttc tca tgc tcc gtg atg cat gag
1347Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
430 435 440gct ctg cac aac cac tac acg cag aag agc ctc tcc ctg tct
ccg ggt 1395Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
Pro Gly445 450 455 460aaa tgagcggccg c 1409Lys427461PRTHomo sapiens
427Met Glu Trp Thr Trp Arg Val Leu Phe Leu Val Ala Ala Ala Thr Gly1
5 10 15Ala His Ser Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys
Lys 20 25 30Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr
Thr Phe 35 40 45Thr Arg Tyr Gly Ile Ser Trp Val Arg Gln Ala Pro Gly
Gln Gly Leu 50 55 60Glu Trp Met Gly Trp Ile Ser Thr Tyr Ser Gly Asn
Thr Asn Tyr Ala65 70 75 80Gln Lys Leu Gln Gly Arg Val Thr Met Thr
Thr Asp Thr Ser Thr Ser 85 90 95Thr Ala Tyr Met Glu Leu Arg Ser Leu
Arg Ser Asp Asp Thr Ala Val 100 105 110Tyr Tyr Cys Ala Arg Arg Gln
Leu Tyr Phe Asp Tyr Trp Gly Gln Gly 115 120 125Thr Leu Val Thr Val
Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe 130 135 140Pro Leu Ala
Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu145 150 155
160Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp
165
170 175Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val
Leu 180 185 190Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr
Val Pro Ser 195 200 205Ser Asn Phe Gly Thr Gln Thr Tyr Thr Cys Asn
Val Asp His Lys Pro 210 215 220Ser Asn Thr Lys Val Asp Lys Thr Val
Glu Arg Lys Cys Cys Val Glu225 230 235 240Cys Pro Pro Cys Pro Ala
Pro Pro Val Ala Gly Pro Ser Val Phe Leu 245 250 255Phe Pro Pro Lys
Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 260 265 270Val Thr
Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Gln 275 280
285Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys
290 295 300Pro Arg Glu Glu Gln Phe Asn Ser Thr Phe Arg Val Val Ser
Val Leu305 310 315 320Thr Val Val His Gln Asp Trp Leu Asn Gly Lys
Glu Tyr Lys Cys Lys 325 330 335Val Ser Asn Lys Gly Leu Pro Ala Pro
Ile Glu Lys Thr Ile Ser Lys 340 345 350Thr Lys Gly Gln Pro Arg Glu
Pro Gln Val Tyr Thr Leu Pro Pro Ser 355 360 365Arg Glu Glu Met Thr
Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 370 375 380Gly Phe Tyr
Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln385 390 395
400Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Met Leu Asp Ser Asp Gly
405 410 415Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
Trp Gln 420 425 430Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu
Ala Leu His Asn 435 440 445His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
Pro Gly Lys 450 455 460428741DNAHomo sapiensCDS(24)..(725)
428gtcgacgttt aaacgccgcc acc atg gaa gcg ccg gcg cag ctt ctc ttc
ctc 53 Met Glu Ala Pro Ala Gln Leu Leu Phe Leu 1 5 10ctg cta ctc
tgg ctc cca gat acc act gga gaa ata gtg atg acg cag 101Leu Leu Leu
Trp Leu Pro Asp Thr Thr Gly Glu Ile Val Met Thr Gln 15 20 25tct cca
gcc acc ctg tct gtg tct cct ggg gaa aga gcc acc ctc tcc 149Ser Pro
Ala Thr Leu Ser Val Ser Pro Gly Glu Arg Ala Thr Leu Ser 30 35 40tgc
agg gcc agt cag agt gtt agc agc aac tta gcc tgg ttc cag cag 197Cys
Arg Ala Ser Gln Ser Val Ser Ser Asn Leu Ala Trp Phe Gln Gln 45 50
55aaa cct ggc cag gct ccc agg ccc ctc atc tat gat gca tcc acc agg
245Lys Pro Gly Gln Ala Pro Arg Pro Leu Ile Tyr Asp Ala Ser Thr Arg
60 65 70gcc act ggt gtc cca gcc agg ttc agt ggc agt ggg tct ggg aca
gac 293Ala Thr Gly Val Pro Ala Arg Phe Ser Gly Ser Gly Ser Gly Thr
Asp 75 80 85 90ttc act ctc acc atc agc agc ctg cag tct gaa gat ttt
gca gtt tat 341Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser Glu Asp Phe
Ala Val Tyr 95 100 105tac tgt cag cag tat gat aac tgg ccg ctc act
ttc ggc gga ggg acc 389Tyr Cys Gln Gln Tyr Asp Asn Trp Pro Leu Thr
Phe Gly Gly Gly Thr 110 115 120aag gtg gag atc aaa cgt acg gtg gct
gca cca tct gtc ttc atc ttc 437Lys Val Glu Ile Lys Arg Thr Val Ala
Ala Pro Ser Val Phe Ile Phe 125 130 135ccg cca tct gat gag cag ttg
aaa tct gga act gcc tct gtt gtg tgc 485Pro Pro Ser Asp Glu Gln Leu
Lys Ser Gly Thr Ala Ser Val Val Cys 140 145 150ctg ctg aat aac ttc
tat ccc aga gag gcc aaa gta cag tgg aag gtg 533Leu Leu Asn Asn Phe
Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val155 160 165 170gat aac
gcc ctc caa tcg ggt aac tcc cag gag agt gtc aca gag cag 581Asp Asn
Ala Leu Gln Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln 175 180
185gac agc aag gac agc acc tac agc ctc agc agc acc ctg acg ctg agc
629Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser
190 195 200aaa gca gac tac gag aaa cac aaa gtc tac gcc tgc gaa gtc
acc cat 677Lys Ala Asp Tyr Glu Lys His Lys Val Tyr Ala Cys Glu Val
Thr His 205 210 215cag ggc ctg agc tcg ccc gtc aca aag agc ttc aac
agg gga gag tgt 725Gln Gly Leu Ser Ser Pro Val Thr Lys Ser Phe Asn
Arg Gly Glu Cys 220 225 230taggatccgc ggccgc 741429234PRTHomo
sapiens 429Met Glu Ala Pro Ala Gln Leu Leu Phe Leu Leu Leu Leu Trp
Leu Pro1 5 10 15Asp Thr Thr Gly Glu Ile Val Met Thr Gln Ser Pro Ala
Thr Leu Ser 20 25 30Val Ser Pro Gly Glu Arg Ala Thr Leu Ser Cys Arg
Ala Ser Gln Ser 35 40 45Val Ser Ser Asn Leu Ala Trp Phe Gln Gln Lys
Pro Gly Gln Ala Pro 50 55 60Arg Pro Leu Ile Tyr Asp Ala Ser Thr Arg
Ala Thr Gly Val Pro Ala65 70 75 80Arg Phe Ser Gly Ser Gly Ser Gly
Thr Asp Phe Thr Leu Thr Ile Ser 85 90 95Ser Leu Gln Ser Glu Asp Phe
Ala Val Tyr Tyr Cys Gln Gln Tyr Asp 100 105 110Asn Trp Pro Leu Thr
Phe Gly Gly Gly Thr Lys Val Glu Ile Lys Arg 115 120 125Thr Val Ala
Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 130 135 140Leu
Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr145 150
155 160Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
Ser 165 170 175Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys
Asp Ser Thr 180 185 190Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys
Ala Asp Tyr Glu Lys 195 200 205His Lys Val Tyr Ala Cys Glu Val Thr
His Gln Gly Leu Ser Ser Pro 210 215 220Val Thr Lys Ser Phe Asn Arg
Gly Glu Cys225 230430866PRTHomo sapiens 430Met Gly Ala Ala Arg Ser
Pro Pro Ser Ala Val Pro Gly Pro Leu Leu1 5 10 15Gly Leu Leu Leu Leu
Leu Leu Gly Val Leu Ala Pro Gly Gly Ala Ser 20 25 30Leu Arg Leu Leu
Asp His Arg Ala Leu Val Cys Ser Gln Pro Gly Leu 35 40 45Asn Cys Thr
Val Lys Asn Ser Thr Cys Leu Asp Asp Ser Trp Ile His 50 55 60Pro Arg
Asn Leu Thr Pro Ser Ser Pro Lys Asp Leu Gln Ile Gln Leu65 70 75
80His Phe Ala His Thr Gln Gln Gly Asp Leu Phe Pro Val Ala His Ile
85 90 95Glu Trp Thr Leu Gln Thr Asp Ala Ser Ile Leu Tyr Leu Glu Gly
Ala 100 105 110Glu Leu Ser Val Leu Gln Leu Asn Thr Asn Glu Arg Leu
Cys Val Arg 115 120 125Phe Glu Phe Leu Ser Lys Leu Arg His His His
Arg Arg Trp Arg Phe 130 135 140Thr Phe Ser His Phe Val Val Asp Pro
Asp Gln Glu Tyr Glu Val Thr145 150 155 160Val His His Leu Pro Lys
Pro Ile Pro Asp Gly Asp Pro Asn His Gln 165 170 175Ser Lys Asn Phe
Leu Val Pro Asp Cys Glu His Ala Arg Met Lys Val 180 185 190Thr Thr
Pro Cys Met Ser Ser Gly Ser Leu Trp Asp Pro Asn Ile Thr 195 200
205Val Glu Thr Leu Glu Ala His Gln Leu Arg Val Ser Phe Thr Leu Trp
210 215 220Asn Glu Ser Thr His Tyr Gln Ile Leu Leu Thr Ser Phe Pro
His Met225 230 235 240Glu Asn His Ser Cys Phe Glu His Met His His
Ile Pro Ala Pro Arg 245 250 255Pro Glu Glu Phe His Gln Arg Ser Asn
Val Thr Leu Thr Leu Arg Asn 260 265 270Leu Lys Gly Cys Cys Arg His
Gln Val Gln Ile Gln Pro Phe Phe Ser 275 280 285Ser Cys Leu Asn Asp
Cys Leu Arg His Ser Ala Thr Val Ser Cys Pro 290 295 300Glu Met Pro
Asp Thr Pro Glu Pro Ile Pro Asp Tyr Met Pro Leu Trp305 310 315
320Val Tyr Trp Phe Ile Thr Gly Ile Ser Ile Leu Leu Val Gly Ser Val
325 330 335Ile Leu Leu Ile Val Cys Met Thr Trp Arg Leu Ala Gly Pro
Gly Ser 340 345 350Glu Lys Tyr Ser Asp Asp Thr Lys Tyr Thr Asp Gly
Leu Pro Ala Ala 355 360 365Asp Leu Ile Pro Pro Pro Leu Lys Pro Arg
Lys Val Trp Ile Ile Tyr 370 375 380Ser Ala Asp His Pro Leu Tyr Val
Asp Val Val Leu Lys Phe Ala Gln385 390 395 400Phe Leu Leu Thr Ala
Cys Gly Thr Glu Val Ala Leu Asp Leu Leu Glu 405 410 415Glu Gln Ala
Ile Ser Glu Ala Gly Val Met Thr Trp Val Gly Arg Gln 420 425 430Lys
Gln Glu Met Val Glu Ser Asn Ser Lys Ile Ile Val Leu Cys Ser 435 440
445Arg Gly Thr Arg Ala Lys Trp Gln Ala Leu Leu Gly Arg Gly Ala Pro
450 455 460Val Arg Leu Arg Cys Asp His Gly Lys Pro Val Gly Asp Leu
Phe Thr465 470 475 480Ala Ala Met Asn Met Ile Leu Pro Asp Phe Lys
Arg Pro Ala Cys Phe 485 490 495Gly Thr Tyr Val Val Cys Tyr Phe Ser
Glu Val Ser Cys Asp Gly Asp 500 505 510Val Pro Asp Leu Phe Gly Ala
Ala Pro Arg Tyr Pro Leu Met Asp Arg 515 520 525Phe Glu Glu Val Tyr
Phe Arg Ile Gln Asp Leu Glu Met Phe Gln Pro 530 535 540Gly Arg Met
His Arg Val Gly Glu Leu Ser Gly Asp Asn Tyr Leu Arg545 550 555
560Ser Pro Gly Gly Arg Gln Leu Arg Ala Ala Leu Asp Arg Phe Arg Asp
565 570 575Trp Gln Val Arg Cys Pro Asp Trp Phe Glu Cys Glu Asn Leu
Tyr Ser 580 585 590Ala Asp Asp Gln Asp Ala Pro Ser Leu Asp Glu Glu
Val Phe Glu Glu 595 600 605Pro Leu Leu Pro Pro Gly Thr Gly Ile Val
Lys Arg Ala Pro Leu Val 610 615 620Arg Glu Pro Gly Ser Gln Ala Cys
Leu Ala Ile Asp Pro Leu Val Gly625 630 635 640Glu Glu Gly Gly Ala
Ala Val Ala Lys Leu Glu Pro His Leu Gln Pro 645 650 655Arg Gly Gln
Pro Ala Pro Gln Pro Leu His Thr Leu Val Leu Ala Ala 660 665 670Glu
Glu Gly Ala Leu Val Ala Ala Val Glu Pro Gly Pro Leu Ala Asp 675 680
685Gly Ala Ala Val Arg Leu Ala Leu Ala Gly Glu Gly Glu Ala Cys Pro
690 695 700Leu Leu Gly Ser Pro Gly Ala Gly Arg Asn Ser Val Leu Phe
Leu Pro705 710 715 720Val Asp Pro Glu Asp Ser Pro Leu Gly Ser Ser
Thr Pro Met Ala Ser 725 730 735Pro Asp Leu Leu Pro Glu Asp Val Arg
Glu His Leu Glu Gly Leu Met 740 745 750Leu Ser Leu Phe Glu Gln Ser
Leu Ser Cys Gln Ala Gln Gly Gly Cys 755 760 765Ser Arg Pro Ala Met
Val Leu Thr Asp Pro His Thr Pro Tyr Glu Glu 770 775 780Glu Gln Arg
Gln Ser Val Gln Ser Asp Gln Gly Tyr Ile Ser Arg Ser785 790 795
800Ser Pro Gln Pro Pro Glu Gly Leu Thr Glu Met Glu Glu Glu Glu Glu
805 810 815Glu Glu Gln Asp Pro Gly Lys Pro Ala Leu Pro Leu Ser Pro
Glu Asp 820 825 830Leu Glu Ser Leu Arg Ser Leu Gln Arg Gln Leu Leu
Phe Arg Gln Leu 835 840 845Gln Lys Asn Ser Gly Trp Asp Thr Met Gly
Ser Glu Ser Glu Gly Pro 850 855 860Ser Ala865431344PRTArtificial
SequenceDescription of Artificial Sequence Synthetic construct
431Met Gly Ala Ala Arg Ser Pro Pro Ser Ala Val Pro Gly Pro Leu Leu1
5 10 15Gly Leu Leu Leu Leu Leu Leu Gly Val Leu Ala Pro Gly Gly Ala
Ser 20 25 30Leu Arg Leu Leu Asp His Arg Ala Leu Val Cys Ser Gln Pro
Gly Leu 35 40 45Asn Cys Thr Val Lys Asn Ser Thr Cys Leu Asp Asp Ser
Trp Ile His 50 55 60Pro Arg Asn Leu Thr Pro Ser Ser Pro Lys Asp Leu
Gln Ile Gln Leu65 70 75 80His Phe Ala His Thr Gln Gln Gly Asp Leu
Phe Pro Val Ala His Ile 85 90 95Glu Trp Thr Leu Gln Thr Asp Ala Ser
Ile Leu Tyr Leu Glu Gly Ala 100 105 110Glu Leu Ser Val Leu Gln Leu
Asn Thr Asn Glu Arg Leu Cys Val Arg 115 120 125Phe Glu Phe Leu Ser
Lys Leu Arg His His His Arg Arg Trp Arg Phe 130 135 140Thr Phe Ser
His Phe Val Val Asp Pro Asp Gln Glu Tyr Glu Val Thr145 150 155
160Val His His Leu Pro Lys Pro Ile Pro Asp Gly Asp Pro Asn His Gln
165 170 175Ser Lys Asn Phe Leu Val Pro Asp Cys Glu His Ala Arg Met
Lys Val 180 185 190Thr Thr Pro Cys Met Ser Ser Gly Ser Leu Trp Asp
Pro Asn Ile Thr 195 200 205Val Glu Thr Leu Glu Ala His Gln Leu Arg
Val Ser Phe Thr Leu Trp 210 215 220Asn Glu Ser Thr His Tyr Gln Ile
Leu Leu Thr Ser Phe Pro His Met225 230 235 240Glu Asn His Ser Cys
Phe Glu His Met His His Ile Pro Ala Pro Arg 245 250 255Pro Glu Glu
Phe His Gln Arg Ser Asn Val Thr Leu Thr Leu Arg Asn 260 265 270Leu
Lys Gly Cys Cys Arg His Gln Val Gln Ile Gln Pro Phe Phe Ser 275 280
285Ser Cys Leu Asn Asp Cys Leu Arg His Ser Ala Thr Val Ser Cys Pro
290 295 300Glu Met Pro Asp Thr Pro Glu Pro Ile Pro Asp Tyr Met Pro
Leu Trp305 310 315 320Glu Pro Arg Ser Gly Ser Ser Asp Tyr Lys Asp
Asp Asp Asp Lys Gly 325 330 335Ser Ser His His His His His His
340432322PRTMus musculus 432Met Ala Ile Arg Arg Cys Trp Pro Arg Val
Val Pro Gly Pro Ala Leu1 5 10 15Gly Trp Leu Leu Leu Leu Leu Asn Val
Leu Ala Pro Gly Arg Ala Ser 20 25 30Pro Arg Leu Leu Asp Phe Pro Ala
Pro Val Cys Ala Gln Glu Gly Leu 35 40 45Ser Cys Arg Val Lys Asn Ser
Thr Cys Leu Asp Asp Ser Trp Ile His 50 55 60Pro Lys Asn Leu Thr Pro
Ser Ser Pro Lys Asn Ile Tyr Ile Asn Leu65 70 75 80Ser Val Ser Ser
Thr Gln His Gly Glu Leu Val Pro Val Leu His Val 85 90 95Glu Trp Thr
Leu Gln Thr Asp Ala Ser Ile Leu Tyr Leu Glu Gly Ala 100 105 110Glu
Leu Ser Val Leu Gln Leu Asn Thr Asn Glu Arg Leu Cys Val Lys 115 120
125Phe Gln Phe Leu Ser Met Leu Gln His His Arg Lys Arg Trp Arg Phe
130 135 140Ser Phe Ser His Phe Val Val Asp Pro Gly Gln Glu Tyr Glu
Val Thr145 150 155 160Val His His Leu Pro Lys Pro Ile Pro Asp Gly
Asp Pro Asn His Lys 165 170 175Ser Lys Ile Ile Phe Val Pro Asp Cys
Glu Asp Ser Lys Met Lys Met 180 185 190Thr Thr Ser Cys Val Ser Ser
Gly Ser Leu Trp Asp Pro Asn Ile Thr 195 200 205Val Glu Thr Leu Asp
Thr Gln His Leu Arg Val Asp Phe Thr Leu Trp 210 215 220Asn Glu Ser
Thr Pro Tyr Gln Val Leu Leu Glu Ser Phe Ser Asp Ser225 230 235
240Glu Asn His Ser Cys Phe Asp Val Val Lys Gln Ile Phe Ala Pro Arg
245 250 255Gln Glu Glu Phe His Gln Arg Ala Asn Val Thr Phe Thr Leu
Ser Lys 260 265 270Phe His Trp Cys Cys His His His Val Gln Val Gln
Pro Phe Phe Ser 275 280 285Ser Cys Leu Asn Asp Cys Leu Arg His Ala
Val Thr Val Pro Cys Pro 290 295 300Val Ile Ser Asn Thr Thr Val Pro
Lys Pro Val Ala Asp Tyr Ile Pro305 310 315 320Leu
Trp433344PRTArtificial SequenceDescription of Artificial Sequence
Synthetic construct 433Met Gly Ala Ala Arg Ser Pro Pro Ser Ala Val
Pro Gly Pro Leu Leu1 5 10 15Gly Leu Leu Leu Leu Leu Leu Gly Val Leu
Ala Pro Gly Gly Ala Ser 20 25 30Leu Arg Leu Leu Asp Phe Pro Ala Pro
Val Cys Ala Gln Glu Gly Leu 35 40 45Ser Cys Arg Val Lys Asn Ser Thr
Cys Leu Asp Asp Ser Trp Ile His 50 55 60Pro Arg Asn Leu Thr Pro Ser
Ser Pro Lys Asp Leu Gln Ile Gln Leu65 70 75 80His Phe Ala His Thr
Gln Gln Gly Asp Leu Phe Pro Val Ala His Ile 85 90 95Glu Trp Thr Leu
Gln Thr Asp Ala Ser Ile Leu Tyr Leu Glu Gly Ala 100 105 110Glu Leu
Ser Val Leu Gln Leu Asn Thr Asn Glu Arg Leu Cys Val Arg 115 120
125Phe Glu Phe Leu Ser Lys Leu Arg His His His Arg Arg Trp Arg Phe
130 135 140Thr Phe Ser His Phe Val Val Asp Pro Asp Gln Glu Tyr Glu
Val Thr145 150 155 160Val His His Leu Pro Lys Pro Ile Pro Asp Gly
Asp Pro Asn His Gln 165 170 175Ser Lys Asn Phe Leu Val Pro Asp Cys
Glu His Ala Arg Met Lys Val 180 185 190Thr Thr Pro Cys Met Ser Ser
Gly Ser Leu Trp Asp Pro Asn Ile Thr 195 200 205Val Glu Thr Leu Glu
Ala His Gln Leu Arg Val Ser Phe Thr Leu Trp 210 215 220Asn Glu Ser
Thr His Tyr Gln Ile Leu Leu Thr Ser Phe Pro His Met225 230 235
240Glu Asn His Ser Cys Phe Glu His Met His His Ile Pro Ala Pro Arg
245 250 255Pro Glu Glu Phe His Gln Arg Ser Asn Val Thr Leu Thr Leu
Arg Asn 260 265 270Leu Lys Gly Cys Cys Arg His Gln Val Gln Ile Gln
Pro Phe Phe Ser 275 280 285Ser Cys Leu Asn Asp Cys Leu Arg His Ser
Ala Thr Val Ser Cys Pro 290 295 300Glu Met Pro Asp Thr Pro Glu Pro
Ile Pro Asp Tyr Met Pro Leu Trp305 310 315 320Glu Pro Arg Ser Gly
Ser Ser Asp Tyr Lys Asp Asp Asp Asp Lys Gly 325 330 335Ser Ser His
His His His His His 340434344PRTArtificial SequenceDescription of
Artificial Sequence Synthetic construct 434Met Gly Ala Ala Arg Ser
Pro Pro Ser Ala Val Pro Gly Pro Leu Leu1 5 10 15Gly Leu Leu Leu Leu
Leu Leu Gly Val Leu Ala Pro Gly Gly Ala Ser 20 25 30Leu Arg Leu Leu
Asp His Arg Ala Leu Val Cys Ser Gln Pro Gly Leu 35 40 45Asn Cys Thr
Val Lys Asn Ser Thr Cys Leu Asp Asp Ser Trp Ile His 50 55 60Pro Arg
Asn Leu Thr Pro Ser Ser Pro Lys Asn Ile Tyr Ile Asn Leu65 70 75
80Ser Val Ser Ser Thr Gln His Gly Glu Leu Val Pro Val Leu His Val
85 90 95Glu Trp Thr Leu Gln Thr Asp Ala Ser Ile Leu Tyr Leu Glu Gly
Ala 100 105 110Glu Leu Ser Val Leu Gln Leu Asn Thr Asn Glu Arg Leu
Cys Val Arg 115 120 125Phe Glu Phe Leu Ser Lys Leu Arg His His His
Arg Arg Trp Arg Phe 130 135 140Thr Phe Ser His Phe Val Val Asp Pro
Asp Gln Glu Tyr Glu Val Thr145 150 155 160Val His His Leu Pro Lys
Pro Ile Pro Asp Gly Asp Pro Asn His Gln 165 170 175Ser Lys Asn Phe
Leu Val Pro Asp Cys Glu His Ala Arg Met Lys Val 180 185 190Thr Thr
Pro Cys Met Ser Ser Gly Ser Leu Trp Asp Pro Asn Ile Thr 195 200
205Val Glu Thr Leu Glu Ala His Gln Leu Arg Val Ser Phe Thr Leu Trp
210 215 220Asn Glu Ser Thr His Tyr Gln Ile Leu Leu Thr Ser Phe Pro
His Met225 230 235 240Glu Asn His Ser Cys Phe Glu His Met His His
Ile Pro Ala Pro Arg 245 250 255Pro Glu Glu Phe His Gln Arg Ser Asn
Val Thr Leu Thr Leu Arg Asn 260 265 270Leu Lys Gly Cys Cys Arg His
Gln Val Gln Ile Gln Pro Phe Phe Ser 275 280 285Ser Cys Leu Asn Asp
Cys Leu Arg His Ser Ala Thr Val Ser Cys Pro 290 295 300Glu Met Pro
Asp Thr Pro Glu Pro Ile Pro Asp Tyr Met Pro Leu Trp305 310 315
320Glu Pro Arg Ser Gly Ser Ser Asp Tyr Lys Asp Asp Asp Asp Lys Gly
325 330 335Ser Ser His His His His His His 340435344PRTArtificial
SequenceDescription of Artificial Sequence Synthetic construct
435Met Gly Ala Ala Arg Ser Pro Pro Ser Ala Val Pro Gly Pro Leu Leu1
5 10 15Gly Leu Leu Leu Leu Leu Leu Gly Val Leu Ala Pro Gly Gly Ala
Ser 20 25 30Leu Arg Leu Leu Asp His Arg Ala Leu Val Cys Ser Gln Pro
Gly Leu 35 40 45Asn Cys Thr Val Lys Asn Ser Thr Cys Leu Asp Asp Ser
Trp Ile His 50 55 60Pro Arg Asn Leu Thr Pro Ser Ser Pro Lys Asp Leu
Gln Ile Gln Leu65 70 75 80His Phe Ala His Thr Gln Gln Gly Asp Leu
Phe Pro Val Ala His Ile 85 90 95Glu Trp Thr Leu Gln Thr Asp Ala Ser
Ile Leu Tyr Leu Glu Gly Ala 100 105 110Glu Leu Ser Val Leu Gln Leu
Asn Thr Asn Glu Arg Leu Cys Val Lys 115 120 125Phe Gln Phe Leu Ser
Met Leu Gln His His Arg Lys Arg Trp Arg Phe 130 135 140Ser Phe Ser
His Phe Val Val Asp Pro Gly Gln Glu Tyr Glu Val Thr145 150 155
160Val His His Leu Pro Lys Pro Ile Pro Asp Gly Asp Pro Asn His Gln
165 170 175Ser Lys Asn Phe Leu Val Pro Asp Cys Glu His Ala Arg Met
Lys Val 180 185 190Thr Thr Pro Cys Met Ser Ser Gly Ser Leu Trp Asp
Pro Asn Ile Thr 195 200 205Val Glu Thr Leu Glu Ala His Gln Leu Arg
Val Ser Phe Thr Leu Trp 210 215 220Asn Glu Ser Thr His Tyr Gln Ile
Leu Leu Thr Ser Phe Pro His Met225 230 235 240Glu Asn His Ser Cys
Phe Glu His Met His His Ile Pro Ala Pro Arg 245 250 255Pro Glu Glu
Phe His Gln Arg Ser Asn Val Thr Leu Thr Leu Arg Asn 260 265 270Leu
Lys Gly Cys Cys Arg His Gln Val Gln Ile Gln Pro Phe Phe Ser 275 280
285Ser Cys Leu Asn Asp Cys Leu Arg His Ser Ala Thr Val Ser Cys Pro
290 295 300Glu Met Pro Asp Thr Pro Glu Pro Ile Pro Asp Tyr Met Pro
Leu Trp305 310 315 320Glu Pro Arg Ser Gly Ser Ser Asp Tyr Lys Asp
Asp Asp Asp Lys Gly 325 330 335Ser Ser His His His His His His
340436344PRTArtificial SequenceDescription of Artificial Sequence
Synthetic construct 436Met Gly Ala Ala Arg Ser Pro Pro Ser Ala Val
Pro Gly Pro Leu Leu1 5 10 15Gly Leu Leu Leu Leu Leu Leu Gly Val Leu
Ala Pro Gly Gly Ala Ser 20 25 30Leu Arg Leu Leu Asp His Arg Ala Leu
Val Cys Ser Gln Pro Gly Leu 35 40 45Asn Cys Thr Val Lys Asn Ser Thr
Cys Leu Asp Asp Ser Trp Ile His 50 55 60Pro Arg Asn Leu Thr Pro Ser
Ser Pro Lys Asp Leu Gln Ile Gln Leu65 70 75 80His Phe Ala His Thr
Gln Gln Gly Asp Leu Phe Pro Val Ala His Ile 85 90 95Glu Trp Thr Leu
Gln Thr Asp Ala Ser Ile Leu Tyr Leu Glu Gly Ala 100 105 110Glu Leu
Ser Val Leu Gln Leu Asn Thr Asn Glu Arg Leu Cys Val Arg 115 120
125Phe Glu Phe Leu Ser Lys Leu Arg His His His Arg Arg Trp Arg Phe
130 135 140Thr Phe Ser His Phe Val Val Asp Pro Asp Gln Glu Tyr Glu
Val Thr145 150 155 160Val His His Leu Pro Lys Pro Ile Pro Asp Gly
Asp Pro Asn His Lys 165 170 175Ser Lys Ile Ile Phe Val Pro Asp Cys
Glu Asp Ser Lys Met Lys Met 180 185 190Thr Thr Ser Cys Val Ser Ser
Gly Ser Leu Trp Asp Pro Asn Ile Thr 195 200 205Val Glu Thr Leu Glu
Ala His Gln Leu Arg Val Ser Phe Thr Leu Trp 210 215 220Asn Glu Ser
Thr His Tyr Gln Ile Leu Leu Thr Ser Phe Pro His Met225 230 235
240Glu Asn His Ser Cys Phe Glu His Met His His Ile Pro Ala Pro Arg
245 250 255Pro Glu Glu Phe His Gln Arg Ser Asn Val Thr Leu Thr Leu
Arg Asn 260 265 270Leu Lys Gly Cys Cys Arg His Gln Val Gln Ile Gln
Pro Phe Phe Ser 275 280 285Ser Cys Leu Asn Asp Cys Leu Arg His Ser
Ala Thr Val Ser Cys Pro 290 295 300Glu Met Pro Asp Thr Pro Glu Pro
Ile Pro Asp Tyr Met Pro Leu Trp305 310 315 320Glu Pro Arg Ser Gly
Ser Ser Asp Tyr Lys Asp Asp Asp Asp Lys Gly 325 330 335Ser Ser His
His His His His His 340437344PRTArtificial SequenceDescription of
Artificial Sequence Synthetic construct 437Met Gly Ala Ala Arg Ser
Pro Pro Ser Ala Val Pro Gly Pro Leu Leu1 5 10 15Gly Leu Leu Leu Leu
Leu Leu Gly Val Leu Ala Pro Gly Gly Ala Ser 20 25 30Leu Arg Leu Leu
Asp His Arg Ala Leu Val Cys Ser Gln Pro Gly Leu 35 40 45Asn Cys Thr
Val Lys Asn Ser Thr Cys Leu Asp Asp Ser Trp Ile His 50 55 60Pro Arg
Asn Leu Thr Pro Ser Ser Pro Lys Asp Leu Gln Ile Gln Leu65 70 75
80His Phe Ala His Thr Gln Gln Gly Asp Leu Phe Pro Val Ala His Ile
85 90 95Glu Trp Thr Leu Gln Thr Asp Ala Ser Ile Leu Tyr Leu Glu Gly
Ala 100 105 110Glu Leu Ser Val Leu Gln Leu Asn Thr Asn Glu Arg Leu
Cys Val Arg 115 120 125Phe Glu Phe Leu Ser Lys Leu Arg His His His
Arg Arg Trp Arg Phe 130 135 140Thr Phe Ser His Phe Val Val Asp Pro
Asp Gln Glu Tyr Glu Val Thr145 150 155 160Val His His Leu Pro Lys
Pro Ile Pro Asp Gly Asp Pro Asn His Gln 165 170 175Ser Lys Asn Phe
Leu Val Pro Asp Cys Glu His Ala Arg Met Lys Val 180 185 190Thr Thr
Pro Cys Met Ser Ser Gly Ser Leu Trp Asp Pro Asn Ile Thr 195 200
205Val Glu Thr Leu Asp Thr Gln His Leu Arg Val Asp Phe Thr Leu Trp
210 215 220Asn Glu Ser Thr His Tyr Gln Ile Leu Leu Thr Ser Phe Pro
His Met225 230 235 240Glu Asn His Ser Cys Phe Glu His Met His His
Ile Pro Ala Pro Arg 245 250 255Pro Glu Glu Phe His Gln Arg Ser Asn
Val Thr Leu Thr Leu Arg Asn 260 265 270Leu Lys Gly Cys Cys Arg His
Gln Val Gln Ile Gln Pro Phe Phe Ser 275 280 285Ser Cys Leu Asn Asp
Cys Leu Arg His Ser Ala Thr Val Ser Cys Pro 290 295 300Glu Met Pro
Asp Thr Pro Glu Pro Ile Pro Asp Tyr Met Pro Leu Trp305 310 315
320Glu Pro Arg Ser Gly Ser Ser Asp Tyr Lys Asp Asp Asp Asp Lys Gly
325 330 335Ser Ser His His His His His His 340438346PRTArtificial
SequenceDescription of Artificial Sequence Synthetic construct
438Met Gly Ala Ala Arg Ser Pro Pro Ser Ala Val Pro Gly Pro Leu Leu1
5 10 15Gly Leu Leu Leu Leu Leu Leu Gly Val Leu Ala Pro Gly Gly Ala
Ser 20 25 30 Leu Arg Leu Leu Asp His Arg Ala Leu Val Cys Ser Gln
Pro Gly Leu 35 40 45Asn Cys Thr Val Lys Asn Ser Thr Cys Leu Asp Asp
Ser Trp Ile His 50 55 60Pro Arg Asn Leu Thr Pro Ser Ser Pro Lys Asp
Leu Gln Ile Gln Leu65 70 75 80His Phe Ala His Thr Gln Gln Gly Asp
Leu Phe Pro Val Ala His Ile 85 90 95Glu Trp Thr Leu Gln Thr Asp Ala
Ser Ile Leu Tyr Leu Glu Gly Ala 100 105 110Glu Leu Ser Val Leu Gln
Leu Asn Thr Asn Glu Arg Leu Cys Val Arg 115 120 125Phe Glu Phe Leu
Ser Lys Leu Arg His His His Arg Arg Trp Arg Phe 130 135 140Thr Phe
Ser His Phe Val Val Asp Pro Asp Gln Glu Tyr Glu Val Thr145 150 155
160Val His His Leu Pro Lys Pro Ile Pro Asp Gly Asp Pro Asn His Gln
165 170 175Ser Lys Asn Phe Leu Val Pro Asp Cys Glu His Ala Arg Met
Lys Val 180 185 190Thr Thr Pro Cys Met Ser Ser Gly Ser Leu Trp Asp
Pro Asn Ile Thr 195 200 205Val Glu Thr Leu Glu Ala His Gln Leu Arg
Val Ser Phe Thr Leu Trp 210 215 220Asn Glu Ser Thr Pro Tyr Gln Val
Leu Leu Glu Ser Phe Ser Asp Ser225 230 235 240Glu Asn His Ser Cys
Phe Asp Val Val Lys Gln Ile Phe Ala Pro Arg 245 250 255Gln Glu Glu
Phe His Gln Arg Ala Asn Val Thr Phe Thr Leu Ser Lys 260 265 270Phe
His Trp Cys Cys His His His Val Gln Val Gln Pro Phe Phe Ser 275 280
285Ser Cys Leu Asn Asp Cys Leu Arg His Ala Val Thr Val Pro Cys Pro
290 295 300Val Ile Ser Asn Thr Thr Val Pro Lys Pro Val Ala Asp Tyr
Ile Pro305 310 315 320Leu Trp Glu Pro Arg Ser Gly Ser Ser Asp Tyr
Lys Asp Asp Asp Asp 325 330 335Lys Gly Ser Ser His His His His His
His 340 345439344PRTArtificial SequenceDescription of Artificial
Sequence Synthetic construct 439Met Gly Ala Ala Arg Ser Pro Pro Ser
Ala Val Pro Gly Pro Leu Leu1 5 10 15Gly Leu Leu Leu Leu Leu Leu Gly
Val Leu Ala Pro Gly Gly Ala Ser 20 25 30Leu Arg Leu Leu Asp Phe Pro
Ala Pro Val Cys Ala Gln Glu Gly Leu 35 40 45Ser Cys Arg Val Lys Asn
Ser Thr Cys Leu Asp Asp Ser Trp Ile His 50 55 60Pro Arg Asn Leu Thr
Pro Ser Ser Pro Lys Asp Leu Gln Ile Gln Leu65 70 75 80His Phe Ala
His Thr Gln Gln Gly Asp Leu Phe Pro Val Ala His Ile 85 90 95Glu Trp
Thr Leu Gln Thr Asp Ala Ser Ile Leu Tyr Leu Glu Gly Ala 100 105
110Glu Leu Ser Val Leu Gln Leu Asn Thr Asn Glu Arg Leu Cys Val Arg
115 120 125Phe Glu Phe Leu Ser Lys Leu Arg His His His Arg Arg Trp
Arg Phe 130 135 140Thr Phe Ser His Phe Val Val Asp Pro Asp Gln Glu
Tyr Glu Val Thr145 150 155 160Val His His Leu Pro Lys Pro Ile Pro
Asp Gly Asp Pro Asn His Gln 165 170 175Ser Lys Asn Phe Leu Val Pro
Asp Cys Glu His Ala Arg Met Lys Val 180 185 190Thr Thr Pro Cys Met
Ser Ser Gly Ser Leu Trp Asp Pro Asn Ile Thr 195 200 205Val Glu Thr
Leu Asp Thr Gln His Leu Arg Val Asp Phe Thr Leu Trp 210 215 220Asn
Glu Ser Thr His Tyr Gln Ile Leu Leu Thr Ser Phe Pro His Met225 230
235 240Glu Asn His Ser Cys Phe Glu His Met His His Ile Pro Ala Pro
Arg 245 250 255Pro Glu Glu Phe His Gln Arg Ser Asn Val Thr Leu Thr
Leu Arg Asn 260 265 270Leu Lys Gly Cys Cys Arg His Gln Val Gln Ile
Gln Pro Phe Phe Ser 275 280 285Ser Cys Leu Asn Asp Cys Leu Arg His
Ser Ala Thr Val Ser Cys Pro 290 295 300Glu Met Pro Asp Thr Pro Glu
Pro Ile Pro Asp Tyr Met Pro Leu Trp305 310 315 320Glu Pro Arg Ser
Gly Ser Ser Asp Tyr Lys Asp Asp
Asp Asp Lys Gly 325 330 335Ser Ser His His His His His His
340440344PRTArtificial SequenceDescription of Artificial Sequence
Synthetic construct 440Met Gly Ala Ala Arg Ser Pro Pro Ser Ala Val
Pro Gly Pro Leu Leu1 5 10 15Gly Leu Leu Leu Leu Leu Leu Gly Val Leu
Ala Pro Gly Gly Ala Ser 20 25 30Leu Arg Leu Leu Asp His Arg Ala Leu
Val Cys Ser Gln Pro Gly Leu 35 40 45Asn Cys Thr Val Lys Asn Ser Thr
Cys Leu Asp Asp Ser Trp Ile His 50 55 60Pro Arg Asn Leu Thr Pro Ser
Ser Pro Lys Asn Ile Tyr Ile Asn Leu65 70 75 80Ser Val Ser Ser Thr
Gln His Gly Glu Leu Val Pro Val Leu His Val 85 90 95Glu Trp Thr Leu
Gln Thr Asp Ala Ser Ile Leu Tyr Leu Glu Gly Ala 100 105 110Glu Leu
Ser Val Leu Gln Leu Asn Thr Asn Glu Arg Leu Cys Val Arg 115 120
125Phe Glu Phe Leu Ser Lys Leu Arg His His His Arg Arg Trp Arg Phe
130 135 140Thr Phe Ser His Phe Val Val Asp Pro Asp Gln Glu Tyr Glu
Val Thr145 150 155 160Val His His Leu Pro Lys Pro Ile Pro Asp Gly
Asp Pro Asn His Gln 165 170 175Ser Lys Asn Phe Leu Val Pro Asp Cys
Glu His Ala Arg Met Lys Val 180 185 190Thr Thr Pro Cys Met Ser Ser
Gly Ser Leu Trp Asp Pro Asn Ile Thr 195 200 205Val Glu Thr Leu Asp
Thr Gln His Leu Arg Val Asp Phe Thr Leu Trp 210 215 220Asn Glu Ser
Thr His Tyr Gln Ile Leu Leu Thr Ser Phe Pro His Met225 230 235
240Glu Asn His Ser Cys Phe Glu His Met His His Ile Pro Ala Pro Arg
245 250 255Pro Glu Glu Phe His Gln Arg Ser Asn Val Thr Leu Thr Leu
Arg Asn 260 265 270Leu Lys Gly Cys Cys Arg His Gln Val Gln Ile Gln
Pro Phe Phe Ser 275 280 285Ser Cys Leu Asn Asp Cys Leu Arg His Ser
Ala Thr Val Ser Cys Pro 290 295 300Glu Met Pro Asp Thr Pro Glu Pro
Ile Pro Asp Tyr Met Pro Leu Trp305 310 315 320Glu Pro Arg Ser Gly
Ser Ser Asp Tyr Lys Asp Asp Asp Asp Lys Gly 325 330 335Ser Ser His
His His His His His 340441344PRTArtificial SequenceDescription of
Artificial Sequence Synthetic construct 441Met Gly Ala Ala Arg Ser
Pro Pro Ser Ala Val Pro Gly Pro Leu Leu1 5 10 15Gly Leu Leu Leu Leu
Leu Leu Gly Val Leu Ala Pro Gly Gly Ala Ser 20 25 30Leu Arg Leu Leu
Asp His Arg Ala Leu Val Cys Ser Gln Pro Gly Leu 35 40 45Asn Cys Thr
Val Lys Asn Ser Thr Cys Leu Asp Asp Ser Trp Ile His 50 55 60Pro Arg
Asn Leu Thr Pro Ser Ser Pro Lys Asp Leu Gln Ile Gln Leu65 70 75
80His Phe Ala His Thr Gln Gln Gly Asp Leu Phe Pro Val Ala His Ile
85 90 95Glu Trp Thr Leu Gln Thr Asp Ala Ser Ile Leu Tyr Leu Glu Gly
Ala 100 105 110Glu Leu Ser Val Leu Gln Leu Asn Thr Asn Glu Arg Leu
Cys Val Lys 115 120 125Phe Gln Phe Leu Ser Met Leu Gln His His Arg
Lys Arg Trp Arg Phe 130 135 140Ser Phe Ser His Phe Val Val Asp Pro
Gly Gln Glu Tyr Glu Val Thr145 150 155 160Val His His Leu Pro Lys
Pro Ile Pro Asp Gly Asp Pro Asn His Gln 165 170 175Ser Lys Asn Phe
Leu Val Pro Asp Cys Glu His Ala Arg Met Lys Val 180 185 190Thr Thr
Pro Cys Met Ser Ser Gly Ser Leu Trp Asp Pro Asn Ile Thr 195 200
205Val Glu Thr Leu Asp Thr Gln His Leu Arg Val Asp Phe Thr Leu Trp
210 215 220Asn Glu Ser Thr His Tyr Gln Ile Leu Leu Thr Ser Phe Pro
His Met225 230 235 240Glu Asn His Ser Cys Phe Glu His Met His His
Ile Pro Ala Pro Arg 245 250 255Pro Glu Glu Phe His Gln Arg Ser Asn
Val Thr Leu Thr Leu Arg Asn 260 265 270Leu Lys Gly Cys Cys Arg His
Gln Val Gln Ile Gln Pro Phe Phe Ser 275 280 285Ser Cys Leu Asn Asp
Cys Leu Arg His Ser Ala Thr Val Ser Cys Pro 290 295 300Glu Met Pro
Asp Thr Pro Glu Pro Ile Pro Asp Tyr Met Pro Leu Trp305 310 315
320Glu Pro Arg Ser Gly Ser Ser Asp Tyr Lys Asp Asp Asp Asp Lys Gly
325 330 335Ser Ser His His His His His His 340442344PRTArtificial
SequenceDescription of Artificial Sequence Synthetic construct
442Met Gly Ala Ala Arg Ser Pro Pro Ser Ala Val Pro Gly Pro Leu Leu1
5 10 15Gly Leu Leu Leu Leu Leu Leu Gly Val Leu Ala Pro Gly Gly Ala
Ser 20 25 30Leu Arg Leu Leu Asp His Arg Ala Leu Val Cys Ser Gln Pro
Gly Leu 35 40 45Asn Cys Thr Val Lys Asn Ser Thr Cys Leu Asp Asp Ser
Trp Ile His 50 55 60Pro Arg Asn Leu Thr Pro Ser Ser Pro Lys Asp Leu
Gln Ile Gln Leu65 70 75 80His Phe Ala His Thr Gln Gln Gly Asp Leu
Phe Pro Val Ala His Ile 85 90 95Glu Trp Thr Leu Gln Thr Asp Ala Ser
Ile Leu Tyr Leu Glu Gly Ala 100 105 110Glu Leu Ser Val Leu Gln Leu
Asn Thr Asn Glu Arg Leu Cys Val Arg 115 120 125Phe Glu Phe Leu Ser
Lys Leu Arg His His His Arg Arg Trp Arg Phe 130 135 140Thr Phe Ser
His Phe Val Val Asp Pro Asp Gln Glu Tyr Glu Val Thr145 150 155
160Val His His Leu Pro Lys Pro Ile Pro Asp Gly Asp Pro Asn His Lys
165 170 175Ser Lys Ile Ile Phe Val Pro Asp Cys Glu Asp Ser Lys Met
Lys Met 180 185 190Thr Thr Ser Cys Val Ser Ser Gly Ser Leu Trp Asp
Pro Asn Ile Thr 195 200 205Val Glu Thr Leu Asp Thr Gln His Leu Arg
Val Asp Phe Thr Leu Trp 210 215 220Asn Glu Ser Thr His Tyr Gln Ile
Leu Leu Thr Ser Phe Pro His Met225 230 235 240Glu Asn His Ser Cys
Phe Glu His Met His His Ile Pro Ala Pro Arg 245 250 255Pro Glu Glu
Phe His Gln Arg Ser Asn Val Thr Leu Thr Leu Arg Asn 260 265 270Leu
Lys Gly Cys Cys Arg His Gln Val Gln Ile Gln Pro Phe Phe Ser 275 280
285Ser Cys Leu Asn Asp Cys Leu Arg His Ser Ala Thr Val Ser Cys Pro
290 295 300Glu Met Pro Asp Thr Pro Glu Pro Ile Pro Asp Tyr Met Pro
Leu Trp305 310 315 320Glu Pro Arg Ser Gly Ser Ser Asp Tyr Lys Asp
Asp Asp Asp Lys Gly 325 330 335Ser Ser His His His His His His
340443346PRTArtificial SequenceDescription of Artificial Sequence
Synthetic construct 443Met Gly Ala Ala Arg Ser Pro Pro Ser Ala Val
Pro Gly Pro Leu Leu1 5 10 15Gly Leu Leu Leu Leu Leu Leu Gly Val Leu
Ala Pro Gly Gly Ala Ser 20 25 30Leu Arg Leu Leu Asp Phe Pro Ala Pro
Val Cys Ala Gln Glu Gly Leu 35 40 45Ser Cys Arg Val Lys Asn Ser Thr
Cys Leu Asp Asp Ser Trp Ile His 50 55 60Pro Arg Asn Leu Thr Pro Ser
Ser Pro Lys Asp Leu Gln Ile Gln Leu65 70 75 80His Phe Ala His Thr
Gln Gln Gly Asp Leu Phe Pro Val Ala His Ile 85 90 95Glu Trp Thr Leu
Gln Thr Asp Ala Ser Ile Leu Tyr Leu Glu Gly Ala 100 105 110Glu Leu
Ser Val Leu Gln Leu Asn Thr Asn Glu Arg Leu Cys Val Arg 115 120
125Phe Glu Phe Leu Ser Lys Leu Arg His His His Arg Arg Trp Arg Phe
130 135 140Thr Phe Ser His Phe Val Val Asp Pro Asp Gln Glu Tyr Glu
Val Thr145 150 155 160Val His His Leu Pro Lys Pro Ile Pro Asp Gly
Asp Pro Asn His Gln 165 170 175Ser Lys Asn Phe Leu Val Pro Asp Cys
Glu His Ala Arg Met Lys Val 180 185 190Thr Thr Pro Cys Met Ser Ser
Gly Ser Leu Trp Asp Pro Asn Ile Thr 195 200 205Val Glu Thr Leu Glu
Ala His Gln Leu Arg Val Ser Phe Thr Leu Trp 210 215 220Asn Glu Ser
Thr Pro Tyr Gln Val Leu Leu Glu Ser Phe Ser Asp Ser225 230 235
240Glu Asn His Ser Cys Phe Asp Val Val Lys Gln Ile Phe Ala Pro Arg
245 250 255Gln Glu Glu Phe His Gln Arg Ala Asn Val Thr Phe Thr Leu
Ser Lys 260 265 270Phe His Trp Cys Cys His His His Val Gln Val Gln
Pro Phe Phe Ser 275 280 285Ser Cys Leu Asn Asp Cys Leu Arg His Ala
Val Thr Val Pro Cys Pro 290 295 300Val Ile Ser Asn Thr Thr Val Pro
Lys Pro Val Ala Asp Tyr Ile Pro305 310 315 320Leu Trp Glu Pro Arg
Ser Gly Ser Ser Asp Tyr Lys Asp Asp Asp Asp 325 330 335Lys Gly Ser
Ser His His His His His His 340 345444346PRTArtificial
SequenceDescription of Artificial Sequence Synthetic construct
444Met Gly Ala Ala Arg Ser Pro Pro Ser Ala Val Pro Gly Pro Leu Leu1
5 10 15Gly Leu Leu Leu Leu Leu Leu Gly Val Leu Ala Pro Gly Gly Ala
Ser 20 25 30Leu Arg Leu Leu Asp His Arg Ala Leu Val Cys Ser Gln Pro
Gly Leu 35 40 45Asn Cys Thr Val Lys Asn Ser Thr Cys Leu Asp Asp Ser
Trp Ile His 50 55 60Pro Arg Asn Leu Thr Pro Ser Ser Pro Lys Asn Ile
Tyr Ile Asn Leu65 70 75 80Ser Val Ser Ser Thr Gln His Gly Glu Leu
Val Pro Val Leu His Val 85 90 95Glu Trp Thr Leu Gln Thr Asp Ala Ser
Ile Leu Tyr Leu Glu Gly Ala 100 105 110Glu Leu Ser Val Leu Gln Leu
Asn Thr Asn Glu Arg Leu Cys Val Arg 115 120 125Phe Glu Phe Leu Ser
Lys Leu Arg His His His Arg Arg Trp Arg Phe 130 135 140Thr Phe Ser
His Phe Val Val Asp Pro Asp Gln Glu Tyr Glu Val Thr145 150 155
160Val His His Leu Pro Lys Pro Ile Pro Asp Gly Asp Pro Asn His Gln
165 170 175Ser Lys Asn Phe Leu Val Pro Asp Cys Glu His Ala Arg Met
Lys Val 180 185 190Thr Thr Pro Cys Met Ser Ser Gly Ser Leu Trp Asp
Pro Asn Ile Thr 195 200 205Val Glu Thr Leu Glu Ala His Gln Leu Arg
Val Ser Phe Thr Leu Trp 210 215 220Asn Glu Ser Thr Pro Tyr Gln Val
Leu Leu Glu Ser Phe Ser Asp Ser225 230 235 240Glu Asn His Ser Cys
Phe Asp Val Val Lys Gln Ile Phe Ala Pro Arg 245 250 255Gln Glu Glu
Phe His Gln Arg Ala Asn Val Thr Phe Thr Leu Ser Lys 260 265 270Phe
His Trp Cys Cys His His His Val Gln Val Gln Pro Phe Phe Ser 275 280
285Ser Cys Leu Asn Asp Cys Leu Arg His Ala Val Thr Val Pro Cys Pro
290 295 300Val Ile Ser Asn Thr Thr Val Pro Lys Pro Val Ala Asp Tyr
Ile Pro305 310 315 320Leu Trp Glu Pro Arg Ser Gly Ser Ser Asp Tyr
Lys Asp Asp Asp Asp 325 330 335Lys Gly Ser Ser His His His His His
His 340 345445346PRTArtificial SequenceDescription of Artificial
Sequence Synthetic construct 445Met Gly Ala Ala Arg Ser Pro Pro Ser
Ala Val Pro Gly Pro Leu Leu1 5 10 15Gly Leu Leu Leu Leu Leu Leu Gly
Val Leu Ala Pro Gly Gly Ala Ser 20 25 30Leu Arg Leu Leu Asp His Arg
Ala Leu Val Cys Ser Gln Pro Gly Leu 35 40 45Asn Cys Thr Val Lys Asn
Ser Thr Cys Leu Asp Asp Ser Trp Ile His 50 55 60Pro Arg Asn Leu Thr
Pro Ser Ser Pro Lys Asp Leu Gln Ile Gln Leu65 70 75 80His Phe Ala
His Thr Gln Gln Gly Asp Leu Phe Pro Val Ala His Ile 85 90 95Glu Trp
Thr Leu Gln Thr Asp Ala Ser Ile Leu Tyr Leu Glu Gly Ala 100 105
110Glu Leu Ser Val Leu Gln Leu Asn Thr Asn Glu Arg Leu Cys Val Lys
115 120 125Phe Gln Phe Leu Ser Met Leu Gln His His Arg Lys Arg Trp
Arg Phe 130 135 140Ser Phe Ser His Phe Val Val Asp Pro Gly Gln Glu
Tyr Glu Val Thr145 150 155 160Val His His Leu Pro Lys Pro Ile Pro
Asp Gly Asp Pro Asn His Gln 165 170 175Ser Lys Asn Phe Leu Val Pro
Asp Cys Glu His Ala Arg Met Lys Val 180 185 190Thr Thr Pro Cys Met
Ser Ser Gly Ser Leu Trp Asp Pro Asn Ile Thr 195 200 205Val Glu Thr
Leu Glu Ala His Gln Leu Arg Val Ser Phe Thr Leu Trp 210 215 220Asn
Glu Ser Thr Pro Tyr Gln Val Leu Leu Glu Ser Phe Ser Asp Ser225 230
235 240Glu Asn His Ser Cys Phe Asp Val Val Lys Gln Ile Phe Ala Pro
Arg 245 250 255Gln Glu Glu Phe His Gln Arg Ala Asn Val Thr Phe Thr
Leu Ser Lys 260 265 270Phe His Trp Cys Cys His His His Val Gln Val
Gln Pro Phe Phe Ser 275 280 285Ser Cys Leu Asn Asp Cys Leu Arg His
Ala Val Thr Val Pro Cys Pro 290 295 300Val Ile Ser Asn Thr Thr Val
Pro Lys Pro Val Ala Asp Tyr Ile Pro305 310 315 320Leu Trp Glu Pro
Arg Ser Gly Ser Ser Asp Tyr Lys Asp Asp Asp Asp 325 330 335Lys Gly
Ser Ser His His His His His His 340 345446346PRTArtificial
SequenceDescription of Artificial Sequence Synthetic construct
446Met Gly Ala Ala Arg Ser Pro Pro Ser Ala Val Pro Gly Pro Leu Leu1
5 10 15Gly Leu Leu Leu Leu Leu Leu Gly Val Leu Ala Pro Gly Gly Ala
Ser 20 25 30Leu Arg Leu Leu Asp His Arg Ala Leu Val Cys Ser Gln Pro
Gly Leu 35 40 45Asn Cys Thr Val Lys Asn Ser Thr Cys Leu Asp Asp Ser
Trp Ile His 50 55 60Pro Arg Asn Leu Thr Pro Ser Ser Pro Lys Asp Leu
Gln Ile Gln Leu65 70 75 80His Phe Ala His Thr Gln Gln Gly Asp Leu
Phe Pro Val Ala His Ile 85 90 95Glu Trp Thr Leu Gln Thr Asp Ala Ser
Ile Leu Tyr Leu Glu Gly Ala 100 105 110Glu Leu Ser Val Leu Gln Leu
Asn Thr Asn Glu Arg Leu Cys Val Arg 115 120 125Phe Glu Phe Leu Ser
Lys Leu Arg His His His Arg Arg Trp Arg Phe 130 135 140Thr Phe Ser
His Phe Val Val Asp Pro Asp Gln Glu Tyr Glu Val Thr145 150 155
160Val His His Leu Pro Lys Pro Ile Pro Asp Gly Asp Pro Asn His Lys
165 170 175Ser Lys Ile Ile Phe Val Pro Asp Cys Glu Asp Ser Lys Met
Lys Met 180 185 190Thr Thr Ser Cys Val Ser Ser Gly Ser Leu Trp Asp
Pro Asn Ile Thr 195 200 205Val Glu Thr Leu Glu Ala His Gln Leu Arg
Val Ser Phe Thr Leu Trp 210 215 220Asn Glu Ser Thr Pro Tyr Gln Val
Leu Leu Glu Ser Phe Ser Asp Ser225 230 235 240Glu Asn His Ser Cys
Phe Asp Val Val Lys Gln Ile Phe Ala Pro Arg 245 250 255Gln Glu Glu
Phe His Gln Arg Ala Asn Val Thr Phe Thr Leu Ser Lys 260 265 270Phe
His Trp Cys Cys His His His Val Gln Val Gln Pro Phe Phe Ser 275 280
285Ser Cys Leu Asn Asp Cys Leu Arg His Ala Val Thr Val Pro Cys Pro
290 295
300Val Ile Ser Asn Thr Thr Val Pro Lys Pro Val Ala Asp Tyr Ile
Pro305 310 315 320Leu Trp Glu Pro Arg Ser Gly Ser Ser Asp Tyr Lys
Asp Asp Asp Asp 325 330 335Lys Gly Ser Ser His His His His His His
340 3454478PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 447Asp Tyr Lys Asp Asp Asp Asp Lys1
544812PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 448Gly Gly Gly Ala Ala Ala Gly Gly Gly Ala Ala
Ala1 5 1044988PRTArtificial SequenceDescription of Artificial
Sequence Synthetic construct 449Glu Ile Val Met Thr Gln Ser Pro Ala
Thr Leu Ser Val Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg
Ala Ser Gln Ser Val Ser Ser Asn 20 25 30Leu Ala Trp Tyr Gln Gln Lys
Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45Tyr Asp Ala Ser Thr Arg
Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr
Glu Phe Thr Leu Thr Ile Ser Ser Leu Gln Ser65 70 75 80Glu Asp Phe
Ala Val Tyr Tyr Cys 8545088PRTArtificial SequenceDescription of
Artificial Sequence Synthetic construct 450Glu Ile Val Met Thr Gln
Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu
Ser Cys Arg Ala Ser Gln Ser Val Ser Ser Asn 20 25 30Leu Ala Trp Tyr
Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu Leu Ile 35 40 45Tyr Asp Ala
Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60Ser Gly
Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro65 70 75
80Glu Asp Phe Ala Val Tyr Tyr Cys 8545188PRTArtificial
SequenceDescription of Artificial Sequence Synthetic construct
451Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly1
5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser Gln Ser Val Ser Ser
Asn 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro Arg Leu
Leu Ile 35 40 45Tyr Asp Ala Ser Thr Arg Ala Thr Gly Ile Pro Ala Arg
Phe Ser Gly 50 55 60Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser
Ser Leu Glu Pro65 70 75 80Glu Asp Phe Ala Val Tyr Tyr Cys
8545288PRTArtificial SequenceDescription of Artificial Sequence
Synthetic construct 452Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu
Ser Leu Ser Pro Gly1 5 10 15Glu Arg Ala Thr Leu Ser Cys Arg Ala Ser
Gln Ser Val Ser Ser Asn 20 25 30Leu Ala Trp Tyr Gln Gln Lys Pro Gly
Gln Ala Pro Arg Leu Leu Ile 35 40 45Tyr Asp Ala Ser Thr Arg Ala Thr
Gly Ile Pro Ala Arg Phe Ser Gly 50 55 60Ser Gly Pro Gly Thr Asp Phe
Thr Leu Thr Ile Ser Ser Leu Glu Pro65 70 75 80Glu Asp Phe Ala Val
Tyr Tyr Cys 854535PRTArtificial SequenceDescription of Artificial
Sequence Synthetic peptide 453Xaa Tyr Gly Ile Ser1
54545PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 454Xaa Tyr Xaa Met Xaa1 54555PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 455Ser
Tyr Gly Met Xaa1 545617PRTArtificial SequenceDescription of
Artificial Sequence Synthetic peptide 456Trp Ile Ser Xaa Tyr Xaa
Gly Asn Thr Xaa Tyr Ala Gln Xaa Xaa Gln1 5 10
15Gly45717PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 457Xaa Xaa Ser Xaa Xaa Xaa Ser Xaa Ile Xaa Tyr
Ala Asp Ser Val Lys1 5 10 15Gly45817PRTArtificial
SequenceDescription of Artificial Sequence Synthetic peptide 458Val
Ile Trp Tyr Asp Gly Xaa Xaa Lys Xaa Tyr Ala Asp Ser Val Lys1 5 10
15Gly4597PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 459Xaa Gln Leu Xaa Xaa Asp Tyr1
54607PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 460Xaa Gln Leu Xaa Phe Asp Tyr1
546111PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 461Arg Ala Ser Gln Xaa Ile Xaa Xaa Xaa Leu Xaa1 5
1046211PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 462Arg Ala Ser Gln Ser Xaa Xaa Xaa Xaa Leu Ala1 5
1046311PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 463Arg Ala Ser Gln Ser Val Xaa Xaa Asn Leu Xaa1 5
104647PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 464Ala Ala Ser Ser Xaa Gln Ser1
54657PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 465Ala Ala Ser Xaa Leu Gln Ser1
54667PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 466Xaa Xaa Ser Thr Arg Ala Xaa1
54679PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 467Leu Gln His Xaa Ser Tyr Xaa Xaa Thr1
54689PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 468Gln Xaa Xaa Xaa Xaa Xaa Pro Xaa Thr1
54699PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 469Gln Gln Tyr Asp Xaa Trp Pro Leu Thr1
547010PRTArtificial SequenceDescription of Artificial Sequence
Synthetic peptide 470Gln Xaa Tyr Xaa Xaa Trp Xaa Xaa Xaa Thr1 5
10
* * * * *